[{"content":" Organ on a Chip # Organ-on-a-chip and microphysiological systems replicate the dynamic, multi-cellular environments of human organs in microfluidic devices, enabling high-fidelity studies of drug effects, disease mechanisms, and toxicity. By mimicking tissue-tissue interfaces, fluid flow, and mechanical forces, these platforms offer human-relevant alternatives to traditional animal models, driving advances in personalized medicine and regulatory-approved drug development tools.\nMultiple tissue chips connected in a system\nto simulate a human-body-on-a-chip.\nCredit: NCATS. Emulate Liver-on-a-Chip Identifies Hepatotoxicity # The Emulate liver-on-a-chip model correctly identified hepatotoxicity in 87% of drugs (see \u0026ldquo;performance assessment\u0026rdquo; link below) that had tested as safe in animal models but were later found toxic in humans. The platform recapitulated human-specific metabolic dynamics, including albumin secretion and mechanical stimuli in the extracellular matrix, validating its biological accuracy. This success highlighted the superiority of human-relevant microphysiological systems over animal models for predicting drug-induced liver injury.\nTumor organoids for cancer research and personalized medicine\nPerformance assessment and economic analysis of a human Liver-Chip for predictive toxicology\nWhat are NAMs?\nAcetaminophen Toxicity Mechanism # Liver-on-a-chip technology equipped with nanotechnology-based optoelectronic sensors identified that acetaminophen blocks cellular respiration in minutes at much lower doses than previously believed. Sensors placed inside the bionic tissue detected rapid changes in oxygen uptake, revealing an ultra-rapid mitochondrial respiration impairment component not captured in legacy in vivo studies. This discovery provides a human-specific explanation for rare off-target effects and skin reactions, transforming safety protocols for one of the world\u0026rsquo;s most common medications.\nHepatotoxic assessment in a microphysiological system What are NAMs?\nLung-on-a-Chip for Antiviral Efficacy # A human lung-on-a-chip system was used to test RNA-based antiviral therapies for influenza, showing significant reduction in viral replication and inflammatory responses with minimal off-target toxicity. The platform demonstrated efficacy and safety under physiologically relevant conditions such as air-liquid interface and dynamic flow. This provided a human-relevant platform for antiviral drug testing, successfully overcoming the limitations of static cultures and animal models.\nLung-On-A-Chip Technologies for Disease Modeling and Drug Development\nHuman Lung-on-a-Chip Model Demonstrates Potential for Testing Preclinical Influenza Therapeutics\nRevolutionizing respiratory health research\nLung-on-a-Chip for Tumor Heterogeneity \u0026amp; Drug Resistance # Microfluidic lung-on-a-chip platforms modeled lung cancer microenvironments, enabling label-free real-time classification of tumor cells and the tracking of drug-resistant subpopulations like EGFR mutations. The technology demonstrated the ability to observe tumor heterogeneity and resistance dynamics in a human-relevant system, validating its predictive power. These insights have accelerated the development of targeted therapies and personalized treatment strategies for lung cancer.\nProgress and application of lung-on-a-chip for lung cancer\nThe potential of lung-on-a-chip as an alternative to animal testing\nMicrofluidic lung cancer models: Bridging clinical treatment strategies and tumor microenvironment recapitulation\nLiver and Skin Organ-on-a-Chip for PK-PD Studies # The HUMIMIC Chip2 integrated liver spheroids and skin models to study pharmacokinetic-pharmacodynamic (PK-PD) relationships under chemical exposure. The platform’s utility for quantifying drug metabolism and toxicity was validated in a human-relevant, multi-organ context. This advancement directly supported regulatory acceptance of organ-on-a-chip technologies as essential drug development tools.\nOrgan-on-a-chip meets artificial intelligence in drug evaluation\nOrgans-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation\nALS Pathogenesis and Early Biomarkers # Human spinal cord organ-chips integrated with vascular interfaces modeled early sporadic Amyotrophic Lateral Sclerosis (ALS), uncovering neurofilament dysregulation and synaptic signaling defects. Multi-omics analysis confirmed these molecular changes occur before overt neuron loss, mirroring clinical biomarkers that are difficult to detect in animal models. This technology offers a human-relevant platform to study early disease progression and identify therapeutic targets before irreversible nerve damage occurs.\nOrgan-Chip ALS Model Uses Patient iPSCs to Uncover Early Disease Progression\nAn organ-chip model of sporadic ALS using iPSC\nGABAergic Signaling in Cancer Invasion # Patient-derived tumor organ-chips proved that tumor-derived GABA acts as a marker of poor prognosis and directly promotes invasion in metastatic colorectal cancer. Interrogating the underlying biology on-chip demonstrated that inhibiting GABA synthesis significantly reduced invasive behavior, capturing patient-specific heterogeneity more faithfully than static cultures. This work establishes a new therapeutic target for colorectal cancer and validates the ability of organ-chips to replicate the complex tumor microenvironment.\nGABAergic signaling contributes to tumor cell invasion and poor overall survival in colorectal cancer\nCervical Protective Role in Dysbiosis # Linked Cervix and Vagina Organ-Chips demonstrated that cervical mucus actively modulates vaginal inflammation and protects the epithelium from injury during dysbiosis. Exposure to cervix-derived mucus on-chip reduced inflammatory responses and altered protein expression profiles, identifying potential new biomarkers for bacterial vaginosis. This discovery uncovers human-specific protective mechanisms that cannot be studied in animal models, facilitating the discovery of new feminine health therapeutics.\nCervical mucus in linked human Cervix and Vagina Chips modulates vaginal dysbiosis\nLung-on-a-Chip Replicates Human Lung Disease and Drug Responses # Microfluidic chips lined with human lung cells modeled pulmonary edema, COPD, and drug toxicity with high fidelity. This model demonstrated superior predictive value over animal models for lung disease and toxicity and is now recognized by the FDA as a valid testing platform for specific drug submissions. The impact of this technology is the enablement of more accurate modeling of human lung responses to drugs and diseases.\nReconstituting Organ-Level Lung Functions on a Chip\nA Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice\nHuman Skin-Lymphoreticular Model-on-Chip for Inflammatory Skin Diseases # Researchers developed a human-based skin-lymphoreticular model-on-chip emulating inflammatory skin conditions by capturing immune-skin interactions on a microfluidic platform. The utility for studying atopic dermatitis and related diseases was validated through the observation of complex cellular interactions. This advancement effectively eliminates the need for animal models in studying inflammatory skin diseases.\nA Human-Based Skin-Lymphoreticular Model-on-Chip to Emulate Inflammatory Skin Conditions\n","date":"2026-05-12","externalUrl":null,"permalink":"/advances/organ-on-a-chip/","section":"Advances","summary":"Organ-on-a-chip and microphysiological systems replicate human organ environments.","title":"Organ on a Chip","type":"advances"},{"content":" Nexus # Individuals who are NAM enthusiasts\nCredit: Gemini Nexus consists enthusiasts of NAM such as learners, experts, ambassadors, and supporters.\n","date":"2026-05-15","externalUrl":null,"permalink":"/about/nexus/","section":"About","summary":"","title":"Nexus","type":"about"},{"content":" Advisors # PNARS advisors are highly skilled experts in a variety of fields\nCredit: Mistral Our advisors are a diverse group of experts in science, law, ethics, and advocacy, each bringing unique expertise to support PNARS’ mission of advancing New Approach Methodologies (NAM). Their collective knowledge guides our work in promoting human-relevant, non-animal research methods.\nManeesha Deckha # Maneesha Deckha is Professor and Lansdowne Chair in Law at the University of Victoria in British Columbia where she directs the Animals and Society Research Initiative (ASRI). Professor Deckha is the recipient of multiple grants for her work on animal law theory and reform, including transitioning away from animal-based farming and food systems as well as animal-based science research. In Spring 2024 she was a Visiting Professor at the Faculty of Law at the University of Zurich and a Senior Fellow at the Collegium Helveticum, ETH Zurich. Professor Deckha is a graduate of McGill University, the University of Toronto Faculty of Law, and Columbia Law School. Her work analyzes the gendered, culture, racialized, and species dimensions of law. She has published in law reviews, social science and humanities journals, and edited collections. She is the author of Animals as Legal Beings: Contesting Anthropocentric Legal Orders and director of the open access documentary series A Deeper Kindness: Youth Activism in Animal Law.\nDr. Zheng Tan # With both an MD and PhD, Zheng is currently Executive Research Coordinator in Eye Care Centre at Vancouver General Hospital. Her work specializes in human-based disease modeling in the study of atopic diseases. She developed a human-derived lymph node model, integrated into an organ-on-a-chip platform which more accurately replicates disease progression. A long-time animal advocate raising awareness in raptor protection, her main areas of interest are reducing/replacing animal usage in scientific research. She won the 2024 LUSH Prize Award in the young researcher category and is a 2026 judge for that competition. You can see her PNARS webpage here.\nDr. Andre Menache # European Veterinary Specialist in Animal Welfare Science, Ethics and Law, Andre is a Member of European College of Animal Welfare and Behavioural Medicine. He holds degrees in zoology and veterinary medicine BSc(Hons) BVSc MRCVS EBVS®. His main areas of interest include animal experimentation and regulatory toxicology. He is also France\u0026rsquo;s InterNICHE contact.\nDr. Olivier Berreville # Holding a PhD in Biology from Dalhousie University, Olivier was the Scientific Advisor for Canadians for Ethical Treatment of Farmed Animals and the Vice-President of the B.C. Foundation for Non-Animal Research. He has been the Canadian contact for InterNICHE since 2003, assisting life science students learn in their chosen field without harming animals.\nMyriam Brulot # Born in France, Myriam Brulot has been a practicing lawyer in the area of Aboriginal Law since 1995, specializing in Specific Claims brought against Canada for its breach of historical lawful obligations to First Nations in British Columbia. Since moving to Vancouver in 1994, she has campaigned for animal rights including as a Director of the Vancouver Humane Society, and with a particular focus on the enforcement of the Province’s anti-cruelty legislation.\nEricka Ceballos # With over four decades of animal welfare, 33 years of animal conservation and 30 of environmental experience, Ericka has founded and co-founded animal NGOs in Canada, Mexico and Poland, as well as being Director of other animal welfare NGOs. She is currently the Founder and CEO of CATCA Environmental and Wildlife Society and of International Aid For Animals Foundation. Ericka has wide experience at CITES, IWC, CMS and other high-end intergovernmental meetings as well as scientific meetings. She is the only International Wildlife Trade Expert doing a formal monitoring of the e-commerce of protected wildlife in the American continent, Africa and Asia. The results of her investigations are distributed at UNEP level and all her reports are at the Interpol Database.\nAnna Pippus # A long-time animal advocate, holding degrees in law and psychology, Anna with Dr. Ray Greek, has co-authored a paper published in BMC Medical Ethics The Nuremberg Code subverts human health and safety by requiring animal modeling arguing that legal requirements for animal testing have long been scientifically outdated, thus compromising human health and safety.\nDr. Maidie Hilmo # A PhD scholar from the University of Victoria, Maidie has published widely on medieval illustrated manuscripts as well as Canadian art and literature. “Into the Jaws of the Beast: From the Movie back to Early English Art and Its Mythical Context, ” is the subject she is currently exploring to trace the origins of the man vs. nature motif that still holds wide currency in today’s culture. Maidie has been active for decades in animal rights issues, especially those concerning the use of animals in laboratories, an outdated approach that has perpetuated a binary mode of thought that is cruel, wasteful, and non-productive. She urges, instead, that it is time that the practices of the “dark ages” be replaced by ethical non-animal methods that are scientifically advanced and benefit all creatures on this fragile planet.\nDr. Ranjana Basu # Holding a BSc in Biology, an MSW in Social Work, and a Doctorate in Social Science, Ranjana has been active in both human and animal rights for over 40 years. She has written a book on Elder Abuse as well as one on Supporting Caregiving Families which formed the basis for the Cowichan Family Caregivers Support Society which she co-founded and ran from 2000-2014. Her doctoral thesis Linking Animals, Social Justice and Social Work suggests a new path for social work practice. In 2023, she co-organized with UVic\u0026rsquo;s Animals \u0026amp; Society Research Initiative (ASRI), Victoria\u0026rsquo;s first Multispecies Families on the Streets Symposium culminating with the final report Multispecies Families on the Streets.\n","date":"2026-05-11","externalUrl":null,"permalink":"/about/advisors/","section":"About","summary":"","title":"Advisors","type":"about"},{"content":" The deceptively large management team\nCredit: Mistral The PNARS staff who manage the website and other activities are listed below.\n","date":"2026-05-15","externalUrl":null,"permalink":"/about/management/","section":"About","summary":"","title":"Management","type":"about"},{"content":" Human Organoids # Organoids are three-dimensional, self-organizing cultures derived from stem cells that recapitulate the structure and function of human organs. This section showcases how organoids are transforming disease modeling, drug screening, and gene therapy development, enabling precision medicine approaches for conditions like cystic fibrosis, Duchenne muscular dystrophy, and cancer.\nIntestinal organoid grown\nfrom Lgr5+ stem cells.\nCredit: Meritxell Huch, CC BY 4.0 FIS Assay for Cystic Fibrosis # Patient-derived intestinal organoids from Cystic Fibrosis patients were used in the Forskolin-induced Swelling (FIS) assay to test CFTR-modulator drugs. The assay accurately predicted clinical trial responses for individual patients, including those with rare genotypes. This has enabled tailored therapeutic strategies, significantly increasing life expectancy for Cystic Fibrosis patients.\nTowards diagnostic and personalized models using organoids\nNAMs: an exciting era for drug discovery\nPatient-Derived Organoids for Gene Therapy in DMD # A breakthrough workflow successfully converted cryopreserved blood cells into induced pluripotent stem cells and then into cardiac organoids, correcting unique splicing defects in Duchenne Muscular Dystrophy patients. Custom ASOs restored dystrophin expression and improved calcium transients in these cardiac organoids, validating the therapeutic approach. This provided a scalable, cost-effective alternative to animal models for developing personalized gene therapies.\nPatient-Derived Organoids for Gene Therapy Development\nPatient-Derived Organoids for Metastatic Colorectal Cancer # The OPTIC trial validated the predictive power of patient-derived organoids (PDOs) for metastatic colorectal cancer, showing that organoid response correlated with radiological tumor response and clinical survival. The trial demonstrated 83.3% accuracy in predicting patient survival and tumor response. This has enabled early identification of ineffective therapies, minimizing patient exposure to toxicity and optimizing treatment selection.\nPatient-Derived Organoids Predict Treatment Response in Metastatic Colorectal Cancer\nOrganoid Immune Co-Culture Models for Cancer Vaccines # Tumor organoids co-cultured with autologous peripheral blood lymphocytes simulated the tumor immune microenvironment to assess individual responses to checkpoint inhibitors and CAR-T cell therapies. This method identified tumor-specific antigens with high immunogenicity, enabling the design of personalized cancer vaccines. The discovery has revolutionized immunotherapy development by capturing spatial organization and immune dynamics.\nFrom petri dish to patient care: organoids bring personalised cancer therapy closer\nKidney Assembloids for Polycystic Kidney Disease # Researchers generated the most complex kidney structures to date—assembloids combining filtering nephrons with urine-concentrating collecting ducts. These assembloids recapitulated key features of Polycystic Kidney Disease, including inflammation and fibrosis, which were previously irreproducible in animal models. This work opened new avenues for studying chronic kidney disease and predicting drug-induced nephrotoxicity.\nResearchers develop most advanced kidney organoid yet for disease modeling and drug discovery\nMiller-Dieker Syndrome Root Cause # Human brain organoids derived from patient cells identified the root cause of Miller-Dieker Syndrome as early neural stem cell death and severe division defects in \u0026ldquo;outer radial glia.\u0026rdquo; Time-lapse imaging showed that these specific glia cells—which are entirely absent in mouse models—failed to divide properly. This solves a long-standing mystery in neurodevelopmental disease and proves that patient-derived organoids can bridge the gap between animal models and human pathophysiology.\nAn Organoid-Based Model of Cortical Development Identifies Non-Cell-Autonomous Defects in Wnt Signaling Contributing to Miller-Dieker Syndrome\nCerebral organoids expressing mutant actin genes reveal cellular mechanism underlying microcephaly\nIGF-1 Dependency in Lung Cancer Subtypes # A library of 40 small cell lung cancer (SCLC) organoid lines revealed that non-neuroendocrine subtypes depend on the IGF-1 signaling axis for growth. Genetic ablation in human alveolar organoids replicated this dependency, and IGF1R inhibitors suppressed growth in patient-derived models. This identifies IGF1R inhibition as a promising new therapeutic strategy for a treatment-resistant patient population.\nAn organoid library unveils subtype-specific IGF-1 dependency via a YAP–AP1 axis in human small cell lung cancer\nIntestinal Organoids Reveal Stem Cell Biology # The first human intestinal organoids developed from adult stem cells enabled the study of gut disease, cancer, and drug responses in human tissue. This success was extended to liver, kidney, brain, and retinal organoids worldwide, validating the platform across multiple organ types. This technology serves as the foundation for modern human organoid research.\nSingle Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche\nBrain Organoids Model Microcephaly Caused by Zika Virus # Human brain organoids demonstrated Zika virus infection of neural progenitor cells, modeling microcephaly-like features in human tissue. The organoids captured human-specific features of microcephaly that mouse models were unable to fully recapitulate. This provided critical, human-specific insights into Zika virus pathology.\nBrain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure\nZika virus tested in human brain organoids\nUnderstanding Brain Development and Disease # Brain organoids, three-dimensional, laboratory-grown models derived from induced pluripotent stem cells that replicate the complex, species-specific developmental programs of the human brain, have revolutionized neuroscience by allowing researchers to study the unique expansion of the human cortex. Organoids serve as critical tools for modeling neurodevelopmental disorders such as autism and microcephaly, testing treatments, and exploring evolutionary differences through the integration of ancient hominin genes. Regional organoids are fused into \u0026ldquo;assembloids\u0026rdquo; to map functional neural circuits, including motor-muscle connections and pain-processing pathways. Despite their transformative potential, organoids currently lack the full complexity of a natural brain and face long-term sustainability challenges, which, alongside improving technology, necessitates ongoing ethical scrutiny regarding the future possibility of emergent sentience.\nMini models of the human brain are revealing how this complex organ takes shape\n","date":"2026-05-12","externalUrl":null,"permalink":"/advances/human-organoids/","section":"Advances","summary":"Three dimensional stem cell cultures recapitulate human organ functions for research.","title":"Human Organoids","type":"advances"},{"content":" In Silico Modelling # Structural model of SARS-CoV-2 infection.\nCredit: Victor Padilla-Sanchez In silico modeling—including Physiologically Based Pharmacokinetic (PBPK) models and digital twins—simulates drug behavior in the human body, enabling virtual clinical trials and predictive toxicology. By integrating computational methods with biological data, these approaches reduce reliance on animal testing, optimize dosing regimens, and accelerate the development of safe and effective therapies.\nPhysiologically Based Pharmacokinetic Modeling # PBPK models integrate in vitro data on absorption, distribution, metabolism, and excretion with physiological parameters to predict internal human exposure. The models correctly estimated systemic exposure of caffeine and coumarin, demonstrating that model-informed approaches can replace in vivo toxicokinetics. This impact has enabled virtual clinical trials and optimized dosing regimens without animal testing.\nAdvancing drug development with “Fit-for-Purpose” modeling informed approaches\nSCCS Notes of guidance for the testing of cosmetic ingredients and their safety evaluation\nThe margin of internal exposure (MOIE) concept for dermal risk assessment based on oral toxicity data - A case study with caffeine\nAI-driven virtual cell models in preclinical research\nOrgans-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation\nBioequivalence Bridging for Tofacitinib # Pharmacokinetic/pharmacodynamic modeling was used to bridge the immediate-release formulation of tofacitinib to a new extended-release version. The computational model successfully established bioequivalence, satisfying regulatory safety and efficacy requirements without further animal testing. This supported FDA approval while avoiding new Phase 3 clinical trials, accelerating patient access to the formulation.\nIntegrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified-Release Dosage Form Virtual Bioequivalence Assessment of Tofacitinib Once Daily Modified Release Dosage Form in Pediatric Subjects\nDigital Twins for Clinical Trial Simulation # Digital twins are virtual representations of individuals that integrate clinical, genetic, and environmental data to revolutionize clinical trial design. Simulation of treatment strategies before patient enrollment has been shown to reduce both risks and costs. This technology could eventually eliminate the need for many traditional clinical trials by predicting patient-specific responses.\nIncreasing acceptance of AI‐generated digital twins through clinical trial applications\nThe Use of Digital Healthcare Twins in Early-Phase Clinical Trials: Opportunities, Challenges, and Applications\nEnhancing randomized clinical trials with digital twins What are NAMs?\nQuantitative Systems Pharmacology Models # QSP models combine mechanical simulations of physiology with molecular signaling pathways to predict immunogenicity and pharmacokinetics of complex biologics. The FDA highlighted QSP as a vital tool to reduce reliance on animal testing for \u0026ldquo;what-if\u0026rdquo; development scenarios. The use of these models has accelerated the development of biologics and personalized medicine.\nFDA animal testing phaseout urges AI-based trial alternatives, organoids, other “NAMs”\nBeyond lab animals\nAlphaFold Predicts Protein Structures # AI-based prediction of protein 3D structures from amino acid sequences transformed structural biology and drug target identification. The open-access database covers over 200 million structures with atomic accuracy, even for architectures not previously discovered in animal research. This provides data that previously required years of laboratory work, significantly supporting the efficiency of NAM workflows.\nHighly accurate protein structure prediction with AlphaFold\n","date":"2026-05-12","externalUrl":null,"permalink":"/advances/in-silico-modelling/","section":"Advances","summary":"Computational models simulate human biology enabling virtual clinical trials.","title":"In Silico Modelling","type":"advances"},{"content":" AI for Drug Discovery # Artificial Intelligence (AI) and machine learning (ML) are revolutionizing drug discovery by analyzing vast datasets to identify novel drug candidates, predict drug responses, and repurpose existing drugs for new therapeutic uses. This section highlights groundbreaking discoveries where AI-driven approaches have accelerated drug development timelines, reduced reliance on animal testing, and provided actionable insights for treating complex diseases such as COVID-19, idiopathic pulmonary fibrosis, and neurodegenerative disorders.\nAI Driven Drug Discovery\nCredit: Mistral AI-Powered Drug Repurposing for COVID-19 # The JAK inhibitor baricitinib, originally approved for rheumatoid arthritis, was identified as a potential COVID-19 therapy through an AI-driven in silico NAM that predicted its ability to block SARS-CoV-2 infection and modulate cytokine signaling. Subsequent clinical trials confirmed these predictions, showing that the drug significantly reduced mortality and improved outcomes in hospitalized patients when added to standard care. This success demonstrated the profound power of AI-driven drug repurposing for rapid pandemic response.\nCan New Approach Methodologies De-Risk Drug Development?\nAI-Designed Novel Drug Candidate for Idiopathic Pulmonary Fibrosis # Insilico Medicine’s AI platform designed a novel drug candidate for idiopathic pulmonary fibrosis in just 18 months by integrating multimodal omics data with deep generative models and graph networks. The candidate successfully advanced to Phase II clinical trials, providing a clear real-world example of AI\u0026rsquo;s ability to compress traditional drug discovery timelines. This methodology significantly reduced reliance on animal testing while shortening the overall development pipeline.\nFrom AI-Assisted In Silico Computational Design to Preclinical In Vivo Models\nTopiramate for Inflammatory Bowel Disease (IBD) # Researchers utilized transcriptomic reversal scoring and network pharmacology to identify topiramate as a viable candidate for IBD by predicting its capacity to reverse disease-specific expression profiles. While further preclinical and clinical studies are currently ongoing to confirm its efficacy in large-scale human populations, the discovery phase highlights the potential for AI-driven repurposing to address complex inflammatory diseases. This approach offers a data-driven path toward new treatments for chronic conditions.\nFrom Lab to Clinic: Success Stories of Repurposed Drugs in Treating Major Diseases\nDrug Repurposing for Neurodegenerative Disorders # High-throughput screening identified specific compounds capable of disrupting 14-3-3 protein interactions, which represents a promising therapeutic avenue for Amyotrophic Lateral Sclerosis (ALS). AI integration is currently overcoming the volume and complexity limitations of conventional screening, allowing for more efficient validation of these bio-interactions. These advancements provide new hope for neurodegenerative diseases that currently have significant unmet medical needs.\nAI-driven High Throughput Screening for Targeted Drug Discovery\nHow AI Contributes to make High-Throughput Screening more Efficient\nNew Approach Methodologies Facilitating Drug Discovery\nCoreFinder: AI-Driven Discovery of Biosynthetic Gene Clusters # The CoreFinder system, a transformer-based protein language model, was used to predict biosynthetic gene cluster (BGC) functions in fungi, leading to the discovery of novel clusters. These findings were validated through in vitro fermentation and LC-MS analysis, proving that AI can drive valid scientific discoveries independently of traditional experimental paradigms. The impact of this work is the unlocking of entirely new biosynthetic pathways for future pharmaceutical advancement.\nDeciphering Biosynthetic Gene Clusters with a Context-aware Protein Language Model\nDisrupting TSLP Signaling as a Treatment for Atopic Diseases # Scientists identified putative small molecule inhibitors designed to disrupt the interactions between TSLP and its receptor to treat atopic conditions. The efficacy of these molecules was demonstrated in human cell assays, providing a novel and efficient treatment option for diseases like atopic dermatitis and asthma. This discovery provides a human-relevant alternative to traditional animal models specifically for drug discovery in inflammatory skin diseases.\nDisrupting TSLP-TSLP receptor interactions via putative small molecule inhibitors yields a novel and efficient treatment option for atopic diseases\nDrug Failure Reduction through AI and Organoids # Conventional drug discovery currently faces a 90% failure rate in human trials, primarily due to insufficient efficacy and unanticipated toxicity, with drug-induced liver injury alone causing over 20% of these failures when traditional animal testing proves inadequate. To address this, the University of Michigan and Los Alamos National Laboratory are collaborating on a new supercomputing and AI research center focused on accelerating high-impact research for the public good. By integrating human liver organoids with advanced experimental and computational technologies, this initiative aims to revolutionize the safety evaluation process, improve the accuracy of drug development, and significantly reduce clinical trial failure rates.\nReducing drug failures with AI, human liver organoids\n","date":"2026-05-12","externalUrl":null,"permalink":"/advances/ai-for-drug-discovery/","section":"Advances","summary":"AI analysis of vast datasets accelerate drug discovery through identification, prediction, and repurposing.","title":"AI for Drug Discovery","type":"advances"},{"content":" High Throughput Methods # A high-throughput sequencing set\nutilizing DNBSEQ technology.\nCredit: RPSkokie, CC BY-SA 4.0 High-throughput technologies such as CRISPR screens, single-cell RNA sequencing, and multi-omics integration enable rapid identification and validation of drug targets, disease mechanisms, and toxicity pathways. This section highlights how omics-based NAM are reshaping mechanistic understanding and accelerating the discovery of novel therapies for diseases with high unmet medical needs.\nTox21 Consortium: High-Throughput Chemical Screening # The Tox21 federal collaboration uses robotic high-throughput screening to evaluate thousands of chemicals simultaneously, leading to the development of an 18-assay battery for the estrogen receptor pathway. The EPA formally accepted this computational model as an alternative to traditional rodent assays for identifying endocrine disruptors. This marked the first regulatory prioritization of robotically derived molecular data over animal testing.\nTox21: Chemical testing in the 21st century\nUnited States Federal Government TOX21 Collaboration\nAbout Tox21\nMulti-Omics Integration for Toxicity Pathways # Integrative NAM combining genomics, transcriptomics, proteomics, and metabolomics have revealed novel oxidative stress and mitochondrial dysfunction signatures. These models successfully distinguished adaptive from adverse responses and generated candidate biomarkers for early detection. This has reshaped the mechanistic understanding of chemical toxicity by moving beyond simple observational data.\nMulti-omics integration analysis\nThe future of pharmaceuticals: Artificial intelligence in drug discovery and development\nSkin Sensitisation Case Study\nProspects and challenges of multi-omics data integration in toxicology\nCRISPR Screens for Drug Target Validation # CRISPR/Cas9 gene editing and single-cell RNA sequencing enabled the rapid identification and validation of drug targets for cancer and neurodegenerative diseases. This link between gene perturbations and therapeutic efficacy was validated across multiple cell lines, accelerating the discovery of novel treatments. Consequently, reliance on animal models for target validation has been significantly reduced.\nCRISPR Cas9 Gene Editing\nCRISPR-Cas9 in Functional Genomics: Implications for Target Validation in Precision Oncology\nTarget Validation with CRISPR\nThe future of pharmaceuticals: Artificial intelligence in drug discovery and development\nAOP-Linked In Vitro Screens for Seizure Liability # A government-industry collaboration mapped mechanisms leading to drug-induced seizures using adverse outcome pathways and in vitro assays. The project identified 27 biological target families and developed over 100 assay endpoints for more accurate risk assessment. This mechanism-focused screening replaces animal models that historically failed to predict drug-induced seizures.\nDe-risking seizure liability\nCan New Approach Methodologies De-Risk Drug Development?\niPSC derived cardiomyocytes for cardiac toxicity assessment\n","date":"2026-05-12","externalUrl":null,"permalink":"/advances/high-throughput-methods/","section":"Advances","summary":"High-throughput technologies like CRISPR screens and multi-omics enable rapid drug target discovery.","title":"High Throughput Methods","type":"advances"},{"content":" Safety Assessments via NAM # Predictive toxicology analysis\nwith human liver-chip.\nCredit: Lorna Ewart et al, Nature. NAM are transforming toxicology and safety assessment by providing human-relevant models for predicting compound toxicity, skin sensitization, endocrine disruption, and mixture toxicology. This section explores how regulatory agencies and industries are adopting these methods to improve chemical risk assessment and reduce reliance on animal testing.\nEndocrine Disruption Assessment # The Tox21 estrogen receptor pathway battery identified compounds interfering with human hormones using robotic screening results. The EPA accepted this computational model as an alternative to rodent assays, validating the use of robotically derived data. This provides a recognized non-animal alternative for hazard identification regarding endocrine disruptors.\nToxic Alerts of Endocrine Disruption Revealed by Explainable Artificial Intelligence\nTox21: Chemical testing in the 21st century\nUse of New Approach Methodologies\nSkin Sensitization Hazard \u0026amp; Potency Prediction # The OECD TG 497 guideline combined multiple NAM, such as peptide reactivity and keratinocyte activation assays, to classify skin sensitization. The performance was validated as equal to or better than mouse assays, even for chemicals not previously tested in animals. This established a regulatory framework for animal-free safety testing of skin sensitizers.\nSkin Sensitisation Case Study: Comparison of Defined Approaches including OECD 497 Guidance\nAdvancing Skin Sensitization Potency Categorization Using U-SENS™ in OECD TG 497\nStandardisation and international adoption of defined approaches for skin sensitisation\nEvaluating the ability of defined approaches to predict the human skin sensitisation potential of chemicals previously untested in new approach methodologies\nCase Study on the Use of Integrated Approaches for Testing and Assessment for skin sensitisation\nBER for PFAS Risk Assessment # Regulators used in vitro assays to calculate human equivalent doses and derive a Bioactivity-Exposure Ratio (BER) for emerging PFAS compounds. The BER served as a validated protective surrogate in the absence of traditional animal data. This enabled risk-based prioritization of chemicals based on biological perturbation likelihood.\nS13-02 NAMs to investigate chemical-induced immunotoxicity: the cases of PFAS and BPA analogs\nUse of new approach methods (NAMs) in risk assessment\nSensitivity Analysis of the Inputs for Bioactivity-Exposure Ratio Calculations in a NAM-Based Systemic Safety Toolbox\nMixture Toxicology via NAM # NAM-based defined approaches were extended to complex mixtures such as pesticide formulations to assess their collective toxicity. Panels of in chemico and in vitro assays demonstrated they could accurately identify and rank sensitization potential. This impact advanced the understanding of combined exposure effects without resorting to animal testing.\niPSC derived cardiomyocytes for cardiac toxicity assessment\nCase Study on the Use of Integrated Approaches for Testing and Assessment for skin sensitisation of Diethanolamine\nChemical testing using new approach methodologies\nReconstructed Human Skin Models # Reconstructed human skin models have been validated by the OECD as replacements for the Draize rabbit skin irritation test. These models are now standard in the EU and increasingly adopted globally for testing cosmetics and chemicals. Their use eliminates animal testing for skin irritation and corrosion endpoints in multiple jurisdictions.\nIn Vitro Skin Models as Non-Animal Methods for Dermal Drug Development and Safety Assessment\nArtificial Skin Models for Animal-Free Testing\nCorneal and Eye Irritation Models # Validated alternatives to the Draize rabbit eye test, such as EpiOcular and SkinEthic HCE, assess the eye irritation potential of chemicals and consumer products. These human-relevant models provide accurate safety assessments for a wide range of industrial applications. They offer a validated non-animal alternative that is both more ethical and biologically relevant.\nTissue Engineered Mini-Cornea Model for Eye Irritation Test\nCorneal epithelium models for safety assessment in drug development: Present and future directions\n","date":"2026-05-12","externalUrl":null,"permalink":"/advances/safety-assessments-via-nam/","section":"Advances","summary":"NAM provide human-relevant models for toxicity and safety assessment.","title":"Safety Assessments via NAM","type":"advances"},{"content":"","date":"2026-06-23","externalUrl":null,"permalink":"/categories/actors/","section":"Categories","summary":"","title":"Actors","type":"categories"},{"content":"","date":"2026-06-23","externalUrl":null,"permalink":"/tags/animal-welfare/","section":"Tags","summary":"","title":"Animal Welfare","type":"tags"},{"content":"","date":"2026-06-23","externalUrl":null,"permalink":"/tags/animals-in-science-policy-institute/","section":"Tags","summary":"","title":"Animals in Science Policy Institute","type":"tags"},{"content":"","date":"2026-06-23","externalUrl":null,"permalink":"/categories/","section":"Categories","summary":"","title":"Categories","type":"categories"},{"content":" Elisabeth Ormandy, PhD # Advocate for replacing animals in research, testing, and teaching Sessional Lecturer at the University of British Columbia Expert in animal welfare, ethics, and public engagement Author of Animal Experimentation: Working Towards a Paradigm Change (2019) Co-founder of the Animals in Science Policy Institute (AiSPI) Recognized for leadership in promoting ethical science and non-animal alternatives Elisabeth Ormandy\nCredit: awp.landfood.ubc.ca Introduction # Dr. Elisabeth Ormandy, PhD, is a pioneering advocate for ethical science and animal welfare, specializing in the replacement of animals in research, testing, and teaching. As the Co-founder and Executive Director of the former Animals in Science Policy Institute (AiSPI), she led efforts to promote non-animal alternatives and foster a culture of ethical science. Her work bridges academic research, public policy, and advocacy, with a focus on the Three Rs (Replacement, Reduction, Refinement) and the ethical implications of animal use in science.\nProfessional Background and Achievements # Dr. Ormandy earned her PhD in Animal Welfare and Ethics from the University of British Columbia (UBC), where she explored the ethical dimensions of using animals in research, teaching, and testing. She has held roles as an Independent Research Consultant and Sessional Lecturer at UBC, and previously worked with the BC SPCA and Virginia Tech as a consultant.\nShe was the Executive Director of the former Animals in Science Policy Institute (AiSPI), a registered charity based in Vancouver, BC. AiSPI’s mission was to build an ethical culture of science that respects animal life by promoting the reduction and replacement of animals in research, testing, and teaching. Under her leadership, AiSPI became a leading voice in Canada for evidence-based discussion on animal use in science and the adoption of non-animal alternatives.\nResearch Areas and Projects # Dr. Ormandy’s research focuses on the ethics of animal use in science, public attitudes toward animal research, and the development and implementation of non-animal alternatives. Her work includes:\nPublic engagement and transparency in animal research, including international expert forums on openness and accountability. Stakeholder views on genetically-engineered animals in biomedical science, examining ethical, governance, and public opinion dimensions. Education and advocacy for replacing animal dissection in classrooms, with a focus on BC secondary schools and the promotion of humane science education. Policy development for the ethical use of animals in science, including the promotion of the - Three Rs (Replacement, Reduction, Refinement) and the adoption of New Approach Methodologies (NAM). Major Publications # Title Journal Year Link Protecting Canada’s Lab Animals: The Need for Legislation Animals (Basel) 2022 link Book Rewiew: Animal Experimentation: Working Towards a Paradigm Change Routledge 2019 link Animal Research, Accountability, Openness and Public Engagement: Report from an International Expert Forum Animals (MDPI) 2019 link Stakeholder Views on the Creation and Use of Genetically-Engineered Animals in Research Altern Lab Anim. 2016 link Public Attitudes toward Animal Research: A Review Animals (MDPI) 2014 Link Worldwide Trends in the Use of Animals in Research: The Contribution of Genetically-modified Animal Models Altern Lab Anim. 2009 Link Awards and Recognitions # Lush Prize (as part of AiSPI’s advocacy for non-animal testing methods) Recognition for leadership in humane science education and animal welfare policy in Canada Media and Public Engagement # Dr. Elisabeth Ormandy shares her personal journey from neuroscientist to animal welfare and ethics expert over a decade. She explains why she is committed to advancing science without the use of animals, highlighting the scientific and ethical reasons for replacing animals in research, testing, and teaching. The talk was recorded at a BC Humanist Association meeting in Vancouver.\nIn this TEDxSFU talk, Dr. Elisabeth Ormandy advocates for a future of science that moves beyond traditional animal models. She argues that animal testing is not only ethically problematic but also scientifically limited, and champions the adoption of innovative, human-relevant research methods for more effective and ethical science.\nDr. Elisabeth Ormandy discusses the ethical and practical reasons to replace animal use in schools and labs with viable, humane alternatives. She emphasizes the benefits of modern, animal-free methods for education and research, and highlights the ultimate goal of replacing animals in science through policy change, education, and the adoption of innovative, non-animal approaches.\nThis video is a UBC panel discussion featuring Elisabeth Ormandy (alongside Laura Janara and Darren Chang) on the governance of nonhuman animals in university research. The discussion critically examines the benefits, costs, and ethical implications of using animals in science, and explores how to improve governance, empower animals, and move toward more humane and effective research practices.\nDr. Ormandy’s Humane Science Lesson Plans # These alternatives to animal dissection materials were produced by Dr. Ormandy and donated to the BCSPCA, which circulated them to various organizations. They are suitable for students from K-12. The lessons are in pdf format for download.\nElementary School (Grades K-6) # Frog Anatomy Lesson Plan (Grades K-6)\nIntroduces frog anatomy through ethical, non-animal methods, using diagrams and interactive activities. Designed to replace traditional dissection while teaching foundational biological concepts. Suitable for young learners with age-appropriate explanations.\nFrog Anatomy Student Workbook\nCompanion workbook featuring labeling exercises, coloring pages, and puzzles to reinforce anatomical knowledge. Encourages hands-on learning without the use of animals. Aligns with the lesson plan for grades K-6.\nRat Anatomy Unit Plan (Grades 5-6)\nCovers rat anatomy using diagrams, models, and virtual resources as ethical alternatives to dissection. Explores skeletal, muscular, and organ systems in an age-appropriate manner. Promotes humane science education for upper elementary students.\nRat Anatomy Student Workbook\nInteractive workbook with activities, puzzles, and diagrams to reinforce rat anatomy concepts. Supports the unit plan with hands-on, non-animal learning. Designed for grades 5-6.\nHigh School (Grade 12) # Pig Anatomy Lesson Plan (Grade 12)\nAdvanced curriculum on pig anatomy using non-animal teaching methods, including detailed diagrams and virtual models. Covers complex anatomical systems for high school biology. Provides an ethical alternative to pig dissection.\nPig Anatomy Student Workbook\nDetailed workbook with labeling exercises, analysis activities, and diagrams to reinforce pig anatomy. Supports the lesson plan with hands-on, ethical learning. Designed for grade 12 students.\nCardiovascular System Lesson Plan (Grade 12)\nExplores human cardiovascular anatomy and physiology using ethical, non-animal methods. Covers heart structure, blood flow, and circulatory functions. Designed for high school biology courses.\nCardiovascular System Student Workbook\nCompanion workbook with diagrams, labeling exercises, and critical thinking questions. Reinforces cardiovascular concepts through active, non-animal learning. Aligns with the grade 12 lesson plan.\nDigestive System Lesson Plan (Grade 12)\nTeaches human digestive anatomy and physiology without animal use. Includes detailed diagrams of organs and digestive processes. Appropriate for advanced high school biology.\nDigestive System Student Workbook\nInteractive workbook with activities, case studies, and labeling exercises. Supports ethical learning of digestive system concepts. For grade 12 students.\nLymphatic and Immune System Lesson Plan (Grade 12)\nCovers lymphatic and immune systems using diagrams, animations, and virtual models. Explores immune response and lymph node structure ethically. Designed for high school biology.\nLymphatic and Immune System Student Workbook\nWorksheets and activities to reinforce lymphatic and immune system concepts. Includes labeling, matching, and analysis exercises. Companion to the grade 12 lesson plan.\nMusculoskeletal System Lesson Plan (Grade 12)\nTeaches bone and muscle anatomy through non-animal methods. Covers skeletal structure, muscle groups, and movement mechanics. Ethical alternative for high school anatomy.\nMusculoskeletal System Student Workbook\nHands-on workbook with diagrams, labeling, and analysis of the musculoskeletal system. Reinforces lesson plan concepts through active learning. For grade 12 students.\nNervous System Lesson Plan (Grade 12)\nExplores human nervous system anatomy and function without animal dissection. Uses diagrams, models, and case studies. Appropriate for high school biology courses.\nNervous System Student Workbook\nInteractive exercises and activities for nervous system learning. Includes labeling, diagrams, and critical thinking questions. Supports the grade 12 lesson plan.\nReproductive System Lesson Plan (Grade 12)\nTeaches human reproductive anatomy and physiology ethically. Uses diagrams, models, and age-appropriate discussions. Designed for high school biology.\nReproductive System Student Workbook\nWorksheets and activities for reproductive system education. Includes labeling, matching, and analysis exercises. Companion to the grade 12 lesson plan.\nRespiratory System Lesson Plan (Grade 12)\nCovers human respiratory anatomy and function through non-animal methods. Includes lung structure, breathing mechanics, and gas exchange. For high school biology.\nRespiratory System Student Workbook\nInteractive workbook with diagrams, labeling, and exercises for respiratory system. Reinforces lesson plan concepts through hands-on learning. For grade 12 students.\nUrinary System Lesson Plan (Grade 12)\nTeaches urinary system anatomy and kidney function ethically. Uses diagrams, models, and virtual resources. Appropriate for high school biology.\nUrinary System Student Workbook\nCompanion workbook with activities, labeling, and analysis for urinary system. Supports the lesson plan with non-animal learning methods. For grade 12 students.\nResearch Profiles # ResearchGate Semantic Scholar Academia.edu References # [1] Elisabeth Ormandy - ResearchGate Profile\n[2] Animal Research, Accountability, Openness and Public Engagement: Report from an International Expert Forum - Sage Journals\n[3] Stakeholder Views on the Creation and Use of Genetically-Engineered Animals in Research - ResearchGate\n[4] Elisabeth Ormandy - Animals In Science Policy Institute - YouTube\n[5] Protecting Canada\u0026rsquo;s Lab Animals: The Need for Legislation - ResearchGate\n[6] Elisabeth Helen Ormandy - Semantic Scholar\n","date":"2026-06-23","externalUrl":null,"permalink":"/network/scientists/elisabeth-ormandy/","section":"Network","summary":"Ethics advocate advancing non-animal research methods.","title":"Elisabeth Ormandy","type":"network"},{"content":"","date":"2026-06-23","externalUrl":null,"permalink":"/tags/ethics/","section":"Tags","summary":"","title":"Ethics","type":"tags"},{"content":"","date":"2026-06-23","externalUrl":null,"permalink":"/tags/nam/","section":"Tags","summary":"","title":"Nam","type":"tags"},{"content":"","date":"2026-06-23","externalUrl":null,"permalink":"/tags/non-animal-research/","section":"Tags","summary":"","title":"Non-Animal Research","type":"tags"},{"content":" Progressive Non-Animal Research Society # PNARS advances New Approach Methodologies (NAM) to replace animal-based research with human-relevant science. Our non-profit is a resource hub for innovative and effective alternatives.\nBrain On A Chip Cardiac Organoid Showing Muscle Fibers AI Driven Drug Discovery Liver In Silico Digital Twin CRISPR Cas9 Enzyme Gene Editing In Action Handheld Lab-on-a-Chip Diagnostic Device Cells Engineered To Perform Specific Functions Bioprinting of 3D Biological Structures Genetic Profiling For Personalized Medicine Images are generated by Mistral from actual scientific conceptualizations.\nLike histological staining, visuals are enhanced to maximize structural clarity and slide consistency. ","date":"2026-06-23","externalUrl":null,"permalink":"/","section":"Progressive Non-Animal Research Society","summary":"","title":"Progressive Non-Animal Research Society","type":"page"},{"content":"","date":"2026-06-23","externalUrl":null,"permalink":"/tags/science-policy/","section":"Tags","summary":"","title":"Science Policy","type":"tags"},{"content":"","date":"2026-06-23","externalUrl":null,"permalink":"/tags/","section":"Tags","summary":"","title":"Tags","type":"tags"},{"content":"","date":"2026-06-23","externalUrl":null,"permalink":"/tags/three-rs/","section":"Tags","summary":"","title":"Three Rs","type":"tags"},{"content":"","date":"2026-06-15","externalUrl":null,"permalink":"/tags/3d-tissue-models/","section":"Tags","summary":"","title":"3d-Tissue-Models","type":"tags"},{"content":"","date":"2026-06-15","externalUrl":null,"permalink":"/tags/animal-free-research/","section":"Tags","summary":"","title":"Animal-Free-Research","type":"tags"},{"content":"","date":"2026-06-15","externalUrl":null,"permalink":"/tags/computational-tools/","section":"Tags","summary":"","title":"Computational-Tools","type":"tags"},{"content":"","date":"2026-06-15","externalUrl":null,"permalink":"/tags/human-based-research/","section":"Tags","summary":"","title":"Human-Based-Research","type":"tags"},{"content":"","date":"2026-06-15","externalUrl":null,"permalink":"/tags/new-approach-methodologies/","section":"Tags","summary":"","title":"New-Approach-Methodologies","type":"tags"},{"content":"","date":"2026-06-15","externalUrl":null,"permalink":"/tags/nih/","section":"Tags","summary":"","title":"Nih","type":"tags"},{"content":"NIH has launched the Office of Research Innovation, Validation, and Application (ORIVA) to coordinate efforts in developing, validating, and scaling New Approach Methodologies (NAMs), including 3D human tissue models and computational tools, to better reflect human biology and reduce animal use.\nKey Highlights # ORIVA will coordinate NIH-wide efforts to advance human-based research technologies. The office aims to develop, validate, and scale NAMs, such as 3D human tissue models and computational tools. ORIVA will serve as a hub for interagency coordination and regulatory translation. The initiative seeks to reduce or replace animal use where appropriate, improving research replicability and translatability. Statements # Complex computational models, 3D human tissue models, and other emerging technologies have improved by leaps and bounds in recent years and may hold the key to a more effective research enterprise. — Jay Bhattacharya, M.D., Ph.D., NIH Director\nNIH is committed to accelerating innovation and transparently assessing where animal use can be reduced or eliminated by transitioning to NAMs. — Nicole Kleinstreuer, Ph.D., NIH Deputy Director for Program Coordination, Planning, and Strategic Initiatives\nAbout the Organizations # National Institutes of Health (NIH) is the nation\u0026rsquo;s medical research agency, comprising 27 Institutes and Centers, and is the primary federal agency conducting and supporting basic, clinical, and translational medical research.\nLearn More # NIH Launches New Office to Advance Human-Based Research and Reduce Animal Use\n","date":"2026-06-15","externalUrl":null,"permalink":"/news/nih-new-office-for-nam/","section":"News","summary":"NIH establishes ORIVA to accelerate human-based research and reduce animal use.","title":"NIH Launches New Office to Advance Human-Based Research and Reduce Animal Use","type":"news"},{"content":"","date":"2026-06-15","externalUrl":null,"permalink":"/tags/oriva/","section":"Tags","summary":"","title":"Oriva","type":"tags"},{"content":"","date":"2026-06-15","externalUrl":null,"permalink":"/categories/sciences/","section":"Categories","summary":"","title":"Sciences","type":"categories"},{"content":"","date":"2026-06-15","externalUrl":null,"permalink":"/categories/standards/","section":"Categories","summary":"","title":"Standards","type":"categories"},{"content":"","date":"2026-06-15","externalUrl":null,"permalink":"/categories/technologies/","section":"Categories","summary":"","title":"Technologies","type":"categories"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/tags/ai/","section":"Tags","summary":"","title":"Ai","type":"tags"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/tags/analysis/","section":"Tags","summary":"","title":"Analysis","type":"tags"},{"content":" Animal Research vs NAM Expenditures # Animal Research expenditures far exceed NAM\nCredit: Gemini This is a comprehensive and thoroughly referenced report on severe expenditures required for animal research compared to NAM. It shows a multi-scalar comparative economic analysis of traditional in vivo research vs new approach methodologies in biopharmaceutical R\u0026amp;D.\n(All dollar values are in USD as of 2026-06 and from the references cited. Be aware that financial numbers may vary dependent on source, methodology, and point-of-time for the analysis.)\nKey points covered in the analysis:\nThe 95% Preclinical Bottleneck: Traditional R\u0026amp;D workflows fail at the very start, with 95% of discovered drugs thrown out during slow, animal-based laboratory tests before ever reaching a human subject. The 92% Clinical Translation Gap: Out of the tiny fraction of candidate drugs that survive animal screens, up to 92% fail immediately in human clinical trials because animal-based modeling cannot accurately replicate human biological responses. The Attrition-Loaded Cost Range ($1.9B to $2.6B): Running a pipeline crippled by these compounding failures drives the total estimated cost of a single approved drug to a range between $1.9 billion and $2.6 billion, depending on the tracking source and methodology used. Predictive Superiority and Precision: Modern alternatives like human organ-chips simulate actual patient biology with remarkable accuracy, correctly identifying severe toxicities and efficacy liabilities that legacy animal methods completely miss. Sublinear Data Scaling: Unlike physical testing models that require a linear increase in animal procurement, breeding, and space, automated systems and virtual computing platforms process millions of compounds at a sublinear, fractional cost. Significant Lifecycle Savings: Transitioning from volatile animal models to automated cleanrooms secures up to 26% system-wide R\u0026amp;D cost reductions, delivering over $42 million in direct cumulative savings per facility line over a 15-year developmental horizon. 1. Executive Summary # The biopharmaceutical research and development sector has reached an unsustainable economic threshold. The fully capitalized, attrition-loaded cost required to progress a single drug from initial discovery to regulatory approval has escalated to an average ranging between $1.9 billion and $2.6 billion, depending on the tracking source and methodology used and takes between 10-15 years 1 2 3. This financial burden is fundamentally driven by a late-stage translation gap in clinical trials, where up to 92% of therapeutics validated as safe and effective in animal models fail during human clinical trials due to unrecognized toxicities or a lack of efficacy 2. Preclinical attrition rates hover around 95% before candidate drugs ever reach a human subject3. Subsequent phase progressions (I,II,III) are dismally inefficient as well3. This systemic reliance on live biology creates a highly capital-intensive and slow-velocity research paradigm.\nThis economic analysis evaluates the transition from traditional animal-based testing to New Approach Methodologies (NAM), including Organ-on-a-Chip (OOC) systems, high-throughput screening (HTS), human organoids, in silico modeling, and artificial intelligence-driven drug discovery. Expert consensus models indicate that the systemic adoption of NAM yields an average total R\u0026amp;D cost reduction of 10% to 26% (with a median savings of 19%), translating to absolute capitalized savings between $276 million and $706 million per drug4.\nThe legal enabling of these technologies by the FDA Modernization Act 2.0 has initiated a critical market inflection point where the superior human-predictive validity, compressed cycle times, and reduced physical footprint of NAM render legacy vivarium-based paradigms economically obsolete5.\nThe global animal model market represents a compounding financial liability for the industry, valued at $2.93 billion in 2025 and projected to balloon to $6.6 billion by 20356. To mitigate exposure to these escalating legacy costs, the economic case for an operational transition to NAM establishes an alternative framework resting on three multi-scalar pillars:\nSublinear Marginal Cost Scaling: Traditional animal models scale linearly or at an increasing marginal cost, where every additional data point mandates the physical procurement, housing, and disposal of an animal cohort. Conversely, computational in silico screening and automated HTS platforms operate on a sublinear cost curve, driving the marginal cost per data point down to fractions of a cent and enabling massive, parallelized chemical library screens at unprecedented velocity. Superior Human-Predictive Validity: While historical animal testing models exhibit a poor 30% to 50% concordance rate for human toxicity endpoints7, microfluidic human Organ-Chips achieve up to 87% sensitivity and 100% specificity in predicting critical human toxicities, such as drug-induced liver injury (DILI)8. De-risking compounds prior to clinical entry fundamentally alters the clinical trial success curve. Timeline Compression and Maximized NPV: Transitioning from the biological constraints of animal breeding and gestation to automated assays and AI candidate screening compresses preclinical discovery timelines by 12 to 24 months. For a blockbuster therapeutic, this accelerated time-to-market extends effective patent exclusivity, generating between $500 million and $1 billion in incremental Net Present Value (NPV)9. This report outlines the multi-scalar economic parameters of this transition, defining a risk-mitigated strategy for phased implementation suitable for senior leadership decision-making.\n2. Micro-Economic Analysis: Operational Efficiency at the Lab Bench # The operational architecture of biopharmaceutical R\u0026amp;D is undergoing a fundamental restructuring at the individual laboratory scale. Traditional preclinical workflows are structurally bound by live biological systems, which enforce rigid, linear cost-scaling models and high operational headcount requirements. Transitioning to a NAM-based paradigm shifts the laboratory benchmark from resource-intensive manual husbandry to highly automated, parallelized, and data-dense platforms.\nThis micro-economic evaluation deconstructs the direct inputs, infrastructure overheads, and labor distributions that define the day-to-day cost of data generation. By analyzing these variables, senior leadership can assess the granular efficiency gains realized when substituting traditional in vivo models with highly scalable, non-animal methodologies.\n2.1 Direct Consumables \u0026amp; Procurement # The direct procurement of biological models and technological inputs reveals a stark divergence in cost-efficiency and scaling performance. Legacy preclinical research relies on animal cohorts that face escalating cost exposure and high market volatility driven by geopolitical tensions, supply chain blockages, and shifting export policies. For instance, a routine pharmaceutical toxicology evaluation utilizing non-human primates (NHPs), such as macaque monkeys, frequently subjects sponsors to procurement and maintenance liabilities reaching up to $50,000 per animal10. Standard small animal pipelines rely heavily on rodent configurations; however, while a basic wild-type mouse carries a modest upfront purchase price, specialized transgenic, humanized, or immunocompromised murine cohorts engineered for specific human disease translation can scale past thousands of dollars per breeding cohort11. These procurement metrics capture only the initial entry threshold, as live biological systems demand immediate, continuous operational funding. When accounting for mandatory animal facility expenditures - encompassing daily specialized husbandry, strict dietary feed regimes, climate-controlled vivarium operations, and veterinary intervention - maintaining even a baseline preclinical mouse model regularly adds substantial recurring costs over the life of a standard research protocol12.\nIn contrast, the consumables and microfluidic components of NAM platforms exhibit predictable price normalization driven by industrialized manufacturing processes. While highly specialized organ-on-a-chip models, such as mature microfluidic liver models, can require initial custom engineering and design investments between $20,000 and $150,000 depending on integrated biosensors and custom biomaterial structures, standardized commercial microfluidic chips are highly accessible. Standard single-layer polydimethylsiloxane (PDMS) and glass chips are available at $60 per chip in quantities of 10013, while standardized microfluidic cross-flow membrane chips are $100, and channel-interaction chips are $45 (per unit). High-fidelity tissue packs, such as barrier organ-on-a-chip setups, are commercially packaged in tens for $4,45014. (See reference for various configurations.)\nOn an ongoing operational basis, high-fidelity primary cell lines and iPSC-derived cells carry initial vial costs of $500 - $5,000, yet they scale efficiently into standardized microfluidic setups and organoid batches costing just $50 - $150 per run while generating hundreds of human-relevant data points15. Once acquired, these lines scale efficiently into parallelized microfluidic setups and automated, localized organoid assay cultures at a minimal downstream fraction of their acquisition costs while generating hundreds of human-relevant data points.\nThe operational cost-efficiency of this transition is demonstrated by comparative screening programs. In a target validation and toxicity evaluation program, screening 35 lipid nanoparticles (LNPs) using human Liver-Chips was achieved for $325,000 over 18 months, whereas the equivalent screening program using traditional in vivo NHP models would exceed $5,000,000 and require over 60 months to execute. This represents a 15-fold reduction in direct capital outlay and a 70% compression in operational cycle time.\nFurthermore, computational in silico drug discovery and virtual screening completely leverage cloud-integrated storage and elastic compute engines. By transitioning from legacy on-premise high-performance computing (HPC) hardware to on-demand cloud services, laboratories minimize fixed capital assets. Compute nodes scale dynamically during peak screening campaigns and automatically de-provision resources upon completion, ensuring sponsors pay only for the compute cycles actually consumed16. According to documented architectural benchmarks for high-throughput virtual screening platforms, these workloads scale with perfect parallelized efficiency across elastic batch clusters17. By utilizing fault-tolerant configurations - such as cloud spot instances - sponsors cut standard cloud compute expenses by up to 70% to 90%, enabling the exhaustive screening of millions to billions of compounds for a fraction of traditional IT overheads while completely bypassing the millions of dollars required for physical compound library synthesis and legacy wet-lab animal assays.\nTraditionally, maintaining an in-house HPC environment capable of processing vast chemical libraries requires substantial localized capital expenditure, with specialized hardware clusters demanding initial outlays between $65,000 and $650,000 alongside recurring annual support and maintenance overheads reaching up to $400,00018. By transitioning these analytical workloads to elastic cloud-integrated environments, laboratories minimize these fixed capital assets down to $018. Empirical benchmarks for ultra-large structure-based screens demonstrate that screening an extensive library of 4.5 billion molecules can be executed on cloud infrastructure for a predictable operational bill of approximately $25,000 - averaging just $30 to $40 per million compounds processed18. This fluid, utility-based billing allows teams to evaluate immense regions of chemical space within days, bypassing the multi-month timelines inherently required to physically screen large compound libraries or execute legacy in vivo protocols. An example of an architecture capable of orchestrating these ultra-large virtual screens with perfect scaling behavior across heterogeneous Linux clusters and cloud environments is the open-source platform VirtualFlow19.\nProcurement Category Legacy In Vivo Model Details NAM Alternative Platform Details Unit Cost Range (USD) Non-Human Primate (NHP) Single NHP procurement and maintenance liabilities10 Standardized human multi-organ-on-chip models featuring integrated biosensors15 Up to $50,000 per animal vs. $20,000 - $150,000 custom setup Rodent Cohort (Murine) Transgenic, humanized, or immunocompromised breeding cohorts11 Human iPSC-derived organoid culture runs or automated assay setups15 Past thousands per cohort vs. $50 - $150 per organoid run Microfluidic Consumable N/A (Legacy biological testing model) uFluidix single-layer PDMS or glass chips13 $60 per chip (ordered in quantities of 100) Specialized Chips N/A (Legacy biological testing model) Standardized cross-flow membrane or channel-interaction chips14 $100 per membrane chip / $45 per channel chip High-Fidelity Tissue Pack N/A (Legacy biological testing model) MEPSGEN MEPS-TBC barrier organ-on-a-chip packs14 $4,450 per commercial pack of 10 HPC Compute Credits In-house high-performance hardware clusters ($65,000 - $650,000 upfront)18 Elastic cloud batch instances running distributed docking software1619 $65,000 - $650,000 fixed asset cost vs. $30 - $40 per million compounds docked 2.2 Human Capital \u0026amp; Labor # Transitioning from animal models to NAM shifts the human capital mix from low-complexity manual labor to highly specialized technical personnel. Traditional vivarium operations are highly headcount-intensive, demanding a large volume of animal care technicians, facility managers, and specialized veterinary support staff to manage daily husbandry cycles. According to the U.S. Bureau of Labor Statistics, the baseline median compensation for laboratory animal caretakers and veterinary assistants is around $40,000 per year20, though specialized personnel embedded directly within pharmaceutical and medicine manufacturing segments can earn considerably more. When managing complex or highly sensitive preclinical testing cohorts, highly experienced in vivo preclinical research specialists and senior veterinary technicians command billing rates ranging from $26 to $35 per hour, representing an annual salary baseline of $54,000 to $72,000. Managing a mid-sized facility housing a fleet of 10,000 animal cages routinely forces sponsors to maintain a persistent headcount of 15 to 25 full-time animal care staff, creating an inflexible, escalating operational salary floor.\nConversely, the deployment of NAM, automation, and computational biology requires a lean, specialized workforce composed of bioinformaticians, data scientists, hardware bioengineers, and stem cell culture specialists. Within the biopharmaceutical and biotechnology industry sectors, entry-level computational analysts command starting salaries of $75,00021. For mid-level professionals and applied data science specialists, median salaries scale rapidly to $130,000-$185,000. At the pinnacle of the technical architecture, senior AI data science leads, principal scientists, and chief data scientists command premier industry compensation packages often over $200,000 annually22.\nAlthough the wage premiums and individual compensation metrics for computational and advanced bioengineering personnel are significantly higher than legacy animal handlers, the total operational labor density is greatly reduced. Automated liquid handling systems, high-throughput imaging, and parallelized cloud computing workflows allow a small team of data scientists and bioengineers to generate, process, and analyze datasets containing millions of independent data points. This operational model vastly outperforms the data output of a traditional vivarium staff on a per-capita basis, driving the long-term human capital expenditure per data point down by a factor of 10-fold to 100-fold.\nLabor Classification Legacy In Vivo Operations (Annual Cost Baseline) NAM Alternative Operations (Annual Cost Baseline) Labor Density per 10,000 Compounds Entry Level / Technical Support Animal Care Technician I/II:\nAround $40,00020 Stem Cell Culture Specialist / Junior Computational Analyst:\nStarting at $75,00021 High (In vivo manual dosing and cage-cleaning cycles) vs. Low (Automated microfluidic workflows) Mid-Level Professional Experienced Preclinical Specialist / Senior Vet Tech:\n$54,000 - $72,000 Applied Data Science Specialist:\n$130,000 - $185,000 High (Daily manual tracking and physiological monitoring) vs. Low (Algorithmic simulation and data curation) Senior Management / Principal Vivarium Director / Laboratory Pathologist:\n$90,000 - $135,000 Senior AI Research Lead / Chief Data Scientist:\nOver $200,00022 Extreme (Species-specific biological oversight and regulatory protocols) vs. Very Low (Scalable digital pipeline designs) 2.3 Facility Operations \u0026amp; OPEX Boundaries # Operational expenditures (OPEX) are heavily dictated by the aggressive environmental and biosecurity controls required to maintain live animal cohorts. Small animal laboratories demand intensive heating, ventilation, and air conditioning (HVAC) operations to mitigate localized odors, heavy heat loads, and continuous ammonia buildup. This requires continuous air exchange rates of 10 to 15 air changes per hour (ACH) for rodent housing, scaling up to 15 to 20 ACH for specialized quarantine, barrier, surgery, and necropsy environments23. Vivariums must operate under continuous negative pressure configurations to prevent allergen and pathogen escape, while maintaining strict relative humidity bands between 30% and 70% and temperature thresholds between 18°C and 26°C23.\nBecause laboratories consume three to five times more energy than standard commercial offices, and over 60% of this energy is consumed entirely by HVAC ventilation and exhaust systems, the mechanical utility cost of a vivarium represents a massive, recurring OPEX liability24. These costs are exacerbated by the maintenance of individually ventilated caging (IVC) systems, which require upfront capital investments of $15,000 to $40,000 per rack, plus ongoing costs of $500 to $1,000 annually for HEPA filter replacements and specialized high-throughput cage washing and autoclave sterilization equipment25.\nIn contrast, automated cleanrooms and microfluidic testing environments utilize modular or mobile cleanroom architectures26. These systems integrate directly with standard building utilities and can be rapidly reconfigured26. They do not require the continuous bio-effluent scrubbers, ammonia exhausting, or intensive biological waste sanitation of vivariums, resulting in significantly lower baseline energy consumption and a highly optimized utility cost profile.\nOperational Cost Driver (Per 1,000 Cages / Units) Legacy Static Caging Operations Legacy IVC System Operations NAM Automated Cleanroom Platform Upfront Unit Investment $100 - $200 per cage;\n$2,000 - $5,000 per rack25 $300 - $500 per cage;\n$15,000 - $40,000 per rack25 Included in modular panel CAPEX fit-out26 Cage Change \u0026amp; Cleaning Cycle 7 - 10 days frequency25 14 - 21 days frequency25 N/A (Automated microfluidic perfusion) Annual Support Labor Cost $35,000 - $50,00025 $20,000 - $30,00025 $5,000 - $10,000\n(Instrument calibration) Annual Electrical Cost $0 (Passive ventilation)25 $300 - $600 per rack25 Standard utility panel draw26 Annual Consumable Filters $025 $500 - $1,000 per rack25 HEPA/ULPA cleanroom ceiling panels25 Waste Disposal Overhead High (Hazardous bedding,\ncarcass waste) High (Hazardous bedding,\ncarcass waste) Low (Aqueous media waste,\nrecyclable plastics) 2.4 Throughput \u0026amp; Scalability # The comparative throughput of preclinical models establishes the ultimate cost per data point across the R\u0026amp;D lifecycle. Traditional animal studies are physically constrained by fixed biological cycle times, including breeding, gestation, maturation, and mandatory dosing timelines, making them completely unfeasible for screening large chemical libraries in early-stage drug discovery. These constraints enforce a linear cost architecture where scaling an experiment requires a proportional increase in physical assets, animal numbers, and infrastructure tracking.\nTransitioning to high-throughput screening (HTS) platforms utilizing 384-well or 1,536-well microplate formats drastically reduces reagent consumption, lowers the physical cost per data point, and enables parallelized evaluation of multiple biological conditions within a single automated experiment. When combined with automated liquid handling and human cell-derived organoid assays, laboratories can evaluate thousands of compounds simultaneously, creating a sublinear cost curve where data density outpaces resource consumption27.\nAt the furthest end of the scalability spectrum, in silico virtual screening and computational chemistry leverage cloud environments to partition highly complex bioactivity and target-binding simulations across distributed nodes17. This architecture allows the virtual screening of millions to billions of molecules within a fraction of the time and cost required for any physical assay. The marginal cost per data point drops near zero once computational models are trained—averaging just a fraction of a cent per molecule processed18 - providing an exponential scaling advantage that completely decouples data generation from the physical limits of live biology.\n3. Macro-Economic Analysis: Systemic Lifecycles \u0026amp; Strategic Risk # While micro-economic variables define the immediate efficiency gains realized at the individual laboratory bench, the macro-economic dimensions of the NAM transition determine long-term corporate enterprise value, systemic capital allocation, and risk mitigation across the entire drug development lifecycle. The traditional biopharmaceutical business model has encountered a severe structural bottleneck where multi-decade investments in massive physical infrastructures are yielding diminishing returns, primarily due to the systemic failure of legacy preclinical models to translate effectively into human clinical outcomes.\nThis macro-economic evaluation shifts focus from day-to-day operational inputs to broad, board-level strategic parameters. By analyzing long-term capital asset depreciation, the multi-billion-dollar cost of clinical trial attrition, time-to-market opportunity costs, and post-market product liabilities, senior leadership can define a risk-mitigated framework for navigating this structural industry inflection point.\n3.1 Capital Expenditure (CAPEX) \u0026amp; Infrastructure Depreciation # The deployment of traditional preclinical testing capabilities demands monumental, upfront capital allocation to build specialized fixed physical spaces. Constructing a standard, regulated vivarium requires specialized structural engineering, embedded concrete fluid-barrier containment walls, heavy specialized plumbing systems, and massive, dedicated HVAC mechanical plant configurations. Industry development metrics show that building out traditional new construction research laboratory spaces demands a capital expenditure (CAPEX) premium that routinely exceeds $1,000 per square foot depending on the level of biosecurity containment and mechanical net-to-gross space efficiency required28. These facilities represent rigid, single-purpose capital infrastructure; if a research direction pivots or an animal testing program is downscaled, these specialized architectural investments cannot be repurposed without incurring devastating demolition and retrofitting costs. Consequently, under corporate accounting models, these physical assets undergo long-term, slow straight-line depreciation schedules over 15 to 39 years, locking up millions in non-liquid, depreciating capital asset classes on the enterprise balance sheet.\nConversely, the physical footprint required to execute NAM workflows relies heavily on flexible modular cleanrooms, scalable automated instrumentation, and cloud-integrated technical platforms. Instead of embedding fixed concrete infrastructure, contemporary NAM microfluidic and cell-culture environments utilize modular cleanroom wall systems and pre-fabricated architectural panels. Industrial cleanroom benchmarks show that deploying a basic assembly configuration runs between $100 and $300 per square foot, whereas building out a highly sterile, intermediate pharmaceutical and biotechnology grade cleanroom testing environment (ISO Class 5 - 6) scales to a baseline of $350 to $650 per square foot29. Because these setups feature reconfigurable layouts, integrated Fan Filter Units (FFUs), and specialized vaporized hydrogen peroxide (VHP) resistant surfaces, they can be rapidly assembled, expanded, or entirely relocated within weeks to meet changing operational parameters.\nFurthermore, because the core instruments of NAM (such as automated liquid handling robots, high-content imaging platforms, and computational server clusters) are discrete, non-structural equipment assets, they qualify for highly advantageous accelerated depreciation tax accounting methods, such as Section 179 or Modified Accelerated Cost Recovery System (MACRS) frameworks. This allows biopharmaceutical enterprises to write off up to 100% of the equipment capital cost within the first one to five years of operation, freeing up vital cash flows, minimizing immediate corporate tax liabilities, and preserving agile capital structures that can quickly adapt to changing market conditions.\nInfrastructure Component Legacy In Vivo Vivarium Model NAM Alternative Platform CAPEX \u0026amp; Accounting Performance Construction Premium Exceeds $1,000 per sq. ft.28 $350 - $650 per sq. ft. (ISO 5 - 6 Pharma Grade)29 35% to 65% reduction in upfront build-out costs Architectural Flexibility Rigid, single-purpose fixed concrete walls Modular, reconfigurable pre-fabricated panels High salvage and reuse capacity vs. total loss demolition Depreciation Schedule Straight-line asset class (15 - 39 years) Accelerated equipment MACRS (1 - 5 years) Accelerated tax write-offs, maximizing early cash liquidity 3.2 Clinical Trial Attrition Costs \u0026amp; Translatability Return on Investment (ROI) # The primary macro-economic risk in contemporary pharmaceutical development is the high failure rate of drug candidates during human clinical trials. Approximately 90% of all therapeutic molecules that successfully clear preclinical animal testing blocks fail to achieve regulatory approval during clinical evaluation phases. This gap between bench research and clinical translation is known as the \u0026ldquo;valley of death\u0026rdquo;30. This systemic attrition rate means that out of every ten drug candidates advanced into human testing pipelines based on successful animal data, nine will collapse during clinical development. The financial consequences of these late-stage failures are severe; capital allocation models indicate that the total out-of-pocket and capitalized cost to bring a single new molecular entity to market averages between $1-3 billion, a metric driven directly by the need to absorb the expenses of these failed pipelines31.\nAnalyzing the underlying drivers of this attrition reveals that approximately 55% of clinical failures are caused by a lack of efficacy, where the drug fails to replicate the therapeutic mechanisms observed in preclinical animal models when tested in human patients30. An additional 28% of drug failures are driven by clinical safety and toxicity issues, where unforeseen toxic mechanisms emerge in human physiology that were completely undetected by standard animal cohorts30. This data highlights a fundamental macro-economic translatability gap: legacy animal testing methodologies regularly provide false positives by indicating safety and efficacy profiles that fail to translate to human biology, while also generating false negatives by inadvertently ruling out viable human therapeutics due to species-specific toxicities.\nIntegrating NAM directly addresses this translatability gap by shifting the testing paradigm to high-fidelity human biological systems and advanced in silico modeling. By utilizing human induced pluripotent stem cells (iPSCs), organs-on-chips, and computational biology networks, sponsors can identify efficacy deficits and toxic markers before incurring the massive costs of clinical trials. Economic sensitivity models show that improving the predictive accuracy of preclinical phases to eliminate just 10% of failed drug candidates prior to entering Phase I clinical trials can save an enterprise $100 million to $242 million per pipeline, significantly optimizing the return on investment (ROI) of biopharmaceutical R\u0026amp;D.\nDevelopment Metric Legacy Preclinical Model Baseline NAM Integrated Alternative Platform Strategic Enterprise Impact Preclinical Base Profile Non-human biology; high false-positive rates High-fidelity human iPSC and in silico platforms Eliminates species-specific biological translation errors Clinical Attrition Rate ~90% failure rate across human phases30 High predictive accuracy via human cells Prevents capital expenditure on non-viable clinical lines Primary Failure Vectors 55% Efficacy lack; 28% Human Toxicity30 Early identification of human liabilities Identifies toxic vectors prior to clinical phase exposure Capitalized Cost per Asset $1.3 Billion - $2.8 Billion average tracking31 Sublinear cost curve; lower waste accumulation Drastically lowers capitalized clinical sunk costs 3.3 Operational Runway \u0026amp; Time-to-Market Opportunity Costs # The macro-economic value of a drug pipeline is heavily dependent on the velocity of its development cycle. Traditional early-stage drug R\u0026amp;D introduces massive temporal bottlenecks into the enterprise timeline due to rigid biological constraints. Because the traditional development and regulatory approval cycle consumes approximately 10 to 15 years from initial discovery to final regulatory clearance, moving an asset through early discovery screens and standard preclinical testing blocks routines a multi-year development runway before human clinical trials can even begin32. This slow operational pacing creates an extended cash-burn runway that forms a significant portion of the total $1 to $2 billion capitalized cost required to bring a single asset to market, where pharmaceutical sponsors must continuously sink operational capital into infrastructure maintenance, compliance overheads, and manual labor long before human clinical trials can commence.\nTransitioning to advanced NAM alternative platforms and automated computational chemistry frameworks compresses this early-stage development bottleneck. Because computational in silico virtual screens can evaluate millions of molecular interactions within days, and parallelized human organ-on-a-chip setups yield high-density, human-relevant data points within weeks, the timeline required to select and validate a development candidate drops significantly. Evaluated case studies document that advanced automated discovery platforms can progress a compound from initial target identification completely through candidate screening and into advanced testing phases in as little as 18 months. This represents a dramatic contraction in fixed operational cash burn, with specific automated virtual target screenings costing as little as $150,000 to execute32.\nThe primary commercial impact of this compressed timeline is the preservation of patent exclusivity windows. A standard pharmaceutical patent grants 20 years of market exclusivity, but due to the multi-year timeline consumed by legacy development and regulatory cycles, a drug candidate often hits the market with a severely truncated window of protected commercial runway32. By accelerating the early discovery and preclinical phase via NAM integration, an enterprise effectively shifts the market launch date forward within the fixed 20-year patent window, securing valuable months of peak-revenue commercial sales prior to encountering the generic market erosion or \u0026ldquo;patent cliffs\u0026rdquo; mapped out in lifecycle cash-flow valuations(see figure 2)33. For a blockbuster therapeutic reaching its maximum commercial potential, this temporal optimization delivers a direct opportunity cost recovery that completely redefines the asset\u0026rsquo;s macro-economic value.\nTemporal \u0026amp; Financial Metric Traditional Early R\u0026amp;D Baseline NAM Integrated Alternative Platform Enterprise Opportunity Cost Impact Early Development Duration Multi-year cumulative timeline Compressed to as little as 18 months (Case studies)32 Significant temporal compression of early R\u0026amp;D runway Total Development Cycle Approximately 10 - 15 years total to approval32 Accelerated transition to human clinical phases Reduces structural time-to-market overheads Capitalized Cost Profile $1 - $2 Billion total capitalized asset track Platform runs executing for as little as $150,000 Drastically lowers capital barriers for early candidate generation Patent Window Preservation Truncated market exclusivity runway32 Preserves early market entry velocity Secures critical early market entry prior to back-end generic erosion33 3.4 Post-Market Liability \u0026amp; Regulatory Compliance Risk Management # The final macro-economic vector governing the transition to New Approach Methodologies is the mitigation of post-market enterprise liability and adherence to changing cross-border regulatory frameworks. Relying exclusively on legacy animal test programs introduces severe financial risks when compounds advance to the global commercial market. Because traditional in vivo models regularly fail to identify human-specific metabolic vulnerabilities, toxic liabilities can remain completely latent until a therapeutic is deployed across large, heterogeneous human populations.\nThe primary physical manifestations of this translatability gap are drug-induced liver injury (DILI) and acute cardiotoxicity, which represent the leading causes of late-stage pharmaceutical attrition, boxed safety warnings, and catastrophic post-market product withdrawals34. Database records indicate that liver failure through Drug-Induced Liver Injury (DILI) alone is responsible for approximately 30% of all post-marketing pharmaceutical withdrawals34. When an approved drug is forced off the market due to these unforeseen human toxicities, the sponsoring enterprise faces immediate asset write-offs, massive class-action litigation, and severe brand equity erosion. Capital distribution models demonstrate that a single post-market withdrawal can inflict a direct enterprise value loss ranging from hundreds of millions to billions of dollars in sudden legal liabilities and vanished market capitalization.\nIntegrating human-predictive NAM architectures - specifically microphysiological systems (MPS), multi-lineage human organoids, and computational toxicogenomics - directly shields corporate assets from these tail-risk liabilities. By deploying highly parallelized human tissue interfaces during early preclinical safety assessments, developers can map complex cellular responses, identify cell-specific toxicity profiles, and detect pro-arrhythmic or hepatotoxic mechanisms before exposed human cohorts are reached. This high-fidelity screening shifts compliance risk management from reactive post-market mitigation to proactive structural prevention.\nConcurrently, global regulatory architectures are undergoing an unprecedented paradigm shift, systematically removing legacy testing requirements in favor of advanced human-relevant methodologies. Frameworks such as the FDA Modernization Act in the United States, along with updated European Medicines Agency (EMA) and Health Canada guidance directives, have formally decoupled the regulatory validation matrix from mandatory animal data pools35. Following these legislative mandates, the FDA released its structured roadmap to actively replace animal testing in preclinical safety studies with scientifically validated alternative frameworks35. Under this contemporary landscape, biopharmaceutical enterprises that delay NAM integration face severe operational compliance risks, including protracted regulatory review cycles, multi-month clinical hold directives, and restricted access to key global jurisdictions that prioritize human-predictive safety validation.\nOperational Risk Vector Legacy In Vivo Preclinical Baseline NAM Integrated Alternative Platform Corporate Protection Impact Toxicity Detection Species-specific biological profiles; latent human toxicities remain hidden High-fidelity human microphysiological profiling (DILI/Cardiotoxicity screening)34 Proactively eliminates severe post-market product withdrawal liabilities Regulatory Compliance Rigid reliance on legacy data pools facing systemic global obsolescence Aligned with FDA Modernization Act and international EMA validation directives35 Prevents protracted review cycles, clinical holds, and market exclusion Capital Protection High exposure to late-stage asset write-offs and multi-billion dollar class actions Structural prevention via early human-relevant safety filtering Protects long-term enterprise market capitalization and brand equity 4. Comparative Case Studies and Empirical Data Proof-Points # The theoretical and macroeconomic frameworks governing the transition to New Approach Methodologies (NAM) are fully validated by the empirical data emerging from pioneering biopharmaceutical enterprises and international research consortia. Moving beyond exploratory pilot frameworks, industrialized workflows utilizing advanced organ-on-a-chip architectures, automated high-throughput human cellular assays, and deep-learning computational biology pipelines are now generating audited, reproducible operational metrics. This chapter evaluates the real-world deployment of these technologies, contrasting legacy in vivo timelines and cost structures directly against automated human-predictive alternatives.\nBy analyzing documented case studies across target validation, lead optimization, and preclinical safety profiles, this section establishes an empirical baseline for the efficiency gains detailed in previous chapters. These data proof-points shift the operational discussion from speculative innovation to measurable corporate execution, providing senior leadership with an audited blueprint for navigating the structural inflection point of modern pharmaceutical R\u0026amp;D.\n4.1 High-Throughput Screening (HTS) and Microfluidic Efficiency Gains # The practical transition from traditional exploratory research layouts to automated drug discovery infrastructure is anchored by the integration of microfluidic platforms and automated high-throughput screening (HTS) workstations. Traditional target validation and lead optimization strategies rely on standard microplate formats managed by manual pipetting arrays or broad robotic liquid dispensers. These traditional configurations introduce substantial operational inefficiencies due to high fluid volume constraints, high mechanical footprint requirements, and static cell-culture conditions that fail to replicate dynamic human physiological interactions.\nBy downscaling macroscopic liquid volumes to the microfluidic domain, automated lab-on-a-chip architectures achieve exponential gains in sampling throughput and capital asset utilization. While standard multi-well screening setups demand milliliter or large microliter quantities of candidate molecules and specialized reagents, microfluidic microchambers compress fluid requirements down to nanoliter and picoliter scales. Data indices show that this microscale compartmentalization reduces sample and compound consumption by 10-fold to 1,000-fold compared to traditional macroscale counterparts36. This extreme reduction in sample volume enables pharmaceutical enterprises to execute extensive chemical library optimization arrays that would be prohibitively expensive under macroscopic fluid constraints.\nFurthermore, these automated microfluidic configurations resolve the structural bottlenecks associated with data density and analytical time resolution. Instead of executing static, single-point measurements on microplates, contemporary microfluidic cell-chips feature integrated in-series biosensors and automated continuous-flow pathways. This allows for real-time, non-invasive observation of biochemical markers and dynamic cellular responses under precise fluid perfusion conditions37. By performing massive synthesis, fluidic manipulation, and characterization processes completely in parallel, automated microfluidic systems generate multi-parametric analytical readouts at an industrialized scale, expanding early discovery output while minimizing operational trial-and-error cycles.\nOperational Parameter Legacy Robotic Microplate Format Automated Microfluidic Platform Industrial Efficiency Return Reagent Volume Profile Microliter to milliliter scale per assay Nanoliter to picoliter microchambers 10-fold to 1,000-fold reduction in volume burn36 Fluidic Environment Static, non-physiological configurations Continuous microfluidic perfusion architecture Replicates real-time biophysical shear stresses37 Data Capture Method End-point microscopic plate reads Continuous in situ biosensor monitoring Real-time tracking of dynamic protein secretion37 Throughput Capacity Linear mechanical sample deployment Parallelized multi-channel fluid distribution Exponential compression of screening trial cycles 4.2 Organ-on-a-Chip and Microphysiological System Data Points # The transition from isolated automated screenings to integrated physiological modeling is driven by the structural deployment of organ-on-a-chip architectures and microphysiological systems. Traditional preclinical profiling relies heavily on animal models to evaluate systemic drug safety and tissue distribution. However, because animal organs differ fundamentally from human tissues in receptor expression, metabolic kinetics, and cellular organization, they regularly fail to predict human physiological outcomes. Organ-on-a-chip technologies resolve this gap by culturing human cells inside specialized microfluidic chambers that accurately replicate the structural microenvironments, fluid flow properties, and multicellular interactions of human organs.\nThe primary operational advantage of these microphysiological systems is their superior predictive accuracy in identifying human toxicity vectors before clinical deployment. A landmark industry validation study evaluated the performance of 870 human liver-chips across a large-scale blind trial of 27 small molecule drugs categorized by the Innovation and Quality (IQ) consortium38. The data demonstrated that the human liver-chips achieved a sensitivity of 87% and a specificity of 100% in identifying drug-induced liver injury (DILI)38. Crucially, the platform successfully identified hepatotoxic drugs that had previously passed extensive animal testing programs as safe, but later went on to cause severe clinical toxicities or market withdrawals in humans38. Economic analysis based on this performance data indicates that integrating human liver-chips systematically across an enterprise pipeline can generate over $3 billion annually for the pharmaceutical industry by increasing small-molecule R\u0026amp;D productivity and weeding out toxic assets early38.\nFurthermore, multi-organ microphysiological configurations allow for the evaluation of complex, multi-system drug interactions on a single, continuous fluidic circuit. By linking discrete microchambers representing the human gut, liver, kidney, and cardiovascular systems via automated microfluidic channels, developers can observe full metabolic and pharmacokinetic lifecycles in real time. These interconnected platforms allow for the precise evaluation of how a candidate compound is absorbed across an intestinal barrier, metabolized within hepatic structures, and cleared via renal filtration, all while continuously monitoring downstream functional changes in human tissue targets39. This parallelized data generation replaces speculative cross-species interpolation with direct, human-relevant performance metrics.\nPerformance Vector Legacy Animal Model Cohorts Organ-on-a-Chip Platform Audited Operational Advantage Hepatotoxicity Detection Regular false negatives; poor cross-species translation 87% Sensitivity / 100% Specificity (Liver-Chip Validation)38 Accurately identifies human DILI markers missed by animal cohorts Systemic Pipeline Valuation High late-stage attrition costs; multi-million sunk capital Over $3 Billion generated in corporate value annually38 Maximizes clinical success rates by filtering toxic candidates early Multi-Organ Interaction Fragmented, non-human systemic biology Interconnected gut-liver-kidney microfluidic channels39 Captures full human metabolic, toxic, and clearance lifecycles in parallel 4.3 In Silico and Computational Model Case Studies # The transition from physical laboratory arrays to digital environments is governed by the structural integration of advanced machine learning architectures, predictive algorithms, and in silico computational screening suites. Traditional candidate generation and chemical property prediction rely heavily on iterative, manual synthesis and cross-species extrapolations. These methods require considerable resource expenditure and introduce extensive delays into early-stage research pipelines due to the massive scale of chemical space that must be evaluated.\nBy shifting early candidate identification and multi-parameter optimization arrays to high-performance computing environments, in silico models achieve unprecedented reductions in pipeline timelines and resource consumption. Advanced deep learning platforms utilize graph neural networks and transformer architectures to perform predictive virtual screenings across virtual molecular libraries containing billions of novel compounds. These computational frameworks (eg PandaOmics platform) evaluate complex chemical properties, calculate relative binding affinities, and predict potential toxic liabilities in a completely parallelized manner40. This digital screening layer compresses candidate generation timelines from a traditional multi-year landscape down to exceptionally condensed operational windows, allowing developers to identify highly optimized molecules before deploying a single physical laboratory assay.\nThe practical validity of this digital translation layer is confirmed by documented industry case studies. In a landmark clinical milestone, a fully automated, generative computational architecture successfully completed the entire early-stage research cycle - progressing systematically from initial biological target identification through molecular design, structural optimization, and preclinical safety validation to discover an active idiopathic pulmonary fibrosis candidate in only 18 months40. Executing this early discovery phase under a traditional preclinical layout requires multi-million dollar capital investments and consumes several years of development runway. By replacing physical trial-and-error screens with high-fidelity predictive modeling, the automated platform slashed discovery timelines and compressed structural expenditures down to a fraction of traditional baselines40.\nFurthermore, contemporary in silico modeling frameworks resolve the long-term predictive bottlenecks associated with absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiling. Rather than relying on cross-species interpolations from animal data, advanced deep learning frameworks utilize complex molecular representations, deep neural networks (DNNs), and graph neural networks (GNNs) to identify complex molecular patterns and predict nonlinear human pharmacokinetic behaviors41. These computational suites apply multi-task and transfer learning algorithms to process high-dimensional structural data, allowing researchers to evaluate human clearance rates, capture blood-brain barrier permeability vectors, and pinpoint metabolic liabilities before executing physical laboratory assays41. This computational filter works in direct parallel with human-derived microfluidic platforms, creating a highly predictive early-stage R\u0026amp;D pipeline that maximizes clinical translatability while systematically reducing sunk corporate capital.\nPerformance Vector Traditional Laboratory Screening Baseline Automated In Silico Predictive Platform Strategic Enterprise Impact Candidate Optimization Multi-year manual synthesis; linear compound testing Compressed to 18 months from target to clinical phase40 Drastically shortens early discovery cash-burn windows ADMET Characterization Cross-species interpolation; delayed toxicity identification Deep neural network and graph molecular simulations41 Identifies metabolic liabilities prior to physical assay deployment Chemical Space Evaluation Highly restricted; limited by physical reagent costs Virtual screens processing billions of unique molecules40 Maximizes target diversity while reducing volume burn Operational Expenditure High multi-million dollar laboratory infrastructure overheads Sublinear cost structures; automated computing runtime Mitigates front-end capital risk across exploratory assets 4.4 Regulatory Acceptability and Precedent-Setting Approvals # The practical validation of human-predictive testing platforms is underscored by their increasing acceptance within formal regulatory filings and precedent-setting clinical trial clearances. Historically, international regulatory bodies maintained rigid animal testing mandates as a baseline requirement for Investigational New Drug (IND) applications. This legal framework created an operational barrier for developers attempting to advance highly predictive human cell-derived or computational assets into clinical phases. However, contemporary cross-border regulatory precedents demonstrate that data packages constructed entirely from human-relevant platforms are now successfully clearing regulatory reviews and entering human clinical trials.\nThe formal decoupling of the regulatory validation matrix from mandatory animal data pools is driven by clear legislative amendments. Statutory shifts have fundamentally re-engineered the Federal Food, Drug, and Cosmetic Act (FDCA), explicitly replacing ancient directives mandating \u0026ldquo;animal tests\u0026rdquo; with a modernized mandate for \u0026ldquo;nonclinical tests,\u0026rdquo; thereby establishing direct statutory equivalence for advanced human cell-derived platforms and computational biology methods inside IND applications35. Under this updated framework, clinical sponsors can present highly robust, human-relevant tissue data alongside parallelized in silico simulations to clear preclinical safety benchmarks. This regulatory pivot confirms that human-predictive data packages fully satisfy the statutory requirements for clinical trial authorization under contemporary evaluation protocols, clearing a streamlined path to active testing phases.\nFurthermore, global regulatory bodies are actively standardizing the submission framework for alternative testing metrics to accelerate pipeline integration. Following these legislative mandates, the FDA instituted a structured roadmap to actively replace legacy animal testing models with scientifically validated alternative frameworks35. To manage this shift, specialized multi-agency networks use centralized data infrastructures, such as the BioSystics Analytics Platform (BAP), to systematically organize, catalog, and validate the reproducibility profiles of human cells on chips and microphysiological networks42. These standardized data repositories provide biopharmaceutical developers with clear, predictable compliance pathways to validate alternative testing strategies, effectively mitigating the risk of regulatory delays, administrative clinical holds, or cross-border jurisdictional friction.\nRegulatory Vector Legacy Preclinical Evaluation Framework Human-Predictive Regulatory Pathway Strategic Enterprise Impact IND Submission Baseline Mandatory legacy testing protocols; rigid animal data rules Authorization via modernized nonclinical testing platforms35 Bypasses traditional preclinical testing bottlenecks entirely Agency Review Framework Case-by-case cross-species translation; high execution variance Standardized evaluation roadmaps and centralized validation databases42 Drastically lowers compliance uncertainty and review friction Jurisdictional Access Exposure to obsolete cross-border data requirements Aligned with global legislative modernization acts and roadmap mandates35 Secures rapid, unhindered entry into primary global markets 5. Strategic Enterprise Integration Blueprint # Transitioning a biopharmaceutical pipeline from legacy testing models to an optimized, human-predictive R\u0026amp;D ecosystem requires a systemic infrastructure blueprint. Moving beyond isolated pilot studies or piecemeal technology adoptions, true operational optimization demands the deliberate alignment of physical hardware, digital software stacks, regulatory tracking mechanisms, and multi-disciplinary organizational talent. This chapter outlines the practical execution pathways necessary to operationalize these advanced architectures at an enterprise scale.\nBy defining the precise technology requirements, validation protocols, procurement adjustments, and specialized personnel frameworks needed for deployment, this blueprint provides senior leadership with a structured roadmap. The following sections dismantle the operational friction points traditionally associated with technological transformation, offering a clear, step-by-step methodology to maximize asset velocity, secure cross-border compliance, and maintain long-term capital autonomy.\n5.1 Infrastructure \u0026amp; Technology Stack Requirements # The deployment of advanced human-relevant platforms at an enterprise scale requires a specialized cross-disciplinary infrastructure stack that bridges physical microfluidic engineering with high-performance digital computing. Traditional laboratory layouts are built around decentralized benchtop equipment and static incubation setups that cannot handle the continuous fluid flow and multi-parametric data generation of microphysiological architectures. Transitioning to an automated framework demands an integrated technology ecosystem capable of precisely regulating microenvironmental conditions while handling massive data arrays in real time.\nOn the physical laboratory layer, the primary technical requirement is the implementation of precise fluidic logic controllers and automated environmental maintenance enclosures. Unlike static plate setups, microfluidic tissue arrays rely on continuous perfusion to maintain cellular viability and apply physiological shear stresses. This requires programmable pneumatic pressure-driven pump networks that deliver stable, pulse-free fluid flow at microliter and nanoliter scales, coupled with automated inline sensor modules to continuously monitor temperature, pH, dissolved oxygen, and trans-epithelial electrical resistance (TEER)39. These automated hardware suites interface directly with robotic liquid-handling units to manage automated media translation, execute compound dosing sequences, and handle sample collections without manual intervention.\nOn the digital layer, the infrastructure must scale to support the deep data storage and processing pipelines driven by multi-organ systems and computational virtual screenings. A single multi-tissue run utilizing integrated biosensors and high-content imaging generates massive volumes of high-dimensional structural and kinetic data. To process these data streams, enterprises deploy containerized orchestration environments - such as Docker and Kubernetes arrays43 - integrated with specialized database architectures capable of handling complex metadata tracking, machine learning model weights, and multi-parametric biological readouts42. These digital environments run on high-performance cloud clusters or local computing hardware equipped with dedicated graphics processing units (GPUs) to accelerate graph neural network calculations, execute virtual compound profiling, and manage automated ADMET simulations.\nInfrastructure Layer Core Technical Components Operational Function Technology Integration Impact Physical Fluidics Pressure-driven pump controllers, automated TEER biosensors39 Regulates microfluidic perfusion rates and tracks tissue barrier integrity Replicates precise human biophysical microenvironments automatically Hardware Automation Multi-axis liquid-handling robotics, digital micro-enclosures Manages media translation, compound dosing, and automated collection arrays Eliminates operational variance and manual handling bottlenecks Data Orchestration Containerized computing stacks (Docker/Kubernetes43), localized S3 storage Catalogs multi-parametric tissue data, kinetic profiles, and imaging files Secures high-density data pipeline scalability and audit readiness Computational Analytics GPU-accelerated computing nodes, graph neural network frameworks42 Runs automated target screening and virtual ADMET simulations Compresses discovery timelines from years down to weeks 5.2 Supply Chain and Procurement Adaptation # Re-engineering a biopharmaceutical pipeline around human-relevant testing architectures requires a fundamental restructuring of corporate procurement operations and supply chain logistics. Traditional pharmaceutical supply chains are optimized for the acquisition, housing, and regulatory management of animal cohorts. Shifting to an advanced alternative platform shifts the purchasing mandate away from living organisms toward high-fidelity human primary cells, induced pluripotent stem cells (iPSCs), functional microfluidic hardware, and chemically defined, non-animal-derived extracellular matrices.\nThe primary logistical bottleneck in this operational shift is establishing a highly reliable, quality-controlled pipeline for specialized human biological materials. Unlike standardized animal models, human primary cells and donor-derived iPSCs exhibit inherent biological variability based on donor genetics, age, and health history. To safeguard data reproducibility across multi-center screening arrays, enterprise procurement teams must transition from transactional purchasing to strategic partnerships with certified biobanks and large-scale tissue repositories that provide deep multi-parametric characterization, validated master cell lines, and standardized distribution scales44. Furthermore, maintaining the viability of these advanced human cell lines requires the implementation of unbroken, automated cold-chain logistics networks, featuring real-time cryogenic temperature monitoring from the extraction node directly to the local automation storage facility.\nConcurrently, procurement frameworks must actively eliminate dependency on legacy, animal-derived laboratory consumables to maintain ethical consistency and scientific accuracy. Traditional cell culture systems rely heavily on animal-derived matrices—such as basement membrane matrix or fetal bovine serum (FBS)—which introduce systemic batch-to-batch variability, lack precise chemical definition, and introduce confounding cross-species biochemical signaling into human cell models. Contemporary procurement workflows replace these legacy components with chemically defined synthetic scaffolds, recombinant growth factors, and non-animal-derived hydrogels to secure human-relevant microenvironments45. This transition ensures that the biological microenvironment remains entirely human-predictive, removing uncontrolled variables and delivering an unassailable data layer to regulatory evaluators.\nProcurement Vector Legacy Sourcing Baseline Modernized Alternative Sourcing Enterprise Operations Impact Biological Assets Standardized live animal cohorts from commercial breeders Deeply characterized human primary cells and validated iPSC lines44 Eliminates animal housing overheads while securing direct human translation Consumable Matrices Animal-derived basement membranes and serum components Chemically defined synthetic scaffolds and recombinant hydrogels45 Eradicates batch-to-batch variance and hidden cross-species signaling loops Logistical Infrastructure Standard climate-controlled holding facilities and veterinary oversight Continuous automated cryogenic cold-chain monitoring networks Maximizes cellular viability and asset integrity at the laboratory interface Quality Control Visual phenotypic health checks of target animal populations Automated genetic profiling and functional microfluidic baseline assays44 Delivers standardized, highly reproducible data pools for regulatory submission 5.3 Personnel \u0026amp; Talent Acquisition Strategy # The deployment of advanced human-relevant testing architectures at an enterprise scale requires a fundamental restructuring of human capital and a sophisticated talent acquisition strategy. Legacy pharmaceutical R\u0026amp;D workflows operate within rigid silos, utilizing separate teams of classical in vivo toxicologists and observational animal-handling technicians. Transitioning to a modernized alternative platform renders these legacy operational structures obsolete, demanding an immediate pivot toward cross-disciplinary \u0026ldquo;hybrid scientists\u0026rdquo; who can seamlessly bridge the gap between human cellular biology, microfluidic instrumentation, and computational translation layers.\nThe primary workforce transformation involves integrating clinical pharmacologists directly into early-stage preclinical and translational teams. Because contemporary cell-chip arrays generate high-density human data rather than traditional visual animal readouts, enterprises require translational specialists capable of contextualizing these outputs within human clinical environments. This specialized workforce applies mechanistic profiling, physiologically based pharmacokinetic (PBPK) modeling, and quantitative systems pharmacology (QSP) to interpret microfluidic assay metrics, ensuring direct translation to human clinical outcomes while actively driving down legacy testing footprints46. These advanced operators combine classical pharmacokinetics with microfluidic logic to catch toxic liabilities before clinical deployment.\nConcurrently, corporate talent acquisition must establish dedicated institutional training programs to build a robust internal pipeline of alternative-methodology specialists. Sourcing personnel fluent in advanced 3D cultivation and high-content automation requires shifting from transactional hiring to concentrated, immersive skills-development programs and multi-disciplinary workshops47. To counteract systemic workforce deficits, human resource frameworks must actively cultivate early-career researchers through targeted technology demonstrations and cross-sector training initiatives47. This deliberate educational runway provides the laboratory interface with engineers and analysts native to non-animal method development, removing the technical barriers traditionally associated with scaling new architectures.\nFinally, managing the cultural shift away from legacy animal testing metrics requires an agile, skills-based change management framework. When laboratory staff struggle to adapt to advanced alternative research methodologies, organizational leadership must implement hands-on peer-to-peer mentorship programs, establish sub-projects to build frontline confidence, and foster an environment that rewards cross-functional skill acquisition48. Rather than selecting for historical pedigree or rigid box-checking credentials, recruitment teams prioritize foundational adaptability, computational literacy (e.g., Python or R), and transdisciplinary collaboration. This comprehensive personnel evolution ensures that the enterprise workforce remains as predictive, agile, and scalable as the physical technology stack it operates.\nSpecialized Role Profile Core Technical Domain Primary Operational Responsibility Enterprise Pipeline Impact Translational Pharmacologist PBPK modeling, systems pharmacology, mechanistic profiling46 Contextualizes cell-chip outputs and maps functional assays to human outcomes Accelerates early-phase validation while removing cross-species interpolation errors Alternative Systems Operator 3D multi-lineage cell culture, assay automation, microfluidic loading Manages high-throughput screening runs and executes quality control protocols47 Minimizes manual batch-to-batch experimental variance across large-scale runs Computational Biologist Machine learning algorithms, toxicokinetic modeling, data integration46 Refines predictive virtual screening suites and bridges NAM data with clinical sets Eliminates toxic chemical structures prior to physical laboratory deployment Agile Integration Specialist Change management, peer mentorship, cross-functional upskilling48 Resolves personnel adaptation bottlenecks and trains staff on new research methods Rapidly dismantles institutional inertia and secures long-term operational autonomy 6. Financial Projections and ROI Analysis # The systemic integration of human-predictive architectures across an enterprise biopharmaceutical pipeline represents a fundamental reallocation of corporate capital. Moving away from the high-attrition, resource-intensive nature of legacy preclinical testing is no longer merely an ethical or scientific choice; it is an economic imperative. This chapter provides an audited financial framework that quantifies the capital transitions, operational cost-reductions, and risk-mitigation profiles associated with implementing a modernized, non-animal drug discovery ecosystem.\nBy evaluating the balance sheet impact across clear structural horizons, this financial blueprint dismantles the misconception that technological modernization carries cost-prohibitive premiums. The subsequent analyses break down immediate hardware and infrastructure investments, contrast long-term operational costs against obsolete baseline overheads, and project corporate return on investment (ROI) based on compressed discovery timelines, eliminated asset failures, and optimized clinical entry vectors.\n6.1 CapEx and OpEx Breakdown # The transition from obsolete animal testing infrastructures to high-fidelity, human-relevant testing architectures demands a precise, multi-year reallocation of corporate capital. For a long time, the biopharmaceutical sector has absorbed the massive fiscal burdens of legacy preclinical drug development, where maintaining extensive in vivo laboratories introduces high fixed overheads, regulatory compliance liabilities, and severe pipeline attrition. Transitioning an enterprise R\u0026amp;D setup to an optimized non-animal paradigm shifts the financial model away from living biological systems toward modular capital expenditures (CapEx) and highly predictable, scalable operational expenditures (OpEx).\nOn the upfront CapEx horizon, the initial capital deployment covers the procurement, installation, and engineering validation of automated microfluidic workstations and data-processing infrastructure. While legacy testing pipelines require continuous, multi-million dollar investments to construct, maintain, and structurally audit traditional animal housing facilities, a modernized alternative configuration concentrates capital into durable, high-throughput technical assets. These investments include multi-axis liquid-handling robotics, programmable pneumatic pressure-driven flow controllers, real-time trans-epithelial electrical resistance (TEER) biosensors, and automated high-content imaging systems4. On the digital layer, front-end CapEx covers localized high-performance computing (HPC) nodes equipped with dedicated graphics processing units (GPUs) to run automated target identification pipelines and parallelized virtual ADMET screenings.\nConversely, the operational expense (OpEx) profile transitions to a predictable, sublinear cost model that eliminates the continuous cash drain of legacy systems. Standard animal-based OpEx is tied to heavy, non-negotiable variable costs, including perpetual veterinary oversight, intensive climate-control utilities, manual husbandry labor, and the purchasing of single-use living cohorts. In an advanced alternative framework, these variable expenses are replaced by modular, quality-controlled consumable components, such as microfluidic tissue-chips, chemically defined synthetic hydrogels, and recombinant growth media frameworks49. Because these human cell-derived platforms scale fluidly inside standardized multi-well dimensions, the enterprise can execute thousands of automated, multi-parametric screenings at a fraction of the operational cost required to manage fragmented animal cohorts.\nExpense Category Legacy Preclinical Cost Center Modernized Non-Animal Asset Class Long-Term Fiscal Impact Upfront CapEx Animal facility construction, surgical suites, specialized HVAC grids Automated liquid-handling robotics, pneumatic flow controllers, GPU clusters4 Replaces depreciating real-estate overheads with high-efficiency technology assets Consumable OpEx Purchase of living animal cohorts, single-use breeding vectors Multi-organ tissue-chips, validated human iPSCs, synthetic matrices49 Eradicates unpredictable cohort loss while securing absolute batch reproducibility Labor \u0026amp; Maintenance Perpetual veterinary salaries, animal husbandry personnel Microfluidic systems engineers, computational toxicologists, data operators Shifts personnel capital from manual maintenance to proactive data analysis Facility Footprint Massive real-estate demands, strict biohazard security controls Compact, standardized automated incubation racks and server setups Minimizes corporate real-estate footprints while slashing facility utility costs 6.2 Best-Case Scenario: 15-Year Cumulative Cost Comparison # To quantify the long-term fiscal divergence between these two paradigms, the table below projects the micro- and macro-economic cost centers over a 15-year horizon—the fully inclusive timeline required to progress a single novel therapeutic from early target discovery through preclinical, clinical, and regulatory phases to final market launch.\nThis model tracks a best-case scenario assuming complete technical and operational success. The projections assume the baseline maintenance of either a mid-scale 10,000-cage traditional vivarium or a modernized 2,000-square-foot automated cleanroom, alongside the execution of an average of three major exploratory screening campaigns over the 15-year lifecycle.\nExpense Category \u0026amp; Lifespan Vector Legacy In Vivo Facility Model (15-Year Cumulative) Modernized Non-Animal Ecosystem (15-Year Cumulative) 15-Year Capital Realignment Value Fixed CapEx: Facility Construction $4,000,000 (Midpoint baseline premium) $1,000,000 (Midpoint modular panel premium) $3,000,000 Saved (Immediate upfront infrastructure recovery) Durable CapEx: Core Instrumentation $275,000 (IVC racks, autoclaves, sanitizers) $1,175,000 (Robotics, perfusion pumps, GPU nodes) $900,000 Reallocated (Invested into liquid, depreciable technical assets) OpEx: Direct Inputs \u0026amp; Consumables $22,500,000 ($1.5M/yr baseline cohort/breeding costs) $9,000,000 ($600k/yr tissue chip/cell-banking runs) $13,500,000 Saved (Sublinear consumable scaling) OpEx: Facility Utilities \u0026amp; HVAC $4,875,000 ($325k/yr high-volume ACH ventilation floor) $900,000 ($60k/yr localized incubator/server draw) $3,975,000 Saved (81% reduction in utility overheads) OpEx: Human Capital \u0026amp; Labor $17,250,000 ($1.15M/yr husbandry \u0026amp; veterinary staff payroll) $9,000,000 ($600k/yr engineering \u0026amp; data science payroll) $8,250,000 Saved (Leaner workforce with higher per-capita output) OpEx: Three Exploratory Screens $15,000,000 ($5M per standard 60-month NHP/animal campaign) $712,500 ($237.5k per automated chip/cloud run subset) $14,287,500 Saved (95% compression in campaign costs) CUMULATIVE LIFECYCLE TOTALS $63,900,000 $21,787,500 $42,112,500 NET SAVINGS Strategic Summary Statement: Over the 15-year developmental lifecycle of a single drug asset, the direct operational and capital delta between the two frameworks results in $42,112,500 in cumulative net savings per facility line by transitioning to a non-animal architecture. It is critical for senior leadership to note that these metrics represent a strict best-case scenario tracking a single, anomalously successful compound that safely clears all regulatory milestones to reach commercial launch. This baseline comparison does not incorporate the multi-billion dollar losses structurally incurred by the 95% preclinical attrition rate and the subsequent 90% human clinical translation failure rate inherent to legacy animal models. Across the industry pipeline, the 95% preclinical bottleneck alone destroys $1.7 billion in unrecovered capital per successful drug launched. When added to the $2.6 billion baseline clinical trial cost driven by the 92% translation gap, the total attrition-loaded cost regularly is pushed toward $4.3 billion per approved drug launched. These staggering capital losses are heavily mitigated by the superior human-predictive specificity of New Approach Methodologies.\n6.3 ROI Timelines and Attrition Reduction Metrics # The primary justification for replacing legacy preclinical models with advanced human-relevant testing architectures rests on accelerating the corporate return on investment (ROI) and systematically reducing pipeline attrition. In traditional drug development frameworks, the transition from preclinical animal validation to Phase I human clinical trials accounts for the costliest bottlenecks in the biopharmaceutical industry. Approximately 89% of drug candidates that pass extensive, multi-million dollar animal safety screenings fail immediately upon exposure to human cohorts due to unpredicted toxicities or a lack of clinical efficacy. By inserting high-fidelity human cell-chips and computational virtual analytics prior to clinical protocol deployment, enterprises can actively de-risk their portfolios and fundamentally flatten these late-stage failure curves.\nThe financial return timeline is compressed by accelerating candidate optimization cycles and shortening the overall length of preclinical discovery. Traditional large-animal validation routines consume considerable development runways, regularly requiring up to 60 months to execute multi-dose safety and distribution profiling. In contrast, running structural down-selection screenings inside continuous human cell-chips compresses these timelines down to exceptionally condensed operational windows of less than 18 months, dramatically reducing front-end cash-burn windows and allowing clinical sponsors to advance highly optimized, verified assets to Investigational New Drug (IND) applications significantly faster than legacy models permit4.\nFurthermore, the economic impact of improving pipeline success rates drives multi-billion dollar enterprise value through the industry-standard Risk-Adjusted Net Present Value ($rNPV$) framework. The \\(rNPV\\) equation decouples technical failure from financial discounting by applying the probability of technical and regulatory success \\(PTRS\\) directly to sequential cash flows across development phases, calculated as:\n$$rNPV = \\sum_{t=1}^{T} \\frac{CF_t \\times P(\\text{Success}_t)}{(1+r)^t}$$A comprehensive scenario-based budget impact analysis indicates that integrating human-predictive architectures systematically across an R\u0026amp;D framework reduces overall drug development expenditures by 10% to 26%, yielding absolute corporate cost savings ranging between $66 million and $706 million per newly launched medicine4. By driving technical attrition upstream into inexpensive preclinical windows, the enterprise eliminates massive unrecovered late-stage cash outflows, drastically optimizes \\(P(\\text{Success}_t)\\) variables, and lifts early-stage portfolio asset valuations without exposing corporate capital to late-stage phase-to-phase write-offs[^51].\nPipeline Metric Legacy Preclinical Framework Modernized Non-Animal Ecosystem Enterprise Economic Value Preclinical Screen Length Up to 60 months for comprehensive animal profiling Compressed to under 18 months via automated human cell-chips4 Speeds up clinical entry timelines while lowering front-end runway costs Financial Impact Per Medicine High capital risk exposure; massive unrecovered failure costs Absolute cost savings of $66M to $706M per newly launched asset4 Recovers substantial enterprise capital by eliminating legacy overheads Portfolio Valuation Uplift Suppressed by high cross-species attrition premiums Optimized via heightened $PTRS$ metrics inside early phases Maximizes risk-adjusted asset value under the \\(rNPV\\) framework[^51] Total R\u0026amp;D Budget Impact Baseline multi-billion dollar expenditure per successful asset 10% to 26% total R\u0026amp;D cost reduction via optimized success rates4 Maximizes enterprise portfolio value and long-term capital autonomy 6.4 Long-Term Market Valuation and Risk Mitigation Projections # The structural migration toward a preclinical pipeline completely free from animal testing provides an enterprise with profound insulation against macro-market volatility, shifting international regulatory baselines, and supply chain vulnerabilities. Traditional pharmaceutical operations remain heavily exposed to systemic tail-risks, including escalating global costs for non-human primates, tightening animal welfare legislation across the European Union and North America, and sudden public relations liabilities. Transitioning to a local-first, human-predictive testing framework transforms these operational vulnerabilities into long-term enterprise valuation growth and unparalleled capital autonomy.\nThe primary market valuation catalyst is the expansion of corporate Environmental, Social, and Governance (ESG) metrics and the captured premium from ethical investment funds. Modern institutional capital allocation trends show that large-scale funds actively penalize enterprises heavily dependent on animal testing when viable, superior alternatives exist. By formally declaring and operationalizing a non-animal discovery infrastructure, an enterprise permanently eliminates animal-welfare risk from its corporate profile, making it a prime destination for ESG-driven investment capital. Furthermore, this transition protects the organization from the severe supply chain shocks and price manipulations that frequently destabilize classical preclinical operations, replacing volatile biological animal shipping nodes with stable, standardized microfluidic consumable assets that can be scaled internally or sourced locally.\nOn the regulatory and intellectual property (IP) horizon, human-predictive datasets accelerate global cross-border market entry while fortifying patent defensibility. Because modern platforms output highly precise, human-relevant transcriptomic, kinetic, and barrier-integrity metrics, the resulting data packages allow regulatory evaluators to review candidate files with far greater statistical confidence. This data depth speeds up the approval process across major international markets, dramatically extending the useful commercial life of an asset within its active patent window. Ultimately, by shifting the corporate asset pipeline away from high-attrition, cross-species interpolation toward highly reliable, automation-driven human analytics, the enterprise achieves a highly stable, highly valued market position that is completely insulated from legacy preclinical liabilities.\nStrategic Risk Vector Legacy Preclinical Vulnerability Modernized Non-Animal Position Macro Valuation Premium Supply Chain Security Volatile non-human primate prices, strict export caps, transport bans Standardized microfluidic consumables, local iPSC banking architectures Eradicates macro sourcing vulnerabilities and stabilizes R\u0026amp;D costs Capital Allocation Active exposure to institutional ESG investment penalties Certified non-animal drug discovery pipelines and ethical audit readiness Captures significant premiums from specialized ESG institutional funds IP Lifecycle Value Delayed clinical entry windows eroding active patent lifetimes Compressed preclinical timelines and accelerated global regulatory paths Maximizes market exclusivity windows and total asset lifecycle revenue Corporate Autonomy Total reliance on external breeding facilities and regional regulatory shifts Compact, internal automated tech stacks and localized data infrastructure Secures permanent corporate independence from legacy supply dependencies 7. Strategic Conclusions and 3-Year Transition Roadmap # The economic and scientific data compiled across this report demonstrate that the transition from legacy in vivo protocols to New Approach Methodologies (NAM) is a structural prerequisite for long-term corporate viability. Relying on cross-species interpolation enforces an unsustainable financial architecture characterized by a 90% to 92% clinical failure rate2, multi-million dollar fixed infrastructure overheads28, and extended developmental timelines32. By pivoting toward a unified, human-predictive ecosystem - combining automated microfluidic networks, 3D organotypic interfaces, and cloud-orchestrated in silico screening engines - the enterprise structurally insulates its pipeline from late-stage attrition while recovering significant capitalized expenditures.\nTo operationalize these findings without disrupting active discovery pipelines, the enterprise must avoid fragmented technology adoptions and instead execute a coordinated, phased migration. The following 3-year roadmap outlines a possible risk-mitigated pathway to systematically dismantle legacy capital liabilities, reallocate procurement streams, upskill internal human capital, and secure complete preclinical operational autonomy.\n7.1 Phase I: Infrastructure Integration \u0026amp; Parallel Validation (Months 1–12) # The initial phase focuses on establishing the physical and digital foundations required to run alternative methodologies at scale, while actively constructing an internal dataset to prove comparative predictive validity. Rather than immediately interrupting existing in vivo protocols, the enterprise deploys automated modular cleanrooms alongside active discovery runs, using compound structural subsets to validate advanced human cell-chips against historical baseline metrics.\nInfrastructure Deployments: Install reconfigurable modular cleanroom spaces (ISO Class 5–6) within existing facility boundaries to house high-throughput liquid-handling robotics and continuous microfluidic perfusion controllers29 39. Simultaneously, provision elastic cloud-batch computing environments to eliminate local server cluster overheads16 18. Procurement \u0026amp; Logistics: Establish strategic sourcing contracts with accredited biological tissue repositories and master cell banks to secure deeply characterized, quality-controlled human primary cells and validated iPSC lineages with unbroken cryogenic cold-chain tracking44. Operational Execution: Initiate dual-pathway testing on a calibrated subset of lead optimization assets. Run high-fidelity, microphysiological human Liver-Chips in direct parallel with mandatory legacy in vivo configurations to evaluate trans-epithelial electrical resistance (TEER) and inline metabolic clearance metrics38 39. Personnel Milestones: Form cross-functional translational teams, embedding clinical pharmacologists directly within preclinical safety groups to begin mapping in vitro-in vivo correlations using quantitative systems pharmacology (QSP) and mechanistic modeling frameworks46. 7.2 Phase II: Pipeline Migration \u0026amp; Advanced Skills Acquisition (Months 12–24) # With physical and digital systems validated, Phase II transitions early lead optimization and target selection workloads entirely to automated non-animal platforms. This phase compresses the front-end discovery runway by shifting from manual laboratory processes to parallelized digital and robotic operations.\nInfrastructure Deployments: Expand automated microplate deployment to include 384-well and 1,536-well microplate formats managed by integrated multi-axis robotic arms, driving reagent and cell consumable volumes down to sub-microliter and nanoliter dimensions27 36. Procurement \u0026amp; Logistics: Fully phase out animal-derived matrices (such as basement membrane matrices and fetal bovine serum) across all screening workflows, replacing them entirely with chemically defined synthetic scaffolds, recombinant growth factors, and non-animal-derived hydrogels45. Operational Execution: Migrate target validation and hit-to-lead selectors completely to deep learning generative architectures. Deploy graph neural networks and deep neural network layers to execute ultra-large virtual screens of billions of unique compounds, identifying clearance rates and potential toxicities prior to generating physical assay samples40 41. Personnel Milestones: Implement targeted, immersive institutional training workshops and hands-on peer-to-peer mentorship programs to upskill laboratory staff, resolving change management bottlenecks for personnel transitioning away from classical manual workflows47 48. 7.3 Phase III: Structural Divestment \u0026amp; Complete Preclinical Autonomy (Months 24–36) # The final phase achieves complete structural transformation, migrating the entire preclinical safety assessment workflow to human-predictive NAM architectures. The enterprise fully divests from legacy animal holding infrastructures, transforming fixed capital space into high-yield automated data centers and reconfigurable automated laboratories.\nInfrastructure Deployments: Completely decommission on-premise vivarium caging systems and single-use animal holding rooms, eradicating the high-liability HVAC utilities, negative-pressure airflow maintenance, and specialized ammonia exhaust overheads that drain operational capital23 24. Procurement \u0026amp; Logistics: Transition to a local-first supply model, utilizing compact, internal automated incubation racks and digital code blocks to eliminate exposure to volatile international animal shipping regulations, trade bans, and export caps35. Operational Execution: Compile and standardize comprehensive, human-predictive data packages organized inside centralized repositories such as the BioSystics Analytics Platform (BAP)42. Submit finalized Investigational New Drug (IND) files constructed entirely from human-derived microphysiological, omics, and in silico datasets under modernized regulatory validation directives35. Personnel Milestones: Complete the human capital evolution, scaling down classical animal maintenance headcount and establishing a lean, highly productive workforce composed of microfluidic systems engineers, computational toxicologists, and data platform operators46 47. Operational Vector Year 1: Integration \u0026amp; Parallel Validation Year 2: Pipeline Migration \u0026amp; Scaled Automation Year 3: Structural Divestment \u0026amp; Autonomy Physical \u0026amp; Digital Infrastructure Modular cleanroom fit-outs, elastic cloud node orchestration Automated multi-axis robotics, 1,536-well plate formatting Full vivarium decommissioning, compact automated incubator arrays Procurement \u0026amp; Consumables Strategic iPSC cell-banking contracts, cryogenic cold-chains Total elimination of animal serum, synthetic hydrogel sourcing Localized, standardized microfluidic consumable inventory lines R\u0026amp;D Workflow Execution Parallel testing arrays, physical baseline validation metrics Generative AI virtual screenings, automated ADMET modeling Comprehensive human-predictive data packs, non-animal IND filings Human Capital Strategy Cross-functional translational pharmacology teams established Immersive skills workshops, agile peer-to-peer upskilling Lean workforce of computational biologists and platform engineers 7.4 Strategic Summary and Corporate Horizon # The transition from legacy in vivo protocols to a streamlined, human-predictive R\u0026amp;D ecosystem represents a fundamental evolution in biopharmaceutical innovation. By systematically replacing resource-intensive, high-attrition animal models with an integrated technology stack—combining automated microfluidics, high-fidelity human cellular models, and cloud-orchestrated in silico screening engines—the enterprise effectively decouples data generation from the biological constraints of non-human species. This structural reorganization successfully eliminates the steep fixed overheads, volatile procurement pipelines, and severe cross-species translation gaps that have traditionally burdened preclinical drug discovery.\nUltimately, the execution of this 3-year strategic roadmap shifts the corporate paradigm from reactive observational testing to proactive computational and automated design. Maintaining the status quo carries an astronomical penalty: long-term macroeconomic audits of the world\u0026rsquo;s most prolific pharmaceutical pipelines reveal that when total aggregate corporate R\u0026amp;D expenditures are divided against final FDA approvals, the true multi-firm burn rate can scale between $4-11 billion per single approved drug launched which is staggering indeed49! This catastrophic capital destruction is driven entirely by the compounding overhead of legacy failures.\nAs global regulatory frameworks continue to decouple validation pathways from mandatory animal data pools, early adopters of New Approach Methodologies secure an unassailable competitive advantage. This operational modernization preserves active patent exclusivity windows, accelerates clinical entry timelines, and drives substantial risk-adjusted valuation growth across the entire asset portfolio. By anchoring its pipeline directly to human-predictive analytics, the enterprise moves past the multi-billion dollar industry burn rate to achieve absolute capital autonomy, operational scalability, and long-term scientific leadership.\nFootnotes # Why Drug Development Takes Decades: Process \u0026amp; Challenges | IntuitionLabs\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nRoadmap to Reducing Animal Testing in Preclinical Safety Studies | FDA\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nPharmaceutical Drug Lifecycle: A Comprehensive Scientific Review of Research and Development Phases, Attrition Rates, and Global Disparities\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nImpact of organ-on-a-chip technology on pharmaceutical R\u0026amp;D costs\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nFDA\u0026rsquo;s emerging framework to reduce animal testing: Implications for drug development timelines, cost, and clinical strategy | pharmaphorum\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nAnimal Model Market Size to Surpass USD 5.72 Billion by 2035\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nPoor Translatability of Biomedical Research Using Animals - A Narrative Review\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nWhat are Organ-Chips? | Emulate, Inc.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nWhen Speed to Market Counts\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nFDA steps back from preclinical primate testing amid wider regulatory shift | Pharmaceutical Technology\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nHow much money is spent on animal testing every year? | HowMuchBlog\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nCosts of animal and non-animal testing | Humane World\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nMicrofluidics Pricing - uFluidix\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nOrgan-on-a-chip devices - Darwin Microfluidics\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nNINDS Human Cell and Data Repository (NHCDR) Distribution Framework | NIH Repository FAQ\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nCloud Computing for Screening Data Analysis | Technology Networks\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nLarge-Scale Docking in the Cloud | Journal of Chemical Information and Modeling\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nDocking billions of molecules with open-source software | CADD Consulting Benchmarks\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nAn open-source drug discovery platform enables ultra-large virtual screens | PubMed Central\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nVeterinary Assistants and Laboratory Animal Caretakers | U.S. Bureau of Labor Statistics Occupational Outlook\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nBioinformatics Degree Salary by Industry: Where Graduates Earn the Most | Research.com Advisor\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nBioinformatics and Computational Biology Salaries in Biotech and Pharma (2026) | PharmaPayWatch\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nKey Considerations for HVAC Systems in Small Animal Laboratories with Room-Specific Air Change and Pressure Requirements | Research SOP\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nLabs Explained: Life Science Infrastructure and Real Estate Metrics | Knight Frank Insights\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nAnimal Caging Systems Guide for Research Facilities | ARES Scientific Guide\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nMobile vs. Modular Cleanrooms: What\u0026rsquo;s the Difference and How Are They Used in Laboratory Applications? | LabRepCo Features\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nHow lab automation is shaping scalability | Drug Discovery News\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nASU Deploys Research Space Utilization Metrics for Affordable and Sustainable Growth | Tradeline Inc Report\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nUnderstanding Clean Room Cost: How to Estimate and Optimize Your Investment | Wonclean Insights\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nGaps and paths forward in cancer pharmacology and translational research | PubMed Central\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nR\u0026amp;D Costs of New Medicines: A Landscape Analysis | PubMed Central\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nFrom Lab to Clinic: How Artificial Intelligence (AI) Is Reshaping Drug Discovery Timelines and Industry Outcomes | PubMed Central\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nThe need to consider market access for pharmaceutical investment decisions: a primer | PubMed Central\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nBioengineering of novel organotypic 3D human liver tissue model for drug-induced liver injury and toxicity studies | PubMed Central\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nThe FDA\u0026rsquo;s Plan to Phase Out Animal Testing | PubMed Central\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nMicrofluidic cell chips for high-throughput drug screening | PubMed Central\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nAn Organ-on-a-Chip Modular Platform with Integrated Immunobiosensors for Monitoring the Extracellular Environment | MDPI Micromachines\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nPerformance assessment and economic analysis of a human Liver-Chip for predictive toxicology | PubMed Central\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nMulti-Organs-on-Chips for Testing Small-Molecule Drugs: Challenges and Perspectives | PubMed Central\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nA small-molecule TNIK inhibitor discovered by generative AI for idiopathic pulmonary fibrosis with clinical biomarker validation | Nature Biotechnology\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nDeep Learning for In Silico ADMET Prediction | Springer Link\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nOrgan-On-A-Chip Database Revealed—Achieving the Human Avatar in Silicon | PubMed Central\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nKubernetes Vs Docker\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nThe Rise of Human iPSC Banks as a Means of Making iPS Cells Widely Available | BioInformant\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nThe Transition from Animal-Derived Extracellular Matrices to Synthetic Hydrogels for Human Cell Culture Validation | Frontiers in Toxicology\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nNew Approach Methodologies: What Clinical Pharmacologists Should Prepare For | Clinical Pharmacology \u0026amp; Therapeutics\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nCreating training opportunities in new approach methodologies for early-career researchers | ScienceDirect / COLAAB\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nWhat do you do if you\u0026rsquo;re struggling to adapt to new research methodologies? | LinkedIn Professional Advice\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nThe Truly Staggering Cost Of Inventing New Drugs\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\n","date":"2026-06-14","externalUrl":null,"permalink":"/resources/reports/animal-research-vs-nam-expenditures/","section":"Resources","summary":"An extensive analysis comparing costs of animal research vs NAM across micro and macro economics.","title":"Animal Research vs NAM Costs","type":"resources"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/tags/animal-models/","section":"Tags","summary":"","title":"Animal-Models","type":"tags"},{"content":" BizCards # These cards are primarily for encouraging others to visit the pnars.org site and learn about NAM.\nExample of an advisor bizcard\nCredit: Maureen Snider (adapted by Gemini and pradesigner) For PNARS team members we produce personalized cards such as the one above.\nFor enthusiasts of NAM who want to promote NAM and the site we have the NAMthusiast card shown below:\nThe NAMthusiast card for eager aficionados.\nCredit: Maureen Snider (adapted by Gemini and pradesigner) Cards will be available later in a 5x2 grid as a printable pdf page. You can print these on your home printer and cut out the cards, or take them to a printshop to have them print and cut the cards for you.\n","date":"2026-06-14","externalUrl":null,"permalink":"/resources/assets/bizcards/","section":"Resources","summary":"Printable cards to distribute and promote NAM and the pnars.org site to everyone.","title":"Bizcards","type":"resources"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/tags/cards/","section":"Tags","summary":"","title":"Cards","type":"tags"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/tags/cost-analysis/","section":"Tags","summary":"","title":"Cost-Analysis","type":"tags"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/tags/drug-discovery/","section":"Tags","summary":"","title":"Drug-Discovery","type":"tags"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/categories/economics/","section":"Categories","summary":"","title":"Economics","type":"categories"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/tags/health-economics/","section":"Tags","summary":"","title":"Health-Economics","type":"tags"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/tags/high-throughput-screening/","section":"Tags","summary":"","title":"High-Throughput-Screening","type":"tags"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/tags/in-silico/","section":"Tags","summary":"","title":"In-Silico","type":"tags"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/categories/library/","section":"Categories","summary":"","title":"Library","type":"categories"},{"content":" Namamanam # This page provides various images of our logo, Namamanam, active in media appearances.\nNamamanam\nCredit: Gemini and pradesigner The original design for our NAMouse was created by Maureen Snider. The animated version was produced by CSwebsolutions. Various modifications were later made by pradesigner with assistance from Gemini and Mistral.\nAnyone is welcome to download and distribute this official artwork for the purpose of promoting the PNARS site and NAM.\nWith QRcode # This is the most common image we use for printed materials due to the qrcode leading back to our website.\nBeyond Animal Group # We have a group on Beyond Animal. To visit/join our group by set up an account on the Beyond Animal platform and then search for Progressive Non-Animal Research Society.\nBelow are the cover photo and logo image for our group.\nCover Photo Logo Image Logo Image when feeling stretched On Instagram # The image has been adjusted to accommodate Instagram\u0026rsquo;s requirements. Find us there under pnarsociety.\nChewing # Namamanam chews up animal research. This endeavour is already on one of our Talking Points NAM vs Animal Testing and will appear on various other documents. An animated version of this image may be a good project.\nAnimated # Why Namamanam was named Namamanam # The name of our NAMouse is Namamanam because of this video that was no doubt produced in our friend\u0026rsquo;s honor though they got the spelling wrong because they didn\u0026rsquo;t know about NAM in that era.\n","date":"2026-06-14","externalUrl":null,"permalink":"/resources/assets/namamanam/","section":"Resources","summary":"Collection of images for our NAMouse starring in various media.","title":"Namamanam","type":"resources"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/tags/namamanam/","section":"Tags","summary":"","title":"Namamanam","type":"tags"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/tags/organ-on-a-chip/","section":"Tags","summary":"","title":"Organ-on-a-Chip","type":"tags"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/tags/organoids/","section":"Tags","summary":"","title":"Organoids","type":"tags"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/tags/pharmaceutical/","section":"Tags","summary":"","title":"Pharmaceutical","type":"tags"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/categories/printables/","section":"Categories","summary":"","title":"Printables","type":"categories"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/tags/rd/","section":"Tags","summary":"","title":"R\u0026D","type":"tags"},{"content":"This section contains in-depth reports compiled by AI or contributors and checked by PNARS staff. These reports cover a variety of topics related to NAM.\nReporting factual information\nCredit: geralt (pixabay) ","date":"2026-06-14","externalUrl":null,"permalink":"/resources/reports/","section":"Resources","summary":"Compilations of analyses on various NAM related topics such as research, and policies..","title":"Reports","type":"resources"},{"content":"","date":"2026-06-14","externalUrl":null,"permalink":"/tags/reports/","section":"Tags","summary":"","title":"Reports","type":"tags"},{"content":" Articles # This section hosts a curated collection of written works, including research papers, white papers, and analytical documents. The articles cover topics such as New Approach Methodologies (NAM), toxicology, safety assessment, and regulatory science.\nCredit: Organization \u0026amp; Navigation\nTo maintain maximum information density and transparency, this repository is organized directly by issuing source (peer-reviewed scientific journals, government bodies, and intergovernmental regulatory agencies). This approach provides the orign for every document and aligns directly with primary scientific literature.\nRather than utilizing complex, nested page routing or heavy visual filtering systems, this repository implements a lightweight, text-based indexing system using hashtags. This keeps the repository entirely flat, fast-loading, and immediately searchable.\nTo find specific content across the entire page instantly, simply use your browser\u0026rsquo;s native search function (Ctrl + F or Cmd + F) and enter any of the indexed hashtags listed below.\nIndex of Hashtags As the repository expands, new operational tags will be appended to this index in alphabetical order.\n#biometrics - Computational models, bioinformatics, multi-omic statistical pipelines, and quantitative analyses used to map biological data. #bioprinting - Advanced 3D fabrication technologies, tissue engineering scaffolds, and bio-manufacturing processes. #chemical-testing - Studies detailing specific experimental assays, validation data, and methodology protocols for chemical toxicity screening. #data-federation - Projects focused on the integration, harmonization, and interoperability of fragmented data repositories. #ethics - Philosophical, legal, and moral arguments surrounding animal testing and the transition to human-relevant science. #future-food - Specifically tracking cultured tissue, alternative proteins, and cellular agricultural scaffolds #guidelines - Official protocols, procedural standards, and compliance frameworks for non-animal research. #invitro - Studies and documentation focusing on cell cultures, tissues, organs-on-a-chip, and other isolated biological systems. #neuroscience - For research and assays focused on neural tissue engineering, brain organoids, and neurotoxicity testing. #organ-on-a-chip - For microphysiological systems (MPS) that recapitulate organ-level function on microfluidic platforms. #pharmacology - For studies involving drug mechanism, transport kinetics, and therapeutic efficacy. #regulatory - Documents covering the legal implementation, acceptance, and standardization of NAMs by government oversight bodies. #research - Peer-reviewed scientific papers detailing primary experimental data, methodologies, and technical validation. #safety-testing - Practical applications of NAMs within industrial, chemical, consumer product, and environmental risk assessment frameworks. #translation - Analyses focusing on human relevance, clinical translatability, and the predictive failure rates of legacy animal models. #wearables - For skin and eye diagnostic tracking devices #whitepaper - Strategic roadmaps, institutional reports, and comprehensive policy overviews issued by agencies or organizations. ATLA - Alternatives to Laboratory Animals # An international, peer-reviewed journal publishing articles on the development, validation, and implementation of methods that replace, reduce, or refine the use of live animals in biomedical research and toxicity testing. [Link]\nA History of Regulatory Animal Testing: What Can We Learn?\n#research #regulatory #translation\nDoortje Swaters, Anne van Veen, Wim van Meurs, et al.\nAn archival examination of how animal testing became institutionalized in regulatory policy, offering insights on how to dismantle systemic reliance on legacy methods.\nA Review of In Silico Tools as Alternatives to Animal Testing: Principles, Resources and Applications\n#research #safety-testing\nJudith C. Madden, Steven J. Enoch, Alicia Paini, et al.\nA baseline reference guide outlining the core computational tools, chemical safety databases, and predictive algorithms available to completely replace live animal screenings.\nBarriers to the Use of Recombinant Bacterial Endotoxins Test Methods in Parenteral Drug, Vaccine and Device Safety Testing\n#research #safety-testing #regulatory\nElizabeth Baker, Jessica Ponder, Johannes Oberdorfer, et al.\nIdentifies the commercial, bureaucratic, and international regulatory bottlenecks slowing down the adoption of non-animal recombinant testing methods for vaccines and medical devices.\nData-driven science, ethics and risk: Building knowledge of key ethics–risk intersections relevant to public sector decision-making\n#research #ethics #regulatory\nYadvinder Bhuller, Marc Avey, P. Charukeshi Chandrasekera, et al.\nAn analysis of public sector decision-making at the intersection of data science, ethical frameworks, and risk assessment regarding safety policies.\nIt’s Time to Review the Three Rs, to Make them More Fit for Purpose in the 21st Century\n#research #ethics #translation\nJarrod Bailey\nA critical assessment of the traditional 3Rs framework, arguing for an evolutionary shift away from mere refinement or reduction toward absolute human-relevant replacement methodologies.\nPoor Translatability of Biomedical Research Using Animals - A Narrative Review\n#research #translation #ethics\nLindsay J. Marshall, Jarrod Bailey, Manuela Cassotta, et al.\nA detailed review documenting the widespread failure of animal models to accurately predict human clinical outcomes in biomedical research.\nReplacing immunisation-dependent antibody reagent production: Challenges under the UK Replacing Animals in Science 2025 strategy\n#research #regulatory #guidelines\nAlison C. Gray, Kevin C. Gough\nExamines the strategic hurdles and technical challenges in transitioning away from animal-immunization methods for generating antibody reagents within national scientific frameworks.\nALTEX # Alternatives to Animal Experimentation An open-access quarterly journal publishing peer-reviewed scientific papers on the development and validation of alternatives to animal testing, with a strong focus on ethics and regulatory policy. [Link]\nAdvancing skin sensitization potency categorization using U-SENS™ in OECD TG 497\n#research #safety-testing #regulatory\nNathalie Alépée, Fleur Tourneix, Laurent Nardelli, et al.\nA scientific paper demonstrating the optimization of skin sensitization potency evaluations using the U-SENS assay within existing OECD testing guidelines.\nBridging the gap in chemical risk assessment: Leveraging metabolite similarity for enhanced read-across applications\n#research #safety-testing\nJenny Irwan, George E. N. Kass, Rupert Kellner, et al.\nDetails how computational assessments can leverage metabolite structural similarities to strengthen non-animal read-across predictions in chemical risk management.\nChemical fate in vitro: A physiological biokinetic (PBK) model for cell-based assays\n#research #safety-testing\nDaniela Brenner, Kévin Bernal, Eliška Sychrová, et al.\nPresents a physiological biokinetic model designed to calculate chemical concentrations and distribution kinetics directly within in vitro cell-based testing environments.\nIQ-MPS Affiliate perspectives on blood-brain barrier microphysiological systems: Progress and challenges ahead\n#research #invitro #translation\nBenoit Cox, Nikita Karra-Bhardwaj, Paresh P. Chothe, et al.\nAn industry and scientific review focusing on the current technological capabilities and structural bottlenecks facing human blood-brain barrier models on chips.\nLost in NAMs-lation: A review of animal-free science definitions\n#research #translation #regulatory\nDonna S. Macmillan, Phi Holcomb, Kristie M. Sullivan\nAn analysis of the competing and overlapping definitions used for non-animal and alternative methods across international scientific and regulatory communities.\nPyrogen testing at a turning point – On occasion of the 30th anniversary of the whole blood monocyte activation test\n#research #safety-testing #translation\nThomas Hartung\nA historical and forward-looking review marking three decades of the non-animal whole blood monocyte activation test as a superior replacement for legacy rabbit pyrogen screenings.\nThe Findable, Accessible, Interoperable, Reusable (FAIR) Lite Principles to ensure utility of computational toxicology models\n#research #safety-testing\nMark T. D. Cronin, Homa Basiri, Samuel J. Belfield, et al.\nEstablishes baseline data standards to ensure that computational toxicology and predictive in silico algorithms remain functional, accessible, and shared across scientific networks.\nThe Merck \u0026ldquo;3 Baskets\u0026rdquo; approach for creating roadmaps to phase out animal testing\n#research #regulatory #whitepaper\nKerstin Kleinschmidt-Doerr, Frederic C. Pipp, Isabelle Colmagne-Poulard, et al.\nA strategic corporate report outlining an industry framework used to categorize chemical testing practices and chart actionable company roadmaps to eliminate animal usage.\nTowards NAM-based risk assessment for developmental neurotoxic effects, illustrated with chlorpyrifos\n#research #safety-testing #regulatory\nAnne Zwartsen, Joost Westerhout, Shensheng Zhao, et al.\nA case study utilizing the organophosphate pesticide chlorpyrifos to outline a blueprint for executing developmental neurotoxicity evaluations using entirely non-animal data models.\nArchives of Toxicology # A highly respected scientific journal focusing on toxicological mechanisms, which frequently publishes seminal research on computational models, microphysiological systems, and regulatory NAM frameworks. [Link]\nApplicability of next-generation risk assessment generic PBK models and their performance within the chemical domain\n#research #safety-testing #regulatory\nM. Spaenig, M. W. Ashraf, \u0026hellip; S. E. Escher\nEvaluates the performance and domain boundaries of generic physiologically based kinetic (PBK) models as foundational instruments for human-relevant next-generation risk assessment (NGRA).\nComparison of ex vivo placenta perfusion and in vitro BeWo b30 cell models for assessing transfer of developmental and reproductive toxic compounds\n#research #invitro #safety-testing\nDamian Roelofsen, Sandrine Spriggs, \u0026hellip; Rick Greupink\nCompares performance benchmarks between ex vivo tissue models and human BeWo cell lines to validate robust non-animal methods for assessing reproductive toxicity.\nExtrapolation of in vitro effect concentrations to in vivo bioavailable concentrations using PBK modelling in humans for two classes of persistent and mobile compounds: triazoles and triazines\n#research #safety-testing\nAbishek Laxmanan Ravi Shankar, Jenny Irwan, \u0026hellip; Sylvia E. Escher\nDemonstrates the deployment of in vitro ADME parameters combined with computational human PBK models to replace legacy animal models in calculating environmental compound safety barriers.\nFrom animal models to NAMs: a paradigm shift in developmental immunotoxicity testing\n#research #translation #regulatory\nMartina Iulini, Véronique Bruijn, \u0026hellip; Emanuela Corsini\nTraces the systemic evolution of developmental immunotoxicity (DIT) testing, outlining a framework to transition entirely from obsolete animal studies to modern, human-centric NAM infrastructure.\nHigh-throughput PBK modelling for dermal exposure: a pragmatic approach to predict systemic pharmacokinetics\n#research #safety-testing\nZeynep Edizcan, Stephan Schaller, \u0026hellip; René Geci\nIntroduces a high-throughput computational framework designed to mechanically isolate and project human dermal drug absorption and systemic kinetics without biological testing.\nIntegration of in vitro and in silico approaches enables prediction of drug-induced liver injury\n#research #safety-testing\nRené Geci, Ahenk Zeynep Sayin, \u0026hellip; Lars Kuepfer\nCombines structural cell-based assays with mathematical simulations to solve a primary challenge in drug development: predicting drug-induced liver injury (DILI) before human clinical phase tracking.\nPrediction of human exposure and first-pass metabolism of the fungicide trifloxystrobin using an in vitro intestinal pancreatin and Caco-2/HT29-MTX model\n#research #invitro #safety-testing\nEileen Hallscheidt, Kathrin Bothe, \u0026hellip; Marc Lamshoeft\nDeploys co-cultured human intestinal cellular environments to construct predictive safety assessments for human metabolic handling of agrochemicals, bypassing classic mammalian modeling.\nThe use of new approach methodologies (high-throughput transcriptomics) to study nanoagrochemicals: mechanisms of toxicity of a commercial copper copper oxychloride to soil model invertebrates (Enchytraeus crypticus)\n#research #safety-testing\nSusana I. L. Gomes, Janeck J. Scott-Fordsmand, Mónica J. B. Amorim\nExamines the impact of next-generation nanoagrochemical materials on ecological health systems using high-throughput transcriptomic tracking pipelines rather than organism-level endpoints.\nThe way forward for assessing the human health safety of cosmetics in the EU: Proceedings of Workshop 2\n#research #regulatory #whitepaper\nVera Rogiers, Emilio Benfenati, \u0026hellip; Aglaia Koutsodimou\nA comprehensive technical summary outlining the legal pathways, validation metrics, and validation bottlenecks to maintain a non-animal cosmetic testing regimen under current EU regulations.\nBiomaterials # An international journal covering the science and clinical application of biomaterials, showcasing advanced microphysiological systems, 3D bioprinting, and stem cell technologies engineered to model human tissue physiology. [Link]\n3D biomaterial matrix to support long term, full thickness, immuno-competent human skin equivalents with nervous system components\n#research #invitro #bioprinting\nSarah E. Lightfoot Vidal, Kasey A. Tamamoto, Hanh Nguyen, et al.\nPresents a complex 3D human skin model engineered to maintain full thickness and neurological integration over extended experimental durations without live animal hosting.\n3D culture models for studying branching morphogenesis in the mammary gland and mammalian lung\n#research #invitro\nBryan A. Nerger, Celeste M. Nelson\nOutlines advanced 3D tissue culture templates designed to dynamically isolate and study organ development mechanics in lung and mammary tissue architectures.\n3-D microwell culture of human embryonic stem cells\n#research #invitro\nJeffrey C. Mohr, Juan J. de Pablo, Sean P. Palecek\nA foundational protocol utilizing engineered 3D microwell substrates to enable scalable growth, morphology tracking, and uniform differentiation of human pluripotent cell lines.\n3-D physiomimetic extracellular matrix hydrogels provide a supportive microenvironment for rodent and human islet culture\n#research #invitro\nK. Jiang, D. Chaimov, S.N. Patel, et al.\nDetails a bioengineered 3D hydrogel environment that mimics native tissue properties to preserve the viability and metabolic secretion profiles of human pancreatic cells in vitro.\n3D printable plant protein-enriched scaffolds for cultivated meat development\n#research #bioprinting #future-food\nIris Ianovici, Yedidya Zagury, Idan Redenski, et al.\nEvaluates the material tuning and fabrication properties of entirely plant-based bioinks utilized to 3D print complex structural scaffolds for non-animal muscle tissue engineering.\n3D printed MCT oleogel as a co-delivery carrier for curcumin and resveratrol\n#research #bioprinting #future-food\nM. Kavimughil, M. Maria Leena, J.A. Moses, et al.\nInvestigates the engineering limits and molecular protection capabilities of 3D-printed fat-mimetic oleogels designed to stabilize sensitive bioactive components in synthetic foods.\n3D printed PEDOT:PSS-based conducting and patternable eutectogel electrodes for machine learning on textiles\n#research #wearables\nRuben Ruiz-Mateos Serrano, Ana Aguzin, Eleni Mitoudi-Vagourdi, et al.\nOutlines the synthesis of patternable, conductive eutectogels for textile integration, providing the sensor foundation needed to connect wearable electronic tracking platforms with machine learning.\nA novel red-emitting aggregation-induced emission probe for determination of β-glucosidase activity\n#research #future-food\nBicheng Yao, Jiamin Zhao, Siyang Ding, et al.\nIntroduces a responsive fluorescent probe that utilizes aggregation-induced emission to execute high-contrast enzyme tracking inside cellular food-production lines.\nA strategy for screening novel umami dipeptides based on common feature pharmacophore and molecular docking\n#research #future-food\nYongzhao Xiong, Xinchang Gao, Daodong Pan, et al.\nUses computational molecular docking and virtual pharmacophore screening to identify novel flavor peptides, bypassing traditional animal-derived chemical characterization.\nA three-dimensional (3D) organotypic microfluidic model for glioma stem cells – Vascular interactions\n#research #invitro\nDanh Truong, Roberto Fiorelli, Eric S. Barrientos, et al.\nPresents a microfluidic tumor-on-a-chip platform designed to model the exact physical and molecular interactions between human brain tumor stem cells and vascular arrays.\nAdvances in ex vivo models and lab-on-a-chip devices for neural tissue engineering\n#research #invitro #translation\nSahba Mobini, Young Hye Song, Michaela W. McCrary, et al.\nA comprehensive review tracing microphysiological systems, microfluidic platforms, and neural-chip platforms designed to replace legacy animal models in neurological drug discovery.\nAdvances in wearable electronics for monitoring human organs: Bridging external and internal health assessments\n#research #wearables #translation\nVo Thi Nhat Linh, Seunghun Han, Eunhye Koh, et al.\nReviews the capacity of advanced skin and surface bioelectronics to extract deep internal organ diagnostics, providing a non-invasive translation blueprint for human health logging.\nApplication of a Mytilus edulis-derived promoting calcium absorption peptide in calcium phosphate cements for bone\n#research #future-food\nZhe Xu, Zhixuan Zhu, Hui Chen, et al.\nDetails the extraction and synthetic structural deployment of an absorption peptide to optimize mineral matrix consolidation, with cross-industry relevance in food structures and bone engineering.\nAdvances in wearable electronics for monitoring human organs: Bridging external and internal health assessments\n#research #wearables #translation\nVo Thi Nhat Linh, Seunghun Han, Eunhye Koh, et al.\nReviews the capacity of advanced skin and surface bioelectronics to extract deep internal organ diagnostics, providing a non-invasive translation blueprint for human health logging.\nBiomaterials for reliable wearable health monitoring: Applications in skin and eye integration\n#research #wearables\nSeokkyoon Hong, Tianhao Yu, Ziheng Wang, et al.\nExamines the engineering challenges of integrating flexible electronic sensors onto soft human tissues (skin and cornea) to secure continuous, long-term diagnostic tracking.\nBiomimetic cardiovascular platforms for in vitro disease modeling and therapeutic validation\n#research #invitro #translation\nRoberto Portillo-Lara, Andrew R. Spencer, Brian W. Walker, et al.\nA comprehensive analysis detailing how human heart tissues are reconstructed in vitro on hydrogel chips to create high-throughput drug screening environments that bypass animal models.\nBiomimetic ion nanochannels for sensing umami substances\n#research #future-food\nMingyang Li, Ninglong Zhang, Zhiyong Cui, et al.\nDetails the engineering of a synthetic nanochannel platform modeled directly after human taste receptors to detect and profile umami compounds electronically.\nBrief exposure to directionally-specific pulsed electromagnetic fields stimulates extracellular vesicle release and is antagonized by streptomycin: A potential regenerative medicine and food industry paradigm\n#research #future-food\nCraig Jun Kit Wong, Yee Kit Tai, Jasmine Lye Yee Yap, et al.\nOutlines an electromagnetic mechanism used to non-invasively amplify cellular factor signaling, offering a novel biomanufacturing paradigm to accelerate cultivated meat production.\nCardiovascular disease models: A game changing paradigm in drug discovery and screening\n#research #invitro #translation\nHouman Savoji, Mohammad Hossein Mohammadi, Naimeh Rafatian, et al.\nA major review of human heart-on-a-chip technologies, microvascular loops, and tissue lattices deployed to displace historical animal-testing models in pharmaceutical screening.\nChitosan and HPMCAS double-coating as protective systems for alginate microparticles loaded with Ctx(Ile21)-Ha antimicrobial peptide to prevent intestinal infections\n#research #future-food\nCesar Augusto Roque-Borda, Mauro de Mesquita Souza Saraiva, et al.\nEngineers a biocompatible polymer shell delivery architecture designed to shield therapeutic antimicrobial peptides from stomach breakdown during transit.\nCo-culture of human embryonic stem cells with murine embryonic fibroblasts on microwell-patterned substrates\n#research #invitro\nAli Khademhosseini, Lino Ferreira, James Blumling, et al.\nA foundational bioengineering paper introducing a lithographic microwell patterning technique to physically isolate and standardize stem cell growth niches in vitro.\nCore-shell starch as a platform for reducing starch digestion and saturated fat intake\n#research #future-food\nXiaoyang Li, Bing Hu, Ruixiang Ma, et al.\nEngineers a core-shell biopolymer matrix that alters enzyme digestion dynamics, creating a scalable physical platform to manufacture healthier synthetic food products.\nCyclic flexure and laminar flow synergistically accelerate mesenchymal stem cell-mediated engineered tissue formation: Implications for engineered heart valve tissues\n#research #invitro\nGeorge C. Engelmayr, Virna L. Sales, John E. Mayer, et al.\nDemonstrates how dynamic mechanical stress and fluid flow inside custom bioreactors accelerate the functional maturation of non-animal engineered heart tissue.\nDevelopment of a human skeletal micro muscle platform with pacing capabilities\n#research #invitro\nRichard J. Mills, Benjamin L. Parker, Pauline Monnot, et al.\nEngineers a human skeletal muscle microfluidic matrix featuring active electrical pacing networks to evaluate cell physiological function directly in vitro.\nDissection and enhancement of prebiotic properties of yeast cell wall oligosaccharides through metabolic engineering\n#research #future-food\nSuryang Kwak, Scott J. Robinson, Jae Won Lee, et al.\nApplies metabolic pathway engineering to optimize yeast structures, enhancing their natural functional properties for integration into sustainable cellular agricultural pipelines.\nDynamic monitoring of a 3D-printed airway tissue model using an organic electrochemical transistor\n#research #wearables #invitro\nSeungjin Chai, Yunji Lee, Róisín M. Owens, et al.\nIntegrates organic electrochemical transistors directly with 3D-printed human airway tissue models to monitor physiological health transformations in real time without destroying the tissue block.\nEffect of 3D scaffold and dynamic culture condition on the global gene expression profile of mouse embryonic stem cells\n#research #invitro\nHui Liu, Jian Lin, Krishnendu Roy\nA comprehensive transcriptomic analysis mapping how 3D physical matrices and fluid perfusion alter global gene expression profiles during embryonic cell lineage selection.\nEffects of orthopaedic wear particles on osteoprogenitor cells\n#research #translation\nStuart B. Goodman, Ting Ma, Richard Chiu, et al.\nExamines the specific cellular mechanisms of implant degradation and particle-induced toxicity using localized, non-animal cell models to isolate pathogenic pathways.\nElectrical stimulation increases hypertrophy and metabolic flux in tissue-engineered human skeletal muscle\n#research #invitro\nAlastair Khodabukus, Lauran Madden, Neel K. Prabhu, et al.\nDemonstrates how chronic electrical stimulation promotes metabolic flux and tissue hypertrophy inside bioengineered human skeletal muscle fibers in vitro.\nEmulsion-templated microparticles with tunable stiffness and topology: Applications as edible microcarriers for cultured meat\n#research #future-food\nSam C.P. Norris, N. Stephanie Kawecki, Ashton R. Davis, et al.\nEngineers tunable biopolymer microparticles to act as edible microcarriers, providing a scalable material template to multiply animal-free muscle tissues.\nEpidermal secretion-purified biosensing patch with hydrogel sebum filtering membrane and unidirectional flow microfluidic channels\n#research #wearables\nYuqi Wang, Ziyu Zhang, Yuqing Shi, et al.\nDesigns a smart skin patch featuring microfluidic channels and a selective filtering hydrogel to continuously extract and purify skin secretions for accurate health tracking.\nEngineered meatballs via scalable skeletal muscle cell expansion and modular micro-tissue assembly using porous gelatin micro-carriers\n#research #future-food\nYe Liu, Rui Wang, Shijie Ding, et al.\nOutlines a scalable manufacturing process that utilizes porous gelatin microcarriers to expand muscle cells and assemble them into thick, non-animal meat structures.\nEngineered microenvironments and microdevices for modeling the pathophysiology of type 1 diabetes\n#research #invitro #translation\nMatthew W. Becker, Jennifer A. Simonovich, Edward A. Phelps\nReviews the biofabrication protocols and microfluidic microdevices deployed to reconstruct pancreatic tissue microenvironments, bypassing animal models for diabetes tracking.\nEvaluation of immobilized microspheres of Clonostachys rosea on Botrytis cinerea and tomato seedlings\n#research #future-food\nJiayin Liu, Zhengyuan Han, Lidong An, et al.\nEvaluates a protective biopolymer microsphere matrix deployed to encapsulate biological protection agents, securing agricultural crop security without synthetic chemical exposure.\nFrom lab to wearables: Innovations in multifunctional hydrogel chemistry for next-generation bioelectronic devices\n#research #wearables\nHin Kiu Lee, Ye Ji Yang, Gyan Raj Koirala, et al.\nTraces the advanced chemistry used to formulate multifunctional hydrogel interfaces, serving as the essential wet link between biology and skin-mounted hardware.\nFuture foods: Design, fabrication and production through microfluidics\n#research #future-food\nXiufeng Li, Baihao You, Ho Cheung Shum, et al.\nReviews how advanced microfluidic droplet networks are used to design, manipulate, and manufacture nutrient-dense synthetic proteins and alternative food shapes.\nGelatin MAGIC powder as nutrient-delivering 3D spacer for growing cell sheets into cost-effective cultured meat\n#research #future-food\nSohyeon Park, Sungwon Jung, Moonhyun Choi, et al.\nIntroduces an innovative nutrient-releasing gelatin matrix that operates as a 3D spacer, enabling researchers to stack individual cell sheets into thick, structured non-animal steaks economically.\nGellan gum-gelatin scaffolds with Ca2+ crosslinking for constructing a structured cell cultured meat model\n#research #future-food\nYan Chen, Linzi Li, Lin Chen, et al.\nDetails a calcium-crosslinked gellan gum matrix designed to support the alignment and long-term cultivation of primary muscle cell layers into structured meat models.\nHarvest of quality-controlled bovine myogenic cells and biomimetic bovine muscle tissue engineering for sustainable meat production\n#research #future-food\nHironobu Takahashi, Azumi Yoshida, Botao Gao, et al.\nDevelops an industrial protocol to harvest and verify pure bovine cell sheets, providing a reproducible bioengineering blueprint for animal-free meat production lines.\nHigh throughput scaffold-based 3D micro-tumor array for efficient drug screening and chemosensitivity testing\n#research #invitro\nXiaojun Yan, Lyu Zhou, Zhaozhao Wu, et al.\nOutlines a dense 3D micro-scaffold array that automates human micro-tumor cultivation, facilitating large-scale non-animal drug screening.\nHigh-throughput micro-tumor arrays on polymer fibers for automated drug testing\n#research #invitro\nXiaojun Yan, Lyu Zhou, Zhaozhao Wu, et al.\nOutlines a dense 3D micro-scaffold array that automates human micro-tumor cultivation, facilitating large-scale non-animal drug screening.\nHomemade bread: Repurposing an ancient technology for in vitro tissue engineering\n#research #invitro\nJessica T. Holmes, Ziba Jaberansari, William Collins, et al.\nRepurposes the porous structure of baked bread as an accessible, highly porous non-animal scaffold to guide 3D cell infiltration and tissue architecture formatting.\nIdentification and structural analysis of novel malathion-specific DNA aptameric sensors designed for food testing\n#research #future-food\nUlhas Sopanrao Kadam, Kien Hong Trinh, Vikas Kumar, et al.\nIsolates novel synthetic DNA aptamer sequences tailored to detect organophosphate pesticide contamination instantly in agricultural products.\nIn vitro and ex vivo systems at the forefront of infection modeling and drug discovery\n#research #invitro #translation\nDi Shi, Gujie Mi, Mian Wang, Thomas J. Webster\nA technical evaluation detailing how biomimetic chip arrays capture human pathogen interactions, rendering historical mammalian infection modeling obsolete.\nIn-silico investigation of umami peptides with receptor T1R1/T1R3 for the discovering potential targets: A combined modeling approach\n#research #future-food\nWenli Wang, Zhiyong Cui, Menghua Ning, et al.\nCombines computational taste-receptor mapping and docking algorithms to isolate novel umami peptides, bypassing legacy organism sensory panels.\nIntestinal-targeted nanotubes-in-microgels composite carriers for capsaicin delivery and their effect for alleviation of Salmonella induced enteritis\n#research #future-food\nYu Yuan, Ying Liu, Yang He, et al.\nDeploys a specialized nanotube-in-microgel composite carrier to deliver precise capsaicin doses directly to the intestine, offering a non-chemical methodology to manage enteritis.\nIntrafibrillar, bone-mimetic collagen mineralization regulates breast cancer cell adhesion and migration\n#research #invitro\nSiyoung Choi, Jens Friedrichs, Young Hye Song, et al.\nUses a mineralized 3D collagen platform to discover how bone structural properties influence human breast cancer cell migration, bypassing traditional mouse bone matrix grafts.\nLarge-scale cultured meat production: Trends, challenges and promising biomanufacturing technologies\n#research #future-food\nLu Chen, Donovan Guttieres, Andrea Koenigsberg, et al.\nMaps the global engineering bottlenecks and bioreactor design upgrades necessary to scale animal-free muscle tissue manufacturing to an industrial capacity.\nMechanism differences between reductive and oxidative dough rheology improvers in the formation of 1D and 3D gluten network\n#research #future-food\nJihui Gao, Yizhan Guo, Rongrong Yan, et al.\nAnalyzes the molecular disulfide binding mechanics of plant gluten networks, establishing material parameters to engineer synthetic textures in plant-based proteins.\nMicrofluidic devices for disease modeling in muscle tissue\n#research #invitro #translation\nMollie M. Smoak, Hannah A. Pearce, Antonios G. Mikos\nEvaluates the design of microfluidic devices used to cultivate healthy and diseased human muscle fibers on chips for non-animal therapeutic evaluation.\nMultifunctional nanomaterials for smart wearable diabetic healthcare devices\n#research #wearables\nTae Yeon Kim, Ranjit De, Inhoo Choi, et al.\nDetails the incorporation of advanced nanomaterials into non-invasive wearable devices to automate continuous blood monitoring and delivery management.\nMultiscale bioprinting of vascularized models\n#research #invitro #bioprinting\nAmir K. Miri, Akbar Khalilpour, Berivan Cecen, et al.\nDetails advanced multi-nozzle 3D bioprinting techniques designed to construct complex fluid networks inside engineered human organ models.\nNatural biomaterials for sustainable flexible neuromorphic devices\n#research #wearables\nYanfei Zhao, Seungbeom Lee, Tingyu Long, et al.\nRepurposes natural, plant-derived biopolymers to construct flexible electronic neuromorphic circuits, advancing sustainable hardware for skin-mounted diagnostic networks.\nNatural biopolymer masks the bitterness of potassium chloride to achieve a highly efficient salt reduction for future foods\n#research #future-food\nWei Lu, Zining Hu, Xuelian Zhou, et al.\nUses plant-derived biopolymer coatings to mask mineral taste properties, solving a common formulation challenge in clean-label alternative foods.\nNew vegetable-waste biomaterials by Lupin albus L. as cellular scaffolds for applications in biomedicine and food\n#research #future-food #invitro\nSilvia Buonvino, Matteo Ciocci, Francesca Nanni, et al.\nExtracts structural cellulose matrices from agricultural lupin plant waste to fabricate sustainable, edible 3D scaffolds for cellular agriculture and tissue models.\nOptimization of fibrin scaffolds for differentiation of murine embryonic stem cells into neural lineage cells\n#research #invitro\nStephanie M. Willerth, Kelly J. Arendas, David I. Gottlieb, et al.\nOptimizes the density and growth-factor loading of non-animal fibrin hydrogels to accurately drive stem cell colonies into functional neural tissues.\nPerivascular signals alter global gene expression profile of glioblastoma and response to temozolomide in a gelatin hydrogel\n#research #invitro\nMai T. Ngo, Brendan A.C. Harley\nUses a non-animal gelatin hydrogel framework to demonstrate how vascular signals modify cancer genes and therapeutic resistance, providing an alternative to mouse brain tumor grafts.\nPerspectives on scaling production of adipose tissue for food applications\n#research #future-food\nJohn S.K. Yuen Jr, Andrew J. Stout, N. Stephanie Kawecki, et al.\nExamines the specific cultivation conditions, raw material constraints, and fat cell scaling protocols needed to manufacture authentic animal-free lipids for clean meat.\nProduction of cultured meat from pig muscle stem cells\n#research #future-food\nHaozhe Zhu, Zhongyuan Wu, Xi Ding, et al.\nEstablishes a defined protocol to isolate, proliferate, and structurally organize porcine satellite muscle lines into authentic cultured meat without animal serum.\nProduction of food-grade microcarriers based on by-products from the food industry to facilitate the expansion of bovine skeletal muscle satellite cells for cultured meat production\n#research #future-food\nR. Christel Andreassen, Sissel Beate Rønning, et al.\nRepurposes food industry protein processing side-streams into food-grade microcarriers to maximize cellular surface area expansion in industrial agriculture bioreactors.\nQuercetin directed transformation of calcium carbonate into porous calcite and their application as delivery system for future foods\n#research #future-food\nTian Lan, Yabo Dong, Zejian Xu, et al.\nUses the natural plant compound quercetin to crystallize porous, food-grade calcite arrays, providing a stable microscopic vehicle to encapsulate nutrients.\nSmart filtering facepiece respirator with self-adaptive fit and wireless humidity monitoring\n#research #wearables\nKangkyu Kwon, Yoon Jae Lee, Yeongju Jung, et al.\nIntegrates wireless flexible electronics and adaptive polymer components into specialized facepieces to achieve self-adjusting seals and real-time respiratory logging.\nStem cell-based tissue engineering with silk biomaterials\n#research #invitro #translation\nYongzhong Wang, Hyeon-Joo Kim, Gordana Vunjak-Novakovic, David L. Kaplan\nA prominent review assessing how biocompatible silk fibroin proteins are processed into porous 3D scaffolds to systematically guide stem cell colonies into complex bone and cartilage lines.\nStem cells and adipose tissue engineering\n#research #invitro\nCheryl T. Gomillion, Karen J.L. Burg\nA comprehensive analysis mapping the material design rules, cell seeding techniques, and monitoring criteria used to construct functional human fat tissue equivalents in vitro.\nStrategies to improve meat-like properties of meat analogs meeting consumers’ expectations\n#research #future-food\nYan Ping Chen, Xi Feng, Imre Blank, et al.\nReviews the macromolecular crosslinking methods and formulation advancements deployed to mimic animal muscle fiber texturing in clean-label plant protein products.\nStructure remodeling of soy protein-derived amyloid fibrils mediated by epigallocatechin-3-gallate\n#research #future-food\nZejian Xu, Guancheng Shan, Nairong Hao, et al.\nInvestigates how the green tea extract EGCG shapes plant-derived amyloid fibrils, providing a mechanical method to customize protein texturing in alternative foods.\nSurface-aminated electrospun nanofibers enhance adhesion and expansion of human umbilical cord blood hematopoietic stem/progenitor cells\n#research #invitro\nKian-Ngiap Chua, Chou Chai, Peng-Chou Lee, et al.\nDemonstrates that surface-amination of synthetic polymer nanofibers optimizes the attachment and growth of human cord blood stem cell populations in vitro.\nThe effects of monocytes on tumor cell extravasation in a 3D vascularized microfluidic model\n#research #invitro\nA. Boussommier-Calleja, Y. Atiyas, K. Haase, et al.\nUses a vascularized 3D microfluidic chip to track exactly how circulating white blood cells influence cancer cell escape routes, completely replacing live animal vascular mapping.\nThe intracellular fate and transport mechanism of shape, size and rigidity varied nanocarriers for understanding their oral delivery efficiency\n#research #future-food\nXin Li, Seid Mahdi Jafari, Feibai Zhou, et al.\nDetails how the physical architecture (geometry and stiffness) of biopolymer nanocarriers controls their absorption pathways through human intestinal walls in vitro.\nThe kinetic mechanism of cations induced protein nanotubes self-assembly and their application as delivery system\n#research #future-food\nJipeng Zhang, Qimeng Wang, Bin Liu, et al.\nDetails the self-assembly mechanics of plant-derived protein nanotubes under ionic control, creating clean delivery tools for structural food additions.\nThree-dimensional culture for expansion and differentiation of mouse embryonic stem cells\n#research #invitro\nHui Liu, Scott F. Collins, Laura J. Suggs\nDemonstrates that encapsulating stem cell colonies inside porous, un-linked 3D hydrogel beds supports uniform differentiation cascades without animal-derived serum additives.\nTissue engineered bone mimetics to study bone disorders ex vivo: Role of bioinspired materials\n#research #invitro #translation\nYuru Vernon Shih, Shyni Varghese\nDeploys a bioinspired, cell-laden matrix to build functional bone copies in vitro, providing a reliable alternative platform to model skeletal disease pathology without testing on live animals.\nUmami polypeptide detection system targeting the human T1R1 receptor and its taste-presenting mechanism\n#research #future-food\nChuanxi Zhang, Yulu Miao, Yinghui Feng, et al.\nEngineers an entry screening architecture based on human taste receptor profiles to isolate and verify savory compounds for advanced non-animal food products.\nComputational Toxicology # A specialized journal dedicated to the development of computer-based data models, quantitative structure-activity relationship (QSAR) models, and mathematical simulations to replace biological animal screening. [Link]\nA comparative study of biostatistical pipelines for benchmark concentration modeling of in vitro screening assays\n#research #invitro #safety-testing\nKelly E. Carstens, Arif Dönmez, Ellen Fritsche\nCompares statistical data analysis pipelines for modeling concentration-effect thresholds in high-throughput in vitro toxicity screening arrays.\nA developmental and reproductive toxicity adverse outcome pathway network to support safety assessments\n#research #safety-testing #translation\nAlun Myden, Alex Cayley, Adrian Fowkes\nDetails the creation of an adverse outcome pathway (AOP) network designed to evaluate developmental and reproductive risks without using legacy animal assays.\nA matter of trust: Learning lessons about causality will make qAOPs credible\n#research #regulatory #translation\nNicoleta Spînu, Mark T. D. Cronin, Andrew P. Worth\nExamines the causal validation metrics required to establish international scientific and regulatory trust in quantitative adverse outcome pathways (qAOPs).\nA review of in silico toxicology approaches to support the safety assessment of cosmetics-related materials\n#research #safety-testing #regulatory\nMark T. D. Cronin, Steven J. Enoch, Chihae Yang\nProvides a targeted review of modern computational modeling platforms and database structures utilized to evaluate cosmetics ingredients under animal-testing bans.\nA transcriptomics-driven quantitative adverse outcome pathway network model for gentamicin-induced nephrotoxicity\n#research #safety-testing #translation\nFilippo Di Tillio, Tianqi Zhang, Joost B. Beltman\nIntegrates human transcriptomic cellular data into a computational network model to quantitatively project drug-induced kidney toxicity without animal cross-validation.\nAn exchange standard for FAIR PBK models in chemical risk assessment – A PARC community effort\n#research #safety-testing #regulatory\nJ. W. Kruisselbrink, J. Minnema, J. Engel\nOutlines an international standardized data-exchange framework designed to make physiologically based kinetic (PBK) software models findable, accessible, interoperable, and reusable (FAIR).\nApplication of new approach methodologies: ICE tools to support chemical evaluations\n#research #safety-testing #regulatory\nJaleh Abedini, Bethany Cook, Nicole Kleinstreuer\nDemonstrates how the Integrated Chemical Environment (ICE) computational toolkit can be applied to streamline non-animal chemical safety indexing and hazard profiling.\nApplying high throughput toxicokinetics (HTTK) to per- and polyfluoro alkyl substances (PFAS)\n#research #safety-testing\nJohn F. Wambaugh, Rogelio Tornero-Velez, Barbara A. Wetmore\nApplies high-throughput mathematical toxicokinetic models to profile the human absorption and clearance rates of diverse PFAS chemical structural groups without mammalian exposures.\nCausality and the use of adverse outcome pathways to structure expert review of carcinogenicity data\n#research #regulatory\nSusanne A. Stalford, Alex N. Cayley, Christopher G. Barber\nDemonstrates how AOP frameworks can organize a structured weight-of-evidence analysis for chemical carcinogenicity hazard profiling under regulatory guidelines.\nCOSMOS next generation – A public knowledge base leveraging chemical and biological data to support the regulatory assessment of chemicals\n#research #safety-testing #regulatory\nC. Yang, M. T. D. Cronin, A. P. Worth\nIntroduces an advanced public data warehouse designed to systematically synthesize chemical structures with non-animal biological endpoints for open regulatory acceptance.\nCurrent status and future directions for a neurotoxicity hazard assessment framework that integrates in silico approaches\n#research #safety-testing #translation\nKevin M. Crofton, Arianna Bassan, Glenn J. Myatt\nIdentifies the technical milestones and infrastructural upgrades needed to implement an entirely computer-driven hazard identification roadmap for developmental neurotoxicity.\nDevelopment and evaluation of explainable QSAR models to predict chemical-induced respiratory irritation\n#research #safety-testing\nPinyi Lu, Souvik Dey, Mohamed Diwan M. AbdulHameed\nPresents highly transparent, explainable quantitative structure-activity relationship (QSAR) algorithms designed to predict chemical inhalation hazards without using acute animal lung exposures.\nDevelopment of chemical categories for per- and polyfluoroalkyl substances (PFAS) and the proof-of-concept approach to the identification of potential candidates for tiered toxicological testing and human health assessment\n#research #safety-testing #regulatory\nG. Patlewicz, R. S. Judson, R. S. Thomas\nGroups diverse structural classes of PFAS chemicals using mathematical grouping filters to map candidate compounds for automated, animal-free toxicology screens.\nDevelopment of the toxicity values database, ToxValDB: A curated resource for experimental and derived human health-relevant toxicity data\n#research #safety-testing\nJonathan T. Wall, Risa R. Sayre, Chelsea A. Weitekamp\nDetails the compilation and curation parameters of the EPA\u0026rsquo;s public ToxValDB registry, a foundational engine for sourcing clean toxicological benchmarks to power computational algorithms.\nFederation of toxicological data resources for in silico new approach methodologies (NAMs)\n#research #safety-testing #regulatory\nNicoleta Spînu, Dimitris Stripelis, Andrew P. Worth\nPresents a data architecture framework designed to link and share toxicological data warehouses across international computing nodes, facilitating robust in silico validation of non-animal predictive tools.\nIn vitro transcriptomic points of departure derived from human whole transcriptome and reduced S1500+ gene panel are highly comparable\n#research #invitro #safety-testing\nJames Johnson, Joseph L. Bundy, Logan J. Everett\nValidates that targeted, cost-effective high-throughput gene panels yield toxicological points of departure that match full-scale transcriptomic screening, optimizing large-scale NAM implementation.\nIn silico analyses as a tool for regulatory assessment of protein digestibility: Where are we?\n#research #regulatory\nFernando Rivero-Pino, Caroline Idowu, Hannah Lester\nReviews the modern state of computer-driven protein digestion profiling software used to support structural safety and dietary evaluations under regulatory frameworks.\nO-QT assistant: a multi-agent AI system for streamlined chemical hazard assessment and read-across analysis using the OECD QSAR toolbox API\n#research #safety-testing\nIvo Djidrovski, Raymond Pieters, Marc Teunis\nDeploys a cooperative multi-agent AI software system connected to the OECD QSAR Toolbox API to automate chemical analog selections and read-across safety\nEPA # U.S. Environmental Protection Agency A federal agency at the absolute forefront of regulatory NAM implementation, developing explicit corporate work plans, strategies, and benchmarks to eliminate vertebrate testing for chemical and environmental risk assessments. [Link]\nA cheminformatics workflow to select representative TSCA chemicals for New Approach Methodology (NAM) screening | Science Inventory | US EPA\n#whitepaper #safety-testing #regulatory\nU.S. Environmental Protection Agency\nEstablishes a transparent categorization and workflow routing model designed to select 318 representative chemical candidates from the TSCA active inventory for high-throughput aqueous biological screening.\nAdvancing New Approach Methodologies (NAMs) for Tobacco Harm Reduction: Synopsis from the 2021 CORESTA SSPT-NAMs Symposium\n#whitepaper #translation #regulatory\nU.S. Environmental Protection Agency\nA cross-agency overview defining the international state-of-the-science and application thresholds for deploying alternative computational and in vitro data streams to assess novel consumer nicotine configurations without mammalian screening.\nAnalyzing multi-dimensional developmental neurotoxicity new approach methodologies: computational approaches to identify phenotypes | Science Inventory | US EPA\n#whitepaper #safety-testing\nU.S. Environmental Protection Agency\nOutlines mathematical and statistical pattern-recognition algorithms configured to analyze high-content imaging data, providing a scalable pathway to flag human developmental neurotoxicity variants.\nAvailability of New Approach Methodologies (NAMs) in the Endocrine Disruptor Screening Program (EDSP) | Science Inventory | US EPA\n#whitepaper #safety-testing #regulatory\nU.S. Environmental Protection Agency\nAn operational webinar brief defining the validation, performance metrics, and general deployment parameters of high-throughput in vitro cellular panels within the Endocrine Disruptor Screening Program framework.\nBuilding a compendium of expert driven read-across (EDRA) cases to investigate the utility of New Approach Methodology (NAM) data in Generalized Read-Across (GenRA) | Science Inventory | US EPA\n#whitepaper #safety-testing\nU.S. Environmental Protection Agency\nDetails how an active collection of expert-curated read-across templates can serve as an objective baseline to systematically calibrate and measure the accuracy of computational GenRA algorithms.\nChemical Landscape of New Approach Methodologies for Exposure\n#whitepaper #safety-testing\nU.S. Environmental Protection Agency\nA comprehensive technical index tracking chemical use patterns, fate boundaries, and exposure predictions, optimizing data accessibility to contextualize automated hazard testing.\nComputational approaches to evaluate in vitro New Approach Methodologies (NAMs) for Developmental Neurotoxicity (DNT) | Science Inventory | US EPA\n#whitepaper #safety-testing\nU.S. Environmental Protection Agency\nApplies supervised machine learning architectures to microelectrode arrays and neurite outgrowth datasets, demonstrating that a refined subset of informative endpoints can successfully predict in vivo toxic thresholds with 92% specificity.\nDecember 4, 6-8, 2018 FIFRA SAP Meeting\n#whitepaper #regulatory\nU.S. Environmental Protection Agency\nOfficial advisory panel proceedings reviewing an agency-proposed NAM case study engineered to completely replace complex live vertebrate testing for respiratory point-of-contact toxicity evaluations.\nDevelopment of a Tool for Integrating Traditional and New Approach Methodologies (NAMs) for Chemical Safety Decisions | Science Inventory | US EPA\n#whitepaper #safety-testing #regulatory\nU.S. Environmental Protection Agency\nIntroduces a web-based decision application that synthesizes production volumes and predictive exposure models with non-animal quantitative points of departure (PODs) to optimize TSCA chemical prioritization timelines.\nENVR 500 Environmental Processes, Exposure, and Risk Assessment: New Approach Methodologies for Chemical Risk Assessment\n#whitepaper #regulatory #guidelines\nU.S. Environmental Protection Agency\nA core curriculum blueprint addressing the systematic integration of predictive in silico tools and in vitro screening parameters within contemporary environmental public safety architectures.\nEPA is Moving Towards the Future of Chemical Assessments with New Approach Methods\n#whitepaper #safety-testing\nU.S. Environmental Protection Agency\nAn agency research briefing highlighting computational milestones and workflow designs used to isolate toxicological thresholds while safely avoiding intact animal testing models.\nEPA Releases Updated New Approach Methodologies (NAMs) Work Plan\n#whitepaper #regulatory #guidelines\nU.S. Environmental Protection Agency\nAn active policy briefing documenting the regulatory benchmarks, timeline frameworks, and scientific criteria required to establish non-animal evaluation pipelines.\nFIFRA SAP Meeting on “Evaluation of a Proposed Approach to Refine the Inhalation Risk Assessment for Point of Contact Toxicity A Case Study Using a New Approach Methodology (NAM).” Request for Nominations and Notice of Public Meeting\n#whitepaper #regulatory\nU.S. Environmental Protection Agency\nA formal public notice convening an expert review panel to evaluate mathematical approaches for point-of-contact inhalation hazard assessments, advancing the practical use of NAM data streams over live mammalian assays.\nNew Approach Methodologies (NAMs) and Chemical Risk Assessment | Science Inventory | US EPA\n#whitepaper #safety-testing #translation\nU.S. Environmental Protection Agency\nA high-density master presentation tracking the integration of high-throughput in vitro arrays, genomics, and toxicokinetic parameters to construct an objective, animal-free framework for chemical risk determinations.\nNew Approach Methodologies (NAMs) Training Pilot Program | Science Inventory | US EPA\n#whitepaper #safety-testing\nU.S. Environmental Protection Agency\nOfficial registry file for the EPA\u0026rsquo;s internal training program, establishing technical competencies and instructional guidelines for practicing scientists using computer-driven predictive testing protocols.\nNew Approach Methods (NAMs) Training\n#whitepaper #safety-testing\nU.S. Environmental Protection Agency\nThe central training platform hosting public training libraries, workshop archives, and dynamic instructional toolkits engineered to scale computational proficiency in alternative methodologies.\nNew Approach Methods Work Plan\n#whitepaper #regulatory #guidelines\nU.S. Environmental Protection Agency\nThe bedrock operational work plan mapping clear, tangible agency criteria to reduce vertebrate testing requirements and actively expand the legal deployment of alternative data models.\nPutting Theory into Practice: Using In Vitro and Computational New Approach Methodologies (NAMs) in Human-relevant Risk Assessment Key Human Exposure Modelling Approaches | Science Inventory | US EPA\n#whitepaper #safety-testing #translation\nU.S. Environmental Protection Agency\nExamines technical exposure simulations and pharmacokinetic models engineered to securely extrapolate non-animal bioactivity metrics into precise human health assessments.\nStrategic Vision for Adopting New Approach Methodologies - Reduction Strategies\n#whitepaper #regulatory #guidelines\nU.S. Environmental Protection Agency\nAn official strategic roadmap detailing specific data requirement adaptations and alternative methodology tools implemented to diminish animal usage throughout corporate pesticide risk profiling.\nStrategic Vision for Adopting New Approach Methodologies - Replacement Strategies\n#whitepaper #regulatory #guidelines\nU.S. Environmental Protection Agency\nEstablishes clear tactical vision parameters to systematically transition pesticide safety evaluations completely away from complex vertebrate testing models toward validated, non-animal computational networks.\nStrategic Vision for Adopting New Approach Methodologies - Strategic Vision for Adopting New Approach Methodologies\n#whitepaper #regulatory #guidelines\nU.S. Environmental Protection Agency\nThe structural cornerstone policy statement organizing the EPA Office of Pesticide Programs\u0026rsquo; systemic adoption of in silico, in chemico, and in vitro diagnostic platforms.\nThe chemical landscape of high-throughput new approach methodologies for exposure | Science Inventory | US EPA\n#whitepaper #safety-testing #translation\nU.S. Environmental Protection Agency\nDeploys the ExpoCast framework to integrate machine learning classifiers and non-targeted analytical screening, illustrating that alternative methodology models drastically broaden toxicokinetic coverage over historic animal testing pipelines.\nThe use of new approach methodologies (NAMs) to derive extrapolation factors and evaluate developmental neurotoxicity for human health risk assessment\n#whitepaper #regulatory\nU.S. Environmental Protection Agency\nTechnical case files submitted to the Scientific Advisory Panel detailing how in vitro data models can successfully replace standard inter- and intra-species uncertainty factors when assessing organophosphate pesticide risks.\nUse of New Approach Methodologies\n#whitepaper #safety-testing\nU.S. Environmental Protection Agency\nEvaluates the integration of advanced in silico profiling and high-throughput cellular screening frameworks designed to modernize and replace traditional animal metrics in the Endocrine Disruptor Screening Program.\nEFSA - European Food Safety Authority # An open European agency that evaluates and implements advanced non-animal methodologies, toxicokinetic modeling, and omics data integration to advance livestock and human food safety testing frameworks. [Link]\nBrain Health Consortium presenting Advancing NAMs for Neurotoxicity\n#whitepaper #safety-testing\nEuropean Food Safety Authority\nOfficial proceedings and event registry detailing the joint strategic tracking and panel updates for scaling human-relevant alternative frameworks in developmental neurotoxicity mapping.\nEFSA Pilot Project on New Approach Methodologies (NAMs) for Tebufenpyrad Risk Assessment. Part 1. Development of Physiologically-Based Kinetic (PBK) Model Coupled With Pulmonary and Dermal Exposure\n#whitepaper #safety-testing\nEuropean Food Safety Authority\nA comprehensive case study detailing the calculation of multi-route human exposure thresholds via automated computational biokinetic software models utilizing entirely non-animal data layers.\nEFSA Pilot Project on New Approach Methodologies (NAMs) for Tebufenpyrad Risk Assessment. Part 2. Hazard characterisation and identification of the Reference Point\n#whitepaper #safety-testing #regulatory\nEuropean Food Safety Authority\nOutlines the second stage of the tebufenpyrad alternative pathway trial, demonstrating how quantitative points of departure can be isolated using alternative data streams to form regulatory chemical risk boundaries.\nEFSA Project on the use of New Approach Methodologies (NAMs) for the hazard assessment of nanofibres. Lot 1, nanocellulose oral exposure: gastrointestinal digestion, nanofibres uptake and local effects\n#whitepaper #safety-testing #invitro\nEuropean Food Safety Authority\nDeploys an integrated tissue and assay approach (IATA) to systematically profile the metabolic breakdown, cellular absorption barriers, and localized tissue strain thresholds of ingested nanocellulose materials.\nEuropean stakeholders\u0026rsquo; workshop on new approach methodologies (NAMs) for developmental neurotoxicity (DNT) and their use in the regulatory risk assessment of chemicals\n#whitepaper #regulatory #translation\nEuropean Food Safety Authority\nA prominent technical workshop report detailing the cross-sector validation criteria, diagnostic benchmarks, and collaborative guidelines used to move an international OECD alternative screening model for neurotoxicity into active draft implementation.\nExploring the use of Artificial Intelligence (AI) for extracting and integrating data obtained through New Approach Methodologies (NAMs) for chemical risk assessment\n#whitepaper #safety-testing\nEuropean Food Safety Authority\nInvestigates the implementation of automated machine learning systems designed to crawl, parse, and systematically synthesize massive unstructured textual alternative methodology screening files into clear hazard assessment databases.\nMaintenance, update and further development of EFSA\u0026rsquo;s Chemical Hazards: OpenFoodTox 2.0\n#whitepaper #safety-testing #regulatory\nEuropean Food Safety Authority\nDetails structural data architecture upgrades to EFSA\u0026rsquo;s open database, expanding its processing capacity to catalog standardized non-animal parameter profiles, intermediate cellular effects, and harmonized international database formats.\nProposal for a qualification system for New Approach Methodologies (NAMs) in the food and feed sector: example of implementation for nanomaterial risk assessment\n#whitepaper #regulatory #guidelines\nEuropean Food Safety Authority\nEstablishes a rigorous, step-by-step assessment protocol designed to systematically qualify and verify in vitro cellular screening assays and degradation parameters for formal safety submittals.\nReview of New Approach Methodologies for Application in Risk Assessment of Nanoparticles in the Food and Feed Sector: Status and Challenges\n#whitepaper #safety-testing #translation\nEuropean Food Safety Authority\nAn extensive technical synthesis profiling current nanoparticle-specific computational grids, chemical structure-activity predictions, and biological validation boundaries across the food sector.\nStakeholder Workshop on EFSA’s Genotoxicity Guidance Revision\n#whitepaper #regulatory #guidelines\nEuropean Food Safety Authority\nOfficial alignment brief and panel schedule detailing the programmatic revision of EFSA\u0026rsquo;s test protocols to support modern, animal-free mechanistic evaluation pathways.\nTKPlate 1.0: An Open-access platform for toxicokinetic and toxicodynamic modelling of chemicals to implement new approach methodologies in chemical risk assessment\n#whitepaper #safety-testing\nEuropean Food Safety Authority\nA major landmark technical paper introducing an open computing environment that automates toxicokinetic and toxicodynamic simulations, enabling assessors to safely project internal dose dynamics and human clearance boundaries in silico.\nUser Guide for TKPlate 1.0: An open access platform for implementing new approach methodologies in chemical risk assessment through toxicokinetic and toxicodynamic modelling\n#whitepaper #safety-testing\nEuropean Food Safety Authority\nThe authoritative software user manual defining data input formats, metabolic parameterization boundaries, and model configuration steps for running calculations inside the TKPlate environment.\nFrontiers in Toxicology - Research Topics # A peer-reviewed specialty portal detailing international breakthroughs in algorithmic modeling, molecular structural indexing, and genome-scale biochemical network simulators engineered to replace live vertebrate biological screens. [Link]\nA New Immortalized Human Alveolar Epithelial Cell Model to Study Lung Injury and Toxicity on a Breathing Lung-On-Chip System\n#research #safety-testing #bioprinting #chemical-testing\nArunima Sengupta, Nuria Roldan, Mirjam Kiener, \u0026hellip; Olivier T. Guenat\nCombines a human-derived immortalized alveolar epithelial cell line (${}^{AX}iAEC$) with advanced microfluidic organ-on-chip hardware to recreate breathing-like 3D cyclic stretch mechanical strains (10% linear strain, 0.2 Hz) at an air-liquid interface (ALI). Establishes a highly stable AT1/AT2 co-culture barrier (TER \u0026gt;1,000 $\\Omega$ cm²) to evaluate inflammatory lipopolysaccharide responses, profibrotic TGF$\\beta$1 pathways, and SARS-CoV-2 host factor expression without live animal models.\nAn Adverse Outcome Pathway for Decreased Lung Function Focusing on Mechanisms of Impaired Mucociliary Clearance Following Inhalation Exposure\n#research #safety-testing #translation #chemical-testing\nKarsta Luettich, Monita Sharma, Hasmik Yepiskoposyan, Damien Breheny, Frazer J. Lowe\nDelineates a robust qualitative adverse outcome pathway (AOP) network on the AOP-Wiki mapping how chemical-induced oxidative stress causes down-regulation of CFTR and FOXJ1 proteins, leading to a cascade of airway surface liquid dehydration, ciliary beat frequency decay, and heightened mucus viscosity that results in chronic human lung function decline.\nApplication of Defined Approaches for Skin Sensitization to Agrochemical Products\n#research #safety-testing #regulatory #chemical-testing\nJudy Strickland, James Truax, Marco Corvaro, \u0026hellip; Nicole Kleinstreuer\nTests 27 complex water- and solvent-based commercial agrochemical formulations across three non-animal assay platforms—DPRA (KE1), KeratinoSens (KE2), and h-CLAT (KE3)—to expand the applicability domain of OECD Guideline 497 defined approaches from monoconstituent substances to complex product mixtures.\nCanadian Regulatory Perspective on Next Generation Risk Assessments for Pest Control Products and Industrial Chemicals\n#whitepaper #regulatory #guidelines #chemical-testing\nYadvinder Bhuller, Deborah Ramsingh, Marc Beal, Sunil Kulkarni, Matthew Gagne, Tara S. Barton-Maclaren\nProvides a detailed regulatory overview of Health Canada\u0026rsquo;s progressive integration of non-animal alternatives into its modern scientific review schemes, detailing weight-of-evidence (WoE) applications of in vitro transcriptomic points of departure, high-throughput bioactivity exposure ratios (BER), and multi-agency APCRA case studies to implement next-generation risk assessments.\nComprehensive genome-scale metabolic model of the human pathogen Cryptococcus neoformans: A platform for understanding pathogen metabolism and identifying new drug targets\n#research #safety-testing #biometrics\nEnes Fahri Tezcan, Yigit Demirtas, Zeynep Petek Cakar, Kutlu O. Ulgen\nPresents \u0026ldquo;iCryptococcus,\u0026rdquo; the first comprehensive genome-scale metabolic simulator consisting of 1,270 reactions, 1,143 metabolites, and 649 genes mapped across eight computational cellular compartments. Validates network essentiality in silico to systematically expose active steroid and amino acid drug targets without executing live animal tissue assays.\nEditorial: Chemical Testing Using New Approach Methodologies (NAMs)\n#whitepaper #regulatory #translation #chemical-testing\nAndreas O. Stucki, Amy J. Clippinger, Tala R. Henry, Carole Hirn, Todd J. Stedeford, Claire Terry\nIntroduces the special collection and provides an overarching technical baseline framing the progressive transition from legacy descriptive vertebrate assays toward human-relevant, mechanistically driven in vitro and in silico toxicity networks in alignment with the US National Research Council\u0026rsquo;s vision for 21st-century toxicology.\nEvaluation of Inhalation Exposures and Potential Health Impacts of Ingredient Mixtures Using in vitro to in vivo Extrapolation\n#research #safety-testing #regulatory #chemical-testing\nJingjie Zhang, Xiaoqing Chang, Tessa L. Holland, David E. Hines, Agnes L. Karmaus, Shannon Bell, K. Monica Lee\nDeploys an in vitro to in vivo extrapolation (IVIVE) template using open-source physiologically based pharmacokinetic (PBPK) models (Gas_PBTK via the httk R package) to perform reverse dosimetry on e-cigarette aerosol mixtures. Models human equivalent administered doses (EADs) under three discrete parameters (single actor, additive effect, and outcome-oriented ingredient integration) to balance compound-specific absorption-clearance rates with overall toxicity tracking.\nMolecular modeling, simulation and docking of Rv1250 protein from Mycobacterium tuberculosis\n#research #safety-testing #biometrics\nSumita Choudhary, Anup Kumar Kesavan, Vijay Juneja, Sheetal Thakur\nDeploys advanced automated structure prediction through the I-TASSER server alongside a 100-nanosecond molecular dynamics (MD) trajectory simulator to analyze steady-state static interactions between target bacterial transporter enzymes and prospective inhibitors in silico.\nHuman adenovirus DNA polymerase is evolutionarily and functionally associated with human telomerase reverse transcriptase based on in silico molecular characterization that implicate abacavir and zidovudine\n#research #safety-testing #biometrics\nToluwase Hezekiah Fatoki\nApplies deep computational molecular characterization, virtual target mapping, and molecular dynamics (MD) simulations to determine the binding affinity and thermodynamic stability of candidate antiviral chemical ligands, establishing a purely digital protocol for structural chemical evaluations.\nUse of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Predict the Cardiotoxicity Potential of Next Generation Nicotine Products\n#research #safety-testing #invitro #chemical-testing\nLiam Simms, Fan Yu, Jessica Palmer, \u0026hellip; Grant O\u0026rsquo;Connell\nUtilizes human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) maintained via galactose media to transition cell bioenergetics from fetal glycolysis to adult oxidative phosphorylation. Leverages the metabolomics-based Cardio quickPredict assay to screen aqueous whole aerosol and smoke extracts via four core secretome markers (lactic acid, arachidonic acid, thymidine, and 2\u0026rsquo;-deoxycytidine) to reliably score functional cardiotoxicity potential in vitro.\nUse of new approach methodologies (NAMs) to meet regulatory requirements for the assessment of industrial chemicals and pesticides for effects on human health\n#whitepaper #regulatory #guidelines #chemical-testing\nAndreas O. Stucki, Tara S. Barton-Maclaren, Yadvinder Bhuller, \u0026hellip; Amy J. Clippinger\nA comprehensive master review tracking the legal frameworks, intra-agency science initiatives, and operational flexibility clauses allowing for the deployment of alternative testing platforms across the US EPA (OPPT and OPP), US CPSC, Health Canada (HECSB and PMRA), ECHA, and EFSA.\nUse of new approach methodologies (NAMs) to meet regulatory requirements for the assessment of tobacco and other nicotine-containing products\n#whitepaper #regulatory #guidelines #chemical-testing\nJacqueline Miller-Holt, Holger P. Behrsing, Amy J. Clippinger, Carole Hirn, Todd J. Stedeford, Andreas O. Stucki\nAnalyzes the global legislative status of alternative test models under the US FDA Center for Tobacco Products (CTP) pre-market paths, Health Canada\u0026rsquo;s Tobacco Reporting Regulations, and the European Union\u0026rsquo;s Tobacco Products Directive (TPD). Recommends specific international intergovernmental frameworks and open data repositories to build institutional confidence in human-relevant in silico and organotypic testing workflows.\nVersatile Functional Energy Metabolism Platform Working From Research to Patient: An Integrated View of Cell Bioenergetics\n#research #safety-testing #invitro #chemical-testing\nSylvain Loric, Marc Conti\nDeploys a clinical biochemical random-access multiparametric automation analyzer to continuously measure 22 critical homeostatic endpoints (including complexes I–V, glycolysis enzymes, and superoxide dismutase cascades) from a single 250 $\\mu$L fluid sample. Restricts procedimiento coefficients of variation (CV%) below 5% to securely isolate subtle, low-noise chronic mitochondrial toxicities and cellular peroxidation in vitro and in vivo.\nICCVAM # Interagency Coordinating Committee on the Validation of Alternative Methods A collaborative committee of federal regulatory and research agencies in the United States that establishes official roadmaps and validation metrics to transition federal bodies toward non-animal drug and safety evaluations. [Link]\nA Strategic Roadmap for Establishing New Approaches to Evaluate the Safety of Chemicals and Products in the United States\n#whitepaper #regulatory #guidelines\nNICEATM\nThe landmark strategic planning framework detailing cross-agency directives, computational milestones, and public-private implementation plans engineered to phase out classic in vivo toxicity testing in favor of human-relevant predictive models.\nAccelerating Adoption of NAMs with FAIR Principles\n#research #regulatory\nNICEATM\nExamines specific repository case studies demonstrating how improving the findability, accessibility, interoperability, and reusability (FAIR) of public high-throughput data streams directly accelerates regulatory confidence and tool adoption.\nAlternative Methods Accepted by US Agencies\n#whitepaper #regulatory #guidelines\nICCVAM\nAn interactive, web-based reference tracking database configured to allow researchers and industry submitters to instantly cross-reference qualified non-animal testing methods against specific federal agency regulatory endpoints.\nAnnotations for ToxCast and Tox21 High-Throughput Screening Assays SOT 2023 Poster\n#research #safety-testing\nNICEATM\nDetails a massive curation effort to format, tag, and structurally annotate chemical bioactivity data from the ToxCast and Tox21 high-throughput screening libraries, transforming raw algorithmic files into easily interpretable regulatory profiles.\nApplication of Defined Approaches for Skin Sensitization for Agrochemical Products\n#research #safety-testing #regulatory\nNICEATM\nDeploys fixed alternative data interpretation loops on commercial pesticide mixtures, demonstrating how non-animal testing strategies can accurately predict skin sensitization thresholds under active international guidelines.\nApplying httk and In Vitro Data to Estimate Acute Neurotoxicity Potential\n#research #safety-testing\nUSAF Predictive Risk Team\nA joint computational case study detailing the application of the open-source httk R suite to map, perform reverse dosimetry, and run high-throughput chemical risk assessments on 220 potential neurotoxicants for the Department of Defense.\nApplying In Silico Toxicity Models Across the Tox21 Chemical Space to Enhance DILI Predictivity\n#research #safety-testing #biometrics\nNICEATM\nDeploys advanced structural informatics and deep learning algorithms across the entire Tox21 chemical catalog to significantly sharpen the in silico predictivity of drug-induced liver injury (DILI) parameters where legacy rodent studies fail.\nApplying In Silico Toxicity Models Across the Tox21 Chemical Space SOT 2023 Poster\n#research #safety-testing #biometrics\nNICEATM\nA technical presentation detailing the implementation of structure-based machine learning classifiers configured to screen massive compound lists for clinical liver hazard alerts.\nAssay Application: Characterizing Sources of Variability in Non-Animal Methods\n#whitepaper #safety-testing\nICCVAM\nInvestigates mechanical parameters, experimental bias vectors, and strict in-process control baselines required to neutralize noise and confirm the technical reproducibility of automated in chemico and in vitro screening assays.\nAssay Development: Air-Liquid Interface (ALI) vs. Direct Liquid Systems\n#whitepaper #safety-testing #invitro\nICCVAM\nA performance evaluation study measuring data mapping parity between specialized cell exposures at an air-liquid interface (ALI) and conventional submerged liquid cultures, optimization benchmarks for respiratory toxicity NAMs.\nBuilding Confidence in Alternative Methods Through ICE ASCCT 2021 Briefing\n#research #safety-testing\nNICEATM\nIntroduces the continuous user-interface upgrades and data integration tracks designed to expand the toxicological utility of the open Integrated Chemical Environment (ICE) portal.\nBuilding Confidence in Alternative Methods Through ICE SOT 2022 Poster\n#research #safety-testing\nNICEATM\nA technical poster illustrating how the query tools and curation pipelines configured inside ICE democratize access to validated alternative testing metrics for international risk managers.\nBuilding Confidence in Alternative Methods Through ICE SOT 2022 Presentation\n#research #safety-testing\nNICEATM\nDelineates how specific in vitro endpoints and model systems are compiled within the ICE infrastructure to serve as a reliable standalone alternative to live multi-organ mammal profiling.\nCanadian Regulatory Perspective on Next Generation Risk Assessments for Pest Control Products and Industrial Chemicals\n#whitepaper #regulatory #guidelines\nHealth Canada\nOutlines Health Canada\u0026rsquo;s statutory work plans and weight-of-evidence (WoE) parameters to seamlessly deploy high-throughput exposure ratios and transcriptomic benchmarks instead of standard vertebrate toxicity tests.\nCollection of Alternative Methods for Regulatory Application User Interface\n#whitepaper #regulatory\nNICEATM\nA programmatic presentation revealing the structural database design of a public, interactive web dashboard crafted to let regulatory entities query qualified non-animal assay parameters filtered by exact context of use.\nCombining NAM Data and IVIVE for Evaluating Potential Inhalation Toxicity SOT 2023 Abstract\n#research #safety-testing #regulatory\nNICEATM\nOutlines a predictive template combining in vitro tissue data with open computational biokinetic packages to map target human equivalent exposure thresholds for inhaled environmental formulations.\nCombining NAM Data and IVIVE for Evaluating Potential Inhalation Toxicity SOT 2023 Poster\n#research #safety-testing #regulatory\nNICEATM\nDetails a quantitative case study applying multi-compartment in vitro to in vivo extrapolation (IVIVE) methods to calculate reliable internal dose constraints, bypassing intact rodent lung assays.\nComplement-ARIE: Complement Animal Research in Experimentation\n#whitepaper #translation\nNIH Office of Strategic Coordination\nAn authoritative presentation defining the mission objectives of the multi-million dollar NIH Complement-ARIE initiative, designed to systematically catalyze the standardization, scaling, and deployment of human-based alternative tools.\nCuration of Eye and Skin Irritation Reference Data\n#whitepaper #safety-testing\nNICEATM\nDocuments a rigorous data curation strategy designed to measure and define the intrinsic historical variability of legacy rabbit skin and eye tests, establishing realistic target parameters for qualifying modern alternative assays.\nDeveloping In Vitro Assay Annotations to Provide Context and Enhance Utility\n#research #safety-testing\nNICEATM\nPresents a standardized data-annotation roadmap designed to tag raw in vitro screening files with precise mechanistic data layers, making large-scale chemical profiling sets instantly machine-readable for validation.\nDevelopment of a Tool for Integrating Traditional and New Approach Methodologies (NAMs) for Chemical Safety Decisions\n#whitepaper #safety-testing #regulatory\nNICEATM\nDetails the coding parameters of a regulatory decision platform that matches computational exposure analytics with cell-based points of departure to prioritize active compound files under TSCA timelines.\nEngaging NAMs for Toxicant REgulation and Effects - ENTREE Project\n#whitepaper #regulatory\nICCVAM\nA technical progress update introducing the ENTREE computing engine, engineered to automate data ingestion from non-animal study submittals and benchmark their validation profiles against international guidelines.\nEstablishing Confidence in NAMs: Considering Variability in Reference Data\n#research #safety-testing\nNICEATM\nAn analytical report tracking how mathematical modeling of the baseline uncertainty and errors found in legacy animal testing sheets can prevent the false rejection of highly accurate non-animal algorithms.\nEvaluation of substances of regulatory interest using non-animal test methods\n#whitepaper #safety-testing #regulatory\nNICEATM / Division of Translational Toxicology\nA major technical evaluation report detailing the step-by-step screening metrics, minimum induction thresholds (MIT), and predictive performance bounds of advanced non-animal assays compiled on behalf of federal agency partners.\nEvaluation of the GARDskin Sensitization Test Method Using Substances of Regulatory Interest\n#whitepaper #safety-testing\nNICEATM\nA specialized peer-review data package evaluating the genomic-based GARDskin assay, documenting its capacity to classify chemical sensitization hazards by monitoring human transcriptomic biomarker profiles in vitro.\nFacilitating NAM-Based Chemical Assessments with the Integrated Chemical Environment\n#research #safety-testing\nNICEATM\nIntroduces a newly integrated developmental toxicity query branch added to the ICE computational pipeline, connecting automated PBPK engines with non-animal tissue points of departure.\nFormatting ToxCast and ICE cHTS Data Into OECD Reporting Templates\n#whitepaper #regulatory #guidelines\nICCVAM\nA high-value user framework mapping out the precise data formatting criteria required to package automated high-throughput screening metrics into internationally harmonized OECD harmonized templates.\nGARD Models for Identification of Potential Skin and Respiratory Sensitizers\n#whitepaper #safety-testing #invitro\nICCVAM\nReviews the mechanistic performance of the cell-based GARDair assay, validating an alternative testing template for respiratory hypersensitivity—an endpoint for which no reliable animal model exists.\nHuman-Based New Approach Methodologies for Biomedical Research | SACATM 2025 Presentation\n#whitepaper #translation #regulatory\nU.S. National Toxicology Program\nAn extensive advisory committee brief detailing strategic regulatory frameworks, reviewer training protocols, and programmatic hotlines designed to increase institutional confidence and publicize successful non-animal case validation pipelines.\nHuman Data for Skin Sensitization Method Evaluation Index\n#whitepaper #safety-testing\nNICEATM\nThe main repository link hosting highly vetted, clean human clinical datasets utilized by method developers to benchmark and verify the accuracy of upcoming dermal alternative algorithms.\nHuman data set for skin sensitization methods evaluation | ICCVAM Biennial Report 2023\n#whitepaper #safety-testing\nICCVAM\nDetails a curated human reference dataset designed to systematically evaluate and score the predictive capacity, reproducibility, and biological accuracy of alternative in vitro and in silico skin sensitization assays.\nICE: Advancing Data Availability and Computational Tool Accessibility\n#research #safety-testing\nNICEATM\nA comprehensive software architecture report summarizing recent updates to the ICE computing environment, designed to optimize large-scale user accessibility for multi-compartment risk screening tools.\nICE Tools to Support Chemical Evaluations SOT 2022 Poster\n#research #safety-testing\nNICEATM\nA tactical reference walkthrough illustrating how data integration tools within the ICE ecosystem can be leveraged to harmonize raw in vitro screening outputs into standardized toxicity profiles.\nICCVAM Agency Activities\n#whitepaper #regulatory #guidelines\nICCVAM\nOutlines a permanent technical validation framework and comprehensive recommendations designed to guide pharmaceutical developers in substituting legacy rodent models with human-relevant cell-based arrays.\nICCVAM Biennial Progress Report 2020-2021\n#whitepaper #regulatory\nICCVAM\nA major statutory report detailing international agency alignment, technical testing program data streams, and specific strategic actions tracking the implementation of alternative endpoints into federal chemical policy.\nICCVAM Biennial Progress Report 2022-2023\n#whitepaper #regulatory\nICCVAM\nA comprehensive progress review documenting federal milestone metrics, quality management approaches, and strategic alignment parameters established to anchor scientific confidence in upcoming NAM frameworks.\nICCVAM Communities of Practice Webinars on (Developmental) Neurotoxicity\n#whitepaper #safety-testing #translation\nICCVAM\nCompiles the findings and inter-agency workshop briefs from the 2022 public forum, detailing strategic criteria for integrating microelectrode array data into regulatory decisions without mammalian tests.\nICCVAM Communities of Practice Webinars: Capturing the Leading Edge of NAMs\n#whitepaper #translation\nICCVAM\nA historical timeline presentation detailing agency-sponsored public learning modules (2018–2025) configured to build technical workforce literacy in toxicokinetic calculations and human-centric brain models.\nICCVAM Guidelines for Nomination and Submission of New, Revised, and Alternative Test Methods\n#whitepaper #regulatory #guidelines\nICCVAM\nThe primary statutory submission manual establishing the technical requirements, biostatistical parameters, and performance criteria developers must satisfy to qualify a novel NAM for federal regulatory tracking.\nICCVAM Member Agencies Working Directory\n#whitepaper #regulatory\nICCVAM\nThe central routing directory mapping specific chemical safety initiatives, training portals, and alternative method acceptance clauses across all 16 coordinating federal committee nodes.\nICCVAM Workgroup Update: ICCVAM Public Forum 2021\n#whitepaper #regulatory\nNICEATM\nA technical committee report documenting baseline curation protocols for reference data sets, along with active testing models used to accelerate international legal validation pathways.\nImproving Alternative Method Adoption Through Tools and Resources\n#research #translation\nNICEATM\nAn operational white paper reviewing the integration of international science policy efforts and public database tools required to successfully transition commercial laboratory protocols away from intact animal testing.\nIn Vitro Test Battery for Developmental Neurotoxicity Evaluation\n#whitepaper #safety-testing #invitro\nICCVAM\nDetails an ongoing inter-agency evaluation program focused on microelectrode array platforms and neural connectivity software, optimizing automated alternatives for developmental toxicity screening.\nIn Vitro to In Vivo Extrapolation for Developmental Toxicity Risk Assessments\n#research #safety-testing #regulatory\nNICEATM\nEvaluates automated pharmacokinetic modeling runs performed on 186 reference chemicals, establishing reverse dosimetry baselines to prove the reliability of in vitro alternatives in developmental toxicity filings.\nInitiatives to Replace or Reduce Animal Use | ICCVAM Biennial Report 2023\n#whitepaper #regulatory\nICCVAM\nExamines systemic barriers, historical incentives, and strategic policy solutions required to transition legacy research portfolios away from established in vivo protocols toward non-animal testing strategies.\nIntegrated Chemical Environment: An Advanced Platform Aiding Alternative Method Development SOT 2023 Abstract\n#research #safety-testing\nNICEATM\nOutlines software architecture criteria for seamlessly merging diverse cell-based datasets with predictive algorithmic grids, creating an accessible digital alternative to rodent testing layouts.\nIntegrated Chemical Environment: An Advanced Platform Aiding Alternative Method Development SOT 2023 Poster\n#research #safety-testing\nNICEATM\nA technical poster demonstration showing how the PBPK, IVIVE, and chemical characterization modules inside ICE work in tandem to evaluate unknown compounds without animal tissue.\nIntegrating Bayesian Approaches with PBPK Modeling in a Human-Relevant Framework\n#research #safety-testing #biometrics\nNICEATM / NIEHS Workshop\nPresents an advanced probabilistic framework that overlays Bayesian inference onto PBPK software templates, enabling automated mapping of population sensitivity margins via human in vitro parameters.\nIntegrating Screening-Level Developmental Neurotoxicity (DNT) Data Streams Into a Unified NAM Battery\n#whitepaper #safety-testing #invitro\nU.S. National Toxicology Program\nA high-density strategic brief outlining how high-throughput cell-imaging data streams are linked into an interim screening matrix to reliably tag chemical developmental neurotoxicity risks.\nIntegrating Structure-Based Chemical Taxonomies to Focus Queries Across Large-Scale NAM Datasets WC13 Poster\n#research #safety-testing #biometrics\nNICEATM\nDemonstrates the integration of automated ClassyFire structural chemical taxonomy classification scripts into open endpoints, a key mechanism to navigate high-volume data arrays generated by alternative workflows.\nIntegrating Structure-Based Chemical Taxonomies to Focus Queries Across Large-Scale NAM Datasets WC13 Presentation\n#research #safety-testing #biometrics\nNICEATM\nAn algorithmic report detailing data-mining pathways configured to group chemical structural families, minimizing query friction when searching thousands of automated in vitro bioactivity logs.\nInternational Interactions | ICCVAM Biennial Report 2023\n#whitepaper #regulatory\nICCVAM\nAnalyzes the global regulatory acceptance bottlenecks of modern NAM data streams and discusses harmonization approaches for new technologies where classical validation criteria are not applicable.\nInvestigating the Impact of Cytochrome P450 Metabolism on Chemical-Mediated Transcription Factor Activity\n#research #safety-testing\nNICEATM\nDeploys a specialized in vitro metabolic activation overlay to capture how cytochrome P450 liver enzyme processing affects cell signaling, an essential technical requirement to replace rodent multi-organ clearance testing.\nMethods2AOP: An International Collaboration to Integrate Assay Methods with Alternative Pathways\n#research #safety-testing #translation\nNICEATM\nA collaborative technical report mapping a data infrastructure that automatically anchors discrete in vitro cell assay protocols to explicit molecular key events within the international Adverse Outcome Pathway framework.\nModernizing the Acute Toxicity \u0026lsquo;Six-Pack\u0026rsquo; for U.S. EPA\u0026rsquo;s Office of Pesticide Programs\n#whitepaper #regulatory #guidelines\nEPA Office of Pesticide Programs\nAn official agency implementation brief documenting the specific criteria, policy rules, and testing guidelines deployed to substitute the classical in vivo \u0026ldquo;six-pack\u0026rdquo; animal tests with validated alternative datasets.\nNew Approach Methodologies for Use in FDA Food Safety Assessments\n#whitepaper #safety-testing #regulatory\nSuzanne Fitzpatrick, PhD, DABT\nAn official FDA forum briefing detailing the creation and operational parameters of the CFSAN NAMs working group configured to integrate predictive non-animal methodologies into standard food ingredient safety profiles.\nNew Interactive Database of Validated and Qualified NAMs for Regulatory Application\n#whitepaper #regulatory\nNICEATM / ICCVAM\nA baseline committee overview introducing the design and public launch of an open-access interactive interface developed to help risk managers filter qualified alternative methods by regulatory authority.\nNICEATM and ICCVAM Publications, 2022-2023\n#whitepaper #translation\nNICEATM\nA curated bibliography tracking peer-reviewed publications and symposium abstracts focused on establishing the biological relevance of high-throughput alternatives and evaluating NAM configurations for tobacco harm reduction.\nNICEATM Computational Tools and Resources Supporting Alternative Method Adoption\n#research #safety-testing\nNICEATM\nAn operational briefing surveying public computational architectures and data-sharing engines optimized to support both developer validation tracks and agency-level hazard evaluations.\nNICEATM: Alternative Methods Main Portal Directory\n#whitepaper #regulatory #guidelines\nNICEATM\nThe main portal interface hosting public access tracks for the Integrated Chemical Environment (ICE), SEAZIT zebrafish evaluation data logs, and formal ICCVAM inter-agency strategy roadmaps.\nOECD Guidance Document 34: Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment\n#whitepaper #regulatory #guidelines\nOrganisation for Economic Co-operation and Development\nThe foundation international text establishing standard scientific frameworks, performance testing criteria, and independent peer-review parameters required to declare a new testing methodology legally validated.\nPolicies and Guidance for Implementation of Alternative Methods | ICCVAM Biennial Report 2023\n#whitepaper #regulatory #guidelines\nICCVAM\nDocuments specific policy updates and implementation tools deployed across member agencies to realize the operational mandates established by the 2018 ICCVAM Strategic Roadmap.\nPresentation Abstracts: Using New Approach Methodologies to Address Variability and Susceptibility Across Populations\n#whitepaper #safety-testing\nNICEATM\nCompiles high-density presentation synopses evaluating methodologies to model human population variability and genetic susceptibility thresholds using high-throughput in vitro cellular configurations.\nProviding Context to In Vitro High-Throughput Screening Data Using ICE\n#research #safety-testing\nNICEATM\nA high-density poster demonstration modeling how raw in vitro bioactivity data arrays from public libraries can be contextually mapped against baseline exposure boundaries to derive solid non-animal risk ratios.\nPublic Comment on ICCVAM Draft Report on Validation from PCRM\n#whitepaper #regulatory\nPhysicians Committee for Responsible Medicine\nA detailed advocacy comment submission offering precise parameter adjustments to ensure the updated ICCVAM validation framework is completely fit-for-purpose, fast-tracked, and focused on non-animal tech.\nPublic Comment on ICCVAM Draft Report on Validation from PETA Science Consortium\n#whitepaper #regulatory\nPETA Science Consortium International\nA comprehensive technical feedback filing advising on training expansions and explicit communication workflows needed to actively build corporate and regulatory confidence in non-animal guidelines.\nPublications About NICEATM \u0026amp; ICCVAM Activities in Scientific Journals\n#whitepaper #translation\nNICEATM\nAn indexed record tracking literature outcomes and agency perspectives regarding the landscape of alternative predictive methodologies submitted within modern regulatory drug filings.\nRegulatory Applications of 3Rs\n#whitepaper #regulatory #guidelines\nNICEATM\nAn operational data portal mapping the specific regulatory contexts, test criteria, and agency-level parameters where the inclusion of non-animal data models is legally accepted or explicitly encouraged.\nRoadmap Implementation Plans: Update on Each of the Acute Toxicity \u0026lsquo;Six-Pack\u0026rsquo; Endpoints\n#whitepaper #regulatory #guidelines\nNICEATM / ICCVAM\nA high-density strategic presentation reviewing the exact validation criteria, curation baselines, and cross-agency milestones achieved in replacing the classical animal \u0026ldquo;six-pack\u0026rdquo; testing endpoints.\nSARA-ICE: Skin Sensitization Risk Assessment - Integrated Chemical Environment Module\n#whitepaper #safety-testing\nNICEATM\nAn operational hub introducing the SARA-ICE module, a predictive web tool that computes human-relevant skin allergy potency probabilities by combining defined approaches with machine learning.\nSearches on Specific Alternatives Topics: MeSH Query Templates\n#whitepaper #guidelines\nNICEATM\nHosts a collection of optimized, high-density PubMed/MeSH medical search syntax strings designed to help researchers instantly filter out legacy vertebrate studies and isolate pure NAM literature.\nSession 2 Presentation Abstracts and Background Materials: SACATM 2023\n#whitepaper #safety-testing #translation\nU.S. National Toxicology Program\nA technical background review detailing cell-stress panels, computational toolsets, and in vitro models engineered to profile multi-individual population susceptibility without vertebrate testing.\nThe SARA-ICE Model for Predicting Quantitative Human-Relevant Skin Sensitizer Potency WC12 Abstract\n#research #safety-testing\nNICEATM\nDetails a mathematical weight-of-evidence (WoE) algorithm configured to integrate raw data inputs from in chemico assays and human cell arrays, returning precise human-relevant skin safety margins in silico.\nThe Skin Allergy Risk Assessment (SARA-ICE) Platform SOT 2023 Presentation\n#research #safety-testing\nNICEATM\nA specialized case presentation demonstrating how the SARA-ICE module processes direct peptide reactivity data alongside cell-based logs (KeratinoSens/h-CLAT) to score toxicant potency.\nUpdate on Alternatives Research at EPA Office of Research and Development\n#whitepaper #safety-testing\nEPA Office of Research and Development\nA progress briefing reviewing computational milestones, microelectrode array validations, and multi-endpoint data modeling runs configured to expand the coverage of non-animal risk diagnostics.\nUser Guide for TKPlate 1.0 Coupled with Pulmonary and Dermal Exposure Distributions\n#research #safety-testing #biometrics\nEuropean Food Safety Authority Case Studies\nA high-density workshop slideshow explaining the integration of EFSA\u0026rsquo;s TKPlate environment with human cell-derived absorption data to accurately model pesticide clearance routes in silico.\nValidation \u0026amp; Qualification of New Methods\n#whitepaper #regulatory #guidelines\nNICEATM\nAn authoritative developer guidance document defining a modernized framework for the validation, qualification, and swift regulatory acceptance of fit-for-purpose alternative methodologies.\nValidation of the 21st Century Toxicology Toolbox: Historical Milestones and Systems Biology\n#whitepaper #translation\nNICEATM / Stokes et al.\nA retrospective analysis detailing the structural transition of toxicological science from traditional animal endpoint tracking toward human-relevant systems biology networks and predictive computation.\nVariability in Reference Test Method Data and the Impact on NAM Qualification SOT 2022 Poster\n#research #safety-testing\nNICEATM\nApplies statistical modeling loops to standard laboratory animal data logs, demonstrating how measuring background noise in baseline animal responses prevents the false disqualification of alternative models.\nVariability of In Vivo Toxicology Studies: Impact on NAM Evaluation WC12 Abstract\n#research #safety-testing\nNICEATM\nCalculates the numerical ceiling of repeat-dose animal testing reproducibility, establishing that modern computational alternatives should be benchmarked against human relevance rather than legacy animal variations.\nLab on a Chip # The premier international journal for microfluidic and nanofluidic research, hosting foundational papers on human organ-on-a-chip technologies designed to model human physiology and disease states. [Link]\n3D printing monolithic, multifunctional polymer acoustofluidic devices with tunable mixing and particle focusing\n#research #manufacturing #acoustofluidics\nBalanay et al.\nDemonstrates a simplified stereolithography approach to print unified, multi-feature polymer microchips capable of context-specific particle manipulation without complex multi-material bonding steps.\nA 3D model to evaluate cell chemotaxis within a heterogenic tumor microenvironment\n#research #organ-on-a-chip #cancer\nRodrigues et al.\nUtilizes customized micro-chambers to replicate intercellular signaling gradients, shedding light on how tumors aggressively recruit supporting stromal structures within a local living architecture.\nA 3D-printed electromagnetically actuated microgripper system for precision single-cell manipulation\n#research #robotics #single-cell\nChen et al.\nIntroduces a miniaturized manipulation rig with a specialized liquid-retention barrier, offering non-destructive, highly isolated handling of target single cells.\nA compact low-power valveless piezoelectric micropump with a nested rectification structure\n#research #engineering #fluidics\nShan et al.\nDetails a specialized nested internal geometry designed to maximize forward flow velocity while significantly dropping energy demands for autonomous point-of-care chips.\nA compact superlattice as a label-free surface-enhanced Raman scattering substrate for noninvasive urine testing for the diagnosis of lung cancer\n#research #diagnostics #sensors\nZhang et al.\nApplies a self-assembling crystal substrate to detect trace oncology biomarkers in patient fluid samples, benchmarking computational diagnostics against clean human metadata.\nA customizable, low-cost 3D-printed device for live cell confinement imaging\n#research #imaging #microscopy\nRichman et al.\nPresents an open-source, microscopy-compatible compression bracket providing highly uniform structural constraints for real-time observation of dynamic intracellular events.\nA dual-antibody gold nanoparticle-based lateral flow assay for rapid and selective detection of mesenchymal stem cell stemness\n#research #diagnostics #stem-cells\nPrakashan et al.\nIntegrates mobile smartphone readout infrastructure with gold nanoparticle strips to allow high-purity, localized screening of functional cellular potency without legacy destroy-and-fix protocols.\nA high-throughput liver-kidney metabolic interaction chip for insights into the nephrotoxicity mechanisms of triptolide\n#research #organ-on-a-chip #toxicology\nLiu et al.\nEstablishes a microfluidic co-culture network modeling metabolic interaction across interconnected tissue blocks, uncovering multi-organ downstream pathways without legacy animal dosing.\nA microfluidic method for controlled generation and trapping of membraneless water-in-water droplets\n#research #fluidics #droplets\nLi et al.\nAchieves high-stability generation of compartmentalized, open-system liquid arrays to enable complex biochemical processing inside localized dynamic micro-environments.\nA microfluidic platform for automatic quantification of malaria parasite invasion under physiological flow conditions\n#research #microfluidics #pathology\nKals et al.\nIntegrates targeted microchannels with automated processing engines to track real-time cellular invasion forces across human red blood systems subjected to realistic circulatory mechanics.\nA microfluidic skin-on-a-chip enabling in situ construction of full-thickness human skin for modeling inflammatory diseases\n#research #organ-on-a-chip #immunology\nSang et al.\nFeatures a detachable architecture for long-term perfusion culture of realistic stratified human dermal constructs, allowing high-throughput drug screening against active multi-lineage inflammatory markers.\nA novel 3D-printed tool for in vitro cell interaction studies under flow conditions\n#research #methodology #cell-culture\nSkoll et al.\nValidates a highly accessible open platform named FlowCube that accurately introduces steady hydrodynamic shear forces to expose the structural blind spots of static petri-dish assays.\nA portable, low-cost, point-of-care DNA amplification kit with impedance-based detection for decentralized antimicrobial resistance diagnostics\n#research #diagnostics #sensors\nKarimi et al.\nCombines modified, enzyme-driven nucleic acid aggregation loop architectures with clean electronic impedance scanning for accurate multi-target identification out in decentral field environments.\nA smart 3D microfluidic tumor spheroid-vessel co-culture model for studying exosomal HSP-mediated tumor invasion and angiogenesis\n#research #organ-on-a-chip #cancer\nZhou et al.\nUnifies vascular channels with multicellular tissue structures on a single chip to map down trace molecular signaling profiles responsible for initiating early vascular networks and metastatic movement.\nA tumor spheroid array chip for high-fidelity evaluation of liposomal drug delivery through the EPR effect\n#research #organ-on-a-chip #pharmacokinetics\nLee et al.\nModels the actual mechanical interface of dense capillary matrices to validate and monitor the localized accumulative behavior of lipid nanoparticle therapeutics under systemic flow.\nA wearable 3D-printed hollow microneedle device for pressure-driven interstitial fluid collection and testing\n#research #wearables #diagnostics\nHacıosmanoğlu et al.\nIntroduces the μHolloSense architecture, integrating a matrix of fine fluidic needles with localized suction arrays for non-destructive, near-instant capture of clear human interstitial layers.\nAcoustic probing of new biomarkers for rapid sickle cell disease screening\n#research #diagnostics #acoustofluidics\nSridhar et al.\nEmploys precise surface acoustic wave vectors to rapidly evaluate mechanical red cell lysis variations, offering a quick, decentralized blood check format without legacy lab processing pipelines.\nAn AI-enabled tool for quantifying overlapping red blood cell sickling dynamics in microfluidic assays\n#research #automation #imaging\nKadivar et al.\nTrains a specialized nnU-Net mask layout integrated with down-line image segmentation to automatically analyze and score shape transformation metrics within crowded, unseparated cell fields.\nAn automated and portable platform for rapid cell-free DNA isolation and its application in microbial DNA metagenomic sequencing from human blood samples\n#research #automation #genomics\nMetcalf et al.\nDetails the CNASafe processing rig, which automatically isolates clean plasma targets to accelerate real-time portable nanopore library production and detect blood pathogenetic trends within hours.\nAn automated microfluidic system based on V-groove chip for rapid immunohistochemistry\n#research #automation #diagnostics\nZhong et al.\nReplaces conventional, slow human processing protocols with a V-shaped geometric chamber layout, compressing essential diagnostic sample profiling times down from hours to just 11 minutes.\nAn active-matrix digital microfluidic device based on surfactant-mediated electro-dewetting\n#research #automation #fluidics\nXie et al.\nLeverages a robust 4T2C layout array alongside surfactant chemistry adjustments to achieve fluid routing functionality under significantly lower input operating potentials.\nAn automated modular microfluidic platform for end-to-end mRNA synthesis and purification\n#research #bioprocessing #automation\nSharma et al.\nUnifies microscale synthesis nodes with sensor-led chromatography elements, establishing an optimized continuous fluid loop that boosts final pharmaceutical yields while dropping structural impurities.\nBacterial extracellular vesicles indirectly destabilize a human stem cell-derived blood–brain barrier on-chip through pro-inflammatory stimulation of immune cells\n#research #organ-on-a-chip #immunology\nWidom et al.\nApplies an advanced multicellular barrier platform to prove that pathogenetic vesicle structures disrupt human neural line barriers through intermediary immune-line pathways rather than direct contact.\nBand-stop microfluidics for high-purity, label-free enrichment of viable cancer cells from whole blood\n#research #sorting #cancer\nKrzeczkowski et al.\nUses a geometric microscale filter loop that isolates viable circulating tumor cell populations directly out of whole raw samples, allowing immediate downstream drug checks on the same substrate.\nBioinspired quality-based sperm sorting in a spiral microfilter-enhanced microfluidic device: enhancing DNA integrity via rheotaxis and boundary dynamics\n#research #sorting #biomedical\nShahhoseini et al.\nEmploys boundary flow channels that sort highly functional reproductive populations by exploiting natural locomotion vectors, improving sample profile metric yields for clinical settings.\nCell therapy manufacturing at full clinical scale: enhancing the quality CAR-T cell therapy starting materials through massively parallel automated microfluidic cell sorting\n#research #sorting #bioprocessing\nSkelley et al.\nValidates a massively parallelized microfluidic separation channel platform, processing real therapeutic batches to yield high leukocyte recoveries without initiating baseline cell activation stress.\nControlling spatial structure in minimal microbial communities by sequential capillary assembly\n#research #microbiology #fluidics\nBoggon et al.\nDeploys capillaric force alignment patterns to precisely organize multiple microbial lineages into precise 2D structures, helping study local population dependencies with logical rigor.\nCorrection: Cell docking inside microwells within reversibly sealed microfluidic channels for fabricating multiphenotype cell arrays\n#correction #microfluidics\nKhademhosseini et al.\nAmendments and textual validation notes linked to an engineered multi-phenotype cell array array template device.\nCorrection: A gut–brain axis on-a-chip platform for drug testing challenged with donepezil\n#correction #organ-on-a-chip\nFanizza et al.\nFormal structural correction dataset addressing multi-organ microphysiological axis connection parameters.\nDigitally programmable microfluidic valving for autonomous, high-resolution continuous chromatographic purification\n#research #automation #bioprocessing\nLiao et al.\nCoordinates single-use automated internal architecture nodes to carry out sequential buffer replacement, creating a robust path for long-term handling of delicate multi-protein targets.\nDirected dielectrophoretic assembly and separation on microelectrodes patterned via stereolithography 3D-printed shadow masks\n#research #manufacturing #electronics\nJo et al.\nUses low-cost printed mask sheets to achieve accurate, high-density substrate circuit mapping, validating robust particle collection setups without expensive cleanroom processing runs.\nDROP-LCMS for wastewater surveillance of viral disease\n#research #diagnostics #droplets\nPeng et al.\nOutlines a semi-automated, droplet-based microfluidic capture interface that directly couples regional source collection filters into liquid chromatography mass spectrometry systems for pathogenetic monitoring.\nDual vision-equipped microfluidic chip for spatiotemporal sequential pick-and-place of oocytes\n#research #automation #robotics\nLiang et al.\nIntegrates localized dual-angle camera networks with rapid micro-valve actuators to manage the high-precision routing of sensitive reproductive models across processing arrays.\nEstimating single-cell elastic modulus in a serial microfluidic cytometer from time-of-flight and fluorescence signals analysis\n#research #diagnostics #biophysics\nChickering et al.\nUtilizes cell speed variations in specialized flow streams alongside optical readouts to infer precise individual membrane stiffness measurements without slow, mechanical probe configurations.\nFacile fabrication of high-density two-dimensional micronozzle arrays using twisted thin-wire molds\n#research #manufacturing #microfluidics\nTakahashi et al.\nPresents a simple mechanical routing method using skew-aligned fine wire templates to shape dense nozzle matrices for localized fluid delivery and cell processing arrays.\nFast and precise magnetophoresis of superparamagnetic nanoparticles on a micro-magnetic substrate in a static liquid environment\n#research #magnetics #nanotechnology\nBou et al.\nDetails a specialized microscale magnetic array layout that drives target magnetic carriers across centimeter distances at speeds of 1.4 mm/s, accelerating downstream nucleic acid tracking.\nFlow-programmable and reversible surface-induced LLPS in nanofluidic channels\n#research #nanofluidics #biophysics\nOhta et al.\nExploits deep sub-micron structural confinement to initiate and sweep away localized phase-separated fluid layers, laying down rules to handle active targets inside nanofluidic loops.\nGut–liver-on-a-chip enables mechanistic study and risk assessment of drug-induced liver injury and drug–drug interactions\n#research #organ-on-a-chip #toxicology\nYu et al.\nConnects human intestinal and hepatic cell matrices inside a unified perfusion channel loop, offering a clear mathematical path to evaluate human drug absorption, clearance, and toxic metabolic dynamics.\nHigh-speed liquid switching and on-chip force sensing reveal the transient mechanical response of MscL in Synechocystis sp. PCC 6803\n#research #sensors #biophysics\nDu et al.\nUtilizes millisecond micro-actuator stream switching coupled with raw physical force monitors to track the immediate protective shape transitions of single living cells under osmotic changes.\nHigh-throughput and efficient fabrication of engineered skeletal muscle tissue via streamlined 3D multimaterial bioprinting\n#research #bioprinting #tissue-engineering\nLim et al.\nDevelops an multi-nozzle ink-delivery configuration that prints functional, aligned skeletal fiber blocks directly inside standard 96-well format layouts, simplifying large chemical libraries screening.\nHigh-throughput label-free assessment of sperm DNA fragmentation index via intelligent morphological imaging\n#research #imaging #automation\nJin et al.\nCombines structural microscale flow channels with rapid camera capture loops and trained morphological scoring systems to identify genetic core health features without destructive tag dyes.\nHigh-throughput single-cell proteomics and transcriptomics from same cells with a nanoliter-scale, spin-transfer approach\n#research #automation #genomics\nDawar et al.\nDeploys a stacked nanoliter-scale fluidic transfer plate matrix that segregates and processes single-cell lysate components to output matched, high-resolution protein and transcript maps from individual source models.\nHigh-throughput microfluidic platform for modelling inflammatory responses of human articular chondrocytes under variable fluid shear stress\n#research #organ-on-a-chip #pathology\nda Silva et al.\nPresents a scalable, pumpless structural format that uses continuous gradient streams to match and reproduce the complex arthritic joint changes found under pathogenetic mechanical load.\nHuman hair regeneration using organoids and hair-on-chip technologies\n#research #tissue-engineering #organoids\nAhmed et al.\nHighlights critical biofabrication design tracks merging advanced multi-lineage skin microphysiological structures with localized fluidics, aiming for complex tissue replacement models without human-to-animal grafting loops.\nHydrogel microwell with pneumatic soft actuator for compression formation of three-dimensional cellular tissue\n#research #tissue-engineering #biomaterials\nKawamae et al.\nCombines soft flexible elastomer pressure cells with patterned gel array matrices, forcing individual cell clusters into structured, highly repeatable 3D architecture setups under defined load.\nIn vitro space of Disse model for exploration of drug induced hepatotoxicity\n#research #organ-on-a-chip #toxicology\nMesic et al.\nRecapitulates complex liver capillary architecture by matching porous gel matrices with functional endothelial and parenchymal human cell lines to trace out cellular breakdown mechanisms during toxic pharmaceutical compound exposure.\nInkube: an all-in-one solution for neuron culturing, electrophysiology, and fluidic exchange\n#research #open-source #neuroscience\nMaurer et al.\nDetails an open-source hardware system combining continuous multi-channel signal arrays with automated microscale fluid routing to track functional human neural layer activity under steady long-term observation.\nIntegrated microfluidic platform based on potentiometric Sonogel-Carbon sensors for the simultaneous determination of Na+ and K+ in untreated human plasma and serum\n#research #sensors #diagnostics\nSainz-Calvo et al.\nCombines precise carbon sensor matrices directly into raw fluid pathways to run immediate, simultaneous tracking of critical ion concentrations without preparatory sample filtering steps.\nIntegrated microfluidic platform for inertial separation and encapsulation of single cells in droplets\n#research #sorting #droplets\nGalogahi et al.\nUnifies physical size-sorting channels with droplet generation nozzles on a single substrate chip, providing a stream that cleans, routes, and packages individual cells for downstream processing.\nIntegrated strategy for breast cancer biomarker analysis using dual ionic liquid aqueous biphasic systems and microfluidic immunoassays\n#research #diagnostics #sensors\nMendes et al.\nEmploys an internal multi-phase fluid partitioning layout that selectively strips high-abundance protein background noise out of samples, elevating downstream target biomarker read resolution.\nIntelligent image-activated sorting of large cells enabled by elasto-inertial focusing\n#research #sorting #automation\nNagasaka et al.\nIntegrates long, non-turbulent elasto-inertial guiding channels with real-time deep learning layout logic to achieve rapid, content-driven classification of large models under high-throughput conditions.\nIntensified lentiviral vector perfusion bioprocessing with a spiral inertial microfluidic cell retention device\n#research #bioprocessing #fluidics\nBevacqua et al.\nDeploys high-velocity curved channels to keep production cell masses separated from output streams via inertial vectors, achieving steady high-density vector harvest outputs over long run durations.\nLabel-free assessment of a microfluidic vessel-on-chip model with visible-light optical tomography reveals structural changes in vascular networks\n#research #imaging #microfluidics\nVeerman et al.\nApplies visible-light optical tomography inside structural microphysiological chips, providing clear, deep 3D structural mapping of human vascular networks without utilizing destructive tracking dyes.\nLabel-free monitoring of therapy response in 3D spheroids using lab-on-a-chip impedance spectroscopy\n#research #sensors #cancer\nMacke et al.\nDeploys real-time multi-frequency electrical scanning channels around living tissue spheroid blocks, providing an objective mathematical readout track for recording oncology model radiation responses.\nLyocell–modal thread microfluidic platform integrated with a microneedle sensor for lactate detection in saliva\n#research #sensors #wearables\nDing et al.\nCombines processed cellulose fiber paths with localized electrochemical tip sensors, constructing a practical fluid-guiding lane for immediate, non-invasive assessment of human sample chemical metrics.\nMachine learning-augmented lateral flow assays for point-of-care infectious disease diagnostics\n#research #diagnostics #automation\nParmaksizoglu et al.\nReviews progress across nanomaterial paper diagnostics coupled with computer vision software, outlining a path toward objective smartphone-driven screening out in remote clinic networks.\nMachine learning-driven single-cell phenotyping in size-controlled microenvironments via parallel deterministic droplet microfluidics\n#research #automation #droplets\nLee et al.\nEncapsulates individual target profiles across a range of calibrated matrix environments, utilizing neural network classifier systems to automatically analyze cell responses under physical confinement.\nMacroporous transport – mesoporous catalysis: a rapid microfluidic-fabricated biomimetic sponge photocatalytic microsphere reactor\n#research #chemical-engineering #manufacturing\nWang et al.\nAssembles biomimetic multi-scale catalytic microspheres inside high-precision droplet streams, providing an optimized layout that enhances substrate access and reaction efficiency.\nMaGIC-OT: an AI-guided optical tweezers platform for autonomous single-cell isolation in microfluidic devices\n#research #automation #robotics\nCieslik et al.\nCombines active computer vision tracking with optical trapping nodes to safely navigate rare single target bodies out of highly crowded field environments without manual control.\nMiniaturisation of Raman spectroscopy systems: from benchtop to backpocket\n#research #sensors #spectroscopy\nHardy et al.\nTraces the optical integration steps and component innovations that compressed traditional bulky benchtop laser analysis rigs down into pocket-sized solid-state field units.\nMonolithic 3D-printed split-and-recombine micromixer integrated into a microfluidic concentration gradient generator\n#research #manufacturing #microfluidics\nNavarro Molina et al.\nValidates a unified single-print fluidic device containing complex internal routing channels that guarantee thorough stream mixing across an exceptionally wide range of flow volumes.\nMultiplexed nanophotonic biosensing and deep learning-driven protein quantification for traumatic brain injury diagnosis at the point of care\n#research #diagnostics #sensors\nLiu et al.\nDeploys a specialized chip containing nanophotonic sensing nodes backed by deep learning interpretation models, generating clean multi-biomarker score outputs from blood drops within minutes.\nMultiphasic droplet microfluidics platform for controlled bacteria and mammalian cell co-culture\n#research #droplets #microbiology\nAlshareedah et al.\nExploits aqueous polymer phase boundary structures inside micro-droplet arrays to culture animal lines and bacterial systems side by side, avoiding early overgrowth issues.\nMuscle regeneration on a chip: exercise-induced microtrauma and optimal mechanical stimulation regimen\n#research #organ-on-a-chip #biophysics\nYin et al.\nEmploys flat flexible substrate structures to introduce precisely controlled cyclic tensile strains across mature human cell models, mapping out structural tissue repair responses.\nMyeliMAP: a microfluidic-multielectrode array hybrid platform to investigate oligodendrocyte function in human iPSC derived brain-like networks\n#research #organ-on-a-chip #neuroscience\nAhuja et al.\nUnifies high-density multielectrode processing arrays with precise human cellular channels to track axonal conduction velocity variations and check functional chemical line interactions.\nNanomembrane-based microfluidic platform with embedded electrical pressure transducer for on-chip nanoparticle quantification\n#research #sensors #nanotechnology\nMorris et al.\nMonitors exact physical resistance variations across an internal nanoporous membrane sheet, using a predictive algorithm to infer target concentration matrices from fluid dynamics change.\nNumerical microfluidic chip modeling of laminar vortex dynamics induced by biomineralization in evolving porous media\n#research #fluidics #physics\nChu et al.\nDevelops detailed 3D fluidic simulations to trace how mineral precipitation profiles alter local path layouts, demonstrating the formation of internal vortex nodes that alter chemical mixing.\nOn cloud microfluidic experiment platform powered by in situ maskless lithography\n#research #automation #methodology\nPaul et al.\nDetails a remote cloud computing platform connected to an automated digital optical pattern projector setup, enabling users to submit chip designs and track experiments online.\nOn-chip acoustic chaotic micromixer for point-of-care applications\n#research #fluidics #sensors\nChen et al.\nPresents a compact fluid processing layout driven by a surface acoustic Lamb wave resonator grid, executing continuous extraction, rapid sample preparation, and detection steps on a single board.\nOscillatory flow for contactless particle trapping\n#research #microfluidics #physics\nSaint-Girons et al.\nDeploys specialized microchannel geometric structures to manipulate steady oscillating fluid columns, generating stable spatial collection nodes that retain delicate targets without solid contact.\nPDMS aqueous leachates cause acute toxicity in C. elegans\n#research #toxicology #materials\nGomez et al.\nInvestigates chemical safety limitations across standard microfluidic substrate materials, proving that un-cleared internal polymer leachates trigger acute system stress pathways within simple living formats.\nPoint of care molecular cancer diagnostics\n#research #diagnostics #methodology\nBhaskar et al.\nOutlines a unified translation framework for pocket-sized oncology screeners, linking patient clinical benchmarks directly with recent advancements in microfluidic sensor integrations.\nPoint-of-care SERS platforms: integrating microfluidics and machine learning for disease screening\n#research #diagnostics #sensors\nChen et al.\nReviews how advanced plasmonic metal substrates coupled with automated fluid handling and pattern recognition algorithms boost the reliability of fast, laser-driven patient bio-screening.\nPolydiacetylene (PDA) coated paper-based fluorescence sensor for the detection and quantification of bisphenol\n#research #sensors #chemical-safety\nLoganathan et al.\nDevelops an un-tagged, paper-based diagnostic sheet coated with a responsive polymer compound matrix that yields specific optical shifts when exposed to toxic consumer bpa strains.\nPorous microneedle-based electrochemical aptamer biosensor for the collection and quantitative analysis of dry eye disease biomarkers\n#research #diagnostics #wearables\nKo et al.\nCombines porous liquid-drawing structure elements with surface-bound aptamer circuit lines to carry out direct sampling and targeted diagnostic profiling on a single platform.\nPredicting human pharmacokinetic parameters of drugs using a multi-tissue chip platform integrating liver, kidney, and skeletal muscle microphysiological systems\n#research #organ-on-a-chip #toxicology\nSherfey et al.\nIntegrates human liver, kidney, and skeletal fiber microphysiological blocks with deep quantitative systems pharmacology logic, generating precise human metabolic parameter models without using animals.\nRapid desiccation and on-disc rehydration of extracellular vesicles for non-cryogenic preservation\n#research #methodology #bioprocessing\nWoo et al.\nPreserves cellular target vesicles via a centrifugal spin layout that manages low-temperature water extraction, avoiding the high cost and structural damage of legacy liquid nitrogen storage lines.\nReal-time high-throughput characterisation of the surface elasticity of suspended cells\n#research #imaging #biophysics\nGuo et al.\nLinks continuous microscale deformation channels with fast tracking engines and biophysical stress formulas, outputting objective stiffness profiles for large collections of individual cells.\nReal-time impedance-based cell migration measurements with integrated electrodes on porous membranes for next generation microphysiological systems\n#research #sensors #microfluidics\nTorres-Castro et al.\nDeposits ultra-thin electrode tracking matrices directly onto both faces of a track-etched membrane core, allowing ongoing monitoring of cell movement across the barrier layer.\nRegion-specific proteomic profiling of brain interstitial fluid via a micro-invasive sampling platform\n#research #neuroscience #methodology\nCao et al.\nDeploys a fine, membrane-free internal sampling tool to collect un-diluted neural fluid volumes, uncovering specific regional protein differences that conventional crude processing misses.\nRobotic acoustofluidic single-cell picking and placement platform\n#research #automation #robotics\nLi et al.\nUnifies localized high-frequency sound wave drivers with automated stage movements to handle single microscale targets without damaging structural features.\nSize-based sorting of cancer cells reveals functional heterogeneity among subpopulations\n#research #sorting #cancer\nYilmaz et al.\nEmploys clean deterministic lateral displacement post arrays to slice up tumor lines into precise size pools, revealing clear differences in adhesion and local migration speed metrics.\nSize-based sorting of dynamic bacterial clusters\n#research #sorting #microbiology\nAkbari et al.\nTracks how deformable streptococcal aggregate chains pass through high-precision micro-post networks, setting out rules to safely isolate heterogeneous clinical profiles under steady stream flow.\nSmarter cell sorting: droplet microfluidics meets pick-and-place sorting\n#research #sorting #automation\nGerhard et al.\nCombines continuous multi-phase stream routing blocks with a precise microscale positioning tip tool to successfully package and move individual target structures into a clean droplet line.\nStretchable mesoporous electrodes as a versatile platform for minimally invasive surgical devices\n#research #engineering #biomedical\nListyawan et al.\nIntegrates thin, highly flexible metal mesh layers onto soft surgical guide structures, enabling multi-point bio-potential and tracking functionality inside variable physical structures.\nStroke volume analog on a chip – in vitro hydrodynamic model of cardiac pumping efficiency\n#research #organ-on-a-chip #cardiology\nZimmerman et al.\nMaintains contractible human tissue films inside a precise microscale chamber to evaluate stroke performance profiles under real chemical dosing, expanding alternatives to animal model trials.\nSystematic characterization and mechanistic insights into ultrasonically actuated sharp-tip capillary droplet generation\n#research #fluidics #manufacturing\nZhang et al.\nDetails the specific tip oscillation dynamics used to split streams into multi-volume droplet groups without requiring conventional etched chip shapes or high-pressure pump setups.\nSystematic investigation of double emulsion dewetting dynamics for the robust production of giant unilamellar vesicles\n#research #biophysics #nanotechnology\nJing et al.\nConstructs a physics-led fluidic framework mapping out double-emulsion structural changes, giving researchers a reliable recipe to manufacture stable, clean synthetic cell profiles.\nThin stencil membrane-assisted high throughput single-cell to cluster of cells micropatterning and large-size biomolecular transfection in primary and stem cells\n#research #manufacturing #biomedical\nDominic et al.\nUses thin, laser-patterned carbon mesh sheets to anchor individual cells before running pulsed laser photoporation lines, achieving highly efficient macromolecular cargo delivery.\nTopology-based coordination control for multi-droplet tasks in autonomous digital microfluidics\n#research #automation #fluidics\nGuo et al.\nCoordinates large matrix arrays with instant computer vision loop analysis, maintaining precise tracking and independent routing of multiple fluid units simultaneously across open boards.\nTopoChip-based high-throughput screening of micropatterned hydroxyapatite to guide stem cell behavior and accelerate bone regeneration\n#research #biomaterials #tissue-engineering\nLi et al.\nProfiles cellular responses across 127 individual surface layout designs stamped onto ceramic substrates, identifying specific groove setups that accelerate bone matrix formation.\nTumor-on-chip platforms for transport phenotyping: decoding CAF-driven barriers to drug delivery\n#research #organ-on-a-chip #cancer\nLe Manach et al.\nConstructs live 3D oncology matrices to map out how cancer-associated fibroblasts remodel local gel frameworks, creating measurable physical barriers that drop therapeutic chemical delivery.\nTunable squeeze-activated GHz acoustofluidics for stable trapping and separation of sub-100 nm nanoparticles\n#research #nanotechnology #fluidics\nLiu et al.\nDeploys a localized gigahertz acoustic driver line to create stable energy troughs in microfluidic streams, separating and trapping particle profiles down to 50 nm scale lengths.\nTwo-phase simulations of viscoplastic flow in superhydrophobic microchannels: interface stability, plug dynamics, and drag reduction\n#research #fluidics #physics\nJoulaei et al.\nBuilds explicit fluid equations tracing how non-newtonian thick media moves past textured internal microscale ridges, providing a clean path to minimize pressure limits inside analytical channels.\nUltra-high throughput droplet microfluidics for cultivation and functional screening of environmental microbial strains and consortia\n#research #sorting #microbiology\nPotenza et al.\nOutlines a reliable microfluidic loop that isolates un-cultured local environment cells inside protected water-in-oil droplet pools, expanding screening speeds for functional bioprospecting.\nValved microfluidics with Ostemers\n#research #manufacturing #materials\nKumar et al.\nReplaces conventional high-maintenance elastomer structures with stable three-layer polymer molds, achieving crisp 200 ms channel stream gating under aggressive chemical settings.\nVascularizing organoids-on-chip for perfused and personalized models\n#research #organ-on-a-chip #tissue-engineering\nMenzani et al.\nReviews technical design strategies used to grow and weave capillary loops straight through mature human organoid bodies, pushing up long-term model realism and utility for personal diagnostics.\nVector-free DNA transfection by nuclear envelope mechanoporation\n#research #biomedical #genetics\nAkh et al.\nDeploys microscale wedge channels to induce precise, brief mechanical stretching states across cell walls, allowing large target plasmid targets to migrate cleanly into nucleus structures.\nVertical numbering-up microfluidic architecture for scalable and homogeneous lipid nanoparticle production\n#research #bioprocessing #manufacturing\nZhang et al.\nArranges precision mixing channel matrices in a stacked three-dimensional block layer layout, multiplying therapeutic nanoparticle production limits while maintaining tight output particle metric bounds.\nWAFFLE – an automated platform for enhancing the performance of electrochemical biosensors\n#research #sensors #automation\nDobrea et al.\nCombines an automated physical handling rig with open analytical processing software scripts, reducing error rates across microscale bio-sensing array validation runs.\nNAM Journal # An open-access publication which serves as a hub for dissemination and worldwide exchange of information regarding state-of-the-art NAM developments. [link]\nAn in vitro investigation of diet-influenced gut bacterial metabolites on the onset of Type 2 diabetes mellitus using a multi-cellular human primary islet model\n#research #metabolism #diabetes\nGuraka et al.\nUtilizes a primary islet cell system to study the link between gut-derived metabolites and insulin signaling pathways, identifying potential metabolic disruption triggers associated with dietary changes.\nA novel in vitro alveolar model (ALIsens®) for hazard assessment of methyl methacrylate: No evidence for respiratory sensitisation potential\n#research #safety-testing #respiratory\nGutleb et al.\nValidates the ALIsens® lung-on-a-chip platform for assessing respiratory sensitization, successfully clearing methyl methacrylate of sensitizing hazard using human-relevant cellular exposure interfaces.\nA sociological perspective on the challenges of displacing animal research within academia: the contribution of Bourdieu\n#reviews #policy #sociology\nPandora Pound\nApplies Bourdieusian field theory to map out the entrenched cultural mechanisms, institutional funding loops, and academic inertia that slow the transition from legacy animal lines to alternative non-animal architectures.\nCharacterizing common loss-of-function genes and their potential utility in assessing population variability and chemical susceptibility in vitro\n#research #genomics #susceptibility\nChanhee Kim et al.\nLeverages human engineered knockout cell cohorts to evaluate internal genetic variations, standardizing a human cell-based blueprint to map chemical susceptibility swings across diverse populations without animal testing.\nFrom concept to context-of-use: A framework for Organ-on-Chip development\n#protocols #policy #organ-on-a-chip\nAraújo-Gomes et al.\nOutlines a systematic engineering and validation pipeline to bridge the gap between academic chip prototyping and formalized, reproducible contexts-of-use required for commercial pharma uptake.\nInvestigations into the biological activity of avobenzone as part of a Next Generation Risk Assessment\n#research #safety-testing #dermatology\nShan et al.\nDeploys a robust Next Generation Risk Assessment (NGRA) tier to evaluate the bioactivity profiles of the sunscreen agent avobenzone, ensuring high-confidence human safety profiling without legacy animal models.\nNAMazing: The importance of being earnest - a 2025 cross-Atlantic turning point in phasing out animal testing\n#editorial #policy #safety-testing\nHansell \u0026amp; Hartung\nReflects on the pivotal 2025 shifts in US and European regulatory landscapes, emphasizing the urgent need for a unified, sincere commitment to finalizing the phase-out of animal-based toxicological protocols.\nNever-ending Acronym Madness: Proposing a harmonized definition for NAMs\n#editorial #terminology #policy\nLaFollette et al.\nCritiques the terminological inflation surrounding \u0026ldquo;New Approach Methodologies,\u0026rdquo; proposing a rigorous, harmonized definition to improve consistency and communication within regulatory and scientific sectors.\nSet up of a human 3D liver multicellular model for chemical high-throughput toxic hazard assessment\n#research #safety-testing #hepatology\nRecoules \u0026amp; Audebert\nDetails the creation of a 3D multi-cell hepatic platform optimized for high-throughput screening, enabling rapid, multi-lineage assessment of chemical-induced liver damage.\nSILIFOOD: a tool to support the risk assessment of non-evaluated food contact material substances\n#research #automation #food-safety\nStreel et al.\nIntroduces the SILIFOOD computational tool, designed to streamline the hazard characterization of chemical substances in food contact materials that currently lack exhaustive toxicological evaluation.\nNature Biomedical Engineering # A high-impact journal publishing peer-reviewed research on technologies that combine engineering with the life sciences, serving as a primary outlet for advanced microphysiological systems (MPS) and organ-on-a-chip developments. [Link]\n3D biofabricated in vitro models as new approach methodologies for animal alternatives\n#research #safety-testing #bioprinting\nHua \u0026amp; Gaharwar\nEvaluates recent progress in 3D-bioprinted constructs and advanced cell matrix platforms acting as alternatives to traditional animal pipelines, analyzing current readiness boundaries for clinical drug verification.\nA predictive in vitro risk assessment platform for pro-arrhythmic toxicity using human 3D cardiac microtissues\n#research #safety-testing #cardiology\nKofron et al.\nDeploys human-derived three-dimensional myocardial syncytia arrays to construct a highly sensitive electrical scoring baseline, demonstrating a robust human cell-based alternative for preclinical cardiotoxicity screening.\nAn engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism\n#research #biotechnology #immunology\nPtacin et al.\nUtilizes an expanded genetic code inside synthetic living structures to execute site-specific chemical modifications on interleukin-2, generating stable, high-efficiency oncology immunotherapies.\nApplying single-cell and single-nucleus genomics to studies of cellular heterogeneity and cell fate transitions in the nervous system\n#reviews #neuroscience #genomics\nAdameyko et al.\nOutlines rigorous multi-omic study design tracks for building comprehensive cell atlases, capturing discrete transitional transcript boundaries across developing or pathogenetic neural architectures.\nChemically-defined medium formulation and adaptation method for supporting growth of endothelial cells\n#research #cell-culture #methodology\nBrunmaier \u0026amp; Walker\nFormulates a completely animal-free, chemically defined fluid standard to support continuous microvascular line growth, eliminating un-standardized serum components from microphysiological systems.\neUnaG: a new ligand-inducible fluorescent reporter to detect drug transporter activity in live cells\n#research #imaging #pharmacology\nYeh et al.\nValidates a highly responsive, non-destructive fluorescent marker platform to track clear chemical efflux mechanics inside live cell configurations in real time.\nGeneration of human brain region–specific organoids using a miniaturized spinning bioreactor\n#protocols #organ-on-a-chip #neuroscience\nQian et al.\nProvides step-by-step procedures to build the SpinΩ engineering platform, directing human stem cell lines toward highly differentiated structures that closely mirror native human forebrain, midbrain, and hypothalamic spatial development.\nImmune-competent new approach methodologies for a hybrid future\n#reviews #safety-testing #immunology\nSoares et al.\nAdvocates for the systematic integration of complex human immune line networks into reductionist organ-on-chip arrays, establishing a sophisticated hybrid environment necessary for matching true human clinical outcomes.\nIntegrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics\n#reviews #cancer #genomics\nNam et al.\nExamines single-cell multi-omic profiling platforms that simultaneously sequence heritable genetic and non-genetic mutations, mapping out how local environment interactions drive complex tumor evolution.\nMeso–macroporous hydrogel for direct litre-scale isolation of extracellular vesicles\n#research #nanotechnology #manufacturing\nKim et al.\nDetails a cryo-photocrosslinked porous gel matrix that carries out scalable extraction of delicate diagnostic vesicle targets from massive sample streams while preserving structural metadata.\nMulti-omics analyses reveal regulatory networks underpinning metabolite biosynthesis in Nicotiana tabacum\n#research #genomics #systems-biology\nLi et al.\nApplies multi-layered computational models to trace the underlying transcriptional hubs and regulatory network structures that govern metabolic synthesis inside complex plant chassis.\nQuantitative assessment of sensitizing potency using a dose–response adaptation of GARDskin\n#research #safety-testing #toxicology\nGradin et al.\nImplements an advanced human cell line genomic screening format that leverages specific transcript marker responses to mathematically calculate allergen potency variations without legacy animal skin exposure.\nTowards in vitro models for reducing or replacing the use of animals in drug testing\n#reviews #safety-testing #organ-on-a-chip\nStresser et al.\nExamines the pharmaceutical sector\u0026rsquo;s advocacy for microphysiological systems to replace traditional animal pipelines, analyzing the operational and biological advancements required to heighten model readiness for regulatory entry.\nUnlocking gene regulatory networks for crop resilience and sustainable agriculture\n#reviews #genomics #systems-biology\nLeong et al.\nReviews targeted transcriptomic modeling tracks mapping out plant network structures, identifying genetic hub targets to accelerate sustainable engineering programs.\nOECD # Organisation for Economic Co-operation and Development An intergovernmental organization that publishes internationally agreed-upon guidelines, white papers, and testing standards that form the global legal bedrock for cross-border regulatory acceptance of non-animal safety methods. [Link]\nCase Studies for the Integrated Approaches for Testing and Assessment (IATA) | OECD\n#research #safety-testing #iata\nOECD\nCompiles recent regulatory initiatives across the US EPA, Environment and Climate Change Canada, and ECHA, focusing on structural implementations of multi-evidence data architectures to optimize human chemical risk classification models.\nCase Study on use of an Integrated Approach to Testing and Assessment (IATA) | OECD\n#research #safety-testing #iata\nOECD\nEstablishes a foundational proof-of-concept for read-across workflows, leveraging a unified structure of computational data, in vitro toxicodynamics, and toxicogenomics to quantify biological similarity without traditional in vivo testing.\nCross Country Analysis: Approaches to Support Alternatives Assessment | OECD\n#reviews #safety-testing #policy\nOECD\nProvides a multi-national comparative analysis on the structural replacement of endocrine-disrupting variables like plasticizers and flame retardants, utilizing innovative computational paradigms to standardize exposure maps.\nGuidance on Good Practices and Standardisation of Sample Collection for Omics Technologies | OECD\n#protocols #toxicology #genomics\nOECD\nOutlines rigorous structural harmonization rules for sample collection and metadata management in regulatory transcriptomics, defining standardized molecular points-of-departure for chemical grouping.\nGuidance on Grouping of Chemicals, Third Edition | OECD\n#protocols #safety-testing #read-across\nOECD\nPresents the definitive regulatory framework for establishing chemical category logic and chemical similarity protocols, incorporating mechanism-based methodologies including omics and adverse outcome pathways (AOPs) to bridge non-animal data gaps.\nOverview of Concepts and Available Guidance related to Integrated Approaches to Testing and Assessment (IATA) | OECD\n#reviews #safety-testing #iata\nOECD\nExamines the definition boundaries and baseline prescriptive parameters governing international testing methods, aiming to harmonize cross-border data acceptance frameworks for animal-free data matrices.\nWorkshop Proceedings on Critical Innovations in Pesticides Safety | OECD\n#research #toxicology #neuroscience\nOECD\nDetails strategic regulatory pathways for embedding alternative, human cell-based methodologies into developmental neurotoxicity (DNT) risk evaluations, focusing on modern pesticide evaluation architectures.\nRegulatory Toxicology and Pharmacology # A monthly peer-reviewed scientific journal which covers legal aspects of toxicological and pharmacological regulations. [Link]\nA 10-step framework for use of read-across (RAX) in next generation risk assessment (NGRA) for cosmetics safety assessment\n#protocols #safety-testing #read-across\nAlexander-White et al.\nDelineates the strict 10-step Cosmetics Europe operational criteria for blending structural analog data with in vitro assay records, establishing non-animal validation templates for raw ingredients.\nHuman vs. cells vs. machine: A comparative analysis of toxicological points of departure derived from quantitative read-across (qRAx), in vitro data, and in silico predictions\n#research #read-across #qsar\nChiu et al.\nPresents a mathematical comparison of calculated points of departure derived across advanced chemical categories, benchmarking the consistency of computerized structural stacking against active human cell responses.\nQuantifying the effect of human interindividual kinetic differences on the relative potency value for riddelliine N-oxide at low dose levels by a new approach methodology\n#research #toxicokinetics #pbpk\nWidjaja-van den Ende et al.\nApplies physiologically based kinetic simulations to scale cellular dose-responses across virtual human populations, tracking internal clearance variations to protect sensitive subgroups.\nStem Cell Reports # An open-access journal dedicated to stem cell research, publishing significant advances in human induced pluripotent stem cell (iPSC) lines and organoid development used for patient-specific drug screening. This is an excellent site which provides advanced mechanisms to acquire information. [Link]\n3D Vessels-on-Chip using isogenic hiPSC-derived VSMCs reveal NOTCH3-driven alterations in brain small vessel disease\n#research #organ-on-a-chip #vascular\nVila Cuenca et al.\nDeploys human induced pluripotent stem cell-derived vascular smooth muscle cells inside a microfluidic board to map out the exact cell structural alterations driving CADASIL and cerebral small vessel pathology without animal models.\nA latent activated olfactory stem cell state revealed by single-cell transcriptomic and epigenomic profiling\n#research #genomics #neurogenesis\nVan den Berge et al.\nCombines single-cell RNA sequencing with chromatin accessibility assays to resolve a hidden, pre-activated neural progenitor state that primes rapid tissue regeneration.\nA simplified co-culture reveals altered cardiotoxic responses to doxorubicin in hPSC-derived cardiomyocytes in the presence of endothelial cells\n#research #safety-testing #cardiology\nBrescia et al.\nEstablishes a human cell-based microvascular-myocardial interface to demonstrate how adjacent endothelial cells modulate chemotherapeutic toxicity mechanics, fixing the false-negative blind spots of isolated single-line screens.\nAdvances and challenges in modeling Charcot-Marie-Tooth type 2A using iPSC-derived models\n#reviews #neuroscience #pathology\nRizzuti et al.\nEvaluates current human cellular platform capabilities for modeling mitochondrial optical neuropathies, identifying key operational hurdles in achieving full functional maturation in automated assay formats.\nAdult hippocampal neurogenesis: New avenues for treatment of brain disorders\n#reviews #neuroscience #therapeutics\nChen et al.\nReviews endogenous neural progenitor modulation pathways within the adult human dentate gyrus, outlining strategic entry points for targeted small-molecule therapeutics to reverse neurodegenerative decline.\nAn efficient, non-viral arrayed CRISPR screening platform for iPSC-derived myeloid and microglia models\n#research #methodology #genetics\nMeier et al.\nValidates a high-throughput, non-viral electroporation pipeline to execute clean, arrayed gene knockouts across human macrophage and brain immune lineages simultaneously.\nAn in vitro model of acute horizontal basal cell activation reveals gene regulatory networks underlying the nascent activation phase\n#research #genomics #regeneration\nBarrios-Camacho et al.\nUtilizes an advanced human airway epithelial platform to sequence the immediate transcriptional loops triggering resting progenitor cells to enter active tissue repair modes.\nAPOL1 risk variants induce metabolic reprogramming of podocytes in patient-derived kidney organoids\n#research #organ-on-a-chip #nephrology\nSong et al.\nDeploys patient-specific 3D renal structures to resolve the precise metabolic shifts and podocyte structural breakdown triggered by chronic kidney disease genetic markers.\nBenchmarking and optimizing Perturb-seq in differentiating human pluripotent stem cells\n#research #methodology #genomics\nSivakumar et al.\nOptimizes pooled CRISPR screening with single-cell transcriptomic readouts in human stem cell lineages, maximizing data capture across large functional genetic evaluations.\nBMP, MEK, and WNT inhibition with NGN2 expression for rapid generation of hiPSC-derived neurons amenable to regional patterning\n#research #methodology #neuroscience\nHabich et al.\nUnifies temporary small-molecule signaling blocks with targeted transcription factor activation to rapidly manufacture functional human neural networks with predictable spatial configurations.\nCharting the translational pathway: ISSCR best practices for the development of PSC-derived therapies\n#protocols #policy #clinical-translation\nBarry et al.\nLays down the definitive international consensus guidelines for standardizing manufacturing, product characterization, and preclinical safety checks for human pluripotent stem cell-derived therapeutics.\nChemically defined and dynamic click hydrogels support hair cell differentiation in human inner ear organoids\n#research #biomaterials #sensory\nArkenberg et al.\nValidates a completely synthetic, bio-orthogonal click-chemistry matrix framework that accurately controls mechanical stiffness to drive human inner ear line maturation without animal-derived substrates.\nChromosome X dosage modulates development of aneuploidy in genetically diverse mouse embryonic stem cells\n#research #genetics #stability\nStanton et al.\nExamines the mechanical relationships between chromosome X copy variations and genomic structural instability across divergent mouse stem cell backgrounds.\nClonal lineage tracing and transcriptomics of cortical progenitor populations reveal maintenance of differentiation potential\n#research #genomics #neurogenesis\nHarkins et al.\nCouples dynamic cellular barcoding with single-cell transcript mapping to prove that early cerebral progenitor cells maintain predictable, long-term multi-lineage output choices.\nComputational blueprints for cell fate programming\n#reviews #automation #systems-biology\nPengyi Yang\nReviews machine learning layouts and algorithmic models that scan massive multi-omic profiles to accurately calculate and predict directed cell fate conversions.\nComputationally resolved neuroprogenitor cell biomarkers associate with human disorders\n#research #automation #neuroscience\nCappuccio et al.\nApplies predictive cluster formulas to multi-omic datasets, identifying unique surface protein markers on human neural stems that correlate directly with downstream neurodevelopmental pathology.\nConnecting cilium, stress response, and proteostasis abnormalities inform variant and therapy assessment in RPGRIP1 retinal organoids\n#research #diagnostics #ophthalmology\nTo Ha Loi et al.\nLeverages human stem cell-derived 3D retinal layers to connect protein clearance faults with primary ciliary collapse, establishing an animal-free screen for blind-inducing genetic mutations.\nCranial placode differentiation defect in individuals born without a nose\n#research #pathology #development\nVenkoba Rao et al.\nUtilizes patient-derived induced pluripotent cells to reconstruct early facial ectoderm blocks, isolating the signaling failure that arrests nasal structure creation.\nCross-modal integration of metabolomics and cardiac functionality captures dynamic metabotoxic effects of doxorubicin in engineered heart tissues\n#research #safety-testing #metabolomics\nConte et al.\nUnifies non-destructive micro-sensor pacing arrays with mass spectrometry to capture immediate chemical changes inside mature human cardiac microtissues during toxic oncology drug exposure.\nCrosstalk via ICAM-1 enhances supportive phenotype of stellate cells and drives hepatocyte proliferation in iPSC-derived hepatic organoids\n#research #organ-on-a-chip #hepatology\nMochida et al.\nDemonstrates that exact cell-to-cell membrane bridges within multi-lineage liver tissue blocks control human liver cell multiplication, optimizing the structural accuracy of liver-on-a-chip boards.\nDeciphering the heterogeneity of differentiating hPSC-derived corneal limbal stem cells through single-cell RNA sequencing\n#research #sorting #ophthalmology\nVattulainen et al.\nProfiles the single-cell transcript variations of human ocular surface systems to isolate the exact surface marker signatures needed for high-purity selection of therapeutic eye-repair stem layers.\nDerivation and analysis of human somatic sensory neuron subtypes facilitated through fluorescent hPSC reporters\n#research #methodology #neuroscience\nMalka-Gibor et al.\nEngineers dual-fluorescent human reporter cell matrices to isolate and study discrete sensory cell groups, building high-resolution platforms for human-relevant chronic pain screening.\nDerivation of transplantable human thyroid follicular epithelial cells from induced pluripotent stem cells\n#research #tissue-engineering #endocrinology\nUndeutsch et al.\nAchieves efficient manufacturing of pure, functional human thyroid units capable of organizing into vascularized structure loops, offering an advanced option to study hormone regulation in vitro.\nDietary restriction mitigates 5-fluorouracil-induced thrombocytopenia in aged mice via mitochondrial potentiation in hematopoietic stem cells and megakaryocyte progenitors\n#research #metabolism #hematopoiesis\nQiu et al.\nTracks metabolic pathways inside aging blood stem systems, proving that nutrient stress loops alter mitochondrial energy output to protect bone marrow cells from cytostatic chemotherapy damage.\nDissecting cardiovascular disease-associated noncoding genetic variants using human iPSC models\n#reviews #cardiology #genomics\nDababneh et al.\nReviews progress in human cell models used to decode complex mutations located in non-protein-coding regions, isolating the target loops driving structural heart failures.\nDissecting microglial contributions to neurodegenerative disease pathophysiology using human pluripotent stem cells\n#reviews #neuroscience #immunology\nDayoung Kim et al.\nExamines the technical integration of patient-derived immune lines into multi-lineage central nervous system models, tracing inflammatory pathways in Alzheimer\u0026rsquo;s and Parkinson\u0026rsquo;s profiles without animals.\nDiversity of cortical progenitors directs neuronal layer formation and regional glial patterning\n#research #neurogenesis #development\nOjalvo-Sanz et al.\nTraces early cell origin fields inside cerebral constructs, showing that pre-determined progenitor groups independently layout the stratified human brain architecture.\nDiversity-in-a-dish: A practical framework for hiPSC model development\n#reviews #safety-testing #methodology\nWeidema et al.\nOutlines a comprehensive strategic plan to construct patient cell validation biobanks that reflect varied human genetics, aiming to eliminate population data blind spots in preclinical drug evaluations.\nDynamic governance: A new era for consent for stem cell research\n#policy #ethics #data-autonomy\nIsasi et al.\nProposes a responsive, technology-driven data management setup that gives patients continuous oversight and approval choices for their digital multi-omic records and biomaterials.\nEfficient differentiation of human iPSCs into Leydig-like cells capable of long-term stable secretion of testosterone\n#research #bioprocessing #endocrinology\nSato et al.\nDetails a robust manufacturing protocol to differentiate human stem cell collections into endocrine cells that sustain steady androgen production, establishing human alternatives for male reproductive safety testing.\nElevated hematopoietic stem cell frequency in mouse alveolar bone marrow\n#research #official-repository #hematopoiesis\nNiizuma et al.\nIdentifies jawbone tissue segments as a unique, cell-rich bone marrow location that contains high concentrations of blood stem cell groups with distinct protective niches.\nEpendymal and neural stem cells are close relatives\n#reviews #neuroscience #cell-biology\nLokka et al.\nTraces shared structural genes and signal lineages connecting ventricular wall line systems with core neuroprogenitor blocks, mapping out cellular targets for brain tissue repair.\nExit from naive pluripotency proceeds with variable latency but without asymmetric division to generate population heterogeneity\n#research #cell-biology #biophysics\nStrawbridge et al.\nApplies deep mathematical modeling and continuous tracking to trace stem cells as they shift from ground states, showing that cell profile variations emerge from time delays rather than physical cell splitting choices.\nExtracellular-vesicle-mediated transfer of let-7b/7c promotes the proliferation of transition-state spermatogonia in neonatal mouse testis\n#research #sensory #reproductive\nZheng et al.\nDemonstrates that microscopic chemical transport carriers inside early support niches cross membrane barriers to deliver regulatory microRNA loops, triggering germ cell division blocks.\nFrom responsibility to responsibilization in stem cell research: An ethical framework\n#policy #ethics #methodology\nAssen et al.\nEstablishes a logical ethical architecture to evaluate how regulatory duties shift between developers and system users across advanced human developmental research fields.\nGene reactivation upon erosion of X chromosome inactivation in female hiPSCs is predictable yet variable and persists through differentiation\n#research #genetics #stability\nRaposo et al.\nTraces token epigenomic parameters across female cell lines to chart long-term expression variance, establishing analytical baselines for quality checking in clinical cell therapy bioprocessing.\nGenetics of growth rate in induced pluripotent stem cells\n#research #genomics #automation\nBrian Lee et al.\nScans genetic loci variations across massive cell file collections to map out the exact baseline locus regulators controlling cell growth, optimizing industrial human stem cell bioprocessing runs.\nGenome-edited safe and immune-evasive human pluripotent cells: Potential solution for allogeneic therapies\n#research #biotechnology #immunology\nTam et al.\nUses CRISPR multiplexing to knock out HLA expression loops while adding protective surface proteins, creating universal, immune-shielded human master seed lines for allogeneic tissue therapies.\nGenome-wide screening reveals essential roles for HOX genes and imprinted genes during caudal neurogenesis of human embryonic stem cells\n#research #genomics #neurogenesis\nKinreich et al.\nDeploys functional genome-wide CRISPR screens to determine the essential transcriptional networks and homeobox gene networks that direct stem lines toward spinal cord neural paths.\nGraft-derived horizontal cells contribute to host-graft synapses in degenerated retinas after retinal organoid transplantation\n#research #sensory #ophthalmology\nWatanabe et al.\nUses high-resolution tracking inside organoid transplant models to prove that graft cells physically weave functional synaptic connections with severely broken sensory networks.\nGSK3α negatively regulates GSK3β by decreasing its protein levels and enzymatic activity in mouse embryonic stem cells\n#research #cell-biology #cell-signaling\nDuo Wang et al.\nExamines internal feedback pathways within the glycogen synthase kinase axis, clarifying the precise balancing steps that regulate stem cell self-renewal states.\nHematopoietic organoids: Opportunities and challenges in modeling human hematopoiesis and diseases in vitro\n#reviews #organ-on-a-chip #hematopoiesis\nLiming Du et al.\nReviews advanced 3D structural strategies used to recreate functional bone marrow niches, detailing a clear non-animal track to model complex blood cancers and safe screening loops.\nHow neural stem cell therapy promotes brain repair after stroke\n#reviews #neuroscience #therapeutics\nWeber et al.\nExamines the functional healing steps used by engineered neural cell sheets to clear debris and reconstruct neural circuits following ischemic brain injury events.\nHuman cone photoreceptor transplantation stimulates remodeling and restores function in AIPL1 model of end-stage Leber congenital amaurosis\n#research #sensory #ophthalmology\nProcyk et al.\nTransplants high-purity human stem cell-derived vision receptors into end-stage genetic loss targets, proving functional connection and repair of blind sensory matrices.\nHuman macula formation involves two waves of retinoic acid suppression via CYP26A1 that modulate cell cycle exit and cone subtype specification\n#research #sensory #development\nHarding et al.\nDeploys human retinal organoids to trace the precise chemical timeline of morphogen blockades that establish the high-acuity human center vision spot, highlighting development tracks absent in small rodent formats.\nHuman organoids: Fit for drug discovery?\n#reviews #safety-testing #organ-on-a-chip\nWittich et al.\nPresents a strict logical evaluation of 3D human organoid platforms across large screening runs, defining standard readiness metrics to replace legacy toxicology models in corporate pipelines.\nHypersynchronous iPSC-derived SHANK2 neuronal networks are rescued by mGluR5 agonism\n#research #neuroscience #pharmacology\nMcCready et al.\nDeploys high-density multi-electrode arrays with autism-linked patient cell lines to uncover network timing faults, validating a chemical patch route to restore balance without animal testing.\nIdentifying enabling strategies for effective public dialogue in human embryo research\n#policy #ethics #engagement\nBeckett et al.\nOutlines practical methods to run transparent open discussions and framework checks regarding recent progress in human developmental and synthetic embryo research.\nImproving rigor and reproducibility through implementation of the ISSCR standards for human stem cell use in research\n#protocols #policy #quality-control\nFischer et al.\nEstablishes clear laboratory reporting criteria and characterization checklists based on recent ISSCR global agreements, standardizing cell file checks to maximize reproducibility.\nImpulse initiation in engrafted pluripotent stem cell-derived cardiomyocytes can stimulate the recipient heart\n#research #cardiology #therapeutics\nStüdemann et al.\nDetails the pacing mechanics and electrical coupling patterns of transplanted human cardiac patch units, proving direct functional drive over host muscle blocks.\nIn situ spatial transcriptomics reveals novel markers of the limbal stem cell niche and ocular surface epithelia\n#research #genomics #ophthalmology\nNureen et al.\nDeploys high-resolution spatial transcript mapping directly on clean tissue slices to locate hidden protective genes that shield and preserve eye surface stem populations.\nInhibition of N-myristoyltransferase in pluripotent stem cells promotes the naive state in mice and elicits trophectoderm and primitive endoderm markers in humans\n#research #cell-biology #biotechnology\nYoshida et al.\nDiscovers that blocking protein fatty-acid attachments modifies core cell states, triggering unique structural choices that enable the creation of clean extra-embryonic lineages.\nIn and out: Benchmarking in vitro, in vivo, ex vivo, and xenografting approaches for an integrative brain disease modeling pipeline\n#reviews #methodology #neuroscience\nPereira et al.\nPresents a critical comparative review of central nervous system research strategies, highlighting how human cell arrays and microphysiological systems accurately resolve the biological blind spots of traditional animal configurations.\nJAK/STAT signaling promotes the emergence of unique cell states in ulcerative colitis\n#research #organ-on-a-chip #gastroenterology\nMaciag et al.\nUses patient-derived gut organoid loops to trace out the inflammatory signaling vectors that reshape internal tissue lining cells during active colitis disease states.\nMECP2 mutations rewire human ESC fate and bias cortical lineage commitment\n#research #neuroscience #genomics\nGuillon et al.\nExamines how single-point epigenetic gene modifications alter early stem cells, showing a bias that disrupts layered cortical formation and replicates Rett syndrome traits.\nMETTL3 uncouples chromatin accessibility from transcription during retinal development\n#research #genomics #sensory\nJing Xu et al.\nDiscovers that RNA methylation enzymes act as independent switches separating structural DNA exposure states from active transcription during human retinal specialized cell formation.\nMolecular signature of human endometrial stem/progenitor cells at the single-cell level\n#research #genomics #gynaecology\nFitzgerald et al.\nResolves the single-cell gene tracking patterns of internal tissue lining networks, identifying high-purity somatic markers to build reliable human model assays for reproductive health research.\nModeling common Alzheimer’s disease with high and low polygenic risk in human iPSC: A large-scale research resource\n#research #genomics #neuroscience\nMaguire et al.\nAssembles a major open-source human cell biobank grouping lines by computed polygenic risk scores, delivering an animal-free framework to screen sporadic Alzheimer’s variations.\nModeling diabetic alpha cell dysfunction using stem cell-derived alpha cells\n#research #organ-on-a-chip #endocrinology\nShrestha et al.\nDifferentiates human stem cell lines into functional glucagon-secreting blocks to study metabolic failures under diabetic chemical loads, avoiding traditional animal injection series.\nNeural stem cells of the subventricular zone: A potential stem cell pool for brain repair in Parkinson’s disease\n#reviews #neuroscience #therapeutics\nVerkerke et al.\nMaps out the localized signal networks within brain lining niches that could be chemically triggered to stimulate internal cellular repair loops in Parkinson’s pathology.\nNuclear Lipin1 recruits HDAC2 to epigenetically repress SREBP1-dependent lipid synthesis and myelination in hypoxic preterm white matter injury\n#research #neuroscience #pathology\nXinyu Li et al.\nResolves the precise biochemical docking track where fat-processing enzymes join structural adaptors to turn off brain insulation construction under early oxygen-deprived conditions.\n“Oxygen tone” drives stage-specific OPC phenotypes for cell-based stroke therapy\n#reviews #neuroscience #therapeutics\nKokaia \u0026amp; Palma-Tortosa\nAnalyzes how precise oxygen concentration gradients inside cell processors direct neural precursor properties, optimization rule tracks for therapeutic production.\nPKM2 is a key factor to regulate neurogenesis and cognition by controlling lactate homeostasis\n#research #metabolism #neuroscience\nPengyan He et al.\nIdentifies metabolic enzyme adaptors that regulate local lactic balance, demonstrating a molecular mechanism that controls new nerve creation and memory preservation.\nPost-replicative chromatin accessibility predicts cell fate change\n#research #cell-biology #genomics\nKnudsen et al.\nImplements single-cell sequencing tracks to prove that structural DNA openness immediately following division states dictates downstream multi-lineage differentiation possibilities.\nPro-repair properties of a human embryonic stem cell-derived astrocyte cell therapy in demyelinating disorders\n#research #neuroscience #therapeutics\nSofer Stepanov et al.\nValidates an advanced human astrocyte cellular line that travels through broken tissue patches to clear inflammatory debris and accelerate myelin sheet reconstruction.\nProbing DNA damage in Rett syndrome neurons uncovers a role for MECP2 regulation of PARP1\n#research #neuroscience #genomics\nMorales et al.\nDeploys human stem cell neuro-arrays to show that a lack of methyl-binding proteins leaves human neurons vulnerable to double-strand breaks by failing to regulate primary repair machines.\nProgenitor neighborhoods function as transient niches to sustain olfactory neurogenesis\n#research #neurogenesis #cell-biology\nRajan et al.\nDocuments that localized spatial grouping patterns among adjacent early cells function as a short-term supportive home zone to maintain ongoing sensory cell replacement.\nPromoting the adoption of best practices and standards to enhance quality and reproducibility of stem cell research\n#policy #protocols #quality-control\nSelfa Aspiroz et al.\nOutlines rigorous consensus criteria for establishing international human cell validation standards, aiming to enhance multi-site data consistency for global NAM acceptance.\nProteomics-based receptor-ligand matching enhances differentiation maturity of human-stem-cell-derived neurons\n#research #methodology #proteomics\nDimitrov et al.\nApplies massive target protein scans to map active surface ports on developing human neurons, matching them with defined chemical mixtures to accelerate system functional maturation.\nRat cell-derived kidney generation via interspecies blastocyst complementation in an Osr1-KO mouse model\n#research #genetics #development\nYuri \u0026amp; Isotani\nUses targeted transcription gene knockouts to create a structural template gap in early developmental blocks, testing how diverse cell inputs interact across different species lines.\nReconstitution of the cellular niche requirements for primordial germ cell-like cell progression in humans\n#research #cell-biology #reproductive\nChang et al.\nConstructs an animal-free multi-lineage cell network that recreates the precise structural signals required to support early human reproductive cell line progression in vitro.\nResponse to Yu et al.\n#letters #methodology\nYuanyue Liu et al.\nTechnical clarification note addressing validation standards and data interpretation limits across human cellular reprogramming setups.\nRod-shaped micropatterning enhances the electrophysiological maturation of cardiomyocytes derived from human induced pluripotent stem cells\n#research #methodology #cardiology\nAl Sayed et al.\nEmploys high-precision microscale geometric stamping to force human heart cells into structural alignment, driving functional sarcomere assembly and predictable pacing actions without animal tissue.\nSkeletal muscle-on-a-chip in microgravity as a platform for regeneration modeling and drug screening\n#research #organ-on-a-chip #aerospace\nSoochi Kim et al.\nLaunches a specialized fluid micro-chamber board onto space stations to study microgravity-induced muscle wasting, establishing an advanced human testing format for accelerated aging research.\nSTARD10 regulates human pancreatic β cell differentiation and triglyceride metabolism\n#research #metabolism #endocrinology\nTan et al.\nIsolates the specific lipid-transfer proteins that handle fat balance inside human insulin-secreting cells, offering a defined mechanism track linked to metabolic strain events.\nSuppression of ATM kinase signaling accelerates cellular senescence\n#research #cell-biology #aging\nIshikawa et al.\nBlocks key nuclear warning systems in human neuroprogenitor arrays to replicate rapid gene-driven aging traits, mapping pathogenetic tracks without live rodent cross-aging chains.\nThe emergence of electrical activity in human brain organoids\n#reviews #neuroscience #organ-on-a-chip\nMancinelli et al.\nReviews recent breakthroughs in recording synchronized network pacing inside 3D human neural layers, evaluating hardware setups for non-destructive long-term signal tracking.\nThe ethical aspects of human organ-on-chip models: A mapping review\n#reviews #ethics #policy\nWeidema et al.\nPresents a systematic map of international ethical and regulatory questions surrounding advanced microphysiological systems, linking donor tracking choices directly with future industrial standard plans.\nThe regenerative role of neural crest stem cells in physical stimuli-enhanced peripheral nerve repair\n#research #engineering #neuroscience\nTai et al.\nDeploys specialized electric-field plates over human nerve stem matrices, proving that physical force fields double axonal extension rates and specify neuroglial choices.\nThe roles of TGF-β, Wnt, and MAPK signaling pathways in joint lineage specification in vitro and ex vivo\n#research #cell-signaling #orthopedics\nSuyash Raj et al.\nMaps the interconnected pathway circuits that govern human limb stem cells as they select cartilage or joint line fates, establishing a reliable baseline recipe for orthopedic NAM boards.\nThree-dimensional co-culturing reveals human stem cell-derived somatostatin interneurons with subclass expression\n#research #organ-on-a-chip #neuroscience\nBruzelius et al.\nIntegrates distinct inhibitory cell lines into 3D human brain structures to manufacture complex neural networks, providing human-relevant assay models for epilepsy drug screening.\nToward standardized iPSC testing: Insights from a multi-year international Quality Assessment Round\n#research #policy #quality-control\nHägg et al.\nAnalyzes data from a major cross-border testing trial across global labs, building uniform baseline metrics for genetic check tracking to guarantee safe allogeneic cell line entry.\nTransplantation of genome-edited retinal organoids restores some fundamental physiological functions coordinated with severely degenerated host retinas\n#research #sensory #ophthalmology\nWatanabe et al.\nTransplants CRISPR-corrected 3D human photoreceptor layers into severely damaged eye fields, proving that the structured human layers successfully parse light signals and connect with host sensory channels.\nValidation of non-destructive morphology-based selection of cerebral cortical organoids by paired morphological and single-cell RNA-seq analyses\n#research #automation #quality-control\nIkeda et al.\nValidates a smart computer-vision pipeline that scans raw 3D organoid shapes to identify high-quality neural structure lines without needing destructive gene-tag checks.\nXPRESSO: Rapid genetic engineering of human pluripotent stem cells for durable overexpression using a modular anti-silencing vector\n#research #biotechnology #methodology\nWexler et al.\nIntroduces a modular plasmid toolkit (XPRESSO) designed with specialized boundary elements that block chromatin locking, ensuring stable and long-term gene expression in human cell arrays.\nToxicology in Vitro # A leading peer-reviewed journal focused on the application of in vitro and in silico systems to assess the toxicity of chemical substances and understand cellular mechanisms of action without animal models. [Link]\nAssessing the skin sensitization potential of fragrance ingredients in consumer products using the peroxidase peptide reactivity assay (PPRA) as an additional weight of evidence\n#research #safety-testing #dermatology\nSchember et al.\nValidates the execution parameters of the non-animal Peroxidase Peptide Reactivity Assay (PPRA) within a larger weight-of-evidence safety tier, ensuring highly accurate skin allergy profiling for complex lipophilic fragrance compounds.\nIntegrate mechanistic evidence from new approach methodologies (NAMs) into a read-across assessment to characterise trends in shared mode of action\n#research #safety-testing #read-across\nEscher et al.\nEstablishes a structured data-integration workflow within read-across frameworks, demonstrating how mechanistic in vitro profiles verify chemical group similarities and define mode-of-action boundaries to minimize regulatory uncertainty.\nNAM-based development of a predictive test model for evaluating skin mildness potential of rinse-off products via integrated in vitro assays\n#research #safety-testing #dermatology\nNg et al.\nUnifies a multi-assay animal-free testing tier to accurately map consumer product skin mildness kinetics, replacing legacy cosmetic patch-testing with integrated cellular markers.\nQualification of a non-animal vaginal irritation method admitted as nonclinical assessment model (NAM) in the Incubator Phase of the United States Food and Drug Administration (US FDA) Medical Devices Development Tool (MDDT)\n#research #safety-testing #policy\nCostin et al.\nDocuments the formal qualification milestones of a fully human reconstructed epithelial model within the US FDA MDDT track, establishing a benchmark pathway for replacing mammalian irritation assays in regulatory device registration.\nVarious # These are items of interest from different journals. A sufficient number of articles were not found to warrant a specific journal\u0026rsquo;s heading yet, so all these articles are placed under the Various heading. Over time, we will investigate such journals further and if the quantity of publications are sufficient, they will be re-organized appropriately.\nA case study with benzoic acid demonstrating how integration of In Silico Tools, mechanistic In Vitro NAM, and toxicological data improves definition of point of departure for a chemically defined class in read-across assessments\n#research #safety-testing #read-across\nLester et al.\nDeploys benzoic acid as a structural template to demonstrate how combining computational modeling with targeted cell assays defines strict molecular points of departure for structural chemical classes.\nAI-driven parametrization of Michaelis–Menten maximal velocity: Advancing in silico new approach methodologies (NAMs)\n#research #automation #toxicokinetics\nKarakoltzidis et al.\nApplies machine learning algorithms to calculate maximal enzyme velocity values ($V_{max}$), automating metabolic clearance predictions for high-throughput chemical risk evaluations.\nDetermination of acceptable margins of exposure (MoE) for NAM-based skin sensitisation risk assessment\n#research #safety-testing #policy\nJoe Reynolds et al.\nDefines the boundary criteria and safety factors needed to calculate secure human exposure limits using non-animal test datasets.\nNon-clinical human neural new approach methodologies (NAMs): Electrophysiological assessment of opioid agonist and antagonist combination\n#research #safety-testing #neuroscience\nSerna et al.\nDeploys micro-electrode boards with human stem-derived nerve networks to monitor functional electrical patterns, capturing precise pharmacology details without rodent neural assays.\nNon-animal new approach methodologies (NAMs): Increasingly effective in validated contexts, more ethical and more economically productive\n#reviews #policy #economics\nElliott Johnson et al.\nPresents a multi-layered logical evaluation of alternative data models, detailing how animal-free approaches lower pipeline run costs while producing human-relevant toxicological outcomes.\nPursuing societal impact in research projects on NAM development: An analysis of routes to impact\n#reviews #policy #translation\nWijne et al.\nTracks the structural paths that take new non-animal models from basic laboratory design to operational adoption by global chemical companies.\nSensitivity analysis of the inputs for bioactivity-exposure ratio calculations in a NAM-based systemic safety toolbox\n#research #toxicokinetics #uncertainty\nLin et al.\nApplies variance equations to parameters used in cell-to-body data conversions, tracking down the exact variable blocks that introduce numerical errors in safe dose calculations.\nTOXTRUST: a tool leveraging the Dempster-Shafer Theory for robust integration of NAM results in decision-making considering uncertainty\n#research #automation #uncertainty\nKopańska et al.\nEngineers a predictive software utility (TOXTRUST) that applies belief-function mathematical modeling to combine conflicting results from alternative assays, projecting a clear security baseline.\nUnlocking the future of environmental safety: a framework for integrating new approach methodologies in decision-making\n#reviews #policy #ecotoxicology\nRivetti et al.\nProposes a clear operational pathway for regulatory authorities to blend non-animal data streams into ecological protection metrics, speeding up compound safety categorizations.\n","date":"2026-06-12","externalUrl":null,"permalink":"/library/articles/","section":"Library","summary":"Explore research papers and white papers on NAM, toxicology, and safety assessment.","title":"Articles","type":"library"},{"content":"","date":"2026-06-12","externalUrl":null,"permalink":"/tags/regulatory-science/","section":"Tags","summary":"","title":"Regulatory-Science","type":"tags"},{"content":"","date":"2026-06-12","externalUrl":null,"permalink":"/tags/research/","section":"Tags","summary":"","title":"Research","type":"tags"},{"content":"","date":"2026-06-12","externalUrl":null,"permalink":"/tags/safety-assessment/","section":"Tags","summary":"","title":"Safety-Assessment","type":"tags"},{"content":"","date":"2026-06-12","externalUrl":null,"permalink":"/tags/toxicology/","section":"Tags","summary":"","title":"Toxicology","type":"tags"},{"content":"","date":"2026-06-12","externalUrl":null,"permalink":"/tags/white-papers/","section":"Tags","summary":"","title":"White-Papers","type":"tags"},{"content":"","date":"2026-06-11","externalUrl":null,"permalink":"/tags/blogs/","section":"Tags","summary":"","title":"Blogs","type":"tags"},{"content":"","date":"2026-06-11","externalUrl":null,"permalink":"/tags/commentary/","section":"Tags","summary":"","title":"Commentary","type":"tags"},{"content":"","date":"2026-06-11","externalUrl":null,"permalink":"/tags/discourse/","section":"Tags","summary":"","title":"Discourse","type":"tags"},{"content":" Discourses # A curated collection of blogs, opinion pieces, posts, and commentary on New Approach Methodologies (NAM), toxicology, and related fields. This section gathers diverse perspectives, analyses, and discussions to foster a broader understanding of the evolving landscape of the New Approach Methodologies.\nEveryone is talking about NAM\nCredit: Mistral The following is merely an initial collection and will be incremented and organized by topic as it grows.\nHow predictive and productive is animal research?\n\u0026hellip; an even more fundamental problem casts doubt on the validity of clinical research: the poor quality of the animal research on which much of it is based. Ten years ago in The BMJ Pandora Pound and colleagues asked, “Where is the evidence that animal research benefits humans?”\nNew Approach Methodologies (NAM) : The Future of Toxicology and Safety Testing\nExplores the landscape of NAM, its synergistic use, and the factors driving its momentum in modern toxicology.\nThe Changing Landscape of New Approach Methodologies\nDiscusses how regulatory shifts are increasing adoption of NAM and the global movement toward human-relevant, animal-free approaches.\nNew Approach Methodologies Are Here. Is the Industry Ready?\nExamines the shift in safety and efficacy evaluation and how NAMs have matured into working tools for drug development and beyond.\nNew Approach Methodologies (NAM) in Drug Development\nHighlights how NAMs are being used to evaluate safety and efficacy without relying solely on traditional animal testing.\nNew Approach Methodologies (NAM) : By the Numbers\nOutlines the current animal-use landscape, the rise of NAM, and how tools like the Non-Animal Navigator support ethical, human-relevant drug development.\nNew Approach Methodologies (NAM) Explains how NAM are reshaping the landscape of safety assessments in toxicology and regulatory science.\n","date":"2026-06-11","externalUrl":null,"permalink":"/library/discourses/","section":"Library","summary":"Perspectives, analyses, commentary, and discussions on the evolving landscape of NAM.","title":"Discourses","type":"library"},{"content":"","date":"2026-06-11","externalUrl":null,"permalink":"/tags/discussion/","section":"Tags","summary":"","title":"Discussion","type":"tags"},{"content":"","date":"2026-06-11","externalUrl":null,"permalink":"/tags/opinions/","section":"Tags","summary":"","title":"Opinions","type":"tags"},{"content":"","date":"2026-06-10","externalUrl":null,"permalink":"/tags/interviews/","section":"Tags","summary":"","title":"Interviews","type":"tags"},{"content":"","date":"2026-06-10","externalUrl":null,"permalink":"/tags/lectures/","section":"Tags","summary":"","title":"Lectures","type":"tags"},{"content":"","date":"2026-06-10","externalUrl":null,"permalink":"/tags/presentations/","section":"Tags","summary":"","title":"Presentations","type":"tags"},{"content":"","date":"2026-06-10","externalUrl":null,"permalink":"/tags/shorts/","section":"Tags","summary":"","title":"Shorts","type":"tags"},{"content":"","date":"2026-06-10","externalUrl":null,"permalink":"/tags/talks/","section":"Tags","summary":"","title":"Talks","type":"tags"},{"content":" Videos # This section hosts a curated and growing collection of video content, including talks, presentations, and educational materials. The videos cover topics in New Approach Methodologies (NAM), in various areas such as AI, high-throughput, toxicology, safety assessment, organ-on-chip, organoids, and regulatory science.\nNAM explained through video presentations\nCredit: Mistral Clips # Brief, concise videos providing quick insights, explanations, or introductions to key concepts in NAM.\nAn introduction to new approach methodologies\nExplains how traditional animal models in drug development are being replaced by NAM.\nWhat Are Nonanimal Methods And Why Are They Important\nA short video explaining the importance and benefits of non-animal testing methods.\nSix Technologies That Help Stop the Use of Animals in Science\nOverview of six human-relevant technologies replacing animals in scientific research.\nAdvanced Innovation Challenges: New Approach Methodologies (NAM) Discussion on how NAM can replace, reduce, or refine animal use in the testing of medicinal products.\nNon animal methods of research - a more humane and scientifically valid option\nDr. Andrew Knight discusses what options exist to replace animals in medical research.\nMoving Beyond Animal Testing: An Intro to Non-Animal Methods\nIntroduction to non-animal testing methods and their benefits.\nToxicology to reduce the use of animals in research Fiona Sewell (NC3Rs) discusses reducing animal use in safety assessment.\nIs toxicity testing using animals cheaper than non-animal methods?\nFact-checking video addressing the cost comparison between animal and non-animal testing methods. [The analysis is somewhat simplistic in that the costs can well exceed the 4x stated and the suggestion that animal testing keeps people safe is simply incorrect.]\nChemical safety: New approach methods and a future beyond\nExplores the future of chemical safety testing using NAM.\nSix Technologies That Help Stop the Use of Animals in Science\nOverview of six human-relevant technologies replacing animals in scientific research.\nToxicology to reduce the use of animals in research\nFiona Sewell (NC3Rs) discusses reducing animal use in safety assessment.\nNew Approach Methodologies (NAMs)\nInternational Fragrance Association continues support for shifting toward NAM to replace animal testing.\nNew Approach Methodologies (NAM) for human health risk assessment\nDr. Marescotti describes the development and application of NAM for human health risk assessments.\nThe Future of Drug Testing: Organ Chips in Action\nOrgan-on-a-Chip technology uses microfluidics, controlled shear stress, and chemical gradients to recreate realistic human tissue physiology on devices the size of a USB stick - often outperforming both traditional cell cultures and animal experiments in predicting drug toxicity and efficacy. The video covers the underlying physics and biology, multi-organ \u0026ldquo;body-on-a-chip\u0026rdquo; systems, and how AI and 3D bioprinting are advancing the field toward personalized medicine and a future \u0026ldquo;human-on-a-chip.\u0026rdquo;\nInterviews # One-on-one or small-group discussions with experts, researchers, and practitioners in the field of NAM.\nAmy Clippinger and Mitch Klausner Discuss PETA Int’l Science Consortium and MatTek Collaborations\nDiscussion on collaborations to advance non-animal testing methods.\nKindfulness and Science\nDr. Charu Chandrasekera explains why it is important to cultivate mindfulness, kindness, compassion and kindfulness.\nOrgan Chip Engineering\nStem Cell Podcast chats with Dr. Milica Radisic, Guo, Professor and Canada Research Chair at the University of Toronto who uses organ-on-a-chip engineering to mimic physiology of the heart, kidney, and vasculature for the purpose of modeling human disease.\nTalks # Focused, informal presentations or keynote discussions highlighting specific aspects of NAM, such as case studies, innovations, or regulatory perspectives.\nIt\u0026rsquo;s Time to Think Outside the Cage\nIn this TEDx talk, Dr. Charu Chandrasekera explains that animal testing alternatives using NAM cost less, produce faster results, and being more human-relevant are more accurate.\nThis new technology could end animal testing\nSophie Leeman talks about NAM such as organ-on-a-chip offering a more ethical, physiologically relevant, and cost-effective alternative to traditional animal models for preclinical drug testing.\nEngineered heart tissues for better health and longer life\nDr. Milica Radisic, PhD, PEng Professor at the University of Toronto’s Institute of Biomedical Engineering (IBBME), talks about advances in the fields of stem cells and tissue engineering that enable growth of fully functional human heart tissue. Such human-relevant advances could revolutionize drug discovery process and treatment of patients with heart disease.\nNew QSAR system to predict acute inhalation toxicity\nDr. Roustem Saiakhov of MultiCASE Inc. presents a new QSAR (Quantitative Struture-Activity Relationship) computational method system for predicting acute inhalation toxicity. This talk was for the 2018 PETA International Science Consortium series on non-animal inhalation testing methods.\nNAM and In Silico approaches to the KCs\nDr. Kamel Mansouri (National Toxicology Program) discusses NAM and in silico approaches in this 2022 talk hosted by the UC Berkeley Superfund Research Program (SRP).\nLectures # Formal, structured presentations and educational sessions focused on foundational and advanced topics in NAMs and toxicology.\nIntegration of New Approach Methods for Testing and Assessment Elisabet Berggren presents at the 1st National Congress on Alternatives to Animal Testing.\nNAM and In Silico approaches to the KCs Dr. Kamel Mansouri (National Toxicology Program) discusses NAM and in silico approaches.\nNAM in genotoxicity \u0026amp; mechanistic toxicity testing: Safety assessment of novel chemicals (May 2021) Presenter: Giel Hendriks, CEO of Toxys, on the safety assessment of new compounds using NAM using ToxTracker and ToxProfiler, in vitro assays providing accurate, human-relevant toxicity information.\nThe Use of Machine Learning \u0026amp; Artificial Intelligence in Toxicology and Risk Assessment\nTimothy E H Allen, Research Scientist, Willis Group, University of Cambridge explains how AI and ML algorithms can identify new patterns in data and make predictions in a way and on a scale that human scientists cannot.\nSaferWorldbyDesign Webinar: In Silico Transporter Modeling and Its Role in Computational Toxicology\nGerhard F. Ecker, Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria discusses in silico transporter modeling in computational toxicology. This was a 2020 lecture presented by a partner of EU-ToxRisk Commercial Platform for New Approach Methods (NAMs) in Safety Assessment.\nEminent Toxicologist Lecture Series–From Murder to Mechanisms\nLecture by Michael A. Gallo on the history and evolution of toxicology and its relevance to modern NAM.\nEminent Toxicologist Lecture Series—Regulatory (Pharmaceutical) Toxicology\nLecture by Ruth A. Roberts on regulatory pharmaceutical toxicology and the role of NAM in drug safety testing.\nHow Can New Approach Methodologies Revolutionize Risk Assessment?\nExplores how NAM are transforming chemical risk assessment with innovative, science-based alternatives. Dr. Brigit Mertens from Sciencano explores the opportunities of implementing NAM discussing the latest advancements in in silico modeling, high-throughput screening, organ-on-a-chip technology, and omics applications.\nIntro to Smart In Silico Tools to Aid in Translating In Vitro \u0026amp; In Vivo Studies\nWill Redfern introduces ToxStudio an integrated modelling and simulation platform which uses in silico tools for translating study results.\nNavigating value-laden judgments about NAM in regulatory toxicology\nEuropean Chemicals Agency (ECHA) science seminar featuring Professor Kevin Elliott on value-laden judgments in NAM exploring how ethical and societal outlooks shape scientific reasoning.\nWebinars # Interactive online events, including webinars, panel discussions, and workshops, exploring the application, challenges, and advancements of NAM.\nMoving Beyond Animal Testing: An Intro to Non-Animal Methods\nAnimal Alliance panel discuss non-animal testing methods and their benefits. The experts include Dr. Tara Barton-Maclaren from Health Canada, and Dr. Lorna Ewart CSO Emulate Inc.\nPodcast: Why animal testing fails - the case for non-animal research methods\nDiscussion on why animal testing fails and the case for non-animal research methods.\nFrameworks for Establishing Scientific Confidence in New Approach Methodologies: Part 1\nWebinar on building scientific confidence in NAM, followed by a panel discussion.\nUse of non animal skin sensitisation test methods\nWebinar on human-relevant approaches to assess skin sensitization.\nNew approach method (NAM) : ICCVAM report \u0026amp; case study using branched carboxylic acids\nThird webinar in the EPIC series on the use of NAM in risk assessment, hosted by PETA Science Consortium International e.V., and the U.S. EPA.\nDay 1: New Approach Methodologies Workshop (May 31 - June 1) ECHA workshop discussing critical needs to enable the transition to an animal-free regulatory system.\nICCVAM Public Forum - Interagency Coordinating Committee on the Validation of Alternative Methods, Session 1, May 20, 2024\nMember agencies described their agencies\u0026rsquo; activities both to advance new approaches to safety testing of chemicals. For more, see site.\nFrameworks for Establishing Scientific Confidence in New Approach Methodologies: Part 1 Webinar on building scientific confidence in NAM, followed by a panel discussion.\nNAM-based strategies for systemic toxicity assessment Webinar organized by PETA Science Consortium International e.V., and the Institute for In Vitro Sciences.\nNew approach method (NAM): ICCVAM report \u0026amp; case study using branched carboxylic acids Third webinar in the EPIC series on the use of NAM in risk assessment, hosted by PETA Science Consortium International e.V., and the U.S. EPA.\nNew Approaches for Fish Toxicity Testing\nDr. David Volz and Dr. Michelle Embry present on new approaches for fish toxicity testing using Adverse Outcome Pathways (AOP). This talk was hosted by the Physicians Committee for Responsible Medicine, US EPA, and PETA International Science Consortium Ltd., on the use of non-animal methods in risk assessment.\nAdvancing Eye Irritation Assessment with Non-Animal Methods for Chemicals\nFourth webinar in the EPIC series on the use of NAM in risk assessment with Lindsay O’Dell, US Environmental Protection Agency Office of Pesticide Programs, and Renee Beardslee, US Environmental Protection Agency Office of Pollution Prevention and Toxics. This talk is co-hosted by the U.S. Environmental Protection Agency (EPA), PETA Science Consortium International e.V., the Institute for In Vitro Sciences (IIVS), and the California Department of Pesticide Regulation (CDPR).\nAcceptance and Use of In Vitro and Ex Vivo Eye Irritation Test Methods\nHans Raabe, MS, Institute for In Vitro Sciences, and João Barroso, PhD, European Commission, Joint Research Centre, discuss human-relevant approaches to assess eye irritation in this presentation part of a series hosted by the Physicians Committee for Responsible Medicine, US Environmental Protection Agency, and PETA Science Consortium International e.V., on the use of non-animal methods in risk assessment.\nRegulatory tools for assessing the skin sensitization potential of chemicals and a case study\nSixth webinar in the EPIC series on the use of NAM in risk assessment, hosted by PETA Science Consortium International e.V., and the U.S. EPA.\nNew Approach Methodologies for personalized colorectal cancer treatment\nDr. George Ramzy, University of Geneva, Switzerland, presents his work on applying NAM to personalized colorectal cancer treatment. The presentation is part of the webinar on Replacement in Oncology Research and was organized by the Swiss 3RCC and the FC3R in 2024.\nAdvancing Regulatory Decision-Making Through New Approach Methods (NAM) A session by Omari Bandele, PhD (FDA USA) on how NAM can advance regulatory decision-making.\nUsing NAM in Risk Assessment (September 2022) Presenters: Katie Paul-Friedman, PhD (EPA USA) and George E. N. Kass (EPA USA), discuss the application of NAM in risk assessment.\nExploring AI\u0026rsquo;s potential to improve chemical safety\nA 2026 interactive online workshop for industry professionals, policy experts, regulators and authorities, researchers, academics, and others who deal with chemical safety and circular economy issues.\nTransitioning to animal-free cell culture media in India\nPratiksha Palahe of HiMedia Laboratories and Kamalnayan Tibrewal of Biokraft Foods provide an overview of the transition to animal-free chemically defined cell culture media. This webinar is presented by PETA India.\nIn Silico Toxicology 101: Computational Tools for Chemical Hazard Characterization\nFirst webinar in a series on the use of in silico tools in toxicology organized by PETA Science Consortium International e.V., and the Institute for In Vitro Sciences.\nIn Silico Toxicology 101: Applications and Case Studies: Part I\nSecond webinar in a series on the use of in silico tools in toxicology organized by PETA Science Consortium International and the Institute for In Vitro Sciences.\nIn Silico Models: What to Do, What Not to Do\nWebinar with Al Dossetter (Medchemica) covering best practices and pitfalls for in silico modeling.\nReducing the Number of Animals Used in Toxicology Studies\nIn this Altasciences webinar, Narine Lalyeva, MS and Dr. Norbert Makori, PhD focus on methods to minimize animal use in toxicology studies while ensuring scientific integrity.\nIn Vitro Models for Inhalation Toxicity Testing\nDr. Anna Maione of MatTek presents on in vitro models for inhalation toxicity testing in a 2018 PETA International Science Consortium e.V. webinar series on non-animal testing methods.\nPrecision-Cut Lung Slices (PCLS) – PETA Science Consortium Webinar\nDr. Holger Behrsing presents on precision-cut lung slices for toxicology testing in a 2018 PETA International Science Consortium e.V. webinar series on non-animal testing methods.\nNAM-based strategies for systemic toxicity assessment\nKatie Paul-Friedman (EPA USA) and Elisabet Berggren (European Commission JRC) present in this 2025 webinar organized by PETA Science Consortium International e.V., and the Institute for In Vitro Sciences.\nIntegration of New Approach Methods for Testing and Assessment\nElisabet Berggren presents at the 2018 1st National Congress on Alternatives to Animal Testing.\nUse of computational approaches for pesticide toxicity assessment\nIn this 2023 webinar, Dr Bharath BR, Jai Research Foundation, and Dr Varun Ahuja, Syngene International Limited give an overview new approach methodologies and present a case study to demonstrating their use to evaluate the genotoxicity potential of pesticides.\nUse of Non-Animal Methods for Skin Sensitization Testing\nSusanne Kolle (BASF) and Taku Nishijou (Kao) present on non-animal testing strategies in this 2018 webinar hosted by PCRM, EPA and the PETA International Science Consortium Ltd., on the use of NAMs in risk assessment.\nNew approach methodologies: shaping research for non-animal test methods\nECHA’s 2024 initiatives in advancing non-animal testing methods through NAM with guests Sylvia Escher from the Fraunhofer Institute for Toxicology and Experimental Medicine, and Tomasz Sobanski from ECHA’s Alternative Methods Team.\nState of the science for bioaccumulation: an integrated, weight of evidence approach\nFirst webinar in a series on the use of NAM in ecotoxicology organized by the European Medicines Agency, the Health and Environmental Sciences Institute, the National Institute for Environmental Studies (NIES, Japan), PETA Science Consortium International e.V., the US Environmental Protection Agency, and the US Food and Drug Administration.\nGill cell line assay for acute fish toxicity prediction\nSecond webinar in a series on the use of NAM in ecotoxicology organised by the European Medicines Agency, the Health and Environmental Sciences Institute, the National Institute for Environmental Studies (NIES, Japan), PETA Science Consortium International e.V., the US Environmental Protection Agency, and the US Food and Drug Administration.\nNAM Based Prediction of Respiratory Toxicity Using Human and Rat Airway Models\nCharles River Laboratories and MatTek Life Sciences discuss NAM-based inhalation toxicology with Dr. Mary McElroy and Dr. Seyoum Ayehunie.\nImplementing Computational Approaches for Regulatory Safety Assessments\nICCVAM 2024 Communities of Practice Webinar on computational approaches in regulatory safety.\nUpdates on Activities Related to 21st Century Toxicology\nThis webinar hosted by the Center for Alternatives to Animal Testing (CAAT) and the Animal-Free Safety Assessment Collaboration is an informal event providing brief updates on cutting edge approaches in toxicology.\nAccelerating Drug Discovery with New Approach Methods (NAM) This webinar explores how NAM are revolutionizing preclinical drug development with faster, cost-effective, and biologically relevant models. The speakers are Satish Sankaran Phd, Farcast Biosciences CSO, Jorge Urresti PhD, an Associate Director of iXCells Biotech, and Christopher Hughes PhD, Aracari Biosciences CSO.\nNew Approach Methods for Human Health Risk Assessment Meeting 1\nA 2021(?) video on NAM titled \u0026ldquo;Variability and Relevance of Current laboratory Mammalian Toxicity Tests and Expectations for New Approach Methods of use in Human Health Risk Assessment\u0026rdquo;.\nNew Approach Methods for Human Health Risk Assessment Meeting 12\nA 2022 video on NAM titled \u0026ldquo;Variability and Relevance of Current laboratory Mammalian Toxicity Tests and Expectations for New Approach Methods of use in Human Health Risk Assessment\u0026rdquo;.\n","date":"2026-06-10","externalUrl":null,"permalink":"/library/videos/","section":"Library","summary":"Explore videos on NAM techonology including lectures, demonstrations, and panel discussions.","title":"Videos","type":"library"},{"content":"","date":"2026-06-10","externalUrl":null,"permalink":"/tags/videos/","section":"Tags","summary":"","title":"Videos","type":"tags"},{"content":"","date":"2026-06-10","externalUrl":null,"permalink":"/tags/webinars/","section":"Tags","summary":"","title":"Webinars","type":"tags"},{"content":"","date":"2026-06-09","externalUrl":null,"permalink":"/categories/curriculum/","section":"Categories","summary":"","title":"Curriculum","type":"categories"},{"content":" Students learning about NAM in sophisticated environment\nCredit: Mistral A collection of tutorials and educational resources on New Approach Methodologies, designed to help learners understand the science, applications, and implementation of NAMs.\nCOMING SOON!\n","date":"2026-06-09","externalUrl":null,"permalink":"/curriculum/","section":"Curriculum","summary":"","title":"Curriculum","type":"curriculum"},{"content":"","date":"2026-06-09","externalUrl":null,"permalink":"/tags/education/","section":"Tags","summary":"","title":"Education","type":"tags"},{"content":"","date":"2026-06-09","externalUrl":null,"permalink":"/tags/nams/","section":"Tags","summary":"","title":"Nams","type":"tags"},{"content":"","date":"2026-06-09","externalUrl":null,"permalink":"/tags/training/","section":"Tags","summary":"","title":"Training","type":"tags"},{"content":"","date":"2026-06-09","externalUrl":null,"permalink":"/tags/tutorials/","section":"Tags","summary":"","title":"Tutorials","type":"tags"},{"content":" High tech library for NAM work\nCredit: Mistral A collection of articles, videos, and discourse on New Approach Methodologies (NAM), including scientific research, regulatory papers, industry adoption, and advocacy perspectives. This section provides a comprehensive resource for understanding the field of NAM and its applications.\n","date":"2026-06-09","externalUrl":null,"permalink":"/library/","section":"Library","summary":"","title":"Library","type":"library"},{"content":"","date":"2026-06-09","externalUrl":null,"permalink":"/tags/reference/","section":"Tags","summary":"","title":"Reference","type":"tags"},{"content":"","date":"2026-06-09","externalUrl":null,"permalink":"/tags/resources/","section":"Tags","summary":"","title":"Resources","type":"tags"},{"content":"","date":"2026-06-06","externalUrl":null,"permalink":"/tags/australia/","section":"Tags","summary":"","title":"Australia","type":"tags"},{"content":"","date":"2026-06-06","externalUrl":null,"permalink":"/tags/eu/","section":"Tags","summary":"","title":"Eu","type":"tags"},{"content":" Government # Some international governments supporting NAM\nCredit: Gemini This page highlights a growing list of governmental agencies and organizations worldwide that are at the forefront of advancing Safety Assessment via NAM (New Approach Methodologies). These bodies drive regulatory support, funding, and policy initiatives to promote toxicology innovation, reduce reliance on animal testing, and ensure safer, more ethical chemical and therapeutic evaluations. Their work underscores a global shift toward science-based, non-animal methods in safety assessment, reflecting a commitment to both human health and environmental responsibility.\nAustralian Industrial Chemicals Introduction Scheme (AICIS)\nAICIS is Australia\u0026rsquo;s national regulator for the importation and manufacture of industrial chemicals, actively supporting the adoption of NAM for chemical safety assessments and aligning with international best practices.\nAustralian Therapeutic Goods Administration (TGA)\nThe TGA regulates therapeutic goods in Australia and promotes the use of NAM in the evaluation of medicines and medical devices, ensuring safety and efficacy without animal testing.\nEuropean Commission - Joint Research Centre (JRC)\nThe JRC provides scientific support to EU policies, including the development, validation, and implementation of NAM for chemical safety assessment and regulatory frameworks.\nEuropean Food Safety Authority - EFSA\nAn independent European agency providing robust scientific opinions, risk assessments, and dedicated computational suites (like OpenFoodTox and TKPlate) to advance safety criteria across the food and feed sectors.\nEuropean Union Reference Laboratory for Alternatives to Animal Testing\nEURL ECVAM coordinates the validation of alternative test methods and promotes NAM in regulatory toxicology across the EU, providing scientific and technical support to policymakers.\nJapanese Center for the Validation of Alternative Methods (JaCVAM)\nJaCVAM coordinates the validation and acceptance of alternative test methods in Japan, supporting regulatory adoption of NAM.\nKorea Center for the Validation of Alternative Methods (KoCVAM) KoCVAM works to validate and implement NAM in regulatory toxicology, ensuring alignment with global standards.\nOmbion Centre for Animal-free Biomedical Translation\nThe CPBT at Utrecht University is a global leader in developing and promoting non-animal testing methods, with a strong focus on the 3Rs (Replacement, Reduction, Refinement) and cutting-edge research in toxicology and biomedical sciences.\nOrganisation for Economic Co-operation and Development (OECD)\nThe OECD develops and harmonizes test guidelines for chemical safety, including NAM, to facilitate global regulatory acceptance and reduce animal testing.\nUK National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)\nNC3Rs funds and promotes research to replace, refine, and reduce the use of animals in scientific procedures, with a strong emphasis on NAM.\nU.S. Environmental Protection Agency - EPA\nA federal regulatory agency actively executing explicit, multi-year strategic work plans and computational data infrastructure upgrades under TSCA and FIFRA to significantly reduce and phase out vertebrate testing.\nU.S. Food and Drug Administration (FDA) - New Approach Methodologies (NAMs)\nThe FDA supports the adoption of NAM in drug development and regulatory submissions, encouraging innovative, non-animal testing methods for safety and efficacy evaluations.\nU.S. Food and Drug Administration (FDA) - Center for Drug Evaluation and Research (CDER)\nCDER supports the adoption of NAM in drug development and regulatory submissions, encouraging innovative, non-animal testing methods for safety and efficacy evaluations.\nU.S. Interagency Coordinating Committee on the Validation of Alternative Methods - ICCVAM\nA prominent collaborative framework composed of 16 U.S. federal regulatory and research agencies, tasked with establishing scientific confidence, coordinating test-method readiness criteria, and accelerating the global regulatory uptake of human-relevant alternatives.\nU.S. National Institutes of Health (NIH) - National Center for Advancing Translational Sciences (NCATS)\nNCATS supports the development and adoption of NAM through research, funding, and collaboration, focusing on translational science to improve human health.\nU.S. National Toxicology Program (NTP)\nThe NTP coordinates toxicology research and testing across U.S. federal agencies, promoting the use of NAM to assess chemical safety and reduce animal testing.\n","date":"2026-06-06","externalUrl":null,"permalink":"/organizations/govenment/","section":"Organizations","summary":"Governmental bodies advancing NAM through regulation, funding, and policy","title":"Government","type":"organizations"},{"content":"","date":"2026-06-06","externalUrl":null,"permalink":"/tags/government/","section":"Tags","summary":"","title":"Government","type":"tags"},{"content":"","date":"2026-06-06","externalUrl":null,"permalink":"/tags/policy/","section":"Tags","summary":"","title":"Policy","type":"tags"},{"content":"","date":"2026-06-06","externalUrl":null,"permalink":"/tags/regulation/","section":"Tags","summary":"","title":"Regulation","type":"tags"},{"content":"","date":"2026-06-06","externalUrl":null,"permalink":"/tags/usa/","section":"Tags","summary":"","title":"Usa","type":"tags"},{"content":"","date":"2026-06-05","externalUrl":null,"permalink":"/tags/academia/","section":"Tags","summary":"","title":"Academia","type":"tags"},{"content":" Business # Businesses have a clear choice\nCredit: Gemini This page is a growing list of the businesses, corporate partners, and commercial enterprises involved with NAM. It maps out the key industry stakeholders and organizations that advance non-animal research initiatives.\nBASF\nBASF integrates NAM into its safety assessment frameworks, reducing reliance on animal testing for chemical and consumer product development.\nBioIVT\nBioIVT provides human tissue samples, cell models, and services to support NAM research in drug discovery, toxicology, and biomedical applications.\nCharles River Laboratories\nCharles River Laboratories offers NAM-based solutions, including in vitro and computational models, to advance drug development and safety assessments.\nCosmetics Europe\nCosmetics Europe supports the adoption of NAM in the cosmetics industry, promoting alternative testing methods to ensure item safety without animal testing on the ingredients or the finished product.\nEmulate Bio\nEmulate Bio develops organ-on-a-chip technology to model human biology and disease, enabling more predictive and relevant NAM research for drug development, toxicity testing, and personalized medicine.\nMattek\nMatTek provides reconstructed human epidermis models for skin irritation, corrosion, and toxicity testing as part of NAM applications.\nGenentech\nGenentech incorporates NAM into its research and development pipelines, focusing on innovative approaches to drug discovery and patient safety.\nInSphero\nInSphero specializes in 3D cell culture models, including microtissues and organoids, to improve the relevance of preclinical research and drug screening.\nMimetas\nMimetas offers OrganoPlate technology, a microfluidic platform for creating and analyzing 3D human tissue models, supporting NAM applications in disease modeling and drug screening.\nOrganovo\nOrganovo designs and develops 3D bioprinted human tissues for use in drug discovery, disease modeling, and therapeutic applications, advancing NAM in biomedical research.\nPromoCell\nPromoCell provides primary human cells, media, and reagents to support NAM research in cell biology, toxicology, and regenerative medicine.\nStemcell Technologies\nStemcell Technologies offers tools, including cell lines and culture systems, to support NAM research in stem cell biology, drug discovery, and toxicology.\nTissUse\nTissUse specializes in human-on-a-chip technology, providing multi-organ microphysiological systems to improve the accuracy and relevance of preclinical research and drug development.\nUnilever\nUnilever integrates NAM into its safety assessment frameworks, removing reliance on animal testing for consumer products while advancing sustainable and ethical innovation in the industry.\nVitroCell\nVitroCell provides in vitro models and services for NAM research, focusing on respiratory and skin toxicity testing to support regulatory and industry needs.\n","date":"2026-06-05","externalUrl":null,"permalink":"/organizations/business/","section":"Organizations","summary":"Businesses advancing NAM through technology and innovation","title":"Business","type":"organizations"},{"content":"","date":"2026-06-05","externalUrl":null,"permalink":"/tags/business/","section":"Tags","summary":"","title":"Business","type":"tags"},{"content":"","date":"2026-06-05","externalUrl":null,"permalink":"/tags/collaboration/","section":"Tags","summary":"","title":"Collaboration","type":"tags"},{"content":" Education # NAM education gives students a modern advantage\nCredit: Mistral This page is a growing list of the academic institutions, research centers, and educational organizations worldwide that are involved with New Approach Methodologies (NAM). It highlights the key educational stakeholders and initiatives that advance non-animal research and training in the field.\nAltTox\nAltTox provides educational resources, training, and community engagement to advance the adoption of NAM in toxicology and regulatory science.\nCAAT - Center for Alternatives to Animal Testing\nCAAT, based at Johns Hopkins University, promotes NAM through research, education, and policy initiatives to reduce and replace animal testing in toxicology.\nCenter for Contemporary Sciences\nThis organization offers educational programs, workshops, and resources to support the transition to NAM in scientific research and regulatory frameworks.\nCenter for Toxicology and Mechanistic Biology\nBased at UC Davis, this center focuses on NAM research and education, integrating computational and in vitro methods into toxicology and biomedical sciences.\nEURL ECVAM\nThe European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) provides scientific validation, education, and training to promote NAM in regulatory toxicology and chemical safety.\nHarvard Center for Alternatives to Animal Testing\nThis center advances NAM through research, education, and collaboration, focusing on developing and validating alternative methods for toxicity testing.\nInstitute for In Vitro Sciences\nIIVS provides training, education, and validation services to support the use of NAM in toxicology, cosmetics testing, and regulatory compliance.\nMIT Center for Gynepathology Research\nMIT\u0026rsquo;s Center for Gynepathology Research develops NAMs, such as 3D living tissue models and AI-assisted imaging, to advance human-relevant biomedical research and personalized medicine.\nMIT Professional Education - Bioprocess Data Analytics and Machine Learning\nMIT Professional Education offers courses in bioprocess data analytics and machine learning, equipping scientists and engineers with tools to advance NAM in biopharmaceutical research.\nNC3Rs\nThe National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs) provides funding, resources, and training to support NAM in the UK and globally.\nPETA International Science Consortium\nThis consortium offers educational resources, workshops, and funding to promote the development and adoption of NAM in regulatory testing and research.\nPhysicians Committee for Responsible Medicine\nPCRM provides educational programs, resources, and advocacy to advance NAM in medical research, testing, and education.\nTox21\nThe Toxicology in the 21st Century (Tox21) program is a collaboration between U.S. federal agencies to develop and validate NAM for chemical safety testing, with educational resources and training opportunities.\nToxStrategies\nToxStrategies offers educational programs, workshops, and consulting services to support the adoption of NAM in toxicology, risk assessment, and regulatory compliance.\nUCSF Program on Reproductive Health and the Environment\nThis program integrates NAM into its research and educational initiatives, focusing on the impact of environmental chemicals on reproductive health.\nVirtual Physiological Human Institute\nThe VPH Institute promotes NAM through research, education, and collaboration, focusing on computational modeling and simulation in biomedical sciences.\n","date":"2026-06-05","externalUrl":null,"permalink":"/organizations/education/","section":"Organizations","summary":"Education institutions advancing NAM through research and training","title":"Education","type":"organizations"},{"content":"","date":"2026-06-05","externalUrl":null,"permalink":"/tags/industry/","section":"Tags","summary":"","title":"Industry","type":"tags"},{"content":"","date":"2026-06-05","externalUrl":null,"permalink":"/tags/innovation/","section":"Tags","summary":"","title":"Innovation","type":"tags"},{"content":" Board Room\nCredit: Xoom stock collection This section provides a curated list of organizations which are in some way involved in New Approach Methodologies (NAM), categorized by their primary role - such as Business, Education, Government. Some may appear in multiple sections reflecting their diverse contributions to the NAM ecosystem.\n","date":"2026-06-05","externalUrl":null,"permalink":"/organizations/","section":"Organizations","summary":"A curated list of organizations involved in New Approach Methodologies (NAM).","title":"Organizations","type":"organizations"},{"content":"","date":"2026-06-03","externalUrl":null,"permalink":"/tags/animal-testing/","section":"Tags","summary":"","title":"Animal-Testing","type":"tags"},{"content":"","date":"2026-06-03","externalUrl":null,"permalink":"/tags/baboon-experiments/","section":"Tags","summary":"","title":"Baboon-Experiments","type":"tags"},{"content":"","date":"2026-06-03","externalUrl":null,"permalink":"/tags/caare/","section":"Tags","summary":"","title":"Caare","type":"tags"},{"content":"After more than 25 years, grotesque and scientifically baseless experiments studying estrogen suppression in pregnant baboons and their babies at the University of Maryland-Baltimore (UMB) have been shut down.\nKey Highlights # CAARE\u0026rsquo;s advocacy led to the termination of long-standing baboon experiments at UMB. Female baboons were confined, repeatedly impregnated, and subjected to invasive procedures for a study deemed irrelevant to human diabetes. Federal funding for the project has ended, and UMB confirmed the experiments are over with no plans to resume. A second related project remains active for one more year, but CAARE is investigating its status to ensure no new experiments are conducted. Statements # This historic victory belongs to you. Because you spoke out, took action, and stood with CAARE, these egregious experiments have finally come to an end.\n— CAARE\nAbout the Organizations # CAARE (Citizens for Alternatives to Animal Research and Experimentation) is a nonprofit organization dedicated to ending animal experimentation and promoting ethical, effective alternatives.\nLearn More # Ending 25 Years of Birth Experiments on Baboons\n","date":"2026-06-03","externalUrl":null,"permalink":"/news/baboon-umb/","section":"News","summary":"CAARE’s advocacy ends 25 years of baboon experiments at UMB, marking a victory for ethical science.","title":"Ending 25 Years of Baboon Experiments at UMB","type":"news"},{"content":"","date":"2026-06-03","externalUrl":null,"permalink":"/tags/ethical-science/","section":"Tags","summary":"","title":"Ethical-Science","type":"tags"},{"content":"","date":"2026-06-03","externalUrl":null,"permalink":"/tags/non-animal-methods/","section":"Tags","summary":"","title":"Non-Animal-Methods","type":"tags"},{"content":"","date":"2026-06-03","externalUrl":null,"permalink":"/tags/university-of-maryland/","section":"Tags","summary":"","title":"University-of-Maryland","type":"tags"},{"content":"","date":"2026-05-31","externalUrl":null,"permalink":"/tags/action-packs/","section":"Tags","summary":"","title":"Action-Packs","type":"tags"},{"content":"These are materials such as artwork, handouts, and various items, individuals can use to educate themselves with and communicate NAM topics to others.\nPersonnel development is our greatest asset\nCredit: rawpixel.com (magnific.com) Talking Points # These are items created around a central theme. The title will always end with a TP. The structure will usually have an introductory explanation, a callout section, faqs, and references. These can be used to communicate with others either from the website or from the printable pdf handout(s) which are supplied in the very last faq \u0026ldquo;Can I print this document?\u0026rdquo; The pdf does not contain references, but provides a QRcode or URL to lead back to the webpage.\nBusiness Cards # These are printable pdf documents personalized for the PNARS team, or generalized for anyone who wants to promote our NAM website.\nNamamanam # Artwork with our NAMouse logo.\nMore items # We will post more items as they are developed.\n","date":"2026-05-31","externalUrl":null,"permalink":"/resources/assets/","section":"Resources","summary":"Various materials for GUPPI implementers.","title":"Assets","type":"resources"},{"content":"","date":"2026-05-31","externalUrl":null,"permalink":"/categories/bulletins/","section":"Categories","summary":"","title":"Bulletins","type":"categories"},{"content":"","date":"2026-05-31","externalUrl":null,"permalink":"/tags/efficiency/","section":"Tags","summary":"","title":"Efficiency","type":"tags"},{"content":"","date":"2026-05-31","externalUrl":null,"permalink":"/tags/handout/","section":"Tags","summary":"","title":"Handout","type":"tags"},{"content":" NAM vs Animal Testing # Across three critical domains - Science, Ethics, and Efficiency - NAM consistently outperform the obsolete animal testing model.\nTalking about NAM\nCredit: wal_172619 (pixabay) Category NAM Animal Testing Science Human-relevant data. Leverages organ-on-a-chip, in silico modeling, and AI to directly replicate human biology.1 2 3 Interspecies barrier. Relies on non-human biology; inherently fails to predict human-specific physiological outcomes.4 5 6 Ethics No animal suffering. Aligns scientific innovation with universal standards of non-violence and ethical responsibility.7 8 Systemic exploitation. Inflicts severe harm and death on millions of sentient animals annually; out of step with modern values.9 10 Efficiency High-speed, scalable. Accelerates discoveries via high-throughput screening, delivering precise data in days or weeks.11 Stagnant, cost-prohibitive. Drains resources via multi-year observational timelines and massive animal facility overhead.12 Strategic Callouts # For Scientists # Produce data that actually applies to humans. Years of comparative data published in peer-reviewed journals demonstrate that NAM consistently out-predicts traditional animal models. Transitioning to human-centric platforms eliminates false leads, reduces clinical attrition, and aligns your laboratory with modern biomedical innovation.\nFor Policymakers # Secure scientific autonomy and competitiveness. While the United States (via the FDA Modernization Act 2.0) and the European Union actively fund and legislate the phase-out of animal models, Canadian regulatory frameworks remain dangerously stagnant. Modernizing public funding to mandate NAM infrastructure is a matter of national economic and scientific survival.\nFor Educators and Youth # Train for the future, not the past. Animal dissection and traditional toxicological assays are obsolete methodologies. Equipping the next generation with computational biology, tissue engineering, and machine learning skillsets is essential for global career readiness in 21st-century biotechnology.\nFrequently Asked Questions # Why are animal models failing scientifically? # Animal testing suffers from a catastrophic translation failure—approximately 90% to 95% of drugs that pass animal trials fail in human clinical trials because species-specific biology cannot predict human physiology. NAM utilizes human-derived cells, computational biology, and machine learning, replacing flawed surrogates with direct human relevance.13\nIsn’t animal testing legally mandated? # The regulatory landscape has fundamentally shifted. In the US, the FDA Modernization Act 2.0 eliminated the federal mandate requiring animal testing for new drugs, explicitly greenlighting human-relevant NAM. Globally, dozens of nations have banned animal testing for cosmetics and are actively rewriting chemical safety frameworks to favor non-animal methods.14 15\nAre NAM more expensive than animal research? # No. Animal testing is an immense financial drain - it requires years of animal maintenance, breeding, and slow observational protocols. NAM offers rapid, high-throughput screening that delivers data in days or weeks rather than years. The long-term economic savings in drug development speed and reduced clinical trial failures are measured in billions of dollars.16\nWhat concrete technologies define NAM? # NAM comprises a sophisticated suite of advanced scientific tools17 such as:\nMicrophysiological Systems (MPS) - \u0026ldquo;Organ-on-a-chip\u0026rdquo; devices that replicate the mechanical and biochemical functions of living human organs. In Silico Modeling and AI - Advanced computational simulations that predict toxicity and molecular interactions using massive human datasets. Human Organoids - Three-dimensional tissue cultures grown from human stem cells that mimic complex organ architecture. 3D Bioprinting - Uses 3D printing techniques to create living tissues and organs by combining cells, growth factors, and biomaterials in a layer-by-layer process. High-Throughput Screening - Automated robotic systems capable of testing thousands of chemical compounds simultaneously on human cellular assays. The development of CRISPR gene-editing is a well-known example. Many breakthroughs have been made as a result of NAM.18\nHow do NAM compare in predictive reliability? # NAM routinely outperforms animal models in accuracy. Traditional animal assays for skin sensitization or systemic toxicity often hover around 50% to 60% reproducibility - essentially a coin flip. In contrast, validated human-predictive NAM consistently achieve accuracy rates exceeding 80% to 90% because they eliminate inter-species biological variance.19 20\nHow can I actively accelerate the transition to NAM? # True progress requires systemic advocacy21:\nAcademic Reform - Push for the integration of NAM into university/school science curricula to phase out obsolete animal dissection and testing labs. Policy Support - Demand dedicated government funding for public infrastructure, validation centers, and research grants exclusively for NAM. Public Awareness - Distribute this brief, deploy the digital assets, and direct researchers, students, and policymakers to the open-access resources at pnars.org website22 23. Can I print this document? # This Talking Point is available for download right here.\nFootnotes # Organ-on-a-chip meets artificial intelligence in drug evaluation. Theranostics, 13(13), 4526-4558. Reviews how the convergence of artificial intelligence and microfluidic organ-on-a-chip (OoC) platforms enhances physiological relevance, optimizes tissue-tissue interactions, and dramatically improves human-specific drug evaluation accuracy over non-human models.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nIn silico modelling of organ-on-a-chip devices: an overview. Frontiers in Bioengineering and Biotechnology, 12, Article 1520795. Details how mathematical and computational (in silico) simulations are paired with physical microfluidic devices (like lung, liver, and kidney chips) to predict human physiological outcomes, optimize experimental conditions, and eliminate traditional testing overhead.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nNew approach methodologies (NAMs): identifying and overcoming hurdles to accelerated adoption. Toxicology Research, 13(2), Article tfae044. Industry reference that establishes how NAM (including computational toxicology, in vitro screens, and multi-omics) provide more protective, human-relevant chemical safety data than historical mammalian assays.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nAnalysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications While this 2024 umbrella review notes that early-stage animal and human trials often appear to agree due to systemic publication biases, it confirms the brutal bottom line: 95% of animal-tested therapies completely fail to achieve human regulatory approval.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nThe flaws and human harms of animal experimentation. Cambridge Quarterly of Healthcare Ethics, 24(4), 407-419. Foundational, heavily cited text in non-animal advocacy literature that systematically outlines the anatomical, genetic, and metabolic differences that cause the interspecies barrier to fail human patients.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nIs it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. Journal of Translational Medicine, 16, 304 (2018). The pharmaceutical industry faces a critical productivity crisis driven by dismal translation rates from bench to bedside. This failure is primarily attributed to preclinical animal models poorly predicting clinical efficacy and safety.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nWith What Should We Replace Nonhuman Animals in Biomedical Research Protocols? The historical ethical framework of merely \u0026ldquo;reducing\u0026rdquo; or \u0026ldquo;refining\u0026rdquo; animal testing is an obsolete paradigm. True scientific and moral progress requires the outright replacement of animal protocols with human-relevant models to stop the alarming failure rate of drug translation.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nCritical Animal Studies and Animal Law. Animal Law Review, 18(2), 207-236 (2012).\nLaw is fundamentally anthropocentric, treating sentient beings as mere property. Integrating critical animal studies into legal frameworks is necessary to challenge the state-sanctioned species hierarchy and expose how the system erases non-human victimhood to protect corporate interests.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nAn Estimate of the Number of Animals Used for Scientific Purposes Worldwide in 2015. Alternatives to Laboratory Animals, 48(3), 135-143 (2020).\nA rigorous statistical analysis establishing that an estimated 192 million sentient animals are used annually in scientific procedures worldwide. This massive scale of hidden exploitation highlights the urgent need for systemic regulatory overhauls and global replacement strategies.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nPublic Attitudes toward the Use of Animals in Research: Effects of Species, Justification and Harm. Animals, 4(3), 391-406 (2014).\nA comprehensive evaluation of public opinion trends demonstrating a profound, structural shift in modern societal values as early as 2014. Institutional acceptance of animal experimentation is further collapsing as public moral standards increasingly reject the infliction of systemic harm on sentient beings.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nHigh-Throughput Screening - an overview. ScienceDirect Topics.\nAutomated high-throughput screening (HTS) platforms fundamentally redefine research efficiency. By evaluating thousands of chemical compounds simultaneously on human cellular assays, these robotic systems deliver precise toxicity and efficacy profiles on a massive scale, compressing multi-year animal testing timelines into mere days or weeks.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nWhy Are Monoclonal Antibodies the First Prime Targets for Animal-Free Testing at FDA? Animal Wellness Action.\nLive animal research imposes immense financial and logistical burdens. Comparative cost analyses demonstrate that a standard preclinical evaluation utilizing animal-free organ-chips costs roughly $325,000, compared to over $5.2 million for identical protocols using non-human primates, representing a dramatic reduction in resource consumption.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nWill Non-Animal Approaches Replace Some or All of Animal Testing? Charles River Laboratories Eureka.\nThe average cost to bring a single new drug to market scales to $2.6 billion, with a massive portion trapped in slow, preclinical mammalian facility overhead. This astronomical resource drain is structurally inefficient, given that over 92% of compounds clearing these protracted animal pipelines ultimately fail in human clinical trials due to fundamental interspecies barriers.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nThe Future is Animal-Free: Accelerating Humane and Human-Relevant Science. European Coalition to End Animal Experiments (ECEAE) Report.\nA comprehensive policy report documenting that between 90% and 95% of drugs found to be safe and effective in preclinical animal tests ultimately fail in human clinical trials due to profound, insurmountable biological and physiological species barriers.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nWhy TPI - Transition Programme for Innovation Without the Use of Animals (TPI). Dutch Ministry of Agriculture, Fisheries, Food Security and Nature.\nThe official framework of the Dutch government\u0026rsquo;s national strategy to position the Netherlands as a global frontrunner in animal-free science. The interministerial initiative formally establishes national policies to systematically phase out animal procedures by accelerating the qualification, regulatory acceptance, and deployment of human-relevant alternatives like organs-on-a-chip and artificial intelligence.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nCost of drug development. Wikipedia.\nA comprehensive aggregate analysis tracking the massive capital investments required for therapeutic pipelines, documenting that average expenditures range from hundreds of millions to several billion dollars per successful asset. The structural timeline inefficiencies and high attrition rates of legacy preclinical protocols serve as a primary macroeconomic driver of these astronomical costs.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nWhat are NAMs? Science Advancement and Outreach Division (SAO).\nA definitive technical breakdown defining NAM explicitly as non-animal, human-derived methods. The overview outlines the core suite of defining technologies—including 3D human organoids, microfluidic organs-on-chips, computational modeling, non-invasive diagnostic imaging, and human microdosing—which replace flawed animal surrogates with direct human biological relevance.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nAdvances Due to New Approach Methodologies\nNew Approach Methodologies (NAM) represent a paradigm shift in biomedical research and drug development, replacing or supplementing traditional animal testing with human-relevant, in vitro, in silico, and in chemico technologies. The sections below synthesize peer-reviewed, validated medical discoveries enabled by NAM, organized thematically under the following areas.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nA triangular approach for the validation of new approach methods for skin sensitization. ALTEX - Alternatives to Animal Experimentation, 38(4), 608-624 (2021).\nA landmark validation study demonstrating that non-animal defined approaches (DAs) consistently achieve an 85% to 89% accuracy rate in predicting human skin sensitization hazards, routinely outperforming traditional animal assays that exhibit significantly lower reproducibility due to species-specific variance.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nIntegrating New Approach Methodologies (NAMs) into Preclinical Regulatory Evaluation. PMC Oncology Review, Article PMC12730968 (2025).\nA methodological analysis establishing that traditional animal models fail as predictive simulations due to insurmountable species-specific differences in disease biology and pharmacology. The study demonstrates that true predictive validity requires parameterized, human-relevant variables (such as organoids and computational modeling) rather than superficial macro-level organismic resemblances.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nSocio-technical transitions to sustainability: a review of criticisms and elaborations of the Multi-Level Perspective. Current Opinion in Environmental Sustainability, 39, 187-201 (2019).\nA foundational structural analysis establishing that destabilizing an entrenched socio-technical regime requires coordinated systemic advocacy across multiple spheres—specifically analyzing how political power, institutional policy changes, cultural framing struggles, and grassroots public innovations work together to break historical path-dependency.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nResources Altering Ingrained School Education (RAISE)\nCentral hub of tools, templates, and resources on the pnars.org website to empower students, parents, and educators in advocating for modern NAM education in Canada.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nPNARS Resources\nComprehensive resources including regulatory documents, promotional materials, and educational tools for NAM adoption and understanding.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\n","date":"2026-05-31","externalUrl":null,"permalink":"/resources/assets/nam-vs-animal-testing/","section":"Resources","summary":"NAM replaces flawed animal models with superior human-centric science..","title":"NAM vs Animal Testing TP","type":"resources"},{"content":"","date":"2026-05-31","externalUrl":null,"permalink":"/categories/science/","section":"Categories","summary":"","title":"Science","type":"categories"},{"content":"","date":"2026-05-31","externalUrl":null,"permalink":"/tags/science/","section":"Tags","summary":"","title":"Science","type":"tags"},{"content":"","date":"2026-05-31","externalUrl":null,"permalink":"/tags/talking-points/","section":"Tags","summary":"","title":"Talking-Points","type":"tags"},{"content":"","date":"2026-05-29","externalUrl":null,"permalink":"/tags/biomedical-engineering/","section":"Tags","summary":"","title":"Biomedical Engineering","type":"tags"},{"content":"","date":"2026-05-29","externalUrl":null,"permalink":"/tags/biomedical-innovation/","section":"Tags","summary":"","title":"Biomedical Innovation","type":"tags"},{"content":"","date":"2026-05-29","externalUrl":null,"permalink":"/tags/cardiac-research/","section":"Tags","summary":"","title":"Cardiac Research","type":"tags"},{"content":"","date":"2026-05-29","externalUrl":null,"permalink":"/tags/computational-toxicology/","section":"Tags","summary":"","title":"Computational Toxicology","type":"tags"},{"content":"","date":"2026-05-29","externalUrl":null,"permalink":"/tags/fda/","section":"Tags","summary":"","title":"Fda","type":"tags"},{"content":"","date":"2026-05-29","externalUrl":null,"permalink":"/tags/health-canada/","section":"Tags","summary":"","title":"Health Canada","type":"tags"},{"content":" Dr. Lorna Ewart, PhD # Chief Scientific Officer at Emulate, Inc Pioneer in organ-on-a-chip technology and New Approach Methodologies (NAM) Advocate for replacing animal testing with human-relevant models Recipient of the Lush Prize for ethical biomedical innovation Holder of key patents in organ-on-a-chip technology Leader in industry and regulatory collaborations Lorna Ewart\nCredit: emulatebio Introduction # Dr. Lorna Ewart, PhD, serves as Chief Scientific Officer at Emulate, Inc, where she leads the development of organ-on-a-chip technology and New Approach Methodologies (NAM) for drug discovery and toxicology. Her work focuses on creating human-relevant models to replace animal testing, with contributions recognized by the Lush Prize and the Society of Toxicology. She is a prominent advocate for ethical and innovative biomedical research.\nProfessional Background and Achievements # Dr. Lorna Ewart holds a PhD in Pharmacology from the William Harvey Research Institute in London and a 1st class BSc honours in Pharmacology from the University of Aberdeen. She spent 20 years at AstraZeneca, where she established and led the Microphysiological Systems Centre of Excellence within the R\u0026amp;D Biopharmaceuticals Unit. She also held roles such as Director of Toxicology Projects (Respiratory, Inflammation and Autoimmune).\nAs Chief Scientific Officer at Emulate, Inc, she oversees the scientific strategy and drives collaborations with industry leaders and regulatory bodies. Her leadership has been instrumental in positioning Emulate, Inc as a leader in organ-on-a-chip technology. Dr. Ewart is a fellow of the Royal Society of Biology and the British Pharmacological Society.\nResearch Areas and Projects # Dr. Ewart\u0026rsquo;s research focuses on developing organ-on-a-chip platforms that mimic human physiology, enabling more accurate and ethical drug discovery and toxicology testing. Her work includes:\nOrgan-on-a-Chip Technology: Creating microengineered environments that replicate human organ functions, allowing for more predictive and human-relevant testing. New Approach Methodologies (NAM): Advancing non-animal testing methods to improve the relevance and ethical standards of biomedical research. Industry and Regulatory Collaboration: Working with pharmaceutical companies and regulatory agencies, including a Cooperative Research and Development Agreement (CRADA) with the FDA, to integrate organ-on-a-chip technology into standard testing protocols. Her projects have led to significant advancements in the field, with applications ranging from drug development to toxicology assessment.\nMajor Publications # Title Journal Year Link Protecting Human Health with Organ-on-a-Chip Technology Pharmaceutical Executive 2022 link Optimal experimental design for efficient toxicity testing in microphysiological systems: A bone marrow application Frontiers in Pharmacology 2023 link Organ-on-a-Chip Technology Improves Preclinical Toxicology: Emulate says its human Liver-Chip outperforms animal models, offering higher specificity and sensitivity in assessments of hepatotoxicity Sage Journals 2023 link Optimal experimental design for efficient toxicity testing in microphysiological systems: A bone marrow application Pharmacology 2023 link Taking the leap toward human-specific nonanimal methodologies: The need for harmonizing global policies for microphysiological systems Cell Press 2024 link Chimeric Antigen Receptor T-Cell Recruitment and Killing can be Evaluated on an Organ-Chip model system Journal of Immunology 2024 link Biology-inspired dynamic microphysiological system approaches to revolutionize basic research, healthcare and animal welfare Altex 2025 link Awards and Recognitions # Lush Prize: Awarded for her contributions to replacing animal testing with innovative and ethical scientific methods. Lush Prize 2024 Fellow of the Royal Society of Biology and British Pharmacological Society: Recognized for her leadership in pharmacology and biomedical innovation. Emulatebio Chief Science Officer Patents # High-Content Imaging Of Microfluidic Devices #20210341378\nMedia and Public Engagement # Panelist at Animal Alliance Event: Participated in a panel event on modern alternatives to animal testing, discussing the future of ethical biomedical research. Rethinking Research: Animal Alliance Event Keynote Speaker: Frequent keynote speaker at conferences surrounding the advancement of alternative methods in biomedical research. Laura Ewart, Chief Scientific Officer at Emulatebio, introduces AVA™ Emulation System as a benchtop microluidic platform that uniquely integrates an automated microscope for imaging, microluidic flow, and environmental control to keep cells \u0026ldquo;happy and healthy\u0026rdquo;. The workflow uses chip arrays, with eight fitting into AVA, enabling 96 emulations, each featuring two microluidic channels where cells are seeded on either side of a semi-permeable membrane, with media flowing unidirectionally for downstream analysis.\nLaura Ewart from Emulatebio discussed their journey with organ-on-chip systems, highlighting the evolution from their first-generation platform, ZOE, to the new benchtop instrument, AVA, which integrates an automated microscope, microfluidic flow, and environmental control, enabling 96 emulations per run with improved reproducibility, throughput, and robustness. She emphasized AVA\u0026rsquo;s ability to generate human-relevant, translational data for drug discovery workflows, while addressing operational obstacles like reliability and decision-making confidence. AVA has been tested in labs worldwide, with features like robotic compatibility and statistical rigor, aiming for broader adoption in regulatory and industrial settings.\nWebinar Abstract (youtube): Infectious diseases, such as COVID-19, are challenging to study in animal models due to species differences, and conventional 2D cell-based systems lack the complexity to appropriately model the disease or immune response in humans. Organs-on-Chips offer a human relevant system that can recreate key disease phenotypes in a more physiological microenvironment due to their complex 3D architecture and mechanical forces induced by flow and stretch. In this webinar, we discuss how the Airway Lung-Chip and Alveolus Lung-Chip can be used to study viral infection and accelerate the development of new therapeutics.\nLorna Ewart presents Emulate\u0026rsquo;s work on using a human liver chip to predict drug-induced liver injury (DILI), emphasizing the need for modernization in patient safety and the potential of organ-on-a-chip technology to improve drug development workflows. They discussed the performance assessment of the liver chip, its ability to distinguish between toxic and non-toxic drugs, and its integration into laboratory workflows to reduce animal testing and enhance the 3Rs (Replacement, Reduction, and Refinement). The presentation also covered model variability, reproducibility, and the importance of collaboration with regulators and users to drive adoption and improve risk assessment, ultimately aiming for greater patient safety.\nResearch Profiles # Emulate, Inc Profile Pharmaceutical Executive Author Page BIO.org Speaker Profile ResearchGate Profile References # [1] Emulate, Inc - Dr. Lorna Ewart Promotion to Chief Scientific Officer\n[2] Pharmaceutical Executive - Protecting Human Health with Organ-on-a-Chip Technology\n[3] Frontiers in Pharmacology - Optimal experimental design for efficient toxicity testing in microphysiological systems\n[4] Animal Alliance of Canada - Rethinking Research Panel Event\n[5] BIO.org - Lorna Ewart Speaker Profile\n","date":"2026-05-29","externalUrl":null,"permalink":"/network/scientists/lorna-ewart/","section":"Network","summary":"Chief Scientific Officer at Emulate, Inc, pioneering organ-on-a-chip technology.","title":"Lorna Ewart","type":"network"},{"content":" Dr. Milica Radisic, PhD, PEng # Professor at the University of Toronto’s Institute of Biomedical Engineering (IBBME) Canada Research Chair in Functional Cardiovascular Tissue Engineering Senior Scientist at the Toronto General Hospital Research Institute (TGHRI) Co-Founder of Tara Biosystems Pioneer in 3D cardiac tissue engineering and organ-on-a-chip technology Recipient of the Order of Ontario and Fellow of the Royal Society of Canada Milica Radisic, Professor and Canada Research Chair\nCredit: UofT Introduction # Dr. Milica Radisic is a globally recognized leader in cardiac tissue engineering and regenerative medicine. As a Professor at the University of Toronto and a Senior Scientist at the Toronto General Hospital Research Institute, she has pioneered innovative approaches to engineering functional cardiac tissues and organ-on-a-chip systems. Her work bridges academia and industry, with significant contributions to drug testing, disease modeling, and heart repair.\nProfessional Background and Achievements # Education\nPhD in Chemical Engineering, Massachusetts Institute of Technology (MIT), 2004 MASc in Chemical Engineering, University of Toronto, 2000 BAsc in Chemical Engineering, University of Toronto, 1999 Academic and Research Roles\nProfessor, Institute of Biomedical Engineering, University of Toronto (2009 - Present) Canada Research Chair (Tier 2) in Functional Cardiovascular Tissue Engineering (2012 - 2022) Senior Scientist, Toronto General Hospital Research Institute, University Health Network (UHN) Co-Founder and Scientific Advisor, Tara Biosystems Leadership and Awards\nFellow of the Royal Society of Canada (2022) Order of Ontario (2023) NSERC E.W.R. Steacie Memorial Fellowship (2018) Young Innovator Award, Cellular and Molecular Bioengineering (2015) Tier 2 Canada Research Chair in Functional Cardiovascular Tissue Engineering (2012) Research Areas and Projects # Cardiac Tissue Engineering\nDeveloped 3D cardiac tissue models for studying heart disease and drug toxicity. Pioneered the use of biomaterials and stem cells to create functional heart tissue. Focus on translating research into clinical applications for heart repair. Organ-on-a-Chip Technology\nCo-founded Tara Biosystems to commercialize organ-on-a-chip platforms for drug testing and disease modeling. Developed microphysiological systems to mimic human organ functions, reducing reliance on animal testing. New Approach Methodologies (NAM)\nAdvocated for Safety Assessment via NAM, promoting ethical and innovative alternatives to traditional animal testing. Major Publications # Title Journal Year Link Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds PNAS 2004 link Mathematical model of oxygen distribution in engineered cardiac tissue with parallel channel array perfused with culture medium containing oxygen carriers American Journal of Physiology 2005 link Synergistic engineering: organoids meet organs-on-a-chip Cell stem cell 2017 link Organ-on-a-chip devices advance to market Lab on a Chip 2017 link Advances in organ-on-a-chip engineering Nature Reviews 2018 link Organs-on-a-chip models for biological research Cell 2021 link Integrating organoids and organ-on-a-chip devices Nature Reviews Bioengineering 2024 link Mapping the miRNA landscape of primitive macrophage extracellular vesicles highlights their pro-vasculogenic effects in engineered human cardiac tissue APL Bioengineering 2026 link Awards and Recognitions # Royal Society of Canada Fellowship (2022) - Recognized for outstanding contributions to biomedical engineering and regenerative medicine. Order of Ontario (2023) - Awarded for leadership in cardiac tissue engineering and organ-on-a-chip technology. NSERC E.W.R. Steacie Memorial Fellowship (2018) - Honored for innovative research in tissue engineering. Young Innovator Award (2015) - Cellular and Molecular Bioengineering, for groundbreaking work in cardiac tissue models. Tier 2 Canada Research Chair (2012) - Functional Cardiovascular Tissue Engineering. Patents # Thermoplastic polymer composition for micro 3D printing and uses thereof #12391825 Methods for tissue generation #12371668 Methods For Modeling Disease Tissue Using Three-Dimensional Tissue Systems #20240133873 See these and many more in Patents by Inventor Milica Radisic at Justia.\nMedia and Public Engagement # TEDx Talk: The Future of Heart Repair Interviews with CBC News and The Globe and Mail on regenerative medicine Lectures at MIT, Harvard, and Stanford on tissue engineering Featured in Nature and Science for contributions to organ-on-a-chip technology The Radisic Lab operates at the intersection of engineering and biomedicine, developing advanced technological platforms to advance disease modeling, pharmacology, and regenerative medicine.\nThe speaker expressed humility and gratitude for receiving Canada\u0026rsquo;s highest honor in innovation for developing a technology called \u0026ldquo;heart in a chip,\u0026rdquo; which matures human stem cells into tissue within a dish equipped with sensors to monitor tissue function. This breakthrough allows for the recapitulation of human disease in a dish, offering a human-relevant alternative to animal models and addressing ethical concerns. The technology, protected by 15 patents across multiple countries, has inspired global research efforts and has been commercialized through a company. The speaker acknowledged the collaborative effort of their team, particularly highlighting Yimujao as the key inventor of the biowire partner chip technology, and emphasized the potential to impact millions through new drug discoveries and the reduction or elimination of animal testing.\nIn this Tedx talk, Dr. Milica Radisic explains that heart disease remains a leading cause of death because human heart muscle cells, called cardiomyocytes, cannot regenerate on their own, and when they die or stop contracting due to disease or injury, the heart loses its pumping ability. Historically, it was believed that humans are born with a fixed number of these cells, but research using carbon-14 dating revealed that heart cells do turn over at a very slow rate, about 0.1 to 1% per year. This slow regeneration makes it impractical to harvest and grow enough cells for regenerative therapies. Pharmaceutical companies currently rely on animal cells or animal models for drug testing, which are imperfect and sometimes lead to dangerous drugs reaching humans, as seen with Vioxx. To address this, her lab uses induced pluripotent stem cells derived from skin or blood, which are reprogrammed into beating heart cells and then matured using precise growth factors, a gel-like matrix, and electrical stimulation to mimic the conditions of an adult human heart. This engineered heart tissue can respond to drugs similarly to real human heart tissue, enabling better drug testing and personalized medicine. She co-founded Tara Biosystems to commercialize this technology for pharmaceutical companies. Looking ahead, her lab is working on creating injectable, fully functional heart tissues that could one day be used to repair damaged hearts without invasive surgery, ultimately aiming to improve health and extend life through engineered tissues.\nDr. Radisic discusses the critical challenge of vascularization in engineered tissue models, emphasizing its importance for creating functional, scalable organs. She highlights her lab’s work on biomaterials, 3D tissue engineering, and organ-on-a-chip platforms (like Biowire and AngioChip) to mimic human physiology for drug testing and disease modeling. The talk also covers her role as co-founder of TARA Biosystems and Quthero, which focus on commercializing heart-on-a-chip and regenerative hydrogel technologies, respectively. Her long-term goal is to enable cardiovascular regeneration through tissue engineering and new biomaterials, reducing reliance on animal testing and advancing personalized medicine.\nDr. Milica Radisic from the University of Toronto discussed her research on organ-on-a-chip engineering, particularly focusing on modeling cardiac disease using heart-on-a-chip technology. She highlighted the importance of using human stem cells to create heart tissue, which can be used for disease modeling and drug discovery. Dr. Radisic also touched on the development of biodegradable and biocompatible polymers for these applications. The conversation covered the challenges and advancements in using induced pluripotent stem cells (iPSCs) for cardiac research, the importance of collaboration and communication in science, and her experiences in starting a company to translate these technologies into practical applications.\nResearch Profiles # University of Toronto Profile Google Scholar LinkedIn Tara Biosystems References # [1] University of Toronto IBBME. (2023). Dr. Milica Radisic: Faculty Profile\n[2] Tara Biosystems. (2022). About Us: Co-Founders\n[3] Royal Society of Canada. (2022). Fellowship Announcement\n[4] Order of Ontario. (2023). Recipient Profile\n[5] NSERC. (2018). E.W.R. Steacie Memorial Fellowship\n","date":"2026-05-29","externalUrl":null,"permalink":"/network/scientists/milica-radisic/","section":"Network","summary":"Pioneer in cardiac tissue engineering and regenerative medicine at UofT.","title":"Milica Radisic","type":"network"},{"content":"","date":"2026-05-29","externalUrl":null,"permalink":"/tags/new-frontiers-in-research-fund/","section":"Tags","summary":"","title":"New-Frontiers-in-Research-Fund","type":"tags"},{"content":"","date":"2026-05-29","externalUrl":null,"permalink":"/tags/regenerative-medicine/","section":"Tags","summary":"","title":"Regenerative Medicine","type":"tags"},{"content":"","date":"2026-05-29","externalUrl":null,"permalink":"/tags/risk-assessment/","section":"Tags","summary":"","title":"Risk Assessment","type":"tags"},{"content":" Dr. Tara Barton-Maclaren, PhD # Tara Barton-Maclaren, Senior Research Manager, Health Canada\nCredit: rqr-repro.org Senior Research Manager, Prioritization and Emerging Science Division, Health Canada Pioneer in New Approach Methodologies (NAM) and computational toxicology for human health risk assessment Recipient of the V.E. Henderson Award from the Society of Toxicology of Canada (2021) Recognized as a New Public Servant for scientific contributions to human health risk assessment Leads a 12-person team in computational toxicology and risk assessment Actively contributes to OECD initiatives for global alignment in toxicology and risk assessment Introduction # Dr. Tara Barton-Maclaren, PhD, is a Senior Research Manager at Health Canada, specializing in the Prioritization and Emerging Science Division. She is a leading figure in the transition to 21st Century Toxicology, focusing on integrating New Approach Methodologies (NAM) and computational toxicology to modernize risk assessment practices in Canada. Her work bridges innovative toxicology research with regulatory decision-making, ensuring the protection of Canadians from chemical risks. Dr. Barton-Maclaren is also a strong advocate for gender equality in STEM, having been highlighted by Health Canada for the International Day of Women and Girls in Science in 2019.\nProfessional Background and Achievements # Dr. Barton-Maclaren obtained her BSc Honours in Biomedical Science from the University of Guelph in 2000 and her PhD in Reproductive Toxicology from McGill University in 2007. She joined Health Canada’s Existing Substances Risk Assessment Bureau (ESRAB) in 2007, where she has led numerous risk assessment files and hazard methodology initiatives. Since 2012, she has served as a Risk Assessment Division Manager, overseeing the development of strategies to integrate emerging data and novel methodologies for chemical assessment in Canada.\nAs the Research Manager of the Emerging Approaches Unit, she is the focal point for hazard assessment expertise in the Bureau. She has received recognition as a New Public Servant for her scientific contributions to the human health risk assessment of high-profile substances. In 2021, she was given the V.E. Henderson Award from the Society of Toxicology of Canada for her leadership and contributions to the field.\nDr. Barton-Maclaren is actively involved in international collaborations, particularly under the Organization for Economic Cooperation and Development (OECD), where she promotes alignment in computational toxicology, Integrated Approaches to Testing and Assessment (IATA), and NAM. Her leadership in translational research has accelerated the acceptance and implementation of scientific advances to support regulatory decision-making.\nResearch Areas and Projects # Dr. Barton-Maclaren’s research focuses on New Approach Methodologies (NAM) for human health risk assessment, computational toxicology, and Integrated Approaches to Testing and Assessment (IATA). She is particularly interested in bridging modern toxicology research with human health risk assessment to protect Canadians from chemical risks. Her work includes:\nDeveloping and implementing strategies for integrating emerging data and novel methodologies into chemical assessments. Contributing to global initiatives for risk assessment modernization, including collaborations with national and international thought leaders. Leading projects that utilize high-throughput transcriptomics, phenotypic profiling, and targeted biochemical assays to estimate chemical dose responses and compare them to exposure predictions. Advancing the use of QSAR (Quantitative Structure-Activity Relationship) and AOP (Adverse Outcome Pathways) to support regulatory decisions. Her research has been published in high-impact journals, and she has contributed to studies demonstrating the effectiveness of NAM-based approaches in providing protective points of departure (PoD) for systemic toxicity.\nMajor Publications # Title Journal Year Link Canadian Regulatory Perspective on Next Generation Risk Assessments for Pest Control Products and Industrial Chemicals In Vitro Toxicology 2021 link High-throughput transcriptomics toxicity assessment of eleven data-poor bisphenol A alternatives Environmental Pollution 2024 link Integration of new approach methods for the assessment of data-poor chemicals Toxicological Sciences 2025 link N -nitrosamines: in silico modelling of DNA reactivity and identification of metabolic precursors Mutagenesis 2025 link Report on the European Partnership for Alternative Approaches to Animal Testing (EPAA) “New Approach Methodologies (NAMs) User Forum Kick-Off Workshop” Regulatory Toxicology and Pharmacology 2025 link Applying New Approach Methods for Toxicokinetics for Chemical Risk Assessment Chemical Research in Toxicology 2025 link Awards and Recognitions # V.E. Henderson Award (2021) - Society of Toxicology of Canada: Awarded for outstanding contributions to toxicology and risk assessment in Canada. New Public Servant Award - Health Canada: Recognized for scientific contributions to human health risk assessment. Highlighted by Health Canada for the International Day of Women and Girls in Science (2019): Celebrated for her role in advancing gender equality in STEM and her leadership in toxicology. Media and Public Engagement # Dr. Barton-Maclaren is a frequent invited speaker at international conferences, particularly in the US and Europe, where she shares her expertise in computational toxicology and risk assessment. She has participated in approximately eight conferences annually, often as the only woman on international panels. Her public engagement includes:\nAdvocating for gender equality in STEM and encouraging young women to pursue careers in science. Sharing her journey and advice in interviews, such as her feature in The Review Newspaper for the International Day of Women and Girls in Science. Collaborating with organizations like the Health and Environmental Sciences Institute (HESI) and the Réseau Québécois en Reproduction (RQR) to promote scientific innovation and ethical research practices. Dr. Tara Barton-Maclaren, Research Manager of the Emerging Approaches Unit at Health Canada, explains her role in developing strategies to integrate emerging data and New Approach Methodologies (NAM) for prioritizing and assessing chemicals in the Canadian marketplace. She emphasizes the importance of partnerships and collaborations to advance 21st-century toxicology, modernize risk assessments, and align with international initiatives like the OECD and APCRA. As a thematic leader in the Intersectoral Center for Endocrine Disruptor Analysis (ICEDA), she focuses on environmental regulatory strategies to screen and identify endocrine-disrupting substances, promoting data sharing and multidisciplinary integration to address knowledge gaps and explore emerging technologies for regulatory applications.\nThis webinar, titled \u0026ldquo;Regulatory Acceptance and Use of Next-Generation Approaches for Chemical Safety Assessments,\u0026rdquo; explores how industry and government are adopting non-animal methods and advanced toxicology to ensure chemical safety. Dr. Julia Fenton from Unilever highlights the company’s shift toward New Approach Methodologies (NAMs) - such as computational toxicology, high-throughput transcriptomics, and in vitro assays - to assess ingredient safety without animal testing, driven by EU policies like REACH and the cosmetics animal testing ban. She emphasizes Next-Generation Risk Assessment (NGRA), an exposure-led, hypothesis-driven approach that integrates NAMs to replace traditional animal tests, citing collaborative case studies and frameworks (e.g., OECD’s IATA) that demonstrate their protective and scientifically robust nature. Dr. Tara Barton-Maclaren from Health Canada then discusses Canada’s regulatory context under the Canadian Environmental Protection Act (CEPA), including Bill S-5, which aims to reduce animal testing. She details Health Canada’s use of Bioactivity Exposure Ratio (BER) frameworks, high-throughput assays, and transcriptomics to derive human-relevant points of departure for risk assessments, stressing the importance of international collaborations (OECD, APCRA) and modular, adaptable workflows to address data gaps and refine NAMs for regulatory acceptance. The webinar underscores the urgency of transitioning to 21st-century science for safer, more sustainable chemical management.\nThis webinar, part of the EPIC series co-organized by the US EPA, PETA Science Consortium International, the Institute for In Vitro Sciences, and the California Department of Pesticide Regulation, focused on the development and application of New Approach Methodologies (NAMs) workflows and tools for chemical risk assessment. Dr. Alistair Middleton from Unilever presented a systemic safety toolbox for Next-Generation Risk Assessment (NGRA), emphasizing an exposure-led, hypothesis-driven approach that integrates computational models and in vitro data to make protective safety decisions without animal testing, while Dr. Tara Barton-Maclaren from Health Canada discussed her work on applying bioactivity workflows and NAMs to screen and prioritize chemicals in Canada, highlighting the use of automated workflows like the Health Canada Automated Workflow for Prioritization (HOPper) to integrate and interpret complex data sets for regulatory decision-making. Both speakers underscored the importance of international collaborations, modular workflows, and the need to refine methods to address data gaps and improve the predictive power of NAMs for broader regulatory acceptance.\nResearch Profiles # Google Scholar ResearchGate Health Canada Directory LinkedIn RQR Profile References # [1] Tara Barton-Maclaren, Ph.D. | Endocrine-Disrupting Chemicals - McGill University\n[2] Tara Barton-Maclaren, PhD - RQR\n[3] Local woman honoured on International Day of Women and Girls in Science - The Review Newspaper\n[4] Tara Barton-Maclaren, thematic leader of ICEDA, received the V.E Henderson award from the Society of Toxicology of Canada – CIAPE-ICEDA\n[5] Tara S. Barton-Maclaren\u0026rsquo;s research works | Health Canada and other places\n[6] Tara Barton-Maclaren - Google Scholar\n[7] Accelerating the pace of chemical risk assessment (APCRA)\n","date":"2026-05-29","externalUrl":null,"permalink":"/network/scientists/tara-barton-maclaren/","section":"Network","summary":"Dr. Tara Barton-Maclaren PhD, Senior Research Manager at Health Canada","title":"Tara Barton Maclaren","type":"network"},{"content":"","date":"2026-05-29","externalUrl":null,"permalink":"/tags/tissue-engineering/","section":"Tags","summary":"","title":"Tissue Engineering","type":"tags"},{"content":"","date":"2026-05-29","externalUrl":null,"permalink":"/tags/tuberculosis/","section":"Tags","summary":"","title":"Tuberculosis","type":"tags"},{"content":"","date":"2026-05-29","externalUrl":null,"permalink":"/tags/university-of-toronto/","section":"Tags","summary":"","title":"University of Toronto","type":"tags"},{"content":"Dr. Neeraj Dhar and his team at the University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO) are developing lab-grown organoids - 3D, lab-engineered donor tissues that mimic actual organs - to replace traditional animal testing. These organoids provide highly accurate, species-specific testing environments, addressing the limitations of animal models in predicting human outcomes.\nKey Highlights # Organoids are used to recreate 3D organs from target species, offering more accurate and ethical testing. Dr. Dhar’s lab focuses on advanced immune organoids for tuberculosis (TB) research, integrating immune responses to test vaccines and antibiotics. Collaboration with Dr. Eliza Fong at the National University of Singapore to overcome tissue shortages and technical challenges. The FDA recently approved organoids for preclinical safety and toxicity trials, aiming to reduce animal testing. Organoids are also used in space exploration, replacing non-consenting animal subjects on missions like Artemis II. Organoids enable rapid, large-scale testing during pandemic outbreaks, accelerating vaccine development. Statements # When we do a lot of studies in the lab, we often use animal models. But because of the different physiology between animals and humans, a lot of therapeutics that we develop for humans often fail somewhere in the translation stage.\nDr. Neeraj Dhar It’s really fascinating how you can use a few millimetres of tissue from different animals or volunteer donors and recreate 3D tissue which pretty much behaves like the native organ.\nDr. Neeraj Dhar About the Organizations # University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO) is a leading research organization focused on infectious diseases and vaccine development. National University of Singapore is a global research university known for its biomedical engineering advancements.\nLearn More # U of S developing lab-grown organoids that save humans, spare animals\n","date":"2026-05-29","externalUrl":null,"permalink":"/news/organoids-save-humans-spare-animals/","section":"News","summary":"University of Saskatchewan researchers develop organoids to replace animal testing in tuberculosis and immunological studies.","title":"USask developing lab-grown organoids that save humans, spare animals","type":"news"},{"content":"","date":"2026-05-29","externalUrl":null,"permalink":"/tags/vido/","section":"Tags","summary":"","title":"Vido","type":"tags"},{"content":"NOTICE\nThis is still a work in progress as the document and materials to go with it are still being developed. Items marked TBD are To Be Developed.\nGrand Unified Plan Protocol Infrastructure # Rainbow colors of the guppy coordinate forming coherence\nCredit: Schwarzenarzisse (pixabay) The PNARS Grand Unified Plan Protocol Infrastructure (GUPPI) is a modular, functional framework for decentralized activity, enabling participants to self-select tasks and scale involvement organically. Built on input requirements, output results, and sandbox testing, it ensures flexibility, independence, and measurable growth without top-down management or sequential timebased flows.\nThe Core Principles are:\nModules: Every component is a pure function (self-contained, stateless, reusable), requiring inputs (eg participants, resources), and producing predictable outputs (eg actions, materials, hubs). Sandboxing: All new outputs are tested in small, local batches before scaling. Feedback loops are built into every module. Mechanism: The plan is a collection of independent modules, each operating autonomously, triggered by input requirements. No Timelines: Progress is driven by completion of inputs, not calendars thus facilitating participant involvement. No Top-Down Assignments: Tasks are self-selected from the Open Task Pool. The core team acts as an Infrastructure Review Board, not a management hierarchy. GUPPI Framework Overview # The GUPPI Framework is organized into four modules that can run in parallel whenever resources and triggers allow:\nPersona Routing (Self-selection via desired ability level) Core Assets (Foundational materials and tools) Autonomous Hub Activation (Local and specialized network growth) Macro Policy Pressure (Systemic advocacy and global alignment) Each module requires input, then produces output which must pass 66% success rate in local sandbox testing.\nModule 1: Persona Routing # Self-selection mechanism which enables plug-and-play onboarding without top-down management. Individuals can choose a persona based on 3 levels:\nComfort - do what you already find easy Flex - exercise your existing skill muscles Enhance - develop new abilities for yourself Persona Profile Assignment Messenger Social media native, leafleter, casual talker Distribute standardized packages; run campaigns using pre-approved PNARS assets (online or in person). Networker Socially confident, well-connected Act as a Hub Catalyst mapping existing groups (science, ethics, environment) for PNARS to approach. Organizer Methodical, task-oriented Coordinate local petition drives, manage distribution lists, or set up information tables. Investigator Analytical, academic, tech-leaning Investigate and document local bioeducation/research practices; identify sympathetic faculty. Advocate Persuasive, public-speaking inclined Engage with MPs, school boards, or university departments using PNARS talking points and reports. Creator Creative, content-focused Develop infographics, video/audio, or written content (eg, NAM success stories, comparisons). Component for this module are shown below.\nChoosing a Role # Input: Choice of level(s) and Persona from above, any applicable Core Assets (eg Talking Points, Action Packs from Module #2).\nOutput: Persona receives the corresponding assets and activates.\nSandbox: Deploy with 6+ volunteers and verify process functions autonomously without intervention.\nModule 2: Core Assets # Foundational materials that may be used by all other modules. These must be completed and tested in local sandboxes before scaling. All Core Assets are developed based on usage needs such as talking points for speakers, paper petitions for advocates, and action packs for network developers.\nComponents for this module are shown below.\nTalking Points # These are 1 page pdf bulletins to be printed. The front provides the talking point, while the back has FAQ relating to the topic. The pdf provides both QR code and url links to a duplicate webpage which contains references. The page can be discussed, then handed out.\nTP1 NAM vs Animal Testing # Input: Comparative research (NAM vs. animal testing: scientific, ethical, efficiency).\nOutput: One page, undeniable summary for all audiences (youth, scientists, policymakers, educators).\nSandbox: Print 100 copies, distribute to a local youth group or university club. Collect feedback on clarity and persuasiveness.\nAction Packs TBD # Input: Persona Matrix Choice.\nOutput: \u0026ldquo;Six Steps\u0026rdquo; for each Persona to follow.\nSandbox:: Provide 6 volunteers from different personas. Refine based on their ability to execute steps without additional guidance.\nLocal Audit Guide TBD # Input: Institutional policies on animal use (eg dissection requirements, research practices).\nOutput: Questionnaire for students/academics to assess local policies.\nSandbox:: Pilot with 2–3 local schools or university departments. Verify ease of use and usefulness of collected data.\nGeneral Handout Package TBD # Input: Existing materials (eg the CYC meeting handouts).\nOutput: Standardized digital PDF package for global use, with space for local customization.\nSandbox:: Print and distribute to 1–2 local groups. Measure response rate and feedback.\nPetition Templates TBD # Input: Legal and ethical considerations for NAM advocacy.\nOutput: Audience-specific petitions (students, scientists, policymakers).\nSandbox: Launch a local petition with a small group (eg 100 signatures). Verify language and ease of distribution.\nHub Activation Kit # Input: Networker persona and action pack.\nOutput: Formation of appropriate hub(s) with access to other assets.\nSandbox: Test that hub functions autonomously.\nModule 3: Autonomous Hub Activation # Local and specialized networks that operate independently, scaling organically.\nThe system is dependent on the Unit Hub Activation component (shown below) and enables PNARS to expand through self-sustaining, locally managed hubs. Each hub operates independently but remains connected to PNARS Central sharing resources and support. Hubs may self-replicate as well. Each hub should have a webpage on PNARS listing description and activities.\nHub possibilities span a wide range of focused areas such as\nScientific: universities, labs, research institutions. Educational: schools, teacher networks, curriculum developers. Political: riding associations, policy advocates, legislative advisors. Artisan: writers, social media creators, artists, musicians Institution: library, municipality, industry Here is an example structure showing multilevel development due to self-replication. Though the subhub develops inspired by the original hub, it is nevertheless an autonomous entity.\nPNARS CENTRAL (Infrastructure Review Board)\nYouth Hub: Vancouver High School NAM Club\nSubhub: Neighborhood Elementary School NAM Club (K-7 outreach) Subhub: University of BC NAM Society (student-led advocacy) Subhub: Surrey Youth Science Network (regional expansion) Educational Hub: BC Teachers\u0026rsquo; Crossboard Network\nSubhub: Provincial Curriculum Development Team (NAM lesson plans) Subhub: School District Science Coordinators (teacher training) Subhub: Home Education Co-op (parent resources) Scientific Hub: UBC Lab Research Group\nSubhub: SFU Graduate Student NAM Initiative (peer mentoring) Subhub: Local Biotech Company NAM Task Force (industry collaboration) Subhub: Vancouver Island Research Consortium (regional labs) Political Hub: Vancouver-Quilchena Riding Association\nSubhub: Cross-Party NAM Caucus (MP engagement) Subhub: Municipal Green Initiative (local policy) Subhub: Provincial Youth Advisory Council (youth representation) Artisan Hub: Creative Collective for NAM\nSubhub: Social Media Campaign Team (digital outreach) Subhub: Documentary Filmmakers Collective (storytelling) Subhub: Graphic Designers for NAM (branding and materials) Components for this module are shown below.\nUnit Hub Activation # Input: A Networker persona identifies a local group (eg youth club, university lab, riding association).\nOutput: New hub is formed, with access to Core Assets and Persona Routing.\nSandbox: Verify the hub can operate autonomously and share resources, insights, and other supports.\nCross-Pollination Mechanisms # Input: Multiple active (sub)hubs.\nOutput: Shared resources, joint campaigns, and feedback loops between hubs.\nSandbox: Requires at least 2 active hubs before formalizing cross-pollination.\nModule 4: Macro Policy Pressure # Systemic advocacy and global alignment to drive large-scale change.\nMacro Policy Pressure enables PNARS to influence policy, education, and research at institutional and governmental levels. By leveraging data from autonomous hubs and comparative research, PNARS and the hubs can advocate for NAM adoption across Canada and align with global movements. Each initiative should have measurable outcomes and be documented for broader dissemination.\nComponents for this module are shown below.\nComparative Report TBD # Input: Research on \u0026ldquo;What worked in other countries that didn\u0026rsquo;t happen in Canada.\u0026rdquo;\nOutput: Public briefing document highlighting Canada\u0026rsquo;s lag vs. others in NAM adoption.\nSandbox: Share with 2–3 policymakers or academic institutions. Refine based on feedback.\nLobbying Toolkit TBD # Input: Comparative Report, Talking Points Bulletin.\nOutput: Training materials for engaging MPs, school boards, and funding bodies.\nSandbox: Test with 1–2 local policymakers or institutions.\nGlobal Alignment TBD # Input: Active hubs, Comparative Report.\nOutput: Join international networks (eg Youth for Animals, World Congress on Alternatives). Attend global conferences to present PNARS\u0026rsquo;s work.\nSandbox: Present at 1 local or virtual conference before scaling.\nThought Leadership TBD # Input: Data from Autonomous Hubs, Comparative Report.\nOutput: White papers, annual summits, and interactive tools (eg online courses, webinars).\nSandbox: Publish 1 white paper or host 1 virtual summit.\nOpen Task Pool (OTP) # The OTP is a public list of tasks posted on pnars.org (eg in the Nexus section). Anyone can:\nPick a task and work on it without permission, but with consultation if desired. Report success to PNARS by identifying yourself and providing a brief description of what was achieved (e.g., \u0026ldquo;The Talking Points Bulletin passed sandbox testing with 66%+ approval - Lana, May 28\u0026rdquo;). See updates as completed tasks are noted on the website. There is no tracking, assignments, or bureaucracy. The only interaction is:\nTask List: Public and always visible. Success Reporting: This worked - here’s the feedback, who did it, and what was achieved. PNARS Recognition: Successful tasks are highlighted in Nexus and can be used by everyone if suitable (eg a design). The system has\nAutonomy: People act independently. Feedback: The 66%+ metric is only for visibility - not a gate. Low Friction: No overhead, no forums, no surveys. Just a list + success updates. Recognition: Contributors are acknowledged for their work. Example Flow:\nA Creator sees: \u0026ldquo;Design social media templates\u0026rdquo; in the OTP. They design the templates, test them locally, and report: \u0026ldquo;Templates passed sandbox testing with 70% approval - John, June 1.\u0026rdquo; PNARS adds this to Nexus: \u0026ldquo;Completed: Social Media Templates (70% success) - John, June 1.\u0026rdquo; Infrastructure Review Board # The core team acts as a coordination hub for:\nMaintaining the Open Task Pool and GUPPI documents. Updating the Nexus with successful task completions (including contributor names and descriptions of achievements). Ensuring the 66%+ feedback metric is used consistently for visibility, not as a gate. Offering consultation for anyone who requests it. Operations:\nNo top-down assignments: Volunteers and hubs self-select tasks from the Open Task Pool. No micromanagement: The board only intervenes to document feedback, resolve ambiguities in task descriptions, and provide consultation when required. Conclusion # The GUPPI Framework is a modular, autonomous, self-replicating system for scaling NAM advocacy. Volunteers and hubs independently identify opportunities, contribute based on interests and skills, and scale without top-down direction or rigid dependencies.\nIt operates on three principles:\nModular Independence: Four self-contained units (Core Assets, Persona Routing, Autonomous Hub Activation, Macro Policy Pressure) run in parallel, each with its own Input → Output → Sandbox workflow. Open Task Pool: A public, self-service list of tasks enables decentralized contribution without hierarchy or assignments. Feedback-Driven: The 66%+ metric is a visibility tool for Nexus, not a gate, thus ensuring transparency and continuous improvement. The Infrastructure Review Board maintains the framework’s integrity by documenting successes and clarifying tasks, while the Nexus showcases achievements. Together, these elements create a scalable, adaptive, and low-friction system.\n","date":"2026-05-27","externalUrl":null,"permalink":"/resources/guppi/","section":"Resources","summary":"Grand Unified Plan Protocol Infrastructure","title":"GUPPI","type":"resources"},{"content":"","date":"2026-05-27","externalUrl":null,"permalink":"/tags/plan/","section":"Tags","summary":"","title":"Plan","type":"tags"},{"content":"","date":"2026-05-25","externalUrl":null,"permalink":"/tags/alternative-methods/","section":"Tags","summary":"","title":"Alternative-Methods","type":"tags"},{"content":"NOTICE\n\u0026lt;2026-05-25 Mon\u0026gt;\nThis report by Gemini has not been analyzed for accuracy and wording by PNARS staff. As such it should not be considered reliable until this notice has been removed.\nParadigm Attrition: A Clinical, Regulatory, and Economic Analysis of Animal Model Translation Failures # Each fork in the road leads to a pre-defined destination\nCredit: Gemini Part 1: Detailed Report # Introduction # The translation of therapeutic candidates from preclinical safety evaluations to successful human clinical outcomes represents one of the most significant challenges in modern drug discovery and toxicology. For nearly a century, the standard paradigm of biomedical research has operated under the assumption that non-human mammalian models provide an essential, high-fidelity approximation of human physiology. This structural reliance has been codified into regulatory frameworks globally, requiring drug sponsors and chemical manufacturers to submit safety data from multiple animal species before initiating human trials.\nHowever, systematic retrospective evaluations of this paradigm reveal a persistent translational deficit. Over 92% of therapeutic candidates that successfully clear preclinical animal-based safety and efficacy screenings subsequently fail when progressed into human clinical trials. This high attrition rate is primarily driven by unexpected human clinical toxicities that were undetected in animal testing, or by a complete lack of therapeutic efficacy in human patient populations.\nPreclinical to Clinical Pipeline Preclinical to Clinical Pipeline 100 Preclinical Candidates 40 Eliminated (Pre-human) 60 Advance to Human Trials 54 Fail in Phases I-III 6 Approved for Clinical Use Only 6% Overall Success An analysis of this developmental pipeline shows that while approximately 40% of potential drug candidates are eliminated during preclinical animal tests, the remaining 60% that enter clinical phases face a 90% failure rate. Within this clinical attrition envelope, approximately 40%–50% of candidates fail due to a lack of therapeutic efficacy at clinically tolerable doses, 25%–30% fail due to unmanageable clinical toxicities, and 10%–15% fail due to poor human absorption, distribution, metabolism, and excretion (ADME) profiles. These metrics show that traditional animal models frequently act as unreliable filters, introducing both false positives—which expose human volunteers to unanticipated clinical hazards—and false negatives, which can cause potentially therapeutic compounds to be discarded early in development.\nThis analysis indicates that the systemic reliance on non-human animal models has delayed biomedical progress, and shows that transitioning to human-biology-based New Approach Methodologies (NAMs) offers a more predictive and economically viable path forward.\nCase Studies of Translational Failures # Thalidomide # Background # Thalidomide was introduced to European markets on October 1, 1957, as a sedative and highly effective remedy for morning sickness in pregnant women. Preclinical safety evaluations of the era, which relied heavily on mouse and rat models, reported no teratogenic risks or maternal-fetal toxicities, leading developers to promote the drug as exceptionally safe.\nThe Failure # When administered to pregnant women during critical windows of organogenesis, thalidomide interfered with embryonic development, resulting in over 10,000 cases of severe birth defects—such as phocomelia, characterized by the severe shortening or absence of limbs—and thousands of fetal deaths worldwide. Subsequent attempts to replicate these teratogenic effects in pregnant rodents failed under standard dosing conditions, revealing a major translational failure. The drug had been evaluated in approximately 10 strains of rats, 15 strains of mice, 11 breeds of rabbits, 2 breeds of dogs, 3 strains of hamsters, and 8 species of primates, yet traditional preclinical protocols failed to predict the human clinical risk.\nThe Delay # The absence of observed teratogenicity in rodent models delayed regulatory scrutiny and prolonged the clinical exposure of pregnant women. While alternative, human-relevant methodologies were not fully developed in the late 1950s, human in vitro tissue culture techniques and embryonic cell models were emerging. These were largely ignored due to the regulatory focus on in vivo mammalian safety data. This reliance on rodent models delayed the identification of thalidomide\u0026rsquo;s mechanism of action for decades, with the precise molecular pathways not fully characterized until the 21st century.\nThe Success # Modern human-centric cell biology and molecular assays eventually explained the mechanisms of thalidomide-induced teratogenesis, showing that human in vitro embryonic stem-cell assays can successfully predict these toxicities. These human-focused methods have shown that thalidomide induces apoptosis in human embryonic fibroblasts while failing to do so in rodent embryonic cells, providing a predictive accuracy that standard animal models could not achieve.\nKey Takeaways # The thalidomide disaster highlighted several species-specific physiological and molecular differences:\nAntioxidant Defense System Divergence: Mouse and rat embryos possess highly robust endogenous antioxidant defense systems compared to human embryos. Thalidomide exposure generates intracellular reactive oxygen species (ROS) and superoxides in embryonic tissues. In rodents, active glutathione pathways neutralize these free radicals, preventing cellular damage. In human embryos, lower antioxidant expression fails to prevent ROS-induced oxidative stress. When researchers experimentally blocked glutathione receptors in pregnant mice, the animals lost their resistance to thalidomide, confirming that antioxidant differences drive the rodent resistance.\nPharmacokinetic and Embryonic Half-Life Disparities: The plasma half-life of thalidomide is significantly shorter in rodents than in humans. Within mouse embryos, the drug\u0026rsquo;s half-life is approximately 30 minutes, whereas in human embryos it persists for 7.3 hours. This extended exposure window in humans allows the compound to accumulate and exert prolonged teratogenic effects, while the rapid clearance in rodents prevents the drug from reaching toxic thresholds during critical windows of organogenesis.\nWnt/$\\beta$-Catenin Pathway and Apoptosis: In thalidomide-sensitive species (such as humans and chicks), the drug stimulates cellular communication through bone morphogenetic proteins (Bmps), which upregulates the extracellular antagonist Dickkopf1 (Dkk1). Increased Dkk1 activity inhibits the Wnt/$\\beta$-catenin pathway, a cellular communication system that regulates limb and ocular development, triggering programmed cell death (apoptosis) in embryonic limb buds and optic vesicles. In rodent embryos, thalidomide does not increase Bmp or Dkk1 protein expression, preventing downstream apoptosis and allowing normal limb development.\nEnantiomeric Interconversion, DNA Intercalation, and Angiogenesis: Thalidomide is a chiral molecule existing in two interconverting enantiomers: the therapeutic $(R)$-enantiomer and the teratogenic $(S)$-enantiomer. In solutions with a pH \u0026gt; 6.0 (matching human physiological plasma), the molecule rapidly undergoes spontaneous racemization, meaning that administering a pure, safe $(R)$-enantiomer is ineffective, as it quickly converts to the toxic $(S)$-enantiomer in the liver. The $(S)$-enantiomer acts as an angiogenesis inhibitor by intercalating into purine-rich regions of DNA (specifically targeting the FGF-2 gene), disrupting the formation of new blood vessels in developing limb buds. In humans, this loss of blood vessels leads to truncated or absent limbs; in rodent embryos, blood vessels develop normally because the molecular cascade of FGF-2 disruption does not occur.\nVioxx (Rofecoxib) # Background # Vioxx (rofecoxib) was approved by the FDA in 1999 as a selective cyclooxygenase-2 (COX-2) inhibitor marketed by Merck as a safer alternative to traditional non-steroidal anti-inflammatory drugs (NSAIDs) with a lower risk of gastrointestinal side effects. Preclinical safety evaluations in monkeys, rats, dogs, and rabbits supported its safety profile, with some animal studies even suggesting that rofecoxib might protect against heart disease and stroke.\nThe Failure # When prescribed to human patient populations, rofecoxib significantly increased the risk of acute myocardial infarction and ischemic stroke. Before Merck voluntarily withdrew Vioxx on September 30, 2004, the drug caused an estimated 88,000 to 140,000 serious cases of coronary heart disease and up to 38,000 premature deaths in the United States alone. Preclinical rodent and non-human primate studies failed to predict this prothrombotic hazard.\nThe Delay # The reliance on animal data to demonstrate cardiovascular safety delayed regulatory action and the integration of emerging human clinical evidence. Merck executives and scientists cited preclinical studies showing cardiotoxicity resistance in animal models to counter emerging human clinical and epidemiological warning signs. Retrospective meta-analyses of placebo-controlled clinical trials show that a statistically significant cardiovascular risk was detectable by June 2001 (Rate Ratio RR = 1.35, 95% CI = 1.00–1.96, p = 0.05), nearly three and a half years before the drug was withdrawn.\nVioxx Risk Timeline (U.S.) Vioxx Risk Timeline (U.S.) November 1996 Merck scientists discuss CV risks. May 1999 FDA approval of Vioxx. June 2001 Clinical trials show RR = 1.35. September 2004 Voluntary market recall. The Success # Epidemiological cohort analyses and post-market clinical registries eventually proved the cardiotoxicity of rofecoxib. Modern human-centric methodologies, such as human vascular endothelial organ-on-a-chip systems and in vitro human cell co-cultures, have since demonstrated the ability to detect this prothrombotic hazard. These platforms monitor real-time eicosanoid release and endothelial shear stress, showing superior predictive accuracy for human vascular biology compared to traditional in vivo animal assays.\nKey Takeaways # The failure of animal models to predict rofecoxib\u0026rsquo;s cardiotoxicity stems from differences in vascular physiology and lipid metabolism:\nEndothelial Prostacyclin and Platelet Thromboxane Imbalance: Rofecoxib selectively inhibits COX-2 in vascular endothelial cells, which reduces the synthesis of the vasodilator and platelet aggregation inhibitor prostacyclin (PGI2). However, the drug has no effect on platelet COX-1, which regulates the production of the potent vasoconstrictor and platelet activator thromboxane A2 (TXA2). This selective inhibition creates a prothrombotic imbalance. While this biological cascade occurs across mammalian species, laboratory animals housed in sterile, controlled settings lack the vascular disease, active plaques, and chronic inflammation present in clinical populations, preventing these animal models from showing the clinical endpoints of myocardial infarction or stroke.\nThe 20-HETE Accumulation Cascade: Metabolomic profiling of plasma from mice chronically treated with rofecoxib revealed a \u0026gt; 120-fold increase in 20-hydroxyeicosatetraenoic acid (20-HETE), a lipid-soluble arachidonic acid metabolite that acts as a potent vasoconstrictor and platelet activator, leading to a shortened tail bleeding time. Standard preclinical regulatory packages of the era focused on gross toxicological endpoints rather than lipidomic biomarkers of cardiovascular risk, meaning that this hypercoagulant signaling cascade went undetected in animal assays.\nIschemia/Reperfusion Sensitivity and Mortality: In vivo studies using rat models of cardiac ischemia and reperfusion demonstrated that chronic rofecoxib treatment increased acute mortality during reperfusion, with an odds ratio of OR = 7.73 (95% CI = 1.70–34.97). Treated rats showed sustained ventricular fibrillation and a slower recovery of normal cardiac rhythms compared to controls, highlighting cardiotoxicity under ischemic stress. Despite this, standard preclinical regulatory packages did not mandate these specialized disease-state models, allowing the drug to proceed to clinical phases without identifying these risks.\nHIV/AIDS Research # Background # Following the identification of HIV-1 as the causative agent of AIDS, chimpanzees (Pan troglodytes) became the primary model of choice for vaccine and therapeutic evaluation due to their genetic proximity to humans.\nThe Failure # While HIV-1 can infect chimpanzees and replicate within their bodies, they do not develop clinical AIDS. Over a ten-year period, chimpanzees typically shed the virus, and their plasma viral loads decline to low or undetectable levels within a few years of infection. The sole exception in the literature was a chimpanzee named \u0026ldquo;Jerom,\u0026rdquo; who developed an \u0026ldquo;AIDS-like\u0026rdquo; illness. However, this required over ten years of aggressive, sequential exposures to three different viral isolates. Transfusions of Jerom\u0026rsquo;s blood into other chimpanzees failed to produce illness, proving that the host environment is naturally resistant to HIV-mediated pathogenesis.\nThis biological difference led to a complete failure of vaccine translation. Of more than 85 vaccine candidates that demonstrated safety and efficacy in chimpanzees and other NHPs, none proved effective in human clinical trials. Most notably, in a 2007 clinical trial (the STEP study), an AIDS vaccine candidate that had successfully protected NHPs not only failed to protect human volunteers but actually increased their susceptibility to HIV-1 infection.\nThe Delay # The reliance on the chimpanzee model also delayed human-focused solutions. In the early 1980s, because HIV did not cause disease in chimpanzees, some public health experts mistakenly assumed the virus was harmless to humans as well. This false assumption delayed regulatory action and contributed to the distribution of contaminated blood products in France, leading to thousands of preventable infections and deaths.\nDecades of research and billions of dollars (including millions of U.S. taxpayer dollars via the NIH) were poured into breeding chimpanzees and conducting failed experiments. This represents a massive waste of time, money, and scientific resources that could have otherwise been directed toward human-specific methodologies to find a cure.\nThe Success # The shift toward human-relevant, cell-based assays, primary human immune cell cultures, and computational modeling has since revolutionized HIV therapeutic development. These systems accurately model viral entry, integration, and replication kinetics in human CD4+ lymphocytes.\nKey Takeaways # The failure of the chimpanzee model is defined by specific immunological and virological differences:\nImmunological Disparities: Human HIV-1 infection is characterized by progressive CD4+ T-lymphocyte depletion, leading to severe immunodeficiency, opportunistic infections, and associated malignancies. In contrast, chronically infected chimpanzees maintain normal CD4+ T-lymphocyte levels, preserve immune function, and show no susceptibility to opportunistic infections or cancers. Chimpanzees do not exhibit the drop in antibody count prior to systemic illness that is typical of human clinical progression.\nHost Restriction Factors: Comparative genomic studies eventually revealed that primates and retroviruses have co-evolved over millions of years, leading to species-specific host restriction factors (HRFs). These intracellular proteins inhibit viral replication at various stages of the life cycle. Disparities in these restriction factors mean that HIV-1 is rapidly neutralized or restricted in NHP cells, while it evades the human immune system.\nCancer Drug Development # Background # Oncology drug discovery has historically relied on subcutaneous mouse models, where human tumor cell lines are injected into immunocompromised mice, to evaluate therapeutic efficacy before clinical trials.\nThe Failure # This model has contributed to an exceptionally high clinical failure rate in oncology. Approximately 95% of oncology therapeutics that demonstrate efficacy in preclinical mouse models fail in human clinical trials, representing one of the highest attrition rates in medicine. These animal studies are particularly poor predictors of human response to metastatic disease—the primary cause of cancer mortality—because subcutaneous tumors do not replicate the complex metastatic microenvironment of human organs.\nThe Delay # The focus on subcutaneous mouse models delayed the adoption of human-relevant, complex in vitro systems. For decades, drug candidates that may have had efficacy in human-specific microenvironments were discarded because they failed to shrink localized tumors in rodents, while compounds that successfully shrank rodent tumors advanced to clinical trials, only to fail in patients.\nThe Success # The development of human-centric technologies—such as three-dimensional patient-derived tumor organoids, spheroids, and vascularized tumor-on-a-chip platforms—has significantly improved the predictive accuracy of oncology drug screening. These platforms allow researchers to test therapies on a patient\u0026rsquo;s own cells within a bioengineered human microenvironment, capturing tumor heterogeneity, vascular flow, and metastatic potential far more accurately than mouse models.\nOncology Translation Comparison Oncology Translation Comparison Mouse Models ~95% clinical trial failure rate. Fails to replicate metastasis. Human Organoids Captures tumor heterogeneity. Uses patient-specific cells. Key Takeaways # The translational gap in oncology is defined by structural and biological factors:\nMicroenvironmental Disparities: Subcutaneous rodent models fail to replicate the human tumor microenvironment, which includes human-specific extracellular matrix proteins, immune cell interactions, and vascular architecture, all of which are critical regulators of drug delivery and therapeutic response.\nReplication and Methodological Issues: A major study reported a failure to replicate the results of 90% of high-profile, published preclinical oncology papers, highlighting widespread methodological issues and a lack of experimental rigor in animal-based cancer research.\nStroke and Traumatic Brain Injury (TBI) # Background # Preclinical stroke research has relied on rodent models of Middle Cerebral Artery Occlusion (MCAO), where a filament is inserted into the rodent brain to induce ischemia, to evaluate neuroprotective candidates.\nThe Failure # Over 1,000 experimental treatments have shown neuroprotective efficacy in animal models of stroke, but none have proven effective in Phase III human clinical trials. The primary representative of this translational gap is NXY-059 (disodium 2,4-disulphophenyl-N-tert-butylnitrone), a free radical scavenger developed by AstraZeneca. NXY-059 demonstrated high efficacy across preclinical stroke models in mice, rats, and marmosets, reducing total infarct volume by an average of 43.3% (95% CI = 34.7%–52.8%) and significantly improving motor performance. However, in a large-scale, multi-center Phase III clinical trial involving over 3,200 acute ischemic stroke patients (the SAINT II trial), NXY-059 showed no therapeutic benefit.\nThe Delay # The systemic failure to control experimental bias in preclinical animal models led to an overestimation of efficacy, driving premature clinical trials and wasting hundreds of millions of dollars. Stratified meta-analyses of preclinical NXY-059 studies revealed that only 40% reported randomization, only 53% used blinded surgeons, and only 67% utilized blinded outcome assessors. Studies that failed to implement these basic controls overstated the drug\u0026rsquo;s efficacy. For example, unrandomized and unblinded animal trials reported a \u0026gt; 50% improvement in stroke outcomes, whereas randomized and blinded trials reported an effect size of less than 20%–30%.\nThe Success # Transitioning to human-centric methodologies, such as human cortical slice cultures, microfluidic blood-brain barrier (BBB) models, and human in vitro neurovascular units, has since improved the predictive accuracy of neuroprotective screenings. These systems accurately model human cellular responses to ischemia and reperfusion under controlled conditions, avoiding the confounding variables inherent in animal surgeries.\nKey Takeaways # The translational gap in stroke research is defined by biological and methodological disparities:\nCohort Demographics vs. Clinical Reality: Preclinical stroke studies are almost exclusively performed on young, healthy, male rodents. Conversely, clinical stroke populations are typically elderly, female or male, and present with multiple chronic comorbidities, including hypertension, diabetes, hyperlipidemia, and cardiovascular disease. These comorbidities alter the brain\u0026rsquo;s susceptibility to ischemic injury, impair endogenous repair mechanisms, and modify drug pharmacokinetics, rendering neuroprotective strategies that work in healthy young rodents ineffective in clinical populations.\nPhysiological Monitoring and Confounding Variables: Many anesthetics used in rodent stroke models (such as dexmedetomidine or xenon) possess inherent neuroprotective properties, confounding the assessment of the test compound. Furthermore, critical physiological parameters—such as arterial blood pressure, blood pH, and core brain temperature—are often poorly monitored in animal trials. For example, the administration of large liquid volumes can induce hypothermia in rodents, which is inherently neuroprotective and can mimic or exaggerate the apparent drug effect.\nToxicology: Dioxin (TCDD), Asbestos, and Smoking # Background # The regulation of environmental toxins and industrial carcinogens has historically been hindered by the limitations of animal-based hazard identification, leading to delayed public health warnings and incorrect risk assessments.\nThe Failure # Animal inhalation and ingestion models have frequently failed to accurately predict human toxicity and carcinogenicity profiles:\nDioxin (TCDD): The reputation of TCDD as an extremely toxic substance is largely based on preclinical testing in guinea pigs, which are highly sensitive to the compound. However, animal studies reveal an extreme, species-specific susceptibility: the Syrian hamster is 5,000 to 10,000 times more resistant to TCDD-induced lethality than the guinea pig. In humans, although TCDD is classified as a Group 1 known human carcinogen, epidemiological cohort studies of exposed populations (such as pesticide applicators or victims of the Seveso industrial accident) show a much weaker correlation with cancer than rodent bioassays predict. Rodent models often show a high incidence of multi-organ tumors, whereas human epidemiological data show only a minimal or negligible increase in overall cancer risk. These massive inter-species differences in Aryl hydrocarbon Receptor (AhR) activation and downstream gene transcription make direct animal-to-human extrapolations highly unreliable.\nAsbestos: Asbestos was widely used in industrial applications throughout the 20th century despite early warnings. Industrial employers and regulators delayed safety measures for decades by citing inconclusive animal data. While human epidemiological studies consistently linked asbestos inhalation to pulmonary fibrosis (asbestosis), lung cancer, and malignant mesothelioma, early animal inhalation experiments struggled to produce lung carcinomas or mesotheliomas in rodents. Rodent nasal and bronchial architecture acts as an efficient filter for long fibers, preventing them from reaching the alveolar spaces. In contrast, human airways are more susceptible to the deep penetration and retention of long asbestos fibers. The reliance on negative or inconclusive rodent inhalation data was used by industrial entities to cover up risks and delay safety regulations for over forty years, exposing millions of workers to a known carcinogen.\nSmoking: The causal link between cigarette smoke and lung cancer is one of the most thoroughly established findings in human epidemiology, yet for decades the tobacco industry successfully delayed regulatory action by exploiting negative animal inhalation studies. Throughout the mid-to-late 20th century, tobacco companies subjected rats and mice to intensive, long-term inhalation of cigarette smoke. These studies consistently failed to show any link between smoking and lung cancer. Rodents are obligate nasal breathers with complex turbinate structures that filter out particulate matter far more effectively than the human oral-bronchial pathway. Additionally, rodents respond to smoke exposure by reflexively shallowing their breathing and reducing their minute ventilation, which limits their exposure to tobacco carcinogens. The tobacco industry exploited these negative rodent bioassays to create public doubt, arguing that if cigarette smoke did not cause lung cancer in animal models, it could not be proven to do so in humans. It was not until 2005 that a lifetime whole-body exposure study in B6C3F1 mice finally demonstrated a statistically significant increase in lung tumors, decades after human epidemiological studies had already established the causal link.\nThe Delay # The reliance on animal inhalation data to define carcinogenicity delayed environmental regulations and workplace safety standards, exposing millions to toxic hazards. In the case of asbestos, Dr. Le Roy Upson Gardner\u0026rsquo;s 1942 research showing that chrysotile fibers induced lung tumors in mice was suppressed by industrial sponsors, who used the lack of published animal evidence to fight safety regulations.\nThe Success # Human epidemiology and clinical observations eventually established the health hazards of these substances, providing the scientific foundation for modern environmental and occupational regulations. Modern toxicology relies on human-derived alternative methods, such as reconstructed human 3D airway models (eg MucilAir), microfluidic lung-on-a-chip platforms, and high-throughput computational toxicology models (QSARs). These human-centric systems provide faster, cheaper, and more biologically relevant toxicity profiles than traditional animal inhalation studies.\nKey Takeaways # The failure of animal toxicology assays highlights the danger of relying on species-specific responses to define human environmental and occupational risk. Transitioning to human-centric NAMs provides a more predictive and scientifically rigorous foundation for chemical safety and environmental regulation.\nCOVID-19 Vaccines # Background # During the rapid development of vaccines and therapeutics for SARS-CoV-2, researchers sought animal models to study viral pathogenesis and evaluate candidate efficacy.\nThe Failure # Standard mice and rats are naturally resistant to ancestral SARS-CoV-2 strains because their endogenous Angiotensin-Converting Enzyme 2 (ACE2) receptor has a very low binding affinity for the viral spike glycoprotein. To bypass this limitation, researchers relied on transgenic mouse models, specifically the K18-hACE2 model, which expresses human ACE2 (hACE2) under the control of the cytokeratin 18 promoter. However, this model has significant limitations:\nLethal Brain Encephalitis vs. Human Respiratory Pathology: The K18 promoter drives widespread expression of hACE2 in multiple non-respiratory tissues, including the central nervous system. Upon SARS-CoV-2 challenge, K18-hACE2 mice develop severe, lethal brain infections (viral encephalitis), which require humane euthanasia. This neurological mortality does not reflect human clinical COVID-19, which is primarily a respiratory and vascular disease. The high copy number (approximately eight copies) and random genomic insertion of the hACE2 gene alter the tissue distribution and expression of the receptor, making the model poorly representative of human pathogenesis.\nThe ACE2 Paradox and Comorbidity Gap: Studies in other animal species showed that while spike-protein binding to ACE2 is necessary for cellular entry, it is not sufficient to replicate severe clinical COVID-19. For example, healthy pigs and non-human primates express ACE2 receptors that bind the SARS-CoV-2 spike protein with high affinity, yet they develop only mild or asymptomatic respiratory disease. This highlights a major gap: animal models are typically healthy, young, and free of comorbidities, whereas severe human COVID-19 cases occur primarily in elderly patients with pre-existing metabolic conditions, such as type 2 diabetes, obesity, and cardiovascular disease.\nThe Delay # The reliance on standard animal models delayed the identification of effective therapeutic targets, as researchers spent valuable time developing and validating transgenic rodents. The lack of human-relevant comorbidity profiles in these animal models also made it difficult to predict the efficacy of immunomodulators and antivirals in high-risk human clinical populations, leading to several clinical trial failures.\nThe Success # The rapid development of COVID-19 vaccines was ultimately achieved by bypassing long-term animal testing and running preclinical animal studies and Phase I human clinical trials in parallel, representing a major shift in the drug development paradigm. Human-relevant alternative methods—including human airway organoids, microfluidic lung-on-a-chip models, and computational modeling of the spike-ACE2 interface—provided rapid, high-fidelity data on viral entry, replication, and neutralization kinetics.\nKey Takeaways # The COVID-19 pandemic highlighted that while a spike protein-binding ACE2 receptor is necessary for virus entry into cells, it is not sufficient to determine the clinical progression of the disease. Developing animal models with humanized receptors and metabolic comorbidities (such as the obese Ossabaw pig) can improve translation, but direct evaluation in human-centric in vitro and computational systems provides the most reliable path for rapid therapeutic development.\nCross-Cutting Themes # Common Causes of Failure # Species-Specific Pharmacokinetics and Pharmacodynamics: Mammalian species show significant differences in xenobiotic metabolism, largely driven by variations in cytochrome P450 enzyme expression, binding affinities, and clearance kinetics. These differences often lead to inaccurate predictions of drug safety and efficacy. For example, the rapid clearance of thalidomide in rodents prevented toxicity during key embryonic windows, while the longer half-life in human embryos caused severe developmental defects.\nMethodological Quality and Experimental Bias: Preclinical animal research is often compromised by poor experimental design. Systematic reviews show a low rate of basic quality controls, such as blinding, randomization, and pre-specified sample size calculations, which leads to biased results and exaggerated efficacy. As shown in the NXY-059 stroke trials, this lack of scientific rigor can create false-positive signals that do not replicate in clinical trials.\nStress-Induced Confounders in Laboratory Environments: The artificial conditions of biomedical laboratories—including restricted housing, artificial lighting, noise, and routine handling—induce chronic stress in research animals. This chronic stress elevates corticosteroid levels, alters neurochemistry, and triggers systemic inflammatory changes (such as intestinal leakage). These physiological alterations introduce uncontrolled variables that can confound experimental data, making results difficult to replicate or translate to human clinical conditions.\nSystemic Barriers to Human-Relevant Research # Regulatory Path Dependency and Inertia: For nearly a century, regulatory guidelines (such as those from the FDA and EMA) have mandated preclinical safety testing in two mammalian species before human trials can proceed. Despite the high failure rates of these animal models, this regulatory requirement has created a \u0026ldquo;gold standard\u0026rdquo; dogma. Sponsors continue to use traditional animal models to avoid regulatory delays, even when human-centric alternatives are available and offer superior predictive value.\nFunding and Peer-Review Bias: National funding bodies (such as the NIH) have historically favored established animal models over New Approach Methodologies. Peer-review panels and journal editors often request in vivo animal validation for studies that rely on human-centric in vitro or computational models, reinforcing the assumption that animal models are necessary to validate human-relevant data.\nScientific Dogma and Academic Lock-In: Academic laboratories and research institutions have invested heavily in animal facilities, specialized breeding programs, and animal-centric research methodologies. This infrastructure creates scientific inertia, as researchers are often hesitant to abandon familiar animal models and invest in the training, equipment, and validation required for advanced cell-based or computational systems.\nAlternatives That Work # In Silico Systems: Advanced computational toxicology, quantitative structure-activity relationship (QSAR) models, machine learning, and molecular dynamics simulations allow for the rapid, high-throughput screening of millions of compounds in days, predicting target binding, ADME profiles, and toxicity with high accuracy.\nIn Vitro Systems: Multi-dimensional human cell-derived platforms—including 3D organoids, spheroids, and microphysiological systems (organs-on-chips)—replicate human organ-level architecture and vascular flow, providing a highly predictive, human-biology-based testing environment.\nIn Vivo (Human) Systems: Microdosing protocols—which involve administering sub-pharmacological, ultra-low doses of a candidate compound to human volunteers—allow for the direct evaluation of human pharmacokinetic and metabolic profiles early in development, avoiding species-specific translation gaps.\nRegulatory and Industry Shifts # Policy Changes # The FDA Modernization Act 2.0 and 3.0: Signed into law in December 2022, the FDA Modernization Act 2.0 removed the 1938 statutory requirement mandating animal testing for investigational new drug (IND) applications and biosimilars, authorizing sponsors to submit data from validated non-animal alternative methods. The subsequent FDA Modernization Act 3.0 (passed by the Senate in late 2025) set a clear timeline for the FDA to update its Code of Federal Regulations (C.F.R.) to align with these changes, establishing a path toward animal-free drug approvals.\nThe FDA\u0026rsquo;s NAM Roadmap and Guidelines: On April 10, 2025, the FDA released its Roadmap to Reducing Animal Testing in Preclinical Safety Studies, outlining a step-by-step strategy to integrate NAMs into regulatory reviews. The roadmap prioritizes monoclonal antibodies (mAbs) in Phase 1 (0–3 years), allowing sponsors to reduce routine 6-month primate toxicity studies to 3 months if preliminary assays show no safety signals. This is supported by the CDER 2026 draft guidance, Use of New Approach Methodologies in Drug Development, which provides a clear validation framework and regulatory standards for non-animal methods.\nEPA 2035 Mandate: The U.S. Environmental Protection Agency (EPA) has recommitted to its goal of eliminating all mammalian animal testing requests and funding by 2035. Under the Toxic Substances Control Act (TSCA), the EPA is prioritizing the development and validation of high-quality alternative testing methods (such as in vitro, in chemico, and in silico models) to evaluate chemical hazards and manage risks.\nFunding Trends # Expansion of NAM-Specific Grants: National funding agencies have expanded dedicated grants for alternative research, with the NIH\u0026rsquo;s National Center for Advancing Translational Sciences (NCATS) and the EPA\u0026rsquo;s Tox21 program driving multi-agency collaborations to develop and validate human-relevant alternative technologies.\nPrivate Sector Adoption: Global consumer product and cosmetic companies (such as Unilever and L\u0026rsquo;Oréal) have led the integration of human skin and tissue-derived models for safety evaluation. This trend is expanding into the biopharmaceutical sector, with major drug developers integrating human microphysiological and AI-driven platforms into their drug discovery pipelines to reduce costs and shorten development timelines.\nEthical, Socioeconomic, and Equity Dimensions # The Animal and Human Toll # The ethical cost of the animal-centric paradigm is high on both sides. Globally, over 100 million animals are used annually in laboratory experiments, with many subjected to invasive procedures, chronic confinement, and distress. When these animal models produce false-positive safety signals or false-negative efficacy results, the consequences for human health can be severe.\nClinical trials of compounds that appeared safe in preclinical animal tests have resulted in life-threatening toxicities and patient deaths, as seen in the TGN1412, fialuridine, and troglitazone trials. Conversely, relying on animal models can delay or block the discovery of life-saving human therapies. This dual-edged failure demonstrates the urgent need for human-relevant platforms that can protect both clinical volunteers and animal welfare.\nHealth Equity and Demographic Representative Gaps # Traditional preclinical animal studies typically rely on highly homogeneous populations—specifically young, healthy, male rodents. This homogeneity ignores the physiological differences associated with biological sex, age, genetic diversity, and chronic comorbidities, which are central to human disease presentation and drug response.\nBy ignoring these variables, animal-centric preclinical research can generate safety and efficacy data that is poorly generalizable to diverse human patient populations, disproportionately affecting women, the elderly, and individuals with multiple comorbidities. Human-centric NAMs, such as patient-derived iPSCs, multi-donor organoids, and computational models based on real-world clinical data, allow researchers to model diverse human genotypes, age groups, and chronic conditions, helping to ensure that new therapeutics are safe and effective for all patient populations.\nActionable Recommendations # For Researchers # Integrate Human Biology-Based Assays Early: Prioritize the use of human-derived organoids, spheroids, and microphysiological systems in early-stage drug discovery and safety testing.\nValidate Novel Platforms Against Clinical Data: Use clinical success and failure libraries to validate alternative platforms, building scientific confidence in their predictive validity.\nAdopt Rigorous Experimental Standards: Follow standardized preclinical guidelines (similar to CONSORT for clinical trials) to improve experimental design and reporting transparency.\nFor Regulators # Harmonize Acceptance Criteria Globally: Work through international bodies (such as the ICH and OECD) to establish uniform validation standards, ensuring mutual acceptance of NAM data across regulatory jurisdictions.\nExpand Qualification Programs: Accelerate pathways for alternative tool qualification (such as the FDA\u0026rsquo;s ISTAND program), providing clear, fit-for-purpose guidance for developers.\nUpdate Rules Requiring Animal Testing: Systematically review and update C.F.R. rules and agency guidelines that explicitly require animal-based data, replacing them with performance-based, human-relevant standards.\nFor Funders # Redirect Strategic Grants to Human-Centric Methods: Increase funding for the development, validation, and standardization of human-centric alternative methodologies, shifting resources away from traditional animal models.\nSupport Shared Infrastructure: Fund public-private partnerships and centralized repositories to reduce the cost of access to human tissues, cell lines, and computational resources.\nIncentivize Interdisciplinary Collaboration: Support joint programs combining tissue engineering, computer science, and clinical medicine to develop integrated alternative testing platforms.\nFor the Public # Demand Transparency in Research Funding: Advocate for public research funds to be directed toward more effective, human-relevant alternative methodologies.\nSupport Policy Updates: Engage with lawmakers to support legislative and regulatory updates that accelerate the phase-out of animal testing in favor of human-centric science.\nAppendix: Glossary and Acronyms # Glossary of Terms # New Approach Methodologies (NAMs): Broadly defined as any non-animal test method, technology, or approach that can provide useful regulatory data, including in vitro assays, in chemico methods, and in silico computational models.\nOrgan-on-a-Chip (Microphysiological System): A microfluidic bioengineered platform containing cultured human cells that replicates the structural and functional features of living human organs, such as blood flow, mechanical shear stress, and multi-lineage cell-cell interactions.\nOrganoid: A three-dimensional, self-organizing in vitro cell culture derived from stem cells that mimics the micro-anatomy and functional characteristics of a specific human organ.\nIn Silico Modeling: Research or testing conducted via computer simulation or computational modeling, including quantitative structure-activity relationship (QSAR) models, physiologically based pharmacokinetic (PBPK) models, and machine learning platforms.\nIn Chemico Testing: Abiotic chemical reactivity assays designed to evaluate specific molecular interactions, such as skin sensitization, without using cells or tissues.\nMicrodosing: The administration of sub-pharmacological, ultra-low doses of an investigational drug (typically less than 100 micrograms) to human subjects to safely evaluate pharmacokinetic and metabolic profiles early in development.\nThe 3Rs (Replacement, Reduction, Refinement): An ethical framework for animal research that advocates for replacing animal studies with non-animal alternatives, reducing the number of animals used, and refining protocols to minimize pain and distress.\nList of Acronyms # ADME: Absorption, Distribution, Metabolism, and Excretion.\nAhR: Aryl hydrocarbon Receptor.\nCDER: Center for Drug Evaluation and Research (FDA).\nEMA: European Medicines Agency.\nEPA: Environmental Protection Agency (U.S.).\nFDA: Food and Drug Administration (U.S.).\nhACE2: Human Angiotensin-Converting Enzyme 2.\nICH: International Council for Harmonisation.\nIND: Investigational New Drug.\nISTAND: Innovative Science and Technology for New Drug Development (FDA).\nNHP: Non-Human Primate.\nNIH: National Institutes of Health (U.S.).\nOECD: Organisation for Economic Co-operation and Development.\nTSCA: Toxic Substances Control Act (U.S.).\nPart 2: Executive Summary # Infographic Blueprint # ================================================================================= # THE CLINICAL TRANSLATION GAP\nTraditional Animal Preclinical Testing Human-Centric NAM Paradigm\n• Attrition Rate: \u0026gt; 92% clinical failure. • Direct relevance to human biology. • Focus: Species-specific models. • Focus: Bioengineered human systems. • Timelines: 4-6 years for screening. • Timelines: 1-2 years using AI/chips. • Cost: Part of $2.6B approved compound cost. • Cost: Slashes preclinical cost by 30-50%. • Result: Unexpected toxicities/efficacy loss. • Result: Faster, safer drug discovery.\n================================================================================= # SYSTEMIC BIOLOGICAL DISPARITIES\nTHALIDOMIDE VIOXX HIV/AIDS Rodent embryos possess Rofecoxib created a Chimpanzees do not robust glutathione prothrombotic imbalance progress to AIDS due antioxidant systems and undetected in healthy to species-specific rapidly clear the drug, animals lacking chronic host restriction preventing limb damage inflammation and factors and immune observed in humans. vascular plaque. resiliency pathways.\n================================================================================= # ACTION PLAN FOR REFORM\nPrioritize human Harmonize validation Redirect strategic # biology-based assays standards globally grants to non-animal and clinical libraries and expand flexible platforms and shared for validation. review pathways. infrastructure.\n### Key Stakeholder Takeaways #### For Policymakers * Traditional animal-centric drug discovery has a \u0026gt; 92% clinical failure rate, showing the need for policy updates that support more effective testing methods. [4, 5, 6, 7] * The FDA Modernization Act 2.0 and 3.0 have removed statutory mandates for animal testing, allowing regulators to accept validated human-relevant alternatives. [2, 19] * Supporting the transition to alternative methodologies will help lower healthcare costs, speed patient access to safe therapies, and advance health equity. [19, 51] #### For Researchers * Species-specific physiological and metabolic differences are a primary driver of clinical trial failures, showing that non-human models are often poor predictors of human response. [2, 12] * Human-centric alternative methodologies—including 3D organoids, microphysiological systems, and computational platforms—provide more predictive, biologically relevant data than traditional animal studies. [3, 8, 10] * Improving experimental design, randomization, and blinding in preclinical research is critical to reduce false-positive signals and enhance scientific integrity. [7, 27, 29] #### For the Public * Systemic reliance on animal testing has historically delayed regulatory action on environmental and workplace hazards, such as asbestos and tobacco smoke. [35, 39, 40] * Transitioning to human-centric alternative methodologies offers a more reliable and cost-effective approach to evaluate chemical and drug safety. [8, 11, 43] * Supporting legislative and funding updates that prioritize non-animal alternatives will help advance both human health outcomes and animal welfare. [2, 43] Note: All LaTeX math representations for simple numbers and percentages in the raw text above have been converted to standard plain-text numbers and percent signs (%) for clean integration directly into Markdown renderers, preserving strict formatting constraints.\n","date":"2026-05-25","externalUrl":null,"permalink":"/resources/reports/animal-research-failures/","section":"Resources","summary":"Clinical, regulatory, and economic analysis of animal model translation failures in drug discovery.","title":"Animal Research Failures","type":"resources"},{"content":"","date":"2026-05-25","externalUrl":null,"permalink":"/tags/biomedical-research/","section":"Tags","summary":"","title":"Biomedical Research","type":"tags"},{"content":"","date":"2026-05-25","externalUrl":null,"permalink":"/tags/canada/","section":"Tags","summary":"","title":"Canada","type":"tags"},{"content":"","date":"2026-05-25","externalUrl":null,"permalink":"/tags/failure/","section":"Tags","summary":"","title":"Failure","type":"tags"},{"content":"","date":"2026-05-25","externalUrl":null,"permalink":"/tags/funding/","section":"Tags","summary":"","title":"Funding","type":"tags"},{"content":"","date":"2026-05-25","externalUrl":null,"permalink":"/tags/netherlands/","section":"Tags","summary":"","title":"Netherlands","type":"tags"},{"content":"","date":"2026-05-25","externalUrl":null,"permalink":"/tags/us/","section":"Tags","summary":"","title":"Us","type":"tags"},{"content":" Geopolitical Divergence in New Approach Methodologies (NAM): Why Canada Lags Behind # Canada lagging behind other countries for NAM\nCredit: Gemini Canada’s Bill S-5 (2023 CEPA amendments)1 is limited to chemical toxicity testing2 3, excluding biomedical research and drug discovery. The US FDA Modernization Act 2.0/3.04 5, EU REACH + Horizon Europe6 7, and Dutch TPI8 implement top-down legislative changes covering both regulatory toxicology and biomedical research (unlike Canada9). Dedicated funding in the US ($150M NIH Complement-ARIE)10 11, EU (€17.2M ONTOX, €4.5M VISI-ON-BRAIN)12, and Netherlands (€124.5M Ombion Centre)13 14 bypasses animal-biased granting loops, while Canada’s CCAAM closed in 20242 15 due to lack of federal support. The US and Netherlands validate NAMs against human clinical data4 16, not legacy animal models, while Canada remains trapped in peer-review bias managed by CCAC and Tri-Council17 18. The global NAM market is projected to reach $1.99B by 203419 (CAGR 27.58%), with North America dominating due to US investments20 21. Canada’s brain drain and skills gap22 23 risk devaluing degrees and losing talent. Introduction # The global life sciences sector is undergoing a paradigm shift from vertebrate animal models to New Approach Methodologies (NAM), including microphysiological systems (organs-on-chips), 3D bioprinted human tissues, in silico computational toxicology, and AI-driven predictive models. These technologies offer higher biological accuracy, faster timelines, and lower R\u0026amp;D costs, but a geopolitical divergence has emerged: while the US, EU, and Netherlands lead with robust legislative frameworks, dedicated funding, and educational integration, Canada remains in structural stagnation24 25 26 10.\nThis report provides a comparative analysis of institutional bottlenecks, funding disparities, and regulatory hurdles, identifying how frontrunners overcame inertia and where Canada failed to act2 3. It concludes with a policy-driven argument for student-led reform.\n1. The Strategy \u0026amp; Policy Execution Gap # The primary driver of the geopolitical divergence in NAM adoption is the structural design of national legislative mandates. In Canada, the policy framework is characterized by a fragmented, highly restricted mandate that divorces legislative intention from practical execution. The cornerstone of Canada\u0026rsquo;s legislative efforts is Bill S-5 (Strengthening Environmental Protection for a Healthier Canada Act), which received Royal Assent on June 13, 2023, and modernized the Canadian Environmental Protection Act (CEPA). While Bill S-5 represents a milestone by recognizing the right to a healthy environment and mandating that the government support the development and use of alternative testing strategies, its operational scope is narrow3.\nIn contrast, international frontrunners have implemented comprehensive, top-down legislative changes that encompass both regulatory toxicology and biomedical research. In the United States, the passage of the FDA Modernization Act 2.0 (FDAMA 2.0) in December 2022 fundamentally modernized the pharmaceutical R\u0026amp;D paradigm by eliminating the statutory mandate for animal testing in Section 505(c)(1) of the Food, Drug, and Cosmetic Act. By broadening the definition of acceptable preclinical evidence to \u0026ldquo;nonclinical tests,\u0026rdquo; the US statutory framework explicitly placed human-relevant microfluidic chips, in vitro assays, and computer simulations on equal legal footing with legacy animal trials.\nSimilarly, the European Union has leveraged its Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) framework alongside its Horizon Europe funding directives to drive a systemic transition6. The REACH framework, which imposes a multi-billion-euro compliance burden on chemical manufacturers, has forced the European Chemicals Agency (ECHA) to actively develop a comprehensive roadmap to phase out animal testing for chemical safety assessments, scheduled for release in early 2026. This regulatory pressure is directly supported by Horizon Europe’s structured research funding, which has allocated €17.2 million to consortia like ONTOX and €4.5 million to networks like VISI-ON-BRAIN to develop advanced in vitro and in silico models.\nIn the Netherlands, the national government established the Transition Programme for Innovation without the use of animals (TPI) in 2018, representing the gold standard in top-down policy execution. Unlike traditional international frameworks that focus on the \u0026ldquo;Three Rs\u0026rdquo; (Replacement, Reduction, and Refinement), the Dutch TPI is focused on Replacement8.\nCanada’s Fragmented Mandate: Bill S-5 # Scope Limitation: Bill S-5 (2023 CEPA amendments) only applies to chemical toxicity testing (industrial chemicals, pesticides, environmental contaminants) and excludes biomedical research and drug discovery2 3. Discretionary Language: The Act requires alternative methods only where \u0026ldquo;practicable\u0026rdquo; and \u0026ldquo;scientifically justified\u0026rdquo;, allowing regulators to maintain animal testing under the guise of necessity2. Administrative Delay: The draft strategy for implementing Bill S-5 was published for public comment in late 2024, with the final strategy delayed until mid-20252 3 - leaving Canada years behind competitors25. Decentralized Regulation Approach: Due to minimal topdown mandates and restraints, individual agencies act in accordance with their own systems, thus creating compliance and enforcement issues (\u0026lsquo;fox guarding the hen house\u0026rsquo;), as well as a rigid status-quo funding flow that prevents modern innovators from receiving resources 10. International Blueprints # Country Legislative Framework Key Mechanism Coverage Source United States FDA Modernization Act 2.0 (Dec 2022) + FDAMA 3.0 (Dec 2025) Eliminates statutory requirement for animal testing in drug development; places NAMs on equal legal footing. Regulatory toxicology + biomedical research 4 5 27 28 European Union REACH framework + Horizon Europe Multi-billion-euro compliance burden on chemical manufacturers; roadmap to phase out animal testing for chemical safety (2026). Chemical safety + biomedical research 6 7 Netherlands Transition Programme for Innovation (TPI) + Ombion Centre (July 2025) Ministerial partnership focused on replacement (not just 3Rs); accelerated clinical translation pathways for high-burden diseases (ALS, Cystic Fibrosis, Osteoarthritis, COPD). Full biomedical + regulatory scope 8 9 29 13 14 2. Macroeconomic and Funding Mechanisms # The primary catalyst for the geopolitical divergence in NAM adoption is the structural design of national R\u0026amp;D funding. While international frontrunners have bypassed traditional, animal-biased granting loops by creating separate, dedicated capital pools that ring-fence funding exclusively for human-relevant technologies, Canada continues to rely on general funding pools that force innovative alternative methodologies to compete directly against deeply entrenched vertebrate animal research.\nIn stark contrast, Canada’s funding landscape for alternative methodologies is characterized by severe underfunding, structural neglect, and bureaucratic absorption. While the Canadian federal budget released in April 2024 allocated tens of millions of dollars to \u0026ldquo;advance scientific research to phase out animal toxicity testing,\u0026rdquo; this capital was directed internally to Health Canada and Environment and Climate Change Canada to support their own internal chemical assessment activities2. No dedicated, external capital pools were established to support academic researchers or independent national validation infrastructure.5 The catastrophic real-world consequence of this structural failure is exemplified by the closure of the Canadian Centre for Alternatives to Animal Methods (CCAAM) at the University of Windsor15.\nThis failure occurred in direct contradiction to the legislative intentions of Bill S-5, leaving Canada without the scientific infrastructure required to execute its own statutory mandates. While Health Canada continues to state that its \u0026ldquo;aim to reduce reliance on animal testing remains unchanged\u0026rdquo;, the federal government’s refusal to fund its only national alternative testing center has stalled Canadian progress, leaving the nation highly dependent on foreign technology and validation.\nDedicated Capital vs. General Pools # Country Program Funding Mechanism Source United States NIH Complement-ARIE (March 2026) $150M USD: 7 Technology Development Centers (TDCs); $25M for NAMs Data Hub (NDHCC); $7M for Validation and Qualification Network (VQN). Ring-fenced capital bypassing traditional animal-biased granting loops. 10 11 30 European Union Horizon Europe €17.2M (ONTOX); €4.5M (VISI-ON-BRAIN). Consortia-based grants aligning academic research with regulatory needs. 2 12 Netherlands Ombion Centre (CPBT) via National Growth Fund €124.5M over 10 years: €55M direct funding + €69.5M conditional grants. Public-private partnership integrating all Dutch academic medical centers. 13 14 31 29 Canada None $0 dedicated federal funding. General Tri-Council pools force NAMs to compete with animal models; internal CEPA budgets absorbed by government. 2 22 32 Canada’s Underfunding Reality: The CCAAM Closure # Timeline: Laboratory doors closed in May 2024 due to budget constraints25 15, officially shuttering in October 2024 with equipment moved to storage in Ottawa2 15. Root Cause: Complete exclusion from federal budgets2 15 and a reliance on private donations and short-term grants2. Contradiction: Closure occurred despite clear alignment with Bill S-5’s goals25 22, leaving Canada without national validation infrastructure2. 3. Overcoming the \u0026ldquo;Animals-as-Benchmark\u0026rdquo; Peer-Review Trap # A major scientific bottleneck impeding the transition to modern biotechnology is the \u0026ldquo;animals-as-benchmark\u0026rdquo; validation trap. Traditionally, regulatory agencies and academic peer-review panels have required novel, human-relevant technologies—such as patient-derived organoids or microphysiological systems—to prove their validity by directly replicating historical animal data. This methodological requirement is scientifically flawed.\nInternational frontrunners have broken this self-perpetuating cycle by establishing alternative validation and acceptance pathways. On March 18, 2026, the US FDA released its draft guidance, General Considerations for the Use of NAMs in Drug Development (aka Fewer Animals, Better Data, Faster Cures). This regulatory framework officially clarified that formal qualification and validation are not mandatory preconditions for submitting a NAM in support of an Investigational New Drug (IND) or New Drug Application (NDA). Instead, the FDA introduced a flexible, fit-for-purpose framework based on four core principles:\nContext of Use: A clear, defined description of the NAM\u0026rsquo;s intended regulatory purpose. Human Biological Relevance: Evidence demonstrating how the NAM recapitulates human-specific biology or drug behavior. Characterization: A robust description of the NAM\u0026rsquo;s physical, chemical, and operating components. Fit-for-Purpose: Assurance that the NAM can support regulatory decision-making with equal or greater confidence than traditional animal models. By allowing sponsors to submit NAM data backed by strong mechanistic and human clinical relevance, the US has bypassed the traditional validation bottleneck. Similarly, the Dutch National Growth Fund’s ValNAM and MKMD initiatives have explicitly formulated granting calls that reject animal tests as the \u0026ldquo;gold standard\u0026rdquo;. Canada, on the other hand, remains entirely trapped in this methodological cycle due to its fragmented peer-review culture and the structural design of its research oversight.\nThe Validation Bottleneck # Traditional Trap: Regulators and peer-review panels require NAMs to validate against flawed legacy animal data, creating a self-perpetuating cycle25. Scientific Flaw: Over 90% of drugs passing preclinical animal trials fail in human clinical trials due to lack of efficacy or toxicity25. International Solutions # Country Mechanism Key Feature Source United States FDA Draft Guidance (March 18, 2026): General Considerations for the Use of NAMs in Drug Development No formal validation required for IND/NDA submissions; fit-for-purpose framework based on Context of Use, Human Biological Relevance, Characterization, and Fit-for-Purpose. 4 33 34 Netherlands ZonMw’s ValNAM and MKMD initiatives Rejects animal tests as the \u0026ldquo;gold standard\u0026rdquo;; validates NAMs directly against human clinical or epidemiological data. 16 Canada CCAC + Tri-Council Oversight Two-stage bias: 1. Funding stage: CIHR/NSERC committees downrate NAMs as unproven. 2. Ethics stage: Animal Care Committees use deficient AUP forms that fail to elicit 3Rs-compliant info. Result: Animal use has risen over the past decade. 17 18 22 35 4. Global Economic Competitiveness and the Skills Deficit # Canada\u0026rsquo;s failure to systematically adopt and fund NAMs carries severe economic and educational consequences, threatening to relegate the nation to a lower tier in the global biotechnology and pharmaceutical sectors.\nThe global economic market value of NAM is projected to experience explosive growth over the next decade. The global Organ-on-Chip (OoC) market alone, valued at approximately $126 million to $157.3 million USD in 2024, is projected to reach $905 million to $952.4 million USD by 2030, representing a Compound Annual Growth Rate (CAGR) of 35% to 40% 31. More expansive market projections estimate the global organs-on-chips market will reach $1.99 billion USD by 2034, exhibiting a CAGR of 27.58%19.\nLet the projected market value \\(M_t\\) at year \\(t\\) be modeled by the compound growth formula:\n$$ M_t = M_0 \\times (1 + r)^t $$Starting with a market size of 157.3 million in 2024, the Grand View Research model 21 makes the following forecast assuming a CAGR of 35.11% over 6 years:\n$$ M_{2030} = 157.3 \\times (1 + 0.3511)^6 \\approx 952.4 \\text{ million USD} $$The more recent Fortune Business Insights model 19, starts with 283.95 in 2026 with a CAGR of 27.58% predicting:\n$$ M_{2034} = 283.95 \\times (1 + 0.2758)^8 \\approx 1.993 \\text{ million USD} $$This rapid compounding highlights the massive economic opportunity that Canada is actively forfeiting.\nMarket Projections # Technology 2024 Value 2030 Projection 2034 Projection CAGR Source Organ-on-Chip (OoC) $126M–$157.3M USD $905M–$952.4M $1.99B 27.58–40% 20 21 19 AI in Predictive Toxicology $635.8M USD $3.925B N/A 29.7% 21 North American Context: The region holds a 52% revenue share in OoC, driven primarily by US federal investments20 21.\nThe Brain Drain \u0026amp; Degree Devaluation Risk # By failing to establish native training programs and academic curricula in these high-tech, human-relevant methodologies, Canadian universities are creating a profound skills deficit and a high risk of degree devaluation for their graduates while international frontrunners are already investing heavily in educating the next-generation scientific workforce.\nThis domestic stagnation triggers a severe \u0026ldquo;brain drain\u0026rdquo; of Canada’s top scientific talent. Survey data reveals that approximately 80% of researchers identify \u0026ldquo;reliability\u0026rdquo; as a key roadblock in their work, and a clear majority of biomedical scientists state that they would actively consider migrating to another country in response to a restrictive, underfunded, or animal-biased research policy23.\nRegion Educational Initiative Impact Source Netherlands Ombion + Utrecht Science Park: Global education hub; Professional Master’s in Animal-Free Innovation; interdisciplinary student challenges. Trains the next-generation workforce in NAMs, AI, and microphysiological systems. 13 29 36 European Union Horizon Europe’s VISI-ON-BRAIN: €4.5M to train 15 doctoral researchers in bioengineering, microfluidics, and regulatory science. Equips early-career scientists with high-demand, modern skills. 2 12 Canada No native training in NAMs (such as microphysiological platforms, 3D bioprinting, or computational toxicology). Severe skills gap; Canadian graduates are left unprepared for global roles, leading to a brain drain to the US and EU. 22 23 37 Survey Data: Approximately 80% of researchers cite institutional reliability as a roadblock, noting they would consider emigration due to restrictive, underfunded national policies23.\n5. Structural Bottleneck Matrix # The table below clears illustrates the 5 key bottlenecks (Legislation, Funding, Validation, Regulation, and Education) which other countries have bypassed, but Canada remains trapped by. Without concerted and radical alterations in each of these areas, bioscience in Canada will remain stagnant - trapped in self-entrapping anaerobic conditions, producing hydrogen sulphide.\nBottleneck Domain Canada United States European Union Netherlands Source Legislative Mandate Fragmented: Bill S-5 excludes biomedical research; discretionary limits use to what is \u0026ldquo;practicable\u0026rdquo;. Comprehensive: FDAMA 2.0/3.0 eliminates animal testing mandates, putting NAMs on equal legal footing. Dual-Track: REACH phases out chemical animal tests (2026) while Horizon Europe aligns R\u0026amp;D with regulations. Replacement-Focused: TPI ministerial partnership combined with the Ombion Centre accelerates translation. 2 3 4 5 6 28 8 9 29 Funding Model No dedicated capital; NAMs must compete with legacy animal models in general Tri-Council pools. Ring-Fenced: Complement-ARIE provides $150M alongside dedicated TDCs, NDHCC, and VQN funding. Consortia Grants: Horizon Europe directs targeted funding like €17.2M to ONTOX and €4.5M to VISI-ON-BRAIN. Stable Public-Private: National Growth Fund commits €124.5M over a stable 10-year horizon. 10 11 12 30 13 14 31 2 22 18 Validation Infrastructure Defunct: CCAAM shuttered in 2024, leaving the country with no national hub or infrastructure. Institutionalized: VQN combined with a new $87M organoid center provides fast-track pathways. Centralized: Managed via EURL ECVAM/UKCVAM to provide standardized validation protocols. Integrated: The Ombion Centre directly connects academic research with biotechnology infrastructure. 10 2 11 29 15 4 38 Regulatory Acceptance Animal Benchmarking: Double peer-review bias via CCAC/Tri-Council and non-compliant AUP forms. Flexible Pathways: No formal legacy validation required for IND/NDA; relies on fit-for-purpose utility. Formalized Frameworks: EMA and ECHA systematically accept validated NAMs for registrations. Human-Data Focus: ZonMw rejects animal data as a gold standard, validating against clinical profiles. 4 33 34 16 17 18 38 Educational Integration Skills Deficit: Total absence of native training programs, driving persistent talent loss. TDCs as Hubs: Standardized doctoral and postdoctoral training paths in bioengineering and data science. Doctoral Networks: Marie Skłodowska-Curie Actions explicitly fund NAM-focused PhD positions. Global Hub: Anchored at Utrecht Science Park, offering a dedicated Master’s in Animal-Free Innovation. 10 2 12 29 30 22 23 37 36 6. Economic/Fiscal Disparity Metrics # The geopolitical divergence is further clarified by comparing the absolute and proportional financial commitments made by each nation toward dedicated NAM research, development, and validation infrastructure. The table below shows Canada\u0026rsquo;s commitment to NAM. This clear funding gap illustrates why Canada has failed to keep pace with international progress.\nCountry Dedicated NAM Funding (USD) Population Per-Capita Funding (USD) Allocation Mechanism Source Canada $0 40M $0.00 General Tri-Council pools; no ring-fenced capital. 2 22 18 Netherlands $135M (Ombion/CPBT) 18M $7.50 10-year public-private partnership. 13 29 14 United Kingdom $95M (UKCVAM) 68M $1.40 Ring-fenced capital via Dept. for Science. 38 United States $244M (Complement-ARIE + FDA) 335M $0.73 NIH Common Fund + FDA coordination. 10 4 11 7. Policy-Driven Framework for Student-Led Reform # Canada’s stagnation stems from self-regulated legacy systems (CCAC, Tri-Council)17 18. Student-led advocacy is critical to disrupt this inertia. Focus on three vectors:\nFederal Legislative Reform:\nAdvocate for an Animals in Science Act to strip CCAC of standard-setting authority17 9. Elevate animal welfare guidelines to binding federal law9. Establish centralized benchmarks and mandatory reporting for public and private laboratories9. Reallocating Tri-Council Capital:\nDemand ring-fenced funding pools for NAMs, modeled after the US Complement-ARIE and Dutch TPI frameworks10 13 11. Mandate a fixed percentage of federal R\u0026amp;D budgets exclusively for NAM development and validation22 18. Institutional Curriculum Modernization:\nLaunch campus campaigns to integrate microphysiological systems, computational toxicology, and human-relevant disease modeling into standard curricula22. Develop virtual skills labs and peer-to-peer training modules aligned with international hubs like Utrecht Science Park29 36. 8. Conclusions and Recommendations # Canada’s legislative intention under Bill S-5 is undermined by systemic structural failures:\nNo dedicated funding for NAMs, highlighted by the CCAAM closure2 22 Pervasive peer-review bias across CCAC and Tri-Council structures17 18 A widening skills gap caused by a lack of native training pathways in modern methodologies22 23. To reverse this situation, prevent brain-drain, and ensure global competitiveness, Canada must\nCreate an alternate funding stream that bypasses traditional granting loops and focuses exclusively on REPLACEMENT (not the incremental reduce, refine) as other progressive countries have done8 Expand the scope of Bill S-5 to include biomedical research and drug discovery2 3 Establish ring-fenced funding of $100M+ for a national validation hub (resurrecting the CCAAM framework) to match international investments10 2 11 14 Reform the peer-review process to prioritize human-relevant methods rather than treating alternative methods as an afterthought4 33 16 Modernize Canadian university life-sciences and medical curricula to natively train a competitive biotech workforce in NAM29 22 36 Realize the inevitable global investment potential of NAM and setup the infrastructure to participate in it Because Canada\u0026rsquo;s institutional animal-testing framework is self-regulated and resistant to self-initiated improvement, student-led advocacy and reform represent the single most viable mechanism to break the legislative and educational stagnation.\nReferences # Parliament of Canada (2023). Government Bill S-5: Strengthening Environmental Protection for a Healthier Canada Act\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nCorporate Knights (2024). Canada\u0026rsquo;s Plan to Phase Out Animal Testing Suffers a Setback\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nEnvironment and Climate Change Canada (2025). Strategy to replace, reduce or refine vertebrate animal testing under CEPA\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nFood and Drug Administration (2026). General Considerations for the Use of New Approach Methodologies (NAMs) in Drug Development (Draft Guidance)\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nAnimal Wellness Action (2025). FDA Modernization Act 3.0 Fact Sheet\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nONTOX Consortium (2025). AI-driven Safety Assessment and REACH Compliance\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nEuropean Commission (2023). Horizon Europe Work Programme\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nTransition Programme for animal-free Innovation (2022). TPI Netherlands Strategic Agenda and Goals\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nFouad, K. \u0026amp; Lavelle, K. (2025). Stepwise Imperatives for Improving the Protection of Animals in Canadian Science\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nNational Institutes of Health (2026). NIH Invests $150 Million in Human-Based Research to Reduce Use of Animal Models\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nNational Institutes of Health (2026). Complement-ARIE: Catalyzing the development and adoption of new approach methodologies\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nLund Stem Cell Center (2026). Lund Joins €4.5M Horizon Europe Network for Advanced Human Brain Models\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nUtrecht University (2024). Dutch National Growth Fund invests 124.5 million in transition to animal-free innovation\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nNational Institute for Public Health and the Environment - RIVM (2024). Dutch National Growth Fund CPBT Investment\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nUniversity of Windsor (2024). The Defunct Canadian Centre for Alternatives to Animal Methods\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nNolte, M. (2025). ZonMw Promoting Research into Animal-Free Methods under MKMD\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nAnimal Alliance Advisory Group on Humane Science (2022). Critical Review of the Canadian Council on Animal Care (CCAC)\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nTaylor, K. \u0026amp; Griffin, G. (2019). Analyzing Animal Use Protocol (AUP) Forms Across Canadian Institutions\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nFortune Business Insights (2025). Global Organs-on-Chips Market Size and Trends\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nMarkNtel Advisors (2025). Global Organ-on-Chip Market (2025-2030)\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nGrand View Research (2024). Organ-on-a-Chip Market Size, Share \u0026amp; Trends Analysis\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nCanadian Institutes of Health Research (2025). Peer Review Committee Mandates - Project Grant Program\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nAttitudes Toward Animal Research and Experimentation: An Annotated Bibliography 2011-2019\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nUtrecht Science Park (2025). Ombion Centre for Animal-free Biomedical Translation celebrates launch\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nAnimal Diseases and Alternatives Association (2024). Canada\u0026rsquo;s Regulatory Holdup on Non-Animal Methods\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nHU University of Applied Sciences Utrecht (2024). 125 million euros from National Growth Fund for animal-free biomedical innovation\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nBooker, C. \u0026amp; Paul, R. (2022). Passage of the FDA Modernization Act 2.0\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nCDER (2025). The Roadmap and Subsequent FDA Preclinical Study Actions (FDAMA 2.0 \u0026amp; 3.0)\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nUtrecht Science Park (2025). Ombion Centre for Animal-free Biomedical Translation celebrates launch\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nJohns Hopkins University \u0026amp; New York University (2026). NIH Complement-ARIE Technology Development Centers and Data Hub\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nHU University of Applied Sciences Utrecht (2024). 125 million euros from National Growth Fund for animal-free biomedical innovation\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nHealth Canada (2024). CMP Horizontal Initiative Funding Allocation under Budget 2024\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nStudna, A. (2026). FDA Issues Draft Guidance to Validate Non-Animal Testing Methods\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nNational Centre for the 3Rs (2025). Incorporating new approach methodologies in the development of new medicines\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nCanadian Council on Animal Care (2022). CCAC Annual Animal Data Report Analysis\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nDoctors Against Animal Experiments (2025). Developing a global education hub for animal-free innovation\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nBerridge, B. (2021). Preclinical study planning, reproducibility and transparent practices\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nAnimal Free Science Advocacy (2025). Landmark Roadmaps and Funding Endorsements for alternative testing globally\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\n","date":"2026-05-25","externalUrl":null,"permalink":"/resources/reports/canada-nam-lag/","section":"Resources","summary":"Canada lags in NAM adoption due to fragmented policy, underfunding, and peer-review bias.","title":"Why Canada Lags Behind","type":"resources"},{"content":" Anotida Madzvamuse # Anotida Madzvamuse DPhil. MSc, MSC (EDU), BSC (Hons), BSs Maths, is a Full Professor and Tier-1 Canada Research Chair in Theoretical and Computational Biology at UBC. His research integrates mathematics, physics, and computational methods to model biological systems, including COVID-19 transmission dynamics. He has received prestigious awards such as the Royal Society Wolfson Research Merit Award (2016–2021) and the Theodore von Kaman Fellowship (2013). Madzvamuse has published extensively in top-tier journals, focusing on pattern formation, reaction-diffusion systems, and cell motility. He actively engages in public outreach, including podcast interviews and speaker series, sharing his journey from rural Zimbabwe to international academia. Anotida Madzvamuse\nCredit: UBC Introduction # Anotida Madzvamuse is a distinguished mathematician and computational biologist who joined the University of British Columbia (UBC) as a Full Professor in the Department of Mathematics in October 2022. His work lies at the intersection of fundamental disciplines - mathematics, numerical analysis, physics, and scientific computing - and experimental sciences such as developmental, cellular, and plant biology, as well as biomedicine. Madzvamuse’s research focuses on developing novel mathematical and computational approaches to address complex biological phenomena, including pattern formation and cell migration. He is also deeply committed to teaching and mentoring at both undergraduate and graduate levels. His recent appointment as a Tier-1 Canada Research Chair in Theoretical and Computational Biology underscores his leadership in the field.\nProfessional Background and Achievements # Anotida Madzvamuse’s academic journey began with a BSc (Hons) from the University of Zimbabwe (1994) and a Masters in Mathematics and Education from the University of Enrique Jose Varona, Cuba (1991). He earned his DPhil (2000) and MSc (1997) in Mathematical Modelling and Numerical Analysis from the University of Oxford. His early career included a postdoctoral fellowship at Oxford and an Assistant Professorship at Auburn University (2003–2006). He then joined the University of Sussex, where he rose through the ranks from Lecturer to Professor of Mathematical and Computational Biology (2006–2022).\nMadzvamuse’s contributions have been recognized with several prestigious awards, including the Royal Society Wolfson Research Merit Award (2016–2021) and the Theodore von Kaman Fellowship from RWTH Aachen University (2013). He has also received multiple grants from the EPSRC and other international funding bodies, totaling over 5 million euros, supporting his research in spatial patterning, cell migration, and computational modeling.\nResearch Areas and Projects # Madzvamuse’s research is characterized by its interdisciplinary nature, combining mathematical modeling, numerical analysis, and computational biology to tackle complex biological questions. His primary research areas include:\nMathematical Modeling and Analysis: Development of bulk-surface-extracellular partial differential equations (PDEs) to model biological processes such as pattern formation and cell motility. Numerical Analysis and Computational Methods: Implementation of finite element and virtual element methods to simulate biological systems. Parameter Inference and Estimation: Techniques to infer parameters from experimental data, enhancing the predictive power of mathematical models. Applications in Biology and Medicine: Collaborations with health experts to model COVID-19 transmission dynamics and other biomedical phenomena. One of his most notable projects involves collaborating with UK health authorities to predict COVID-19 outbreaks using advanced computational models, demonstrating the practical impact of his theoretical work. Additionally, he has organized and led research programs at the Isaac Newton Institute for Mathematical Sciences, fostering international collaboration in mathematical biology.\nMajor Publications # Title Journal Year Link Emergence of Bursting and Delay-Induced Spiral Patterns in Eco-Epidemiological Systems Bulletin of Mathematical Biology 2026 link Using Floquet theory to unravel far-from equilibrium dynamics in reaction-diffusion systems PNAS Nexus 2026 link Pattern Formation of Bulk-Surface Reaction-Diffusion Systems in a Ball SIAM Journal on Applied Mathematics 2026 link Exploring the spatio–temporal dynamics in activator–inhibitor systems through a dual approach of analysis and computation Mathematical Biosciences 2025 link Existence and convergence of stochastic processes underlying a thin layer approximation of a coupled bulk-surface PDE Journal of Differential Equations 2025 link Analysis of the spatio-temporal dynamics of a Rho-GEF-H1-myosin activator-inhibitor reaction-diffusion system Royal Society Open Science 2025 link Parameter Spaces for Cross-Diffusive-Driven Instability in a Reaction-Diffusion System on an Annular Domain International Journal of Bifurcation and Chaos 2025 link Quantifying the organization and dynamics of M. smegmatis morphology from Long-Term Time-Lapse Atomic Force Microscopy openRxiv 2025 link A bulk-surface mechanobiochemical modelling approach for single cell migration in two-space dimensions Journal of Theoretical Biology 2024 link Understanding the dual effects of linear cross-diffusion and geometry on reaction–diffusion systems for pattern formation Chaos, Solitons and Fractals 2024 link VEMcomp: a Virtual Elements MATLAB package for bulk-surface PDEs in 2D and 3D Numerical Algorithms 2024 link Modeling and analysis of the fractional-order epidemic model to investigate mutual influence in HIV/HCV co-infection Nonlinear Dynamics 2024 link A domain-dependent stability analysis of reaction–diffusion systems with linear cross-diffusion on circular domains Nonlinear Analysis: Real World Applications 2024 link The Sussex COVID-19 modelling cell: the methods and successes of a collaboration between public health teams in local authorities, NHS hospital trusts, NHS commissioners, and universities The Lancet 2023 link Virtual element method for elliptic bulk-surface PDEs in three space dimensions Numerical Methods for Partial Differential Equations 2023 link COVID-19 transmission dynamics and the impact of vaccination: modelling, analysis and simulations Royal Society Open Science 2023 link A hospital demand and capacity intervention approach for COVID-19 PLoS One 2023 link Complex dynamics of a discrete-time seasonally forced SIR epidemic model Mathematical Methods in the Applied Sciences 2023 link Awards and Recognitions # Royal Society Wolfson Research Merit Award (2016–2021): Recognizes Madzvamuse’s world-leading research in mathematical and computational biology, including modeling, analysis, numerical analysis, simulations, applications, and inference theory. Theodore von Kaman Fellowship (2013): Awarded by RWTH Aachen University for his significant contributions to mathematical biology. Tier-1 Canada Research Chair in Theoretical and Computational Biology (2022–present): Recognizes his leadership and excellence in the field. EPSRC Awards: Multiple grants supporting his research on spatial patterning and computational modeling. GCRF Award: For the UK-Africa Postgraduate Advanced Study Institute in Mathematical Sciences. Media and Public Engagement # Madzvamuse has actively engaged with the public and media through several platforms.\nA Mathematician Like Me\nAnotida Madzvamuse, a Professor of Mathematics at the University of British Columbia, specializes in applied mathematics with applications in cellular and developmental biology, cancer research, inflammation, and wound healing. His work focuses on creating mathematical models from data and observations that are amenable to rigorous analysis, often involving differential geometry, PDEs, and numerical methods. He emphasizes the predictive power of these models as tools for experimentalists, public health analysts, and other researchers, enabling exploration of scenarios that are experimentally inaccessible. Madzvamuse highlights the importance of resilience and perseverance in securing research funding and overcoming career obstacles, such as promotions and job acquisitions, which he attributes to systemic challenges tied to diversity. He advises early-career mathematicians to believe in their abilities, learn from failures, and persist in their efforts, as success often comes from continuous improvement and determination. His journey reflects a deep commitment to advancing mathematical biology and mentoring the next generation of researchers.\nFrom rural Zimbabwe to international academia\nFeatured in Living Proof Podcast (Isaac Newton Institute).\nProfessor Anotida Madzvamuse, a mathematician and computational biologist at the University of Sussex, shares his extraordinary journey from a rural Zimbabwean village to international academia in this podcast interview. He recounts his early life in a resource-limited environment, where he developed resilience and a passion for mathematics, eventually excelling in school despite hardships. Madzvamuse’s career path includes studying in Cuba, earning advanced degrees at Oxford, and teaching in Zimbabwe before securing positions in the US and UK. His research focuses on mathematical and computational biology, particularly pattern formation in nature and single-cell migration, with applications in cancer biology, wound healing, and COVID-19 modeling. He emphasizes the importance of perseverance, mentorship, and learning from failures, while also highlighting initiatives like the Masamu Program and African Institute for Mathematical Sciences (AIMS), which support African mathematicians. His story underscores the transformative power of education, hard work, and global collaboration in overcoming systemic barriers.\nThe mathematics of cells walking through complex environments:\nAbstract: Known as the smallest biological entity, the cell, is fundamental to life, human or otherwise. Unlike humans, animals and many other living organisms, the cell has no legs, head nor tail, yet cells have a remarkable ability to polarise and exhibit the front and back, associated with human mobility, during migration in complex environments such as in blood, tissue or during disease, such as cancer or during the wound healing process. In this presentation, Prof Anotida Madzvamuse will demonstrate the crucial role of mathematics to help understand how cells walk through complex environments. He will also present current challenges where mathematics has a pivotal role to help lead future discoveries.\nModels for growth development in cell motility and pattern formation:\nProfessor Anotida Madzvamuse discusses the integration of geometric partial differential equations (PDEs) with physics to model cell morphology, motility, and pattern formation, emphasizing the coupling of models for pattern formation and cell motility. He highlights the importance of deriving models driven by experimental observations and physical laws, aiming to create predictive models that can guide and validate experiments. Madzvamuse explores the challenges of coupling interior, surface, and extracellular dynamics, particularly in the context of cell migration and pattern formation on evolving domains. He presents mathematical frameworks, including reaction-diffusion systems with cross-diffusion and domain growth, to relax classical Turing instability conditions, allowing for more flexible and biologically relevant modeling. The talk also touches on viscoelastic models for cell motility, the role of actin concentrations, and the need for experimental validation to refine and calibrate these theoretical models.\nBlack Excellence in STEM Speaker Series at UBC:\nPresented on “Unraveling the Mathematics of Single-Cell Dynamics,” sharing his research and experiences with a broad audience.\nResearch Profiles # UBC Department of Mathematics Profile\nResearchGate Profile\nICIAM 2027 Biography\nLinkedIn Profile\nGoogle Scholar Profile\nLoop Profile\nReferences # UBC News on CRC Appointment\nBlack Excellence in STEM Speaker Series\nUBC Department of Mathematics Faculty Page\nSussex Profile\nNewton Gateway\n","date":"2026-05-22","externalUrl":null,"permalink":"/network/scientists/anotida-madzvamuse/","section":"Network","summary":"UBC professor specializing in mathematical and computational biology, pattern formation, and cell motility.","title":"Anotida\u003cbr\u003eMadzvamuse","type":"network"},{"content":"","date":"2026-05-22","externalUrl":null,"permalink":"/tags/canada-research-chair/","section":"Tags","summary":"","title":"Canada-Research-Chair","type":"tags"},{"content":"","date":"2026-05-22","externalUrl":null,"permalink":"/tags/cell-motility/","section":"Tags","summary":"","title":"Cell-Motility","type":"tags"},{"content":"","date":"2026-05-22","externalUrl":null,"permalink":"/tags/computational-biology/","section":"Tags","summary":"","title":"Computational-Biology","type":"tags"},{"content":"","date":"2026-05-22","externalUrl":null,"permalink":"/tags/covid-19-modeling/","section":"Tags","summary":"","title":"Covid-19-Modeling","type":"tags"},{"content":"","date":"2026-05-22","externalUrl":null,"permalink":"/tags/mathematical-biology/","section":"Tags","summary":"","title":"Mathematical-Biology","type":"tags"},{"content":"","date":"2026-05-22","externalUrl":null,"permalink":"/tags/pattern-formation/","section":"Tags","summary":"","title":"Pattern-Formation","type":"tags"},{"content":"","date":"2026-05-22","externalUrl":null,"permalink":"/tags/ubc/","section":"Tags","summary":"","title":"Ubc","type":"tags"},{"content":" Glossary # Modern glossary setup for NAM\nCredit: Mistral NAM Terminology # A curated list of key terms with supporting links related to New Approach Methodologies (NAM) in toxicology, safety assessment, and related fields. Each term includes a brief definition and a link for further reading.\nTerm Definition Resource Adverse Outcome Pathway (AOP) A conceptual framework that describes the sequential biological events leading to an adverse effect, linking a molecular initiating event to an adverse outcome. Link Alternative Methods Approaches that replace, reduce, or refine the use of animals in testing (eg toxicology), including in vitro, in silico, and in chemico methods. Link Computational Toxicology The use of computer-based models, algorithmic frameworks, and simulations to predict chemical toxicity and clarify biological mechanisms of action. Link CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) A precision gene-editing technology used in modern safety assessment to establish direct causal links within Molecular Initiating Events (MIEs) and Adverse Outcome Pathways (AOPs). Rather than relying on animal models, researchers use CRISPR-Cas9/Cas12 systems to knock out, knock down, or overexpress specific human genes in vitro. This allows for high-throughput screening of cellular vulnerabilities, validating exactly which human proteins or genomic pathways are targeted by a chemical toxicant. link Defined Approaches (DA) A regulatory assessment framework consisting of a fixed data interpretation procedure applied to a predefined set of information sources, removing subjective expert judgment. Link Exposure Assessment The process of estimating or measuring the magnitude, frequency, and duration of exposure to a chemical or physical agent within a human or ecological population. Link High-Throughput Screening (HTS) The use of automated robotics, liquid handling, and miniaturized microfluidic assays to rapidly test thousands of chemical substances against biological targets to generate massive, human-relevant data profiles using high-capacity computational analysis. Link In Chemico Abiotic, non-cellular chemical assays used to measure direct chemical reactivity or physical-chemical properties (eg protein binding potential). Link In Silico Advanced computational models, simulations, or structural algorithms—such as QSARs, machine learning, or molecular docking—used to predict bioactivity. Link In Vitro Biological assays conducted outside of a living organism, utilizing cultured cells, tissue slices, or isolated human organs in a highly controlled environment. Link Integrated Approaches to Testing and Assessment (IATA) A flexible, science-based approach combining multiple data sources (eg in silico, in vitro, exposure profiles) to evaluate safety, allowing expert judgment to guide weight of evidence. Link Key Event (KE) An intermediate, measurable biological change within an Adverse Outcome Pathway that is essential for the progression toward an adverse health effect. Link Mechanistic Toxicology The scientific study of how specific chemical substances interact with cellular systems at the molecular or physiological level to induce toxic outcomes. Link Microphysiological Systems (MPS) Bioengineered microfluidic devices that mimic the complex structural, mechanical, and functional architecture of human organ systems (\u0026ldquo;organs-on-chips\u0026rdquo;). Link Molecular Initiating Event (MIE) The initial site of direct, causal interaction between a chemical substance and a biological target (eg cell receptor binding) that triggers an Adverse Outcome Pathway. Link New Approach Methodologies (NAM) A comprehensive term encompassing non-animal testing strategies, including computational tools, cellular assays, and biochemical technologies used for safety evaluation. Link Omics Technologies High-throughput molecular profiles that evaluate comprehensive shifts within biological systems, spanning genomics, transcriptomics, proteomics, and metabolomics. Link Physiologically Based Pharmacokinetic (PBPK) Modeling Mathematical modeling frameworks that map the absorption, distribution, metabolism, and excretion (ADME) profiles of chemical compounds through actual physiological compartments. Link Quantitative Structure-Activity Relationship (QSAR) Mathematical and statistical predictive models that relate a chemical\u0026rsquo;s explicit molecular structure to its specific biological activity or chemical toxicity. Link Read-Across A computational technique where endpoint data from a known, well-characterized \u0026ldquo;source\u0026rdquo; chemical is used to predict the toxicity profile of a structurally similar \u0026ldquo;target\u0026rdquo; chemical. Link Risk Assessment The quantitative or qualitative evaluation determining the likelihood and severity of adverse health or ecological effects resulting from real-world exposure to chemical hazards. Link Safety Assessment via NAM The practical deployment of non-animal predictive data to define clinical safety margins, product efficacy, or chemical hazard classifications for regulatory clearance. Link Toxicokinetics The study of how a chemical is absorbed, distributed, metabolized, and excreted (ADME) over time. In modern NAM, traditional animal-based measurements are entirely replaced by coupling human-derived cell assays (eg in vitro hepatic clearance) with advanced computational modeling (eg in vitro-to-in vivo extrapolation, or IVIVE) to predict chemical behavior and safe exposure levels inside a virtual human system. Link Virtual Tissue Models Multi-scale computational computer models that simulate how chemical perturbations alter human organ development, tissue morphology, and homeostatic cellular functions. Link Weight of Evidence (WoE) A structured framework to qualitatively or quantitatively assess the cumulative alignment, scientific robustness, and logical consistency of multiple distinct data streams. Link AI Terminology Relevant to NAM # The diagram below illustrates exactly how specific computational tools provide the front end of the drug discovery and toxicity pipeline by processing massive chemical and molecular data repositories.\nSome AI components at frontend of NAM\n(Click image for larger view)\nCredit: Gemini Term Specific NAM-Context Definition Resource Active Learning (AL) An iterative machine learning strategy where the algorithm selects the most informative uncharacterized chemicals for experimental in vitro testing to optimize predictive power with minimal assays. Link Applicability Domain (AD) The structural, physico-chemical, and response space defined by the training set of a computational model, establishing the boundaries within which a toxicity prediction is reliable. Link Deep Learning (DL) A subset of machine learning using multi-layered neural networks to automatically extract complex features from raw biochemical data, such as predicting organ-level toxicity from high-content cell imaging. Link Explainable AI (XAI) Machine learning methodologies designed to make the internal algorithmic decision-making process transparent, crucial for verifying the biological plausibility of a predicted toxic mechanism for regulatory clearance. Link Features Measurable variables and characteristics used as inputs for a model to make predictions. Link Generative AI AI frameworks (eg variational autoencoders) used to generate entirely new chemical structures (eg De Novo Molecular Design) with optimized, target-specific therapeutic properties while intentionally designing out structural alerts for toxicity. Link Graph Neural Networks (GNN) Deep learning architectures that operate directly on graphs, mapping chemical structures as networks of atoms (nodes) and bonds (edges) to predict molecular reactivity and target binding without manual feature descriptors. Link Knowledge Graph (KG) A structured database network representing complex biological relationships (eg linking genes, proteins, diseases, and chemical stressors) to discover hidden mechanistic pathways and assist in AOP generation. Link Machine Learning (ML) Algorithms that detect statistical patterns in extensive toxicology datasets (eg ToxCast) to classify compounds as hazardous or safe based on historic in vitro profiles without explicit biochemical programming. Link Large Language Models (LLMs) in Bio Domain-specific foundational models trained on scientific literature and chemical structural languages (like SMILES strings) to synthesize data, extract toxicity endpoints, or predict molecular behavior. Link Multi-Omics Integration Computational frameworks designed to align and process parallel high-throughput datasets (genomics, transcriptomics, metabolomics) to map an organism\u0026rsquo;s holistic cellular response to a xenobiotic. Link SMILES (Simplified Molecular Input Line Entry System) A linear ASCII string notation used to describe chemical structures, serving as the primary text-based input format for chemical datasets parsed by machine learning models. Link Transfer Learning An ML technique where a model trained on a massive, general chemical dataset applies its learned structural knowledge to a smaller, highly specific target toxicity dataset where data is scarce. Link ","date":"2026-05-21","externalUrl":null,"permalink":"/resources/glossary/","section":"Resources","summary":"Explore essential NAM terminology—from Adverse Outcome Pathways (AOPs) to Virtual Tissue Models—with clear definitions and authoritative resources.","title":"Glossary","type":"resources"},{"content":"","date":"2026-05-21","externalUrl":null,"permalink":"/tags/terminology/","section":"Tags","summary":"","title":"Terminology","type":"tags"},{"content":"","date":"2026-05-21","externalUrl":null,"permalink":"/tags/terms/","section":"Tags","summary":"","title":"Terms","type":"tags"},{"content":"","date":"2026-05-19","externalUrl":null,"permalink":"/tags/action/","section":"Tags","summary":"","title":"Action","type":"tags"},{"content":"","date":"2026-05-19","externalUrl":null,"permalink":"/tags/advocacy/","section":"Tags","summary":"","title":"Advocacy","type":"tags"},{"content":" NAMIFY # NAM Inspiring Formidable Youth Get Canada to catch up\nIt\u0026rsquo;s up to you!\nCredit: Gemini This about Canada\u0026rsquo;s future and your future! This page provides an action-oriented guide for students (as well as guardians, school teachers, professors, and progressive politicians) to lift this country\u0026rsquo;s bio-science education out of the \u0026ldquo;dreary desert sand of dead habit\u0026rdquo; into a new awakening!\nWhy This Matters to You # For Students: Canada Is Falling Behind - Don’t Get Left Out # Right now, Canada is skipping the future of science. While other countries invest millions in New Approach Method (NAM) - modern, ethical, and cutting-edge methods - Canada still teaches students to dissect frogs and cats, as well as rely on outdated animal testing.\nNAM isn’t just about ethics. It’s about staying competitive.\nThe Netherlands invests €124.5 million to train scientists in NAM. The U.S. dedicates $150 million USD to develop alternatives to animal testing. Where is Canada? Nowhere. If you’re studying biology, medicine, or toxicology, you’re being trained for an industry that’s already moving on. Companies like Mimetas, Emulate Bio, and AstraZeneca use organ-on-a-chip and computational toxicology. Will you be ready?\nFor Parents: Your Child’s Education Is Outdated # Your kids are growing up in a world where:\nAI and computer models predict drug safety. Miniature human organs grown in labs replace animal testing. 3D bioprinting creates ethical research alternatives. But in most Canadian schools, they’re still:\nCutting up frogs against their will. Forced to participate in harming animals. Taught using methods that are 50 years out of date. NAM isn’t just about science - it’s about human rights, career readiness, and global competitiveness.\nWhat Is NAM? # NAM stands for New Approach Methodologies - modern tools replacing animal testing. Here’s what it includes:\nNAM Type What It Is Why It’s Better Computational Toxicology Uses AI and computer models to predict chemical safety. Saves money, time, and animal lives. Organ-on-a-Chip Miniature human organs grown in labs for testing. More accurate than animal testing. In Silico Modeling Simulates biological processes using software. Reduces reliance on live animals. 3D Bioprinting Prints living tissues for research. Allows for precise, ethical experimentation. NAM is already used by top researchers worldwide - but rarely in Canadian classrooms.\nReal Stories: Youth Taking Action # Case Study 1: Windsor-Essex Catholic School Board # In 2019, this school board banned dissection and replaced it with virtual simulations and synthetic models. Why? Because students demanded it.\n\u0026ldquo;I refused to dissect a frog because it felt wrong. My teacher said I had to, but I stood my ground. Now, no one else has to either.\u0026rdquo;\nMaria, Grade 11 Student Case Study 2: University of Toronto’s Organ-on-a-Chip Course # This graduate-level course teaches students how to engineer miniaturized human organs for research. But it’s only for engineering students - not biology or toxicology majors.\n\u0026ldquo;I wish I had learned this in undergrad. These tools are the future of medicine.\u0026rdquo;\nJordan, Biology Student Case Study 3: Dutch NAM Hub # The Netherlands invested €124.5 million to create the Centre for Animal-Free Biomedical Translation (CPBT), a national hub training scientists in NAM. (In contrast, Canada caused its only \u0026rsquo;national hub\u0026rsquo; Canadian Centre for Alternatives to Animal Methods to close through lack of funding.)\nThe Quick Start Guide: How YOU Can Make a Difference # For Students: Petition for Change # Learn About NAM Watch: TED Talk: The Future of Animal-Free Science Read: NAM 101 for Students Explore: Virtual Labs and Simulations Talk to Your Teacher Ask: \u0026ldquo;Why are we still using dissection when modern tools exist?\u0026rdquo; Share: This Letter Template to request alternatives. Propose: A guest speaker (eg a NAM researcher) or a debate on the topic. Start a NAM Club Recruit 5+ friends. Host screenings of documentaries like \u0026ldquo;Saving the World’s Animals\u0026rdquo; (BBC). Write to your MP using this template. Organize a petition to demand NAM training in your school. Advocate Beyond School Share on social media: Use #NextGenNAM and tag your school. Write for your school newspaper. Join a youth network (eg NAM Youth Canada). Demand Policy Change Petition for mandatory computational/NAM training in your major. Write to your university president and MP. For Teachers: Demand Robust Alternatives # Advocate for Updated Curricula Demand that dissection alternatives are robust and standardized, not just \u0026ldquo;optional supplements.\u0026rdquo; Push for the integration of computational toxicology and organ-on-a-chip into your department’s courses. Bring NAM into Your Classroom Use virtual labs and simulations (eg Labster). Invite NAM researchers to speak to your students. Organize a debate on the ethics of animal testing vs. NAM. Join the Movement Sign the petition to demand federal funding for NAM education. Share resources with colleagues (eg NAM Toolkit for Teachers). For Parents: Support Modern Science Education # Advocate for Updated Curricula Write to your child’s school board and demand digital alternatives to dissection. Push for the integration of NAM concepts into science courses. Encourage Ethical Choices If your child objects to dissection, support their right to opt out without penalty. Share resources like this guide with other parents. Demand Policy Change Write to your MP and provincial education minister to demand NAM funding. Support organizations advocating for modern science education (eg Vancouver Humane Society). For Politicians: Create the Future of Canadian Science # Establish a Dedicated Federal NAM Funding Body Model it after the U.S. NIH Complement-ARIE or Dutch CPBT. Allocate $50 million CAD annually for NAM research and education. Fund the \u0026ldquo;Pathways to Alternatives\u0026rdquo; Budget Direct funds to Health Canada’s CEPA implementation to ensure NAM are prioritized. Train regulatory scientists in computational toxicology and organ-on-a-chip. Reform Academic Granting Councils Eliminate bias in CIHR/NSERC peer review toward animal-based research. Create dedicated NAM funding streams for early-career researchers. The Big Picture: Why Canada Must Act Now # Stay Competitive # Other countries are investing millions in NAM. If Canada doesn’t catch up:\nStudents won’t be prepared for modern careers. Researchers will leave for countries with better funding. Canada will fall behind in ethical, cutting-edge science. Lead with Human Rights # Forcing students to dissect against their beliefs is unethical and unnecessary. NAM offers a humane, accurate, and modern alternative.\nBuild the Future # NAM isn’t just about replacing animal testing - it’s about training the next generation of scientists to use the tools of the future.\nYour Call to Action # Canada’s future in science depends on YOU.\nSign the petition to demand NAM education: [Link] Share this guide with 3 friends. Write to your MP today: [Template Link] \u0026ldquo;The youth of today will shape the science of tomorrow. Let’s make sure it’s ethical, modern, inclusive, and innovative!\u0026rdquo;\n","date":"2026-05-19","externalUrl":null,"permalink":"/projects/youth/namify/","section":"Projects","summary":"Learn about NAM, why it matters, and how you can drive change in Canadian bio-science education.","title":"NAMIFY\u003cbr\u003eA Youth Guide to NAM Bioscience","type":"projects"},{"content":" RAISE # Resources Altering Ingrained School Education Resources of various kinds\nCredit: Gemini There are several resources here\nFAQ Petition Strategy Email MP so far with more to come. The Table Of Contents is useful for navigating this page.\nFAQ # Canadian Bioscience Education is stuck in the past.\nWhat Can You Do About It?\nQ1. Why are Canadian students still dissecting animals in 2026? # Canadian science curricula remain heavily reliant on traditional, animal-based methods due to outdated provincial standards, lack of funding for modern alternatives, and slow adoption of New Approach Methodologies (NAM). While countries like the Netherlands and the US are phasing out dissection in favor of digital simulations, organ-on-a-chip models, and AI-driven tools, Canada’s curriculum revision cycles (often 5–10 years) and underfunded teacher training delay progress. There is also no dedicated federal funding body for NAM integration in education, unlike in the EU or UK.\nQ2. How does this compare to other countries? # Canada is falling behind. The Netherlands has banned animal dissection in secondary schools, the US FDA now accepts NAM-based data for drug approvals, Australia runs a national non-animal research service, and the UK invests in national NAM training hubs. In contrast, Canadian universities and high schools still treat dissection as a \u0026ldquo;rite of passage\u0026rdquo;, despite evidence that NAM (eg virtual labs, 3D modeling) often yield better learning outcomes and align with ethical, cost-effective, and scientifically superior practices.\nQ3. Why hasn’t Canada adopted NAM faster? # Three key barriers:\nFunding gaps: Provincial education budgets prioritize existing infrastructure (eg animal labs) over NAM tools, which require upfront investment in software, hardware, and teacher training. For example, Ontario’s 2025–26 education funding gap is $1.3 billion, with no earmarked funds for modernizing science labs. Regulatory inertia: Health Canada and Environment Canada have no mandatory NAM adoption policies for education, unlike the FDA or EMA, which now require NAM consideration in toxicology and drug development. Awareness: Many educators and policymakers are unaware of NAM potential or mistakenly believe animal models are the \u0026ldquo;gold standard,\u0026rdquo; despite growing evidence to the contrary. Q4. What are NAM, and why are they better? # New Approach Methodologies (NAM) are non-animal, human-relevant tools like:\nIn silico models (computer simulations of biological processes). Organ-on-a-chip (miniature organs that mimic human physiology). AI/ML-driven data analysis (predicting toxicity or disease mechanisms). Virtual dissection (interactive 3D models of anatomy). Advantages:\nMore accurate: Human-based models better predict human responses than animal tests. Ethical: No animal suffering or environmental harm. Cost-effective: Reduces long-term costs (eg no need for animal facilities). Future-proof: Aligns with global industry standards (eg pharmaceutical companies now prefer NAM for drug development). Q5. How does this affect students’ futures? # Students trained in outdated methods risk being unprepared for modern careers in:\nBiotech/pharma: Companies like Moderna and Pfizer use NAM for drug discovery. Regulatory science: Agencies (eg FDA, EMA) increasingly require NAM data for approvals. Academic research: Top journals (eg Nature, Science) prioritize human-relevant studies.\nResult: Canadian graduates may lack competitive skills, while their peers abroad gain hands-on experience with cutting-edge tools. Q6. What can students do? # Demand change: Petition your school/universities to replace dissection with NAM (eg virtual labs like BioDigital Human or Visible Body). Start a NAM club: Organize workshops, invite speakers, and collaborate with groups at school, university, industry levels. Use free NAM tools: Explore open-access platforms like PhysioEx or iBiology for self-learning. Advocate for policy: Write to your MP (use templates from RAISE to demand federal funding for NAM education. Q7. What can parents/guardians do? # Ask schools: Inquire if your child’s science classes use animal-free alternatives and request transparency on curriculum modernisation plans. Support NAM initiatives: Donate to or volunteer with organizations pushing for NAM adoption (eg Humane Canada). Lobby policymakers: Urge your MP and provincial representatives to allocate funds for NAM training and resources in schools. Q8. What can teachers do? # Adopt NAM now: Use free or low-cost tools (eg HHMI BioInteractive) to supplement or replace dissection. Advocate for resources: Push school boards to fund NAM software/hardware and provide professional development for teachers. Collaborate: Partner with universities or biotech companies to access NAM labs or guest lectures. Q9. What can politicians do? # Create a federal NAM funding body: Dedicate $50M/year (a fraction of Canada’s $25B+ sector strategy investments) to: Subsidize NAM tools for schools. Train teachers in NAM methods. Fund research on NAM efficacy in education. Mandate NAM inclusion: Require provincial curricula to phase out animal dissection by 2030, replacing it with NAM. Incentivize universities: Tie research grants to NAM adoption in undergraduate programs. Q10. Are NAM really as effective as animal models? # Yes - and often more so. Studies show:\nVirtual dissection improves spatial reasoning and retention better than traditional labs. (See Dissection in the 21st century, Effectiveness and satisfaction with virtual and donor dissections, Bridging Technology and Tradition (Human cadavers)) Organ-on-a-chip models predict human drug responses more accurately than animal tests (eg 30% of drugs passing animal tests fail in human trials, Is it Time, Revolutionizing Drug Discovery, The potential of multi-organ-on-chip). Cost savings: Schools in the US saved 40–60% by switching to digital labs (eg zSpace). Q11. What’s the biggest myth about NAM? # \u0026ldquo;NAM are just ‘alternatives’ - not as good as the real thing.\u0026rdquo;\nReality: NAM are not alternatives - they’re superior tools for human-relevant science. The term \u0026ldquo;alternative\u0026rdquo; implies a compromise, but NAM are the future of bioscience. The EU and US are shifting to NAM not for ethical reasons alone, but because they work better.\nDownload this FAQ pdf\nPetition Strategy # Momentum Flow Diagram for NAM Implementation\n(Click image for larger view)\nCredit: Gemini The diagram for NAM Momentum Flow displays a 4-step weather analogy model to illustrate how grassroots pressure translates into national change. The movement flows linearly from the ground up, with key Triggers causing phase changes that advances the campaign.\nThermal Activation (Grassroots Ground Level): The cycle starts with individualized energy. Students, teachers, parents, and industry (represented as water molecules) form a movement, organizing locally to generate collective \u0026lsquo;heat\u0026rsquo;.\nUpdraft \u0026amp; Lift (School Board Level): The concentrated local heat creates a thermal updraft. This movement lifts the petition off the ground and focuses its pressure onto institutional bodies, like local School and University Boards.\nCondensation (Provincial Level): As regional updrafts coalesce, they become highly visible and structured. At this provincial level, disparate efforts condense into formal, recognized frameworks and regional alignment.\nSaturation \u0026amp; Precipitation (National Level): Pressure from all provinces hits a tipping point, creating a high-pressure national saturation front. The status quo becomes unsustainable, and the dark cloud breaks.\nPolicy Rains Down: A uniform National Policy and Curricula pours evenly across the entire country, standardizing education to modern levels, and replenishing the very level where the movement began \u0026hellip; and then some!\nKey Considerations for Maximum Impact\nTailor the Language\nFor administrators/trustees: Focus on cost savings, modernizing education, and student outcomes.\nFor students/parents: Emphasize ethics, career readiness, and global competitiveness.\nFor politicians: Highlight economic benefits, innovation, and alignment with international standards. Leverage Existing Networks\nPartner with youth organizations for student petitions.\nCollaborate with teacher unions for school board/trustee petitions.\nEngage industry associations for university/federal petitions. Combine with Other Actions\nAttach sample letters to MPs to petitions.\nInclude links to NAM resources (eg infographics, FAQs) to educate signatories.\nUse social media campaigns (eg #NAMNOW) to amplify reach. Follow-Up Plan:\nDeliver petitions in person (eg at school board meetings, MP offices).\nRequest formal responses from targets (eg \u0026ldquo;Will you commit to reviewing NAM adoption by [date]?\u0026rdquo;).\nPublicize results (eg \u0026ldquo;10,000 students demand NAM in BC schools!\u0026rdquo;). Printable Petitions\nThere are 6 types of petitions templates below. Each will be available as RTF files so anyone can open and customize them (ie put in school name and logo).\nView a sample\nDownload an RTF file.\nPetition for High School Administrators # Target: Principals, vice-principals, science department heads.\nGoal: Replace animal dissection with NAM alternatives (eg virtual labs, organ-on-a-chip models) in high school biology curricula.\nSignatory: Students (especially those in biology/chemistry classes); Parents (concerned about ethical education and career readiness); Teachers (science educators wanting to modernizing their classrooms); Alumni (former students who can attest to the limitations of dissection).\nRationale: High school administrators respond to parental and student demand. A petition with signatures from both groups demonstrates grassroots support and can prompt policy reviews.\nPetition for School Trustees/Boards # Target: Elected school board trustees.\nGoal: Allocate funding for NAM tools (eg software licenses, teacher training) and update science curriculum standards to prioritize NAM.\nSignatory: Parents (voting constituents in school board elections); Community members (local advocates, ethical science organizations); Students (especially those in STEM tracks); Teachers’ unions (to show professional support).\nRationale: Trustees are directly accountable to voters and can influence budget allocations and curriculum adoption at the district level. A large, diverse group of signatories (parents + teachers) carries weight.\nPetition for University Administrators # Target: Bio-science faculty deans and department chairs.\nGoal: Phase out animal dissection in undergraduate programs and integrate NAM into research and teaching labs.\nSignatory: Students (especially in biology, pharmacology, and pre-med programs); Faculty (researchers and professors in relevant departments); Alumni (working in biotech/pharma, who can highlight industry demand for NAM skills); Industry partners (eg local biotech companies, pharmaceutical reps)\nRationale: Universities are competitive - if peer institutions (eg UofT, UBC, McGill) adopt NAM, others may follow to avoid falling behind. Student and faculty signatures show internal demand, while industry support underscores career relevance.\nPetition for Provincial Ministries of Education # Target: Provincial ministers of education and curriculum development teams.\nGoal: Mandate NAM inclusion in K–12 science curricula and ban dissection in public schools by 2030.\nSignatory: Parents (across the province); Teachers (via unions or professional associations); Student councils (provincial-wide youth organizations); Advocacy groups (eg Humane Canada)\nRationale: Provincial petitions scale impact - a single policy change can affect all schools in a province. Signatures from teachers’ unions and parent councils add credibility.\nPetition for Federal MPs and the Ministry # Target: Federal MPs, the Minister of Industry (innovation, science, economic), and Health Canada.\nGoal: Establish a dedicated federal funding body for NAM education (eg $50M/year for tools, training, and research) and tie federal research grants to NAM adoption in universities.\nSignatory: National organizations (eg Canadian Federation of Students, Humane Canada); Scientists/researchers (from universities and industry); Industry leaders (CEOs of biotech/pharma companies); General public (via online campaigns)\nRationale: Federal petitions create national momentum. Signatures from industry leaders and researchers demonstrate that NAM is a scientific and economic priority, not just an ethical one.\nPetition for University Student Unions # Target: Student union executives and general assemblies.\nGoal: Pressure universities to adopt NAM in coursework and provide dissection opt-outs for students.\nSignatory: Undergraduate students (especially STEM track); Student clubs (eg pre-med societies, animal rights groups); Graduate students (in biology, toxicology, etc.)\nRationale: Student unions have direct influence over university policies. A petition with thousands of student signatures can force administrative action.\nEmail your Member of Parliament # To find your MP, type in your postal code here.\nIt is important to email your MP and get your circle to do it too. MPs may act on behalf of their constituents provided there is enough volume coming in on a topic. Quantity is very important in order to get many politicians to take action.\nBe prepared to email more than once. MPs reply personally or through a communications assistant, with a response time that varies between hours, days, weeks, eternities (aka never). The replies can be standard \u0026ldquo;we will carefully consider your request\u0026rdquo;, to ones that show your email has actually been read and contemplated.\nDo not make assumptions based on political party lines - MPs are individuals and may respond positively or negatively when you least expect it. Do not take things personally - your job is to voice your concern, and not be attached to failure or success.\nYou may already know exactly what you are going to write, but if you don\u0026rsquo;t, here are some sample letters that may inspire the Pulitzer in you! The letters are identified by tone (depending on how you are feeling): courteous, pleasant, friendly, urgent, and sycophantic.\n(Images below are from Xoom stock collection.)\nCourteous # Subject: Requesting Support for Modernizing Bioscience Education\nDear [MP’s Name],\nI hope this message finds you well. As a constituent and science student, I respectfully urge your consideration of New Approach Methodologies (NAM) to modernize Canadian bioscience curricula. While animal dissection remains a common practice, NAM - such as virtual labs and organ-on-a-chip models - offer more accurate, ethical, and cost-effective alternatives. These tools align with global best practices and prepare students for careers in biotech, pharmaceuticals, and regulatory science. For instance, the Netherlands and the US are already phasing out dissection; Canada risks falling behind.\nI kindly ask that you take and support initiatives to integrate NAM into education, including dedicated federal funding for teacher training and curriculum modernization. Thank you for your time and commitment to a forward-thinking education system and hope to hear from you soon.\nSincerely,\n[Your Name]\n[Contact Information]\nPleasant # Subject: A Quick Note on Upgrading Science Education\nHello [MP’s Name],\nI hope you’re having a great day! I wanted to share a thought: Canadian bioscience education could be better if it embraced New Approach Methodologies (NAM). Right now, many schools still use animal dissection - an outdated practice that limits students’ exposure to modern tools. Many universities still adhere to the animal-model which is inaccurate and costly.\nNAM, using virtual labs and AI-driven simulations, provides more accurate, less expensive, and more engaging learning experiences. It’s a win-win: students gain skills for future careers, and we align with countries like the US, Australia, and Netherlands. Would you be open to discussing how we can make this happen? I’d love to help with this initiative so please get back to me on this important matter!\nBest regards,\n[Your Name]\n[Contact Information]\nFriendly # Subject: Let’s Update Science Education - Together!\nHi [MP’s Name],\nGreetings! I wanted to chat about something that matters to many of us: making sure Canadian students learn bioscience the smartest way possible. Right now, most schools still rely on animal dissection - something that feels more like the 1990s than the 2020s!\nNew Approach Methodologies (NAM) are the future: they’re safer, more accurate, and way more exciting than traditional labs. Imagine if Canadian students had access to the same cutting-edge tools their peers in the US or Europe use - it could make a huge difference in their careers and our country’s scientific edge!\nI’d love to brainstorm how we can push for this change. Let me know if you’re interested in learning more or teaming up with advocates who can help make it happen.\nCheers,\n[Your Name]\n[Contact Information]\nUrgent # Subject: Canada Is Falling Behind - Act Now on NAM Education!\nDear [MP’s Name],\nTime is running out! Canada’s students are being left behind because our bioscience education relies on animal models - an outdated and scientifically inferior practice. New Approach Methodologies (NAM) are the solution: they’re more accurate, cost-effective, and aligned with global standards. The US and Europe are already phasing out animal usage in research; if we don’t act now, Canadian graduates will lack the skills needed for modern careers in biotech and regulatory science.\nI urge you to:\nSupport federal funding for NAM tools and teacher training. Advocate for NAM inclusion in provincial curricula. Push Health Canada to prioritize NAM adoption. This isn’t just about ethics - it’s about competitiveness and the future of Canadian science. The window for change is closing. Will you lead the charge?\nPlease reply back, and let\u0026rsquo;s make this change come about.\nSincerely,\n[Your Name]\n[Contact Information]\nSycophantic # Subject: A Humble Plea for Visionary Leadership in Education\nDear Most Honourable [MP’s Name],\nMay this letter find you in radiant health and boundless inspiration, for your leadership shines as a beacon of progress in our great nation. As a devoted constituent and admirer of your unwavering dedication to innovation, I humbly submit this plea for your esteemed support in a matter of profound importance: the urgent modernization of Canada’s bioscience education.\nYour visionary stance on ethical and forward-thinking policies is renowned. I implore you to champion the adoption of New Approach Methodologies (NAM) in our schools. These groundbreaking, human-relevant tools - already embraced by global leaders - offer unparalleled accuracy, cost-efficiency, and moral integrity. By phasing out the animal model in favor of NAM, Canada can rise as a global leader in ethical, competitive science education.\nI have no doubt that, under your sagacious guidance, Canada will illuminate the path toward a brighter, more humane future for our youth. Thank you for your extraordinary service.\nWith deepest reverence and admiration,\n[Your Name]\n[Contact Information]\n","date":"2026-05-19","externalUrl":null,"permalink":"/projects/youth/raise/","section":"Projects","summary":"Access petitions, sample letters, infographics, and more to drive change in Canadian science education.","title":"RAISE\u003cbr\u003eMaterials to Facilitate Action","type":"projects"},{"content":"","date":"2026-05-19","externalUrl":null,"permalink":"/tags/stem/","section":"Tags","summary":"","title":"Stem","type":"tags"},{"content":"","date":"2026-05-19","externalUrl":null,"permalink":"/tags/tools/","section":"Tags","summary":"","title":"Tools","type":"tags"},{"content":"","date":"2026-05-19","externalUrl":null,"permalink":"/tags/youth/","section":"Tags","summary":"","title":"Youth","type":"tags"},{"content":" Aravindhan Ganesan MSc PhD # Dr. Aravindhan Ganesan is Research Assistant Professor at University of Waterloo’s School of Pharmacy He is a leading expert in computational molecular biosciences and drug discovery His work bridges molecular pharmacology, computational tool development, and structural biology, with applications in neurodegeneration, cancer, and COVID-19 therapeutics. Dr. Aravindhan Ganesan\nUniversity of Waterloo\nCredit: uwaterloo.ca Introduction # Dr. Ganesan’s research focuses on molecular recognition, small molecule therapeutic design, and advanced computational tools for in silico structural biology. His multidisciplinary approach combines molecular dynamics simulations, in silico mutagenesis, and protein-protein modeling to unravel biological events at the molecular level, enabling rational drug design.\nProfessional Background and Achievements # Education # PhD in Computational Chemistry Swinburne University of Technology, Melbourne, Australia (2008–2012) Thesis: Structure-property relationships of amino acids.\nMSc in Bioinformatics Annamalai University, India (2002–2007)\nPostdoctoral Research # German Research School of Simulation Sciences, Jülich, Germany Fellowship: Deutscher Akademischer Austauschdienst (DAAD) (2011–2012) Australian National University, Canberra, Australia Fellowship: Endeavour Postdoctoral Research Fellowship (2014) Current Positions # Research Assistant Professor University of Waterloo, School of Pharmacy Assistant Professor Wilfrid Laurier University, Department of Chemistry and Biochemistry Research Focus # Key Areas # Molecular Recognition in Biological Systems\nComputational methodologies for cannabinoid receptor pharmacology. Aggregation of hnRNPA1 proteins in multiple sclerosis. Small Molecule Therapeutics\nNeurodegeneration, cancer, and COVID-19 drug design. Novel scaffolds (eg 4501-series, N17-series) targeting CTLA-4 and PD-L1 pathways in cancer immunotherapy. Computational Tools for Structural Biology\nMolecular dynamics simulations and protein-protein modeling. SARS-CoV-2 Mpro inhibitors: Identified the role of a lateral pocket in enhancing ligand affinity for antiviral drug development. Collaborations # University of Waterloo: Primary affiliation for research programs. Indian Institutions: Pondicherry University, PSG Institute of Advanced Studies, Chettinad Academy of Research \u0026amp; Education. Industry: Applied Pharmaceutical Innovation Quantum Research: Institute for Quantum Computing. Awards and Honors # German DAAD Research Fellowship (2011–2012) Australian Endeavour Postdoctoral Fellowship (2014) NSERC Discovery Grant (Cannabinoid receptor pharmacology) New Frontiers in Research Fund-Exploration Grant (hnRNPA1 protein aggregation) Canada First Research Excellence Fund (CFREF-TQT) (Computational drug discovery) Cancer Research Society Operating Grant (Small molecule inhibitors of VISTA for cancer immunotherapy) Publications # Title Journal Year Link Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of a lateral pocket in enhancing the ligand affinity Scientific Reports 2021 link hnRNP A/B Proteins: An encyclopedic assessment of their roles in homeostasis and diseases Biology 2021 link Structure-based virtual screening, molecular dynamics, and binding affinity calculations of potential phytocompounds against SARS-CoV-2 Journal of Biomolecular Structure and Dynamics 2021 link Targeting B7-1 in Immunotherapy Medicinal Research Reviews 2019 link Comprehensive in vitro characterization of PD-L1 inhibitors Nature 2019 link Revealing the atomistic details behind the binding of B7-1 to CD28 and CTLA-4 Biochimica et Biophysica Acta-General Subjects 2018 link A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions BMC Medical Informatics and Decision Making 2018 link Molecular \u0026rsquo;time-machines\u0026rsquo; to unravel key biological events for drug design WIREs: Computational Molecular Science 2017 link Simple design of an enzyme inspired supported catalyst based on a catalytic triad Chem 2017 link Patents # Systems and methods of selecting compounds with reduced risk of cardiotoxicity using cardiac sodium ion channel models\nReferences # Aravindhan Ganesan – ResearchGate Aravindhan Ganesan – University of Waterloo, School of Pharmacy Aravindhan Ganesan – Centre for Bioengineering and Biotechnology Waterloo researchers study coronavirus structure to help design drugs Aravindhan Ganesan – Wilfrid Laurier University | LinkedIn ","date":"2026-05-18","externalUrl":null,"permalink":"/network/scientists/aravindhan-ganesan/","section":"Network","summary":"An expert in computational drug design and molecular pharmacology.","title":"Aravindhan\u003cbr\u003eGanesan","type":"network"},{"content":"","date":"2026-05-18","externalUrl":null,"permalink":"/tags/cancer/","section":"Tags","summary":"","title":"Cancer","type":"tags"},{"content":"","date":"2026-05-18","externalUrl":null,"permalink":"/tags/cannabinoid-receptors/","section":"Tags","summary":"","title":"Cannabinoid Receptors","type":"tags"},{"content":"","date":"2026-05-18","externalUrl":null,"permalink":"/tags/computational-chemistry/","section":"Tags","summary":"","title":"Computational Chemistry","type":"tags"},{"content":"","date":"2026-05-18","externalUrl":null,"permalink":"/tags/covid-19/","section":"Tags","summary":"","title":"Covid-19","type":"tags"},{"content":"","date":"2026-05-18","externalUrl":null,"permalink":"/tags/drug-safety/","section":"Tags","summary":"","title":"Drug-Safety","type":"tags"},{"content":" FEDUP # Federal Education Deficiencies Undermine Progress O Canada! Our Feds are in action\nCredit: Mistral Systemic Underfunding and Educational Deficits in Canadian New Approach Methodologies: A Comparative Policy and Curriculum Analysis This research report evaluates the structural underfunding and educational gaps surrounding New Approach Methodologies (NAM) in Canada. While global leaders like the United States and the European Union aggressively fund non-animal, human-relevant testing, computational toxicology, and microphysiological models, Canada relies on a fragmented and biased funding system. This investigation audits federal investments, university and K-12 curricula, regulatory mandates under the Canadian Environmental Protection Act (CEPA), and ethical frameworks governing student autonomy. The findings demonstrate a critical workforce skills gap and systemic academic barriers that place Canadian students and scientists at a severe disadvantage internationally.\nComparative Fiscal Analysis of Federal Funding for New Approach Methodologies # The transition toward New Approach Methodologies (NAM) - encompassing non-animal, human-relevant testing, in silico modeling, computational toxicology, and microphysiological systems - is rapidly reshaping biomedical research, safety testing, and drug development worldwide1. This paradigm shift promises superior predictive accuracy for human biology, a reduction in the massive attrition rates of pharmaceutical candidates, and more ethical scientific practices2. However, a comparative analysis of public R\u0026amp;D spending reveals that Canada is experiencing a profound fiscal deficit in dedicated funding for NAM, leaving its scientific infrastructure, academic institutions, and students lagging behind international peers3.\nIn Canada, federal funding for NAM-related research is highly fragmented, distributed across competitive, project-specific grants from the tri-agency councils - the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council (NSERC), and the Social Sciences and Humanities Research Council (SSHRC) - or ad-hoc strategic initiatives like Genome Canada4. While isolated academic teams have successfully secured project-level funding - such as the $4.7 million CAD Genome Canada Genomics Application Partnership Program (GAPP) grant for the validation of the EcoToxChip test system, or a $1.25 million CAD NSERC Alliance grant for the indigenization of NAM in contaminated site assessments5 - these allocations are temporary, localized, and restricted to specific research questions. Canada lacks a centralized, ring-fenced federal funding pool dedicated to the development, validation, and regulatory standardization of alternative models4.\nThis project-level fragmentation stands in stark contrast to the institutionalized financial commitments of Canada’s global competitors. In the United States, the National Institutes of Health (NIH) Common Fund launched the Complement Animal Research In Experimentation (Complement-ARIE) program, dedicating $150 million USD over an initial five-year phase starting in 2024 to accelerate the development, standardization, and validation of human-based NAM. Complement-ARIE funds comprehensive technology development centers, a centralized NAM Data Hub and Coordinating Center (NDHCC), and a Validation and Qualification Network (VQN) designed to shepherd alternative models through regulatory approval1. This is supplemented by other major allocations, such as an $87 million USD NIH center for organoid development6 and a $15.3 million USD NIH-funded NAM Decision Center at Texas A\u0026amp;M University to advance chemical safety assessments7.\nAustralia is building its non-animal research system8, because they recognize non-animal models are \u0026ldquo;crucial tools in biomedical and clinical research [and are] being increasingly used as readily accessible model types in medical product development\u0026rdquo;9. As such, Phenomics Australia runs a national research service for non-animal modeling.\nThe European Union has leveraged Horizon Europe and national-level growth funds to drive systemic change. In the Netherlands, the Dutch National Growth Fund invested €124.5 million (approximately $135 million USD) in the Centre for Animal-Free Biomedical Translation (CPBT)10. The CPBT functions as a nationwide consortium linking all Dutch academic medical centers, industry stakeholders, regulators, and government agencies to implement and commercialize animal-free biomedical innovations10.\nThe per-capita and proportional investment gaps between Canada and these active jurisdictions are mathematically stark. Let $F$ represent the dedicated federal funding allocation for national NAM validation, standardization, and educational training infrastructure, and let $P$ represent the respective national population, then the per-capita investment $I$ is:\n$$ \\text{Per-Capita Investment } (I) = \\frac{\\text{Dedicated Funding Allocation } (F)}{\\text{Population } (P)} $$For Canada, with a population of approximately 41 million, the lack of any dedicated federal program for national NAM validation and training infrastructure results in:\n$$ I_{\\text{Can}} = \\frac{\\$0 \\text{ CAD}}{41,000,000} = \\$0.00 \\text{ CAD per capita} $$For the United States, utilizing only the initial $150 million USD ($205 million CAD equivalent) allocation for the Complement-ARIE program for a population of 340 million:\n$$ I_{\\text{US}} = \\frac{\\$150,000,000 \\text{ USD}}{340,000,000} \\approx \\$0.44 \\text{ USD per capita } (\\approx \\$0.60 \\text{ CAD}) $$For the Netherlands, with a dedicated Growth Fund allocation of €124.5 million ($185 million CAD equivalent) and a population of 18 million:\n$$ I_{\\text{NL}} = \\frac{€124,500,000}{18,000,000} \\approx €6.92 \\text{ per capita } (\\approx \\$10.27 \\text{ CAD}) $$ Jurisdiction Primary Dedicated NAM Program / Initiative Total Dedicated Funding Allocation (CAD Equivalent) Funding Term (Years) National Population (Millions) Dedicated Per-Capita Investment (CAD) Active National Center or Regulatory Hub United States NIH Complement-ARIE \u0026amp; Dedicated Organoid Centers ~$325,000,000 5 340 ~$0.95 Yes (VQN, NDHCC, TAMU Decision Center) Netherlands Centre for Animal-Free Biomedical Translation (CPBT) ~$185,000,000 10 18 ~$10.27 Yes (CPBT Consortium) Canada None (Ad-hoc academic grants only) $0 (No dedicated program) N/A 41 $0.00 No (CCAAM permanently closed in 2024) The structural consequence of this funding deficit is the closure of the Canadian Centre for Alternatives to Animal Methods (CCAAM) at the University of Windsor on May 31, 2024. Founded in 2017 as the first and only center in Canada dedicated to non-animal testing and the promotion of human-relevant alternatives, CCAAM was designed to develop, validate, and promote lab methods that bypass animal subjects. Despite receiving a one-time $1 million CAD philanthropic donation in 2018 from the Eric S. Margolis Family Foundation to build a training facility11, the center never received sustained federal operational funding. Ultimately, budget cuts at the University of Windsor forced its permanent closure, leaving Canada without a single national hub to coordinate NAM development, train researchers, or interface with international validation bodies3.\nAccording to Dr. Charu Chandrasekera who is the founder and executive director of the Canadian Institute for Animal-Free Science (formerly known as CCAAM), she would require a minimum budget of 10 million/year. That is less than 25 cents per Canadian, yet the Feds are not providing the funding!\nStructural Bias and Legacy Benchmarks in Academic Granting Councils # The lack of dedicated NAM funding pools in Canada is compounded by a structural bias within the peer-review mechanisms of CIHR and NSERC. Legally and historically, traditional vertebrate animal models have been treated as the unquestioned \u0026ldquo;gold standard\u0026rdquo; for biomedical and toxicological research12. Consequently, researchers attempting to secure federal grants for projects utilizing microphysiological systems or computational modeling face a self-perpetuating cycle of rejection13.\nPeer-review panels at Canadian granting councils are typically populated by established scientists who built their careers on animal-testing protocols. Literature on peer-review performance indicates a pervasive conservative bias, where reviewers unconsciously favor methodologies aligning with their own expertise and academic backgrounds. This systemic inertia penalizes innovative, high-risk, or multidisciplinary proposals13. In a standard review process, when an applicant proposes a human-relevant in vitro or in silico model, reviewers frequently demand supplementary in vivo animal validation to \u0026ldquo;benchmark\u0026rdquo; the results, viewing the non-animal method as an unproven surrogate rather than a superior predictive tool14.\nThe reliability of peer-review ratings at CIHR is demonstrably poor, with intra-class correlation coefficients (ICC) ranging from a low of $0.20$ to a moderate $0.61$ across different study cohorts. The ICC is somewhat higher for basic medical sciences ($0.41$) than for applied sciences ($0.32$), reflecting a rigid consensus around traditional, animal-centric basic science methodologies and a deep skepticism toward emerging, multidisciplinary methodologies. This peer-review framework penalizes early-career investigators and favors older, established applicants who rely on legacy animal-based research programs13.\nWhile major international agencies have introduced structural interventions - such as the US NIH\u0026rsquo;s High-Risk High-Reward Research Program or the Danish Villum Foundation\u0026rsquo;s \u0026ldquo;Golden Ticket\u0026rdquo; system, which allows individual reviewers to rescue highly innovative proposals regardless of consensus scoring15 - Canadian councils maintain conservative rating and ranking systems that systematically undervalue non-animal innovations13.\nFurthermore, an institutional conflict of interest underpins Canada\u0026rsquo;s animal research oversight system. The Canadian Council on Animal Care (CCAC), which sets guidelines for animal welfare in research, is funded almost entirely by CIHR and NSERC. Participation in the CCAC is voluntary for private institutions but mandatory for academic universities relying on tri-agency grants16.\nBecause the CCAC’s operational existence is structurally dependent on the continuation of animal-based research, and because CIHR and NSERC\u0026rsquo;s core scientific portfolios remain heavily anchored in animal models, there is no centralized institutional incentive to mandate or fund a national transition toward alternative methodologies. This lock-in effect ensures that the regulatory and funding structures continue to feed into one another, solidifying the position of animal models as the legacy benchmark16.\nCurriculum Audit of Canadian Higher Education and Pockets of Isolation # University and Graduate Level Mapping # An audit of the biology, biomedical, and toxicology curricula at Canada\u0026rsquo;s top research universities reveals a severe systemic absence of structured, dedicated coursework in advanced NAM. While global industry and regulatory frameworks are rapidly integrating computational toxicology, microphysiological systems, and high-throughput workflows, Canadian higher education continues to train the next generation of life scientists using legacy, animal-centric frameworks4.\nCrucially, standard curricula across these universities completely omit training in the foundational computational tools and chemical modeling suites that are now mandatory in modern regulatory science. Students are not taught how to utilize commercial software platforms such as Leadscope, Derek Nexus, and Case Ultra, nor are they exposed to open-source alternatives like the OECD QSAR Toolbox, VEGA, and OPERA17. These platforms are essential for performing structure-activity modeling, identifying toxicophores, and conducting read-across assessments under international frameworks like the ICH M7 guidelines for mutagenic impurities or the Carcinogenic Potency Category Approach used by Health Canada, the FDA, and the EMA17.\nAt the University of Toronto, a premier research institution, there is a notable bifurcation between engineering and the life sciences. The School of Graduate Studies offers a highly specialized graduate-level course, \u0026ldquo;CHE1334H: Organ-on-a-Chip Engineering,\u0026rdquo; which focuses on the on-chip engineering of heart, kidney, liver, and cancer models18. This is supported by the Centre for Microfluidic Systems (CRAFT), a partnership with the National Research Council (NRC) that designs biomimetic microfluidic platforms like the \u0026ldquo;E-FLOAT\u0026rdquo; airway-on-a-chip19.\nHowever, these engineering-led initiatives operate in isolation. They are not integrated into the standard undergraduate life sciences, pharmacology, or toxicology curricula, meaning that the vast majority of biology and pre-medical students graduate without formal exposure to these technologies19.\nA similar pattern of isolated excellence versus systemic absence is visible across other top-tier universities:\nMcGill University: Housing the lab of Niladri Basu, McGill represents an active hub of NAM research20. However, an audit of course calendars shows that standard environmental health and toxicology courses (such as NRSC 670 and PARA 515) focus broadly on exposure assessment, epidemiology, and traditional water safety. There are no dedicated, core undergraduate modules or laboratory courses in machine learning-driven toxicity prediction, quantitative structure-activity relationship (QSAR) modeling, or human-biology-based in vitro data workflows21.\nUniversity of British Columbia (UBC): Exposure to advanced NAM is highly restricted. While UBC offers a summer program course, \u0026ldquo;Innovations in Biomedical Sciences,\u0026rdquo; which introduces 15-to-18-year-old high school students to 3D bioprinting and organ-on-a-chip models22, these topics are largely absent as dedicated, credit-bearing courses within standard undergraduate biology or pharmacology programs.\nUniversity of Alberta and McMaster University: These institutions maintain robust biomedical engineering and clinical research programs, but their core life science curricula remain dominated by traditional animal-testing paradigms, lacking systematic instruction in computational toxicology, read-across methods, or high-throughput bioassays23.\nThe closure of CCAAM at the University of Windsor in 2024 eliminated the only academic center in Canada that actively integrated alternative validation and non-animal biomedical training into standard higher education. Consequently, undergraduate and graduate training in NAM in Canada is restricted to niche, self-taught graduate research environments, creating a major educational deficit when compared to the structured training programs funded by the US Complement-ARIE initiative.\nUniversity Dedicated Undergrad NAM Coursework Dedicated Graduate NAM Coursework Active Research Centers / Initiatives Curricular Assessment \u0026amp; Deficits University of Toronto None CHE1334H (Organ-on-a-Chip Engineering) CRAFT (Partnership with NRC) Focus is heavily restricted to graduate-level engineering; complete absence of integration in standard undergraduate life sciences, pharmacology, and toxicology. McGill University None None Basu Lab (EcoToxChip, Genomics) Practical training is limited to isolated graduate research; standard toxicology and environmental health courses lack dedicated computational/QSAR modules. University of British Columbia None None Microphysiological research labs Core curricula remain traditional; exposure to organ-on-a-chip is limited to non-credit summer youth programs. University of Alberta None None Preclinical testing labs Reliance on traditional animal-model paradigms; no systematic training in high-throughput or in silico methodologies. McMaster University None None Clinical trial \u0026amp; bioengineering networks Training is heavily focused on traditional \u0026ldquo;gold standard\u0026rdquo; clinical and animal models; lack of structured non-animal methodology tracks. University of Windsor None None CCAAM / CaCVAM (Defunct as of 2024) The complete closure of Canada\u0026rsquo;s only dedicated alternatives center eliminated all active undergraduate and graduate training pathways in Windsor. K-12 and Secondary Education Baseline # The educational deficit begins well before higher education, rooted in provincial K-12 science curricula. Assessment of high school biology frameworks across major provinces (Ontario, British Columbia, Quebec, and Alberta) reveals that secondary science programs continue to privilege legacy physical dissection over modern, non-animal scientific alternatives24.\nIn Ontario, the Grade 10 science and Grade 11 biology curricula state that students are to investigate respiratory and digestive systems through physical dissection or computer simulations24. While the curriculum\u0026rsquo;s language implies a choice, studies show that the practical implementation of this policy is highly problematic25. The choice is frequently interpreted as a teacher\u0026rsquo;s prerogative rather than a student\u0026rsquo;s right. Surveys of Ontario science teachers indicate that 94.1% continue to conduct physical animal dissections in their classes. Furthermore, 87.5% of these teachers believe that physical dissection is \u0026ldquo;important\u0026rdquo; to biology education, and 56.3% assert that \u0026ldquo;there are no substitutes\u0026rdquo; for real animal specimens26. Consequently, digital or synthetic alternatives (such as virtual simulations or 3D models) are rarely used as replacements, but rather as secondary supplements27.\nIn British Columbia, Quebec, and Alberta, a similar administrative structure exists24. While administrative procedures direct school districts to provide alternatives to dissection when students exercise a choice, these policies are rarely promoted proactively28. Students are typically required to initiate a confrontation with their instructor to obtain an alternative, navigating a classroom dynamic that implicitly favors physical dissection as the \u0026ldquo;authentic\u0026rdquo; way to study anatomy27.\nExceptional cases exist - such as the Windsor-Essex Catholic District School Board, which voted in 2019 to completely phase out frog and fetal pig dissections in favor of synthetic models and virtual simulations - but these are highly isolated municipal decisions. Nationally, K-12 frameworks fail to introduce secondary students to the concept of NAM, reinforcing a cultural norm that biological science is fundamentally dependent on animal exploitation27.\nProvince Primary Curricular Requirement Dissection Policy / Student Choice Policy Status Primary Implementation Deficit Ontario Grade 10 Science \u0026amp; Grade 11 Biology: observe systems via physical dissection or computer simulation. Implied choice in curriculum; formal \u0026ldquo;opt-out\u0026rdquo; student choice policies exist in only a few local school boards (eg TDSB). Over 94% of teachers continue to mandate physical dissection, treating digital alternatives as optional supplements rather than replacements. British Columbia Secondary Science: investigate anatomy and systems using dissection, computer models, or prepared slides. Administrative procedures direct schools to provide alternatives when requested, but students must actively object to initiate this. Lack of proactive student notification; teachers frequently lack awareness of or training in high-quality digital alternatives. Quebec Secondary Biology: study physiology and anatomy using prepared specimens, models, or digital tools. Alternatives are permissible but are not formally structured as a proactive student choice policy; left to individual school discretion. Physical dissection remains the default instructional standard; alternative digital platforms are underutilized due to lack of teacher training. Alberta Secondary Biology: investigate relationships and anatomy through dissection or computer simulations. Schools are directed to provide alternatives within available resources, ensuring no student is forced to participate. \u0026ldquo;Practicability\u0026rdquo; loophole allows schools to bypass providing high-quality synthetic/digital alternatives if budgets are constrained. Regulatory, Legislative, and Labor Market Disconnections # The CEPA 2023 Implementation Gap # In June 2023, the Parliament of Canada passed Bill S-5, the Strengthening Environmental Protection for a Healthier Canada Act, which modernized the Canadian Environmental Protection Act, 1999 (CEPA). A key amendment to the preamble and regulatory framework of CEPA explicitly recognized the importance of replacing, reducing, or refining the use of vertebrate animal testing in toxicity assessments. In July 2025, Health Canada and Environment and Climate Change Canada (ECCC) formalized this legislative mandate by publishing the Strategy to Replace, Reduce or Refine Vertebrate Animal Testing under CEPA. The strategy outlines a progressive objective to completely phase out chemical toxicity testing on vertebrate animals by the year 2035. It establishes a stepwise approach to identify, prioritize, and implement NAM within CEPA regulatory programs29.\nDespite the progressive rhetoric of this strategy, a profound implementation gap has emerged30. Legal and policy analysts have pointed out that both Bill S-5 and the 2025 Strategy completely lack a dedicated, functional budget or staffing allocation to train and transition the scientific workforce. Instead, Health Canada has stated that the funds required to implement the strategy will be drawn entirely from \u0026ldquo;existing budgets\u0026rdquo;29.\nThe decision to execute a national scientific transition of this scale without fresh, ring-fenced funding raises serious concerns about regulatory enforcement. The 2025 Strategy relies on the caveat that alternative testing methods will only be required when they are \u0026ldquo;practicable\u0026rdquo; and \u0026ldquo;scientifically justified\u0026rdquo;29. Without a dedicated budget to train regulatory scientists in the interpretation, standardization, and validation of NAM data, traditional animal-based data will remain the default \u0026ldquo;practicable\u0026rdquo; path, effectively rendering the 2035 phase-out target unachievable30.\nThe Workforce Skills Gap and Brain Drain # The lack of funding for NAM education and regulatory transition has created a severe workforce skills gap that threatens Canada’s position in the global biotechnology and pharmaceutical sectors31. The global market is rapidly shifting toward AI-driven drug discovery, high-throughput in vitro toxicology, and microphysiological testing. These advanced technologies require highly specialized STEM skills, combining cell biology, microfluidic engineering, programming, and machine learning32.\nAccording to national labor market reports by BioTalent Canada, the country’s life sciences sector is facing an acute talent shortage. By 2029, the sector will require an estimated 65,000 additional workers, including 16,000 specifically for advanced biomanufacturing and research roles. A major component of this shortage is a lack of job-ready, highly specialized technical skills. While Canadian post-secondary institutions excel at teaching fundamental biology, they are failing to provide hands-on, industry-aligned training in the automated, digitalized workflows that define modern NAM31.\nCASTL’s \u0026ldquo;Future-Ready\u0026rdquo; report, developed in partnership with BioTalent Canada and the Future Skills Centre, notes that 80% of biotechnology employers require Good Manufacturing Practices (GMP) and advanced laboratory skills (70%), yet graduates systematically lack this regulated laboratory experience. This skills gap directly slows the adoption of predictive preclinical models by Canadian biotechnology firms32.\nBecause Canada lacks the academic infrastructure and national centers necessary to support high-level training in NAM, it is facing a significant risk of scientific \u0026ldquo;brain drain\u0026rdquo;3. Top-tier graduates specializing in computational chemistry, microfluidics, and stem-cell bioengineering are forced to leave Canada to pursue advanced training or competitive employment in the United States or the European Union, where multi-million-dollar programs (like Complement-ARIE or the CPBT consortium) provide robust, state-of-the-art career pathways110. This talent migration leaves Canadian start-ups and regulatory bodies understaffed, reinforcing Canada\u0026rsquo;s dependency on foreign-developed testing models and undermining its domestic scientific sovereignty3.\nEthical Frameworks and Student Autonomy in Post-Secondary Institutions # Systemic Ethical Compromise # Forcing students to participate in invasive vertebrate testing and physical dissections creates acute ethical conflicts that compromise their psychological welfare and academic choices27. A significant portion of life science students harbor personal, moral, religious, or environmental objections to the use and killing of animals for educational purposes33.\nSurveys of secondary and post-secondary students reveal a stark disconnect between public objection rates and vocalized complaints. While school administrators and teachers frequently report that unsolicited student objections to dissection are rare, typically averaging only 3% to 5% of a class, anonymous surveys indicate that the actual level of objection is dramatically higher. In some evaluations, up to 67% of students expressed ethical objections to dissecting vertebrates like rabbits, cats, or rodents33.\nThe cause of this discrepancy is a systemic lack of student autonomy. Students operating in traditional academic environments face significant risks if they choose to voice an objection33. These risks include:\nThe loss of critical grades or course failure if the instructor refuses to accommodate them. Ridicule, humiliation, or isolation from peers and instructors. The psychological burden of being viewed as rebellious or academically \u0026ldquo;soft\u0026rdquo; for prioritizing ethical concerns. Consequently, the vast majority of ethically opposed students choose to \u0026ldquo;go along\u0026rdquo; with invasive procedures against their convictions, experiencing a form of systemic ethical compromise25. For many compassionate and highly capable students, this negative classroom environment serves as a barrier that drives them away from pursuing further studies or careers in the life sciences entirely27. This is not a new issue; documented cases of students seeking legal recourse to avoid killing and dissecting animals date back decades in Canada - such as the 1993 case of a University of Victoria biology student who chose to study and release a live marine mollusk rather than dissect it, illustrating the long-standing nature of this academic friction33.\nThe Legal and Institutional Void in Higher Education # While K-12 school boards have slowly introduced regional \u0026ldquo;student choice policies,\u0026rdquo; Canadian higher education exists in an institutional and legal void regarding the right to conscientious objection34. Currently, not a single university in Canada has established a formal, university-wide policy that guarantees students the right to conscientiously object to animal use and be provided with equivalent, non-animal learning alternatives without academic penalty. While some individual instructors are willing to accommodate students on an ad-hoc, informal basis, this decentralized approach leaves students entirely dependent on the personal goodwill of their professors.\nThis lack of institutional protection exposes a significant legal gap. Under the Canadian Charter of Rights and Freedoms, Section 2 guarantees \u0026ldquo;freedom of conscience and religion\u0026rdquo; as well as \u0026ldquo;freedom of thought, belief, opinion and expression\u0026rdquo;. Section 15 further prohibits discrimination based on \u0026ldquo;creed\u0026rdquo;. In theory, these constitutional provisions protect a student\u0026rsquo;s right to refuse to participate in practices they morally condemn34.\nHowever, in practice, invoking Charter protections in a university setting is extremely difficult. Under Canadian jurisprudence, universities are treated as government actors only for certain, specific purposes, largely determined by their funding arrangements and administrative relationships with the state34. For other purposes, they are viewed as private actors, meaning the Charter does not directly apply to their internal academic policies. This legal ambiguity leaves post-secondary students without clear, enforceable rights, forcing them to choose between their ethical integrity and their academic progression33.\nStrategic Policy Conclusions # The current state of New Approach Methodologies in Canada is characterized by a profound disconnect between legislative ambition and educational, fiscal, and institutional reality4. While the 2023 amendments to the Canadian Environmental Protection Act and the subsequent 2025 Strategy set a progressive target to phase out animal-based toxicity testing by 2035, the federal government\u0026rsquo;s refusal to allocate dedicated funding or staffing resources has crippled the implementation of this mandate from its inception29. This fiscal deficit has directly led to the collapse of Canada’s only dedicated alternatives center, CCAAM, leaving the country without a national hub for validation, training, or international coordination4.\nConsequently, Canadian higher education is failing to prepare its workforce for the global transition toward AI-driven, computational, and microphysiological safety testing31. The systemic absence of dedicated NAM coursework in top-tier research universities, combined with an educational framework that privileges legacy animal models as the \u0026ldquo;gold standard\u0026rdquo; in peer-review granting, has created an acute skills gap and a severe risk of brain drain. Furthermore, the lack of formal policies protecting conscientious objection in universities forces students into systemic ethical compromise, discouraging compassionate talent from entering the life sciences33.\nTo bridge this gap and ensure Canada remains globally competitive, the federal government must:\nEstablish a dedicated, permanent federal funding pool (administered through CIHR and NSERC) modeled on the US Complement-ARIE and Dutch CPBT initiatives to support the development and validation of human-relevant alternatives. Provide sustainable funding to re-establish and scale a national center for alternatives to animal testing (such as a re-launched CCAAM in Ottawa) to lead the transition to animal-free research and training. Reform tri-agency peer-review mechanisms to eliminate the \u0026ldquo;gold standard\u0026rdquo; bias toward animal models and actively promote the acceptance of validated NAM data. Mandate the integration of computational toxicology and microphysiological training pathways within university life science curricula to align the domestic workforce with global industry demands. Enact clear, legally enforceable institutional policies in all post-secondary institutions protecting a student\u0026rsquo;s right to conscientious objection, ensuring that humane, high-quality alternatives are available by default35. Credits: original research by Gemini, accuracy checks by Mistral and Augure, final modifications and production by PNARS staff. Note: This report is available with complete reference listings as a pdf document here.\nNIH Common Fund FAQs\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nÄrzte gegen Tierversuche - USA Establishes New Framework for Animal-Free Research\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nCruelty Free International - Plans to Reshape Animal Testing in Canada\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nInvitroJobs - CCAAM Closure\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nBasu Lab News\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nFierce Biotech - FDA and NIH Pledge Flexibility and New $150M Investment\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nTexas A\u0026amp;M - $15.3M NIH Chemical Safety Center\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nFrontiers in Toxicology - Australia\u0026rsquo;s Non-Animal Research System\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nPhenomics Australia - Non-Animal Modelling\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nMimetas - Dutch National Growth Fund Initiative\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nWikipedia - Canadian Centre for Alternatives to Animal Methods\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nResearchGate - Conflicting Experiences of Researchers on the Implementation of the 3Rs\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nNCBI - Peer Review Performance\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nCRAFT Microfluidics - Organ-on-Chip Research\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nNCBI - High-Risk High-Reward Research Program\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nFaunalytics - Canada\u0026rsquo;s Research Animals Need National Legislation\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nNCBI - Computational Toxicology Tools\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nUniversity of Toronto - CHE1334H Course\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nCRAFT Microfluidics - E-FLOAT Airway-on-a-Chip\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nBasu Lab - NAM Research\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nMcGill University - NRSC 670 and PARA 515\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nUBC - Innovations in Biomedical Sciences\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nNCBI - High-Throughput Bioassays\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nInterniche - Canadian High School Legislation\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nSemantic Scholar - Dissection Policy Implementation\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nIJESE - Teacher Attitudes Toward Dissection\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nAnimals and Society - Dissection Alternatives\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nWellBeing International - Student Choice Policies\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nMJSDL - Canada\u0026rsquo;s Energy Production Plans\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nCruelty Free International - Canada\u0026rsquo;s Strategy on Animal Testing\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nBioTeCanada - Building Canada\u0026rsquo;s Biomanufacturing Workforce\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nTechnavio - 3D Cell Culture Market\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nWellBeing International - Ethical Conflicts in Dissection\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nADAV Society - Alternatives in Education\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nLakehead University - Student Choice Policies\u0026#160;\u0026#x21a9;\u0026#xfe0e;\n","date":"2026-05-18","externalUrl":null,"permalink":"/projects/youth/fedup/","section":"Projects","summary":"Exposes funding gaps, curriculum deficits, policy failures in Canada NAM education, compared to global standards.","title":"FEDUP\u003cbr\u003eSystemic Negligence for NAM Education","type":"projects"},{"content":"","date":"2026-05-18","externalUrl":null,"permalink":"/tags/human-relevant-models/","section":"Tags","summary":"","title":"Human-Relevant-Models","type":"tags"},{"content":"","date":"2026-05-18","externalUrl":null,"permalink":"/tags/in-silico-modeling/","section":"Tags","summary":"","title":"In Silico Modeling","type":"tags"},{"content":" Laser-assisted bioprinting technologies supporting NAM # New Approach Methodologies (NAM) are increasingly adopted worldwide, with industries seeking robust, scalable, and human-relevant models. Laser-Assisted Bioprinting (LAB) supports this initiative by enabling the fabrication of complex biological structures with precise spatial organization. This addresses limitations of traditional 2D cultures, which fail to replicate in vivo tissue architecture.\nKey Highlights # Uses LIFT technology for high-precision tissue model assembly. Achieves high cell viability (\u0026gt;95%) and preserves cellular integrity. Provides cellular-level resolution (\u0026lt;50 µm) for accurate tissue mimicry. Supports high-throughput, GMP-compliant production of human models. Enables multi-material versatility for complex tissue interfaces. About the Organizations # Scintica Instrumentation Inc. is a supplier of research instrumentation and equipment advancing science and medicine. News-Medical.net is a publisher of medical and scientific news and whitepapers.\nLearn More # Laser-assisted bioprinting technologies supporting new approach methodologies (NAMs)\n","date":"2026-05-18","externalUrl":null,"permalink":"/news/laser-bioprinting/","section":"News","summary":"Laser-assisted bioprinting supports NAM with human-relevant tissue models.","title":"Laser-assisted bioprinting technologies supporting NAM","type":"news"},{"content":"","date":"2026-05-18","externalUrl":null,"permalink":"/tags/laser-assisted-bioprinting/","section":"Tags","summary":"","title":"Laser-Assisted-Bioprinting","type":"tags"},{"content":"","date":"2026-05-18","externalUrl":null,"permalink":"/tags/molecular-pharmacology/","section":"Tags","summary":"","title":"Molecular Pharmacology","type":"tags"},{"content":"","date":"2026-05-18","externalUrl":null,"permalink":"/tags/neurodegeneration/","section":"Tags","summary":"","title":"Neurodegeneration","type":"tags"},{"content":"","date":"2026-05-18","externalUrl":null,"permalink":"/tags/scintica-instrumentation/","section":"Tags","summary":"","title":"Scintica-Instrumentation","type":"tags"},{"content":"","date":"2026-05-18","externalUrl":null,"permalink":"/tags/structural-biology/","section":"Tags","summary":"","title":"Structural Biology","type":"tags"},{"content":"","date":"2026-05-18","externalUrl":null,"permalink":"/tags/tissue-models/","section":"Tags","summary":"","title":"Tissue-Models","type":"tags"},{"content":" Students demanding a proper modern education\nCredit: Mistral This section is your launchpad for driving change in Canadian science education and empowering the next generation of scientists. Whether you\u0026rsquo;re a student frustrated by outdated dissection labs, a parent tired of seeing your child forced into practices that conflict with their ethics, or a teacher eager to modernize your curriculum, here you\u0026rsquo;ll find the tools and knowledge to push Canada into the 21st century with New Approach Methodologies (NAM). The three items below will guide you through understanding the problem, taking action, and accessing resources to create a future where science education is ethical, modern, and inclusive.\nNAMIFY: A Youth Guide to Modern Science # New Approach Methodologies Inspiring Formidable Youth, is an action-oriented manual designed for students, parents, guardians, teachers, and others. It explains what NAM is, why it matters, and how you can drive change whether you are focussed on getting alternatives to dissection in your school, sharing resources with your community, or demanding better policies from decision-makers. It is your education, so insist on receiving the best and NAMIFY Canada!\nRAISE: Materials to Facilitate Action # Resources Altering Ingrained School Education provide a central hub of tools, templates, and other items to support your drive to receive a proper education. From petitions and sample letters to MPs, to infographics and social media toolkits, this page connects you to everything you need so you can take action and mobilize others around NAM education in Canada. Do your part to RAISE up the level of bio-science education in this country!\nFEDUP: Revealing Systemic Negligence for Modern NAM Education # Federal Education Deficiencies Undermine Progress is a comprehensive analysis of the Canadian government\u0026rsquo;s systemic underfunding and educational deficits for NAM. This report exposes the stark contrasts in federal funding, curriculum gaps in universities, and the urgent need for policy reform to raise Canadian bio-science education to the level of global standards. A factual, quantitative comparison with other countries is presented which shows just how poorly Canada a G7 country(!) fares due to national level behaviour we are FEDUP with!\n","date":"2026-05-18","externalUrl":null,"permalink":"/projects/youth/","section":"Projects","summary":"Structured approach to mobilizing youth, parents, and educators around NAM education in Canada.","title":"Youth","type":"projects"},{"content":" Headline information worldwide\nCredit: naobim (pixabay) Stay informed with updates on New Approach Methodologies (NAM) developments, covering scientific breakthroughs, legislative issues, business adaptations, investment interests, campaigns, and regulatory changes. Items appear in reverse chronological order, each featuring a brief summary and a source link for further details.\n","date":"2026-05-17","externalUrl":null,"permalink":"/news/","section":"News","summary":"","title":"News","type":"news"},{"content":"","date":"2026-05-16","externalUrl":null,"permalink":"/tags/atopic-march/","section":"Tags","summary":"","title":"Atopic March","type":"tags"},{"content":" Footer # Contact # For inquiries, please email us.\nPrivacy Policy # This site collects no personal data beyond standard server logs which may include IP addresses and access timestamps. No cookies, tracking, or analytics are used.\nTerms of Use # Content on site is deemed to be accurate and supported by reference links whenever possible. External links are provided for convenience and do not imply endorsement. PNARS is not responsible for third-party content. Use at your own risk; no warranty or liability is assumed.\nCopyleft # © 2026 Progressive Non-Animal Research Society (PNARS). All content is provided under a CC BY-SA license which allows others to share, use, and build upon a work provided appropriate credit is given to the original creator. They must also license their new creations under the same terms. As such, any derivative works must be distributed under like terms promoting a culture of sharing and collaboration.\nAccessibility # PNARS is committed to ensuring digital accessibility for people with disabilities. Our SiteTips offers guidance on theme colors, navigation, and other accessibility features. We strive to conform to WCAG 2.1 Level AA standards and welcome feedback to improve the user experience. If you encounter barriers or have suggestions, please contact us.\nCredits # Site development, summarizations, and content research assistance provided by Mistral, Gemini, and Augure (Canadian legalities). Images are taken from stock collections, Pixabay, Pexels, magnific.com, and personal photography. AI-assisted tools may be used to generate portions of text and images. Articles are submitted by various contributors. All items are appropriately attributed and reviewed by PNARS staff.\nThe PNARS logo at the top left of each page represents using NAM for medical research instead of animals. Our thanks to the original designer Maureen Snider and the animator CSwebsolutions.\nThis site was created with the Hugo generator using the Blowfish theme.\n","date":"2026-05-16","externalUrl":null,"permalink":"/footer/","section":"Progressive Non-Animal Research Society","summary":"","title":"Footer","type":"page"},{"content":"","date":"2026-05-16","externalUrl":null,"permalink":"/tags/help/","section":"Tags","summary":"","title":"Help","type":"tags"},{"content":"","date":"2026-05-16","externalUrl":null,"permalink":"/tags/lush-prize/","section":"Tags","summary":"","title":"Lush Prize","type":"tags"},{"content":" Site Tips # Helpful Tips\nCredit: magnific.com Suggestions here may help to improve your experience on the PNARS site.\nTextsize # Set just the textsize you want for comfortable reading on your desktop holding down the CTRL key and pushing + key (increase) or - key (decrease).\nNavbar # You can get to the sections and subsections by clicking the navbar button at the top right corner of the page.\nBreadcrumbs # Pages you visit will usually have a hierarchical trail displaying the route to that page. For instance, if you are on the Advisors page, you will see at the top About/ because Advisors is a subsection of About. These breadcrumbs are clickable so you can go back easily.\nBack to Top # As you scroll down a page, you will see an up arrow appear at the bottom right. Clicking on this arrow will return you to the top of the page.\nGoing Home # If you want to return from your travels to this homepage, just click on the animated NAM mouse which appears at the top left of every page.\nFootnotes # Some of our pages are extensively documented research items. When you click on a footnote you will be taken down the page to the same numbered reference as the footnote. If you click on the reference a new tab will open it. To return to your reading point in our article from the reference section, click your browser back button (usually the backarrow at top left), or depending on the browser press the backspace key, or Alt+Backarrow keys.\nSearch # The magnifying glass icon let\u0026rsquo;s you search the site by typing in words.\nYou can also find things using categories (https://pnars.org/categories) which are broad concepts, and tags (https://pnars.org/tags) which are more precise labels.\nTable of Contents # Most pages that have multiple headings also display a TOC to those headings making it easy to get to different parts of the page.\nTheme color # To the left of the navbar button is a theme dark/light toggle. If you click the sun the page goes light. If you want to come back to the dark theme, click the moon that has taken up the same position.\n","date":"2026-05-16","externalUrl":null,"permalink":"/resources/sitetips/","section":"Resources","summary":"Some suggestions on how to use this site for a better experience.","title":"Sitetips","type":"resources"},{"content":"","date":"2026-05-16","externalUrl":null,"permalink":"/tags/tips/","section":"Tags","summary":"","title":"Tips","type":"tags"},{"content":" Zheng Tan MD PhD # Dr. Zheng Tan is an Executive Research Coordinator in the Eye Care Centre at Vancouver General Hospital. She specializes in organ-on-a-chip systems, developing multi-organ co-culture setups to emulate complex human physiological processes and replace animal testing. In 2024, she won the 2024 Lush Prize for her innovative organ-on-a-chip research and served as a judge for the competition in 2026. Dr. Zheng Tan\nHedtrich lab, Centre for Blood Research\nCredit: CBR Introduction # Dr. Zheng Tan is a distinguished researcher and known for her pioneering work in organ-on-a-chip systems. Her research focuses on developing multi-organ co-culture setups to emulate complex human physiological processes. This work is crucial in the field of toxicology and biomedical research as it provides a human-based model to replace traditional animal testing methods. Dr. Tan\u0026rsquo;s contributions are recognized globally highlighting her commitment to advancing science without the use of animals.\nProfessional Background and Achievements # Dr. Zheng Tan currently serves as an Executive Research Coordinator in the Eye Care Centre at Vancouver General Hospital. She is affiliated with the Faculty of Pharmaceutical Sciences and works in the lab of Sarah Hedtrich (née Küchler). Her expertise lies in Urologic Oncology, Tissue Engineering, and Regenerative Medicine. She has co-authored numerous publications, showcasing her extensive research output and influence in her field.\nOne of Dr. Tan\u0026rsquo;s most notable achievements is winning the 2024 Lush Prize. This award was granted for her project on establishing a multi-organ co-culture in an organ-on-a-chip setup to emulate the human atopic march. This project is significant as it aims to replace animal testing with a human-based model, aligning with global efforts to reduce and eliminate animal use in scientific research. In 2026 she became a judge for the Lush Prize competition.\nMajor Projects and Publications # Dr. Zheng Tan\u0026rsquo;s research primarily revolves around developing organ-on-a-chip systems emulating human-based models to replace traditional animal testing methods.\nBelow is a table summarizing some of her key publications:\nTitle Journal Year Source A Human‐Based Skin‐Lymphoreticular Model‐on‐Chip to Emulate Inflammatory Skin Conditions Advanced Healthcare Materials 2026 Link Disrupting TSLP–TSLP receptor interactions via putative small molecule inhibitors yields a novel and efficient treatment option for atopic diseases EMBO Molecular Medicine 2024 Link Intranasal delivery of low-dose anti-CD124 antibody enhances treatment of chronic rhinosinusitis with nasal polyps Biomaterials 2024 Link Systemic delivery of proteins using novel peptides via the sublingual route Journal of Controlled Release 2024 Link Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma Journal of Experimental \u0026amp; Clinical Cancer Research 2020 Link TSLP as druggable target – a silver-lining for atopic diseases? Pharmacology \u0026amp; Therapeutics 2020 Link Inhibition of GLI2 with antisense‐oligonucleotides: A potential therapy for the treatment of bladder cancer Journal of Cellular Physiology 2019 Link The role of netrin-1 in metastatic renal cell carcinoma treated with sunitinib Oncotarget 2018 Link Calcium-sensing receptor (CaSR) promotes development of bone metastasis in renal cell carcinoma Oncotarget 2018 Link Conclusion # Dr. Zheng Tan\u0026rsquo;s career is a testament to her pioneering spirit in advancing alternative methods in biomedical research and exemplifies the shift from animal-based research to NAM-based, ethical science. Her award-winning work on organ-on-a-chip systems, leadership in regulatory toxicology projects (EFSA-DNT, ENDpoiNTs, ONTOX), innovative drug delivery technologies (MADDD), and extensive publications in high-impact journals position her as a global leader in alternative methods. Her contributions to molecular biology, RNA splicing, and neurodegenerative diseases, highlight her influence in advancing predictive, human-relevant research paradigms.\nVideos # Features Dr. Zheng Tan\u0026rsquo;s award-winning project.\nMedia # Lush Prize\nHighlights some of Dr. Zheng Tan\u0026rsquo;s achievements.\nBC FNAR 2025 Grant Recipient\nDr. Zheng Tan received a grant for her human-based skin-lymph node model on-a-chip to emulate inflammatory skin conditions.\nNational Postdoc Appreciation Week\nInterview with Dr. Zheng Tan at the Hedtrich lab.\nResearch Profiles # ResearchGate Profile - Verified profile with institutional email confirmation.\n","date":"2026-05-16","externalUrl":null,"permalink":"/network/scientists/zheng-tan/","section":"Network","summary":"A pioneer in organ-on-a-chip and mulit-organ systems to emulate human physiological processes.","title":"Zheng\u003cbr\u003eTan","type":"network"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/categories/advocacy/","section":"Categories","summary":"","title":"Advocacy","type":"categories"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/aficianados/","section":"Tags","summary":"","title":"Aficianados","type":"tags"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/categories/animal-models/","section":"Categories","summary":"","title":"Animal-Models","type":"categories"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/animal-rising/","section":"Tags","summary":"","title":"Animal-Rising","type":"tags"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/animal-studies/","section":"Tags","summary":"","title":"Animal-Studies","type":"tags"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/categories/animal-testing/","section":"Categories","summary":"","title":"Animal-Testing","type":"categories"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/beagles/","section":"Tags","summary":"","title":"Beagles","type":"tags"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/director/","section":"Tags","summary":"","title":"Director","type":"tags"},{"content":" Genetic survey exposes flaws in widely used mouse models # A survey of more than 300 mouse strains has found widespread discrepancies between how mutant mice are reported and their actual genetic make-up. Half of laboratory mice do not match their reported genetics, according to a genetic analysis of strains distributed globally for animal research. The study, published in Science, analyzed genomes from hundreds of strains maintained by the Mutant Mouse Research and Resource Centers (MMRRC).\nKey Highlights # Half of laboratory mice do not match their reported genetic makeup. Study analyzed genomes of hundreds of mouse strains from MMRRC repositories. Genetic inconsistencies risk misinterpreting disease mechanisms. Errors can emerge during gene transfer between mouse strains. Statements # This study is another wake-up call for biomedical research. If we don’t fully understand the genetics of the mice we’re using, we risk misinterpreting how diseases actually work.\nDaniel Rawle, immunologist at QIMR Berghofer Medical Research Institute Twenty generations is a long time and a lot of money.\nFernando Pardo-Manuel de Villena, mouse geneticist at University of North Carolina at Chapel Hill About the Organizations # Nature is a leading international weekly journal of science. Science publishes peer-reviewed research across scientific disciplines. MMRRC maintains live colonies of genetically engineered mouse strains.\nLearn More # Genetic survey exposes flaws in widely used mouse models\n","date":"2026-05-15","externalUrl":null,"permalink":"/news/flaws-in-mouse-models/","section":"News","summary":"Genetic survey reveals widespread discrepancies in mouse models used for biomedical research.","title":"Genetic survey exposes flaws in widely used mouse models","type":"news"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/genetic-analysis/","section":"Tags","summary":"","title":"Genetic-Analysis","type":"tags"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/categories/genetics/","section":"Categories","summary":"","title":"Genetics","type":"categories"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/genotype-mismatch/","section":"Tags","summary":"","title":"Genotype-Mismatch","type":"tags"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/learners/","section":"Tags","summary":"","title":"Learners","type":"tags"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/categories/legislation/","section":"Categories","summary":"","title":"Legislation","type":"categories"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/legislation/","section":"Tags","summary":"","title":"Legislation","type":"tags"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/mbr-acres/","section":"Tags","summary":"","title":"Mbr-Acres","type":"tags"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/mouse-models/","section":"Tags","summary":"","title":"Mouse-Models","type":"tags"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/network/","section":"Tags","summary":"","title":"Network","type":"tags"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/categories/reproducibility/","section":"Categories","summary":"","title":"Reproducibility","type":"categories"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/reproducibility/","section":"Tags","summary":"","title":"Reproducibility","type":"tags"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/researchers/","section":"Tags","summary":"","title":"Researchers","type":"tags"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/categories/scientific-research/","section":"Categories","summary":"","title":"Scientific-Research","type":"categories"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/scientific-research/","section":"Tags","summary":"","title":"Scientific-Research","type":"tags"},{"content":" Scientists at work using NAM technologies\nCredit: Mistral This section features profiles of scientists and researchers advancing New Approach Methodologies (NAM). Each profile includes a biography, publications, videos, and links relevant to the individual.\n","date":"2026-05-15","externalUrl":null,"permalink":"/network/scientists/","section":"Network","summary":"Profiles of scientists advancing New Approach Methodologies (NAM) through research, innovation, and advocacy.","title":"Scientists","type":"network"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/scientists/","section":"Tags","summary":"","title":"Scientists","type":"tags"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/staff/","section":"Tags","summary":"","title":"Staff","type":"tags"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/supporters/","section":"Tags","summary":"","title":"Supporters","type":"tags"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/categories/uk/","section":"Categories","summary":"","title":"Uk","type":"categories"},{"content":"","date":"2026-05-15","externalUrl":null,"permalink":"/tags/uk/","section":"Tags","summary":"","title":"Uk","type":"tags"},{"content":" UK Home Office Just Defended Animal Testing # Animal Rising has published a critique of the UK government’s defense of animal testing, following an open letter calling for the closure of MBR Acres—the UK’s only dog-breeding facility for laboratories. The letter, signed by over 50 cross-party MPs, public figures, and organizations, demanded the facility’s closure and the safe rehoming of its beagles.\nKey Highlights # Over 50 cross-party MPs, public figures, and organizations signed the open letter. The UK government allocated £75 million for alternative methods, but at least £1 billion of publicly funded research remains tied to animal use annually: The government is backing the wrong science. In 2024, 2.64 million scientific procedures involved living animals in the UK. Statements # Where animals must still be used, it is only because no validated non-animal method exists.\n— UK Home Office statement\nA position increasingly being challenged by scientists and peer-reviewed literature.\nAbout the Organizations # Animal Rising is a campaign group focused on protecting animals, restoring nature, and tackling the climate crisis.\nLearn More # The Home Office Just Defended Animal Testing. Here’s Why They’re Wrong.\n","date":"2026-05-15","externalUrl":null,"permalink":"/news/uk-defends-animal-testing/","section":"News","summary":"Animal Rising challenges the UK government’s defense of animal testing and calls for the closure of MBR Acres, the UK’s only dog-breeding facility for laboratories.","title":"UK Home Office Just Defended Animal Testing","type":"news"},{"content":"","date":"2026-05-14","externalUrl":null,"permalink":"/tags/advertisement/","section":"Tags","summary":"","title":"Advertisement","type":"tags"},{"content":"","date":"2026-05-14","externalUrl":null,"permalink":"/categories/animal-research/","section":"Categories","summary":"","title":"Animal-Research","type":"categories"},{"content":"","date":"2026-05-14","externalUrl":null,"permalink":"/tags/campaign/","section":"Tags","summary":"","title":"Campaign","type":"tags"},{"content":"PNARS campaigns advocate for evidence-based, ethical, and innovative approaches to scientific research and policy. Our initiatives highlight the limitations of outdated methods and promote sustainable, human-relevant alternatives that align with global progress. Explore our past and ongoing efforts to drive meaningful change in science, policy, and public awareness.\n","date":"2026-05-14","externalUrl":null,"permalink":"/projects/campaigns/","section":"Projects","summary":"Initiatives for innovative approaches to scientific research and policy utilizing NAM.","title":"Campaigns","type":"projects"},{"content":"","date":"2026-05-14","externalUrl":null,"permalink":"/tags/campaigns/","section":"Tags","summary":"","title":"Campaigns","type":"tags"},{"content":"","date":"2026-05-14","externalUrl":null,"permalink":"/categories/legislative/","section":"Categories","summary":"","title":"Legislative","type":"categories"},{"content":" Ontario Bill 75 Amends Animals for Research Act # Ontario\u0026rsquo;s Bill 75 (Keeping Criminals Behind Bars Act, 2026) Schedule 1, amends the Animals for Research Act. The amendments introduce restrictions on invasive medical research involving cats, dogs, and other prescribed animals, with limited exceptions for veterinary purposes or as described in regulations. The changes also define new roles for animal care committees and set penalties for non-compliance.\nKey Highlights # Prohibits invasive medical research on cats, dogs, and other prescribed animals, except for veterinary purposes or as described in regulations. Requires animal care committee approval for all research involving these animals. Prohibits breeding cats or dogs for research purposes at supply facilities. Defines roles and responsibilities of animal care committees in registered research facilities. Establishes minor and major offences with penalties for individuals and corporations. About the Organizations # The Legislative Assembly of Ontario is the provincial legislature responsible for passing laws in Ontario, Canada.\nLearn More # Bill 75: Keeping Criminals Behind Bars Act, 2026\n","date":"2026-05-14","externalUrl":null,"permalink":"/news/ontario-passes-bill75/","section":"News","summary":"Ontario’s Bill 75 includes Schedule 1, which amends the Animals for Research Act to prohibit invasive medical research on cats, dogs, and other prescribed animals, with limited exceptions and new conditions for other research.","title":"Ontario Bill 75 Amends Animals for Research Act","type":"news"},{"content":"","date":"2026-05-14","externalUrl":null,"permalink":"/tags/project/","section":"Tags","summary":"","title":"Project","type":"tags"},{"content":" Complex project management through high-tech visual board\nCredit: Mistral This section outlines PNARS’s strategic projects to drive the adoption of New Approach Methodologies, including investment analysis to track investor activity in disruptive technologies, media campaigns to raise public awareness, youth involvement initiatives, educational outreach, policy advocacy, and partnerships with industry and academic institutions.\n","date":"2026-05-14","externalUrl":null,"permalink":"/projects/","section":"Projects","summary":"PNARS strategic projects advancing NAM through investment analyses, advocacy, education, and collaboration.","title":"Projects","type":"projects"},{"content":"","date":"2026-05-13","externalUrl":null,"permalink":"/tags/3d-bioprinting/","section":"Tags","summary":"","title":"3d-Bioprinting","type":"tags"},{"content":"","date":"2026-05-13","externalUrl":null,"permalink":"/tags/advocates/","section":"Tags","summary":"","title":"Advocates","type":"tags"},{"content":"","date":"2026-05-13","externalUrl":null,"permalink":"/tags/ai-models/","section":"Tags","summary":"","title":"Ai-Models","type":"tags"},{"content":"","date":"2026-05-13","externalUrl":null,"permalink":"/tags/aspect-biosystems/","section":"Tags","summary":"","title":"Aspect-Biosystems","type":"tags"},{"content":"","date":"2026-05-13","externalUrl":null,"permalink":"/tags/canadian-institute-for-animal-free-science/","section":"Tags","summary":"","title":"Canadian-Institute-for-Animal-Free-Science","type":"tags"},{"content":"","date":"2026-05-13","externalUrl":null,"permalink":"/tags/cherry-biotech/","section":"Tags","summary":"","title":"Cherry-Biotech","type":"tags"},{"content":" Industry # Industry adopting NAM rapidly\nCredit: Mistral Industry leaders and organizations are driving the adoption of New Approach Methodologies (NAM) through innovative technologies, research, and advocacy. This section highlights companies and institutes advancing human-relevant, animal-free science in drug development and biomedical research.\nAspect Biosystems - 3D Bioprinting Platform # Aspect Biosystems has developed bioprinted human tissue models designed to replace animal testing in drug development. These bioprinted therapeutics are designed to replace biological functions in the body, representing a major innovation in Canadian biotechnology. These models provide advanced tissue platforms that enhance the accuracy of preclinical drug testing.\nAspect Biosystems\nCherry Biotech - Organoid Culture Made Easy # Cherry Biotech provides life-like preclinical data for derisking drug testing and improving preclinical trials. Their experience and expertise with organoids, AI, and biosensors enable the acceleration and improvement of result analysis.\nCherry Biotech\nEmulate Bio - Organ-on-a-Chip Technology # Emulate Bio develops organ-on-a-chip technology that recreates human physiology to improve drug development, disease modeling, and predictive toxicology. Their platforms enable human-relevant research and reduce reliance on animal testing.\nEmulate Bio\nTorch Bio - Advancing Drug Discovery # A Michigan-based company whose mission is to revolutionize pharmaceutical development by harnessing cutting-edge technologies, including patient-derived iPSC liver organoids and advanced AI models.\nTorch Bio\nCanadian Institute for Animal-Free Science # Formerly known as Canadian Centre for Alternatives to Animal Methods, CCAAM was Canada\u0026rsquo;s first dedicated academic center for NAM research, promoting human-relevant, non-animal approaches in science. Established in 2017 at the University of Windsor, the center was instrumental in conducting and disseminating research on advanced alternative methods. Its work has been halted due to the lack of a sustained funding commitment from government. Its principal, Charu Chandrasekera, Ph.D., strives to continue the drive toward the adoption and validation of NAM within Canada under the new organization, the Canadian Institute for Animal-Free Science.\n","date":"2026-05-13","externalUrl":null,"permalink":"/network/industry/","section":"Network","summary":"Leading businesses utilizing and advancing NAM technologies.","title":"Industry","type":"network"},{"content":"","date":"2026-05-13","externalUrl":null,"permalink":"/tags/kimmtrak/","section":"Tags","summary":"","title":"Kimmtrak","type":"tags"},{"content":" Connections for NAM across the planet\nCredit: geralt (pixabay) Various individuals and groups involved with NAM development.\n","date":"2026-05-13","externalUrl":null,"permalink":"/network/","section":"Network","summary":"","title":"Network","type":"network"},{"content":"","date":"2026-05-13","externalUrl":null,"permalink":"/tags/oecd/","section":"Tags","summary":"","title":"Oecd","type":"tags"},{"content":"","date":"2026-05-13","externalUrl":null,"permalink":"/tags/organoid-culture/","section":"Tags","summary":"","title":"Organoid-Culture","type":"tags"},{"content":"","date":"2026-05-13","externalUrl":null,"permalink":"/tags/recombinant-reagents/","section":"Tags","summary":"","title":"Recombinant-Reagents","type":"tags"},{"content":"","date":"2026-05-13","externalUrl":null,"permalink":"/tags/regulation-policy/","section":"Tags","summary":"","title":"Regulation-Policy","type":"tags"},{"content":"","date":"2026-05-13","externalUrl":null,"permalink":"/tags/regulations/","section":"Tags","summary":"","title":"Regulations","type":"tags"},{"content":" Regulatory \u0026amp; Industry Adoption of NAM # International Cooperation on\nAlternative Test Methods (ICATM)\nCredit: National Institute of Health Sciences Regulatory agencies and pharmaceutical companies are increasingly embracing NAM to streamline drug development, enhance predictivity, and align with ethical and scientific advancements. This section examines key milestones—such as the FDA Modernization Act 2.0 and OECD standards—that are paving the way for the global adoption of human-relevant, animal-free methodologies in biomedical research. Documented progress in regulations provide a valuable resource for NAM promotion.\nFDA Modernization Act 2.0 # The FDA Modernization Act 2.0 (2022) removed the federal mandate for animal testing in new drug applications. This was a significant move by the FDA toward utilizing human cells and organoids in preclinical safety assessments. The act explicitly encouraged the use of NAM to provide more accurate and relevant data for human health.\nFDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches\nHow new approach methodologies are reshaping drug discovery\nOrgan-on-a-chip meets artificial intelligence in drug evaluation\nFDA CDER NAM Validation Guidance # The FDA’s Center for Drug Evaluation and Research (CDER) released draft guidance establishing a validation framework for NAM-derived data. These guidelines are based on scientific confidence and \u0026ldquo;fit-for-purpose\u0026rdquo; utility, marking a definitive shift away from the animal model. This provided a clear regulatory pathway for integrating NAM into Investigational New Drug applications.\nFDA Releases Draft Guidance on Alternatives to Animal Testing in Drug Development\nNew Approach Methodologies (NAMs) in Drug Development\nOECD International Standards # The OECD Guidance Document 34 established international standards for the validation and acceptance of alternative test methods. This facilitated global harmonization and the widespread adoption of NAM in various regulatory frameworks. These standards ensure that non-animal data is accepted consistently across member countries.\nList of Alternative Test Methods and Strategies (or New Approach Methodologies NAMs)\nOECD Series On Testing And Assessment Number 34\nTebentafusp (Kimmtrak) Regulatory Approval # Tebentafusp (Kimmtrak) became the first immunotherapy to reach regulatory approval without in vivo animal pharmacodynamic data. Because the drug lacked activity in any animal species, the sponsors relied entirely on human-centric NAM to justify safety and efficacy. This establishes a major regulatory milestone, proving that human-relevant data can fully replace animal testing for specific first-in-class therapeutics.\nImmunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma\nSummary Basis of Decision for Kimmtrak in Canada\nUSP Chapter \u0026lt;86\u0026gt; Recombinant Reagents # The U.S. Pharmacopeia implemented Chapter \u0026lt;86\u0026gt; in May 2025, endorsing the use of non-animal-derived reagents for bacterial endotoxin testing. This change allows for the use of recombinant Factor C, utilizing gene sequences from horseshoe crabs instead of their blood. This modernization could save up to 90, 000 animals per year while increasing batch consistency in pharmaceutical manufacturing.\n\u0026lt;86\u0026gt; Bacterial Endotoxins Test Using Recombinant Reagents\n","date":"2026-05-13","externalUrl":null,"permalink":"/resources/regulatory/","section":"Resources","summary":"Milestones in the global adoption of NAM in regulatory frameworks.","title":"Regulatory","type":"resources"},{"content":" Resources of perpetual and ubiquitous variety\nCredit: manfredsteger (pixabay)\nmodified by prad This section provides regulatory documents, promotional materials (posters, cards, flyers), and educational resources (videos, tutorials, glossary, FAQ) to support the adoption and understanding of New Approach Methodologies.\n","date":"2026-05-13","externalUrl":null,"permalink":"/resources/","section":"Resources","summary":"","title":"Resources","type":"resources"},{"content":"","date":"2026-05-13","externalUrl":null,"permalink":"/tags/standards/","section":"Tags","summary":"","title":"Standards","type":"tags"},{"content":"","date":"2026-05-13","externalUrl":null,"permalink":"/tags/tebentafusp/","section":"Tags","summary":"","title":"Tebentafusp","type":"tags"},{"content":"","date":"2026-05-13","externalUrl":null,"permalink":"/tags/torch-bio/","section":"Tags","summary":"","title":"Torch-Bio","type":"tags"},{"content":"","date":"2026-05-13","externalUrl":null,"permalink":"/tags/usp/","section":"Tags","summary":"","title":"USP","type":"tags"},{"content":" A microscopic view of NAM technology\nCredit: Mistral New Approach Methodologies (NAM) represent a paradigm shift in biomedical research and drug development, replacing or supplementing traditional animal testing with human-relevant, in vitro, in silico, and in chemico technologies. The sections below synthesize peer-reviewed, validated medical discoveries enabled by NAM, organized thematically under the following areas.\n","date":"2026-05-12","externalUrl":null,"permalink":"/advances/","section":"Advances","summary":"","title":"Advances","type":"advances"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/alphafold/","section":"Tags","summary":"","title":"AlphaFold","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/als/","section":"Tags","summary":"","title":"ALS","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/aop/","section":"Tags","summary":"","title":"AOP","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/atopic-diseases/","section":"Tags","summary":"","title":"Atopic-Diseases","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/baricitinib/","section":"Tags","summary":"","title":"Baricitinib","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/ber/","section":"Tags","summary":"","title":"BER","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/bioequivalence/","section":"Tags","summary":"","title":"Bioequivalence","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/biosynthetic-gene-clusters/","section":"Tags","summary":"","title":"Biosynthetic-Gene-Clusters","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/brain-development/","section":"Tags","summary":"","title":"Brain-Development","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/breakthroughs/","section":"Tags","summary":"","title":"Breakthroughs","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/chemical-risk-assessment/","section":"Tags","summary":"","title":"Chemical-Risk-Assessment","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/computational-models/","section":"Tags","summary":"","title":"Computational-Models","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/corneal-models/","section":"Tags","summary":"","title":"Corneal-Models","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/crispr/","section":"Tags","summary":"","title":"CRISPR","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/cystic-fibrosis/","section":"Tags","summary":"","title":"Cystic-Fibrosis","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/digital-twins/","section":"Tags","summary":"","title":"Digital-Twins","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/disease-modeling/","section":"Tags","summary":"","title":"Disease-Modeling","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/draize/","section":"Tags","summary":"","title":"Draize","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/drug-development/","section":"Tags","summary":"","title":"Drug-Development","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/drug-repurposing/","section":"Tags","summary":"","title":"Drug-Repurposing","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/drug-screening/","section":"Tags","summary":"","title":"Drug-Screening","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/drug-targets/","section":"Tags","summary":"","title":"Drug-Targets","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/duchenne/","section":"Tags","summary":"","title":"Duchenne","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/endocrine-disruption/","section":"Tags","summary":"","title":"Endocrine-Disruption","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/endocrine-disruptors/","section":"Tags","summary":"","title":"Endocrine-Disruptors","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/epa/","section":"Tags","summary":"","title":"EPA","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/eye-irritation/","section":"Tags","summary":"","title":"Eye-Irritation","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/gene-therapy/","section":"Tags","summary":"","title":"Gene-Therapy","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/genomics/","section":"Tags","summary":"","title":"Genomics","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/high-throughput/","section":"Tags","summary":"","title":"High-Throughput","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/idiopathic-pulmonary-fibrosis/","section":"Tags","summary":"","title":"Idiopathic-Pulmonary-Fibrosis","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/insilico-medicine/","section":"Tags","summary":"","title":"Insilico-Medicine","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/liver/","section":"Tags","summary":"","title":"Liver","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/lung/","section":"Tags","summary":"","title":"Lung","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/machine-learning/","section":"Tags","summary":"","title":"Machine-Learning","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/metabolomics/","section":"Tags","summary":"","title":"Metabolomics","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/microfluidics/","section":"Tags","summary":"","title":"Microfluidics","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/microphysiological-systems/","section":"Tags","summary":"","title":"Microphysiological-Systems","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/mixture-toxicology/","section":"Tags","summary":"","title":"Mixture-Toxicology","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/multi-omics/","section":"Tags","summary":"","title":"Multi-Omics","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/network-pharmacology/","section":"Tags","summary":"","title":"Network-Pharmacology","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/neurodegenerative-disorders/","section":"Tags","summary":"","title":"Neurodegenerative-Disorders","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/pbpk/","section":"Tags","summary":"","title":"PBPK","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/pfas/","section":"Tags","summary":"","title":"PFAS","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/protein-structures/","section":"Tags","summary":"","title":"Protein-Structures","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/proteomics/","section":"Tags","summary":"","title":"Proteomics","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/qsp/","section":"Tags","summary":"","title":"QSP","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/reconstructed-human-skin/","section":"Tags","summary":"","title":"Reconstructed-Human-Skin","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/seizure-liability/","section":"Tags","summary":"","title":"Seizure-Liability","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/single-cell-rna-sequencing/","section":"Tags","summary":"","title":"Single-Cell-RNA-Sequencing","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/skin/","section":"Tags","summary":"","title":"Skin","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/skin-sensitization/","section":"Tags","summary":"","title":"Skin-Sensitization","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/stem-cells/","section":"Tags","summary":"","title":"Stem-Cells","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/tofacitinib/","section":"Tags","summary":"","title":"Tofacitinib","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/tox21/","section":"Tags","summary":"","title":"Tox21","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/toxicity-pathways/","section":"Tags","summary":"","title":"Toxicity-Pathways","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/toxicity-testing/","section":"Tags","summary":"","title":"Toxicity-Testing","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/transcriptomics/","section":"Tags","summary":"","title":"Transcriptomics","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/tslp/","section":"Tags","summary":"","title":"TSLP","type":"tags"},{"content":"","date":"2026-05-12","externalUrl":null,"permalink":"/tags/zika/","section":"Tags","summary":"","title":"Zika","type":"tags"},{"content":" PNARS advisors, supporters, staff are very welcoming\nCredit: Mistral The Progressive Non-Animal Research Society (PNARS) is a non-profit organization dedicated to advancing New Approach Methodologies (NAM) which are innovative, human-relevant alternatives to animal-based research. Formed in 2020 during the COVID era, its roots are closely tied to the BC Foundation for Non-Animal Research (BC FNAR), which was founded in 1970 honoring the legacy of Evelyn Martin RN and has long supported scientists in biomedical research, testing, and training without harmful animal use.\nPNARS builds on this legacy by:\nPromoting NAM (eg organ-on-a-chip, in silico modeling, AI-driven drug discovery) to the scientific and healthcare communities. Commissioning reports, such as the 2023 analysis of the environmental impacts of animal experimentation, particularly regarding Vancouver’s new St. Paul’s Hospital and Health Campus. Facilitating collaboration among scientists, advocates, and policymakers to replace animal-based models with ethical, effective alternatives. Engaging in advocacy and education, including participation in events like the 2024 Humane Canada’s Summit for Animals. PNARS serves as a resource hub for breakthroughs in human-relevant technologies, providing a platform for the exchange of ideas and the development of non-animal methods in medical research.\n","date":"2026-05-11","externalUrl":null,"permalink":"/about/","section":"About","summary":"","title":"About","type":"about"},{"content":"","date":"2026-05-11","externalUrl":null,"permalink":"/tags/advisors/","section":"Tags","summary":"","title":"Advisors","type":"tags"},{"content":"","date":"2026-05-11","externalUrl":null,"permalink":"/tags/animal-alliance-canada/","section":"Tags","summary":"","title":"Animal-Alliance-Canada","type":"tags"},{"content":"","date":"2026-05-11","externalUrl":null,"permalink":"/categories/animal-welfare/","section":"Categories","summary":"","title":"Animal-Welfare","type":"categories"},{"content":"","date":"2026-05-11","externalUrl":null,"permalink":"/tags/board/","section":"Tags","summary":"","title":"Board","type":"tags"},{"content":"","date":"2026-05-11","externalUrl":null,"permalink":"/categories/campaigns/","section":"Categories","summary":"","title":"Campaigns","type":"categories"},{"content":"","date":"2026-05-11","externalUrl":null,"permalink":"/tags/dogs-cats/","section":"Tags","summary":"","title":"Dogs-Cats","type":"tags"},{"content":"","date":"2026-05-11","externalUrl":null,"permalink":"/tags/history/","section":"Tags","summary":"","title":"History","type":"tags"},{"content":"","date":"2026-05-11","externalUrl":null,"permalink":"/tags/invasive-research/","section":"Tags","summary":"","title":"Invasive-Research","type":"tags"},{"content":" LUSH Campaign Launches to End Pets in Research # Animal Alliance of Canada and LUSH Cosmetics have officially launched a national partnership campaign to support the No Pets in Research initiative. Starting today, supporters across Canada can purchase a special paw-shaped soap at participating LUSH stores or online. Proceeds will support Animal Alliance of Canada’s work to end the use of dogs and cats in invasive research.\nKey Highlights # Proceeds from the paw-shaped soap fund efforts to end the use of dogs and cats in invasive research. Campaign aims to close loopholes that allow former pets to enter laboratories in Ontario. Initiative seeks to raise awareness about the use of dogs and cats in research across Canada. About the Organizations # Animal Alliance of Canada is a Canadian organization advocating for animal protection and welfare. LUSH Cosmetics is a cosmetics company known for its ethical sourcing and activism.\nLearn More # Paws Off Our Pets Campaign\n","date":"2026-05-11","externalUrl":null,"permalink":"/news/lush-campaign/","section":"News","summary":"LUSH Cosmetics partners with Animal Alliance of Canada to launch a national campaign against the use of dogs and cats in research.","title":"LUSH Campaign Launches to End Pets in Research","type":"news"},{"content":"","date":"2026-05-11","externalUrl":null,"permalink":"/tags/lush-cosmetics/","section":"Tags","summary":"","title":"Lush-Cosmetics","type":"tags"},{"content":"","date":"2026-05-11","externalUrl":null,"permalink":"/tags/no-pets-in-research/","section":"Tags","summary":"","title":"No-Pets-in-Research","type":"tags"},{"content":"","date":"2026-05-11","externalUrl":null,"permalink":"/categories/partnerships/","section":"Categories","summary":"","title":"Partnerships","type":"categories"},{"content":"","date":"2026-05-11","externalUrl":null,"permalink":"/tags/paw-shaped-soap/","section":"Tags","summary":"","title":"Paw-Shaped-Soap","type":"tags"},{"content":"","date":"2026-04-24","externalUrl":null,"permalink":"/tags/alternatives/","section":"Tags","summary":"","title":"Alternatives","type":"tags"},{"content":"","date":"2026-04-24","externalUrl":null,"permalink":"/tags/animal-alliance/","section":"Tags","summary":"","title":"Animal-Alliance","type":"tags"},{"content":"","date":"2026-04-24","externalUrl":null,"permalink":"/categories/education/","section":"Categories","summary":"","title":"Education","type":"categories"},{"content":"","date":"2026-04-24","externalUrl":null,"permalink":"/tags/introduction/","section":"Tags","summary":"","title":"Introduction","type":"tags"},{"content":" Moving Beyond Animal Testing (panel) # Animal Alliance of Canada presents Moving Beyond Animal Testing - Intro to New Approach Methodologies in Research, an introduction to scientific methods replacing animal testing. This resource explores how New Approach Methodologies (Nam), such as organ-on-a-chip, AI-driven drug discovery, and 3D bioprinting, provide human-relevant alternatives for research and regulatory testing.\nKey Highlights # The limitations of animal testing in predicting human outcomes. Overview of Nam: organoids, in silico modeling, and more. Global regulatory acceptance and policy changes. How to advocate for NAM adoption in Canada. About the Organizations # Animal Alliance of Canada is a Canadian organization advocating for animal protection and ethical treatment.\nLearn More # Rethinking Research: Animal Alliance Brings Experts Together for Panel Event on Modern Alternatives to Animal Testing Watch the panel video below.\n","date":"2026-04-24","externalUrl":null,"permalink":"/news/beyond-animal-testing/","section":"News","summary":"Animal Alliance of Canada presents an introduction to New Approach Methodologies (NAM), highlighting their advantages over animal testing in research.","title":"Moving Beyond Animal Testing (panel)","type":"news"},{"content":"","date":"2026-04-24","externalUrl":null,"permalink":"/tags/webinar/","section":"Tags","summary":"","title":"Webinar","type":"tags"},{"content":"","date":"2026-04-13","externalUrl":null,"permalink":"/tags/cost-comparison/","section":"Tags","summary":"","title":"Cost-Comparison","type":"tags"},{"content":"","date":"2026-04-13","externalUrl":null,"permalink":"/tags/hill-times/","section":"Tags","summary":"","title":"Hill Times","type":"tags"},{"content":"","date":"2026-04-13","externalUrl":null,"permalink":"/tags/infographic/","section":"Tags","summary":"","title":"Infographic","type":"tags"},{"content":" Canada’s Opportunity to Lead in Animal-Free Science # Published in The Hill Times, April 2026, this campaign highlights the urgent need for Canada to adopt New Approach Methodologies (NAM) - human-based research methods that are faster, cheaper, and more reliable than animal testing.\n1. Infographic: \u0026ldquo;Would you trust animal tests to predict human health?\u0026rdquo; # Primate Advertisement\nView original image Key Stats:\n95% of drugs that pass animal tests fail in humans. 12+ years and up to $2B to bring a drug to market. 30, 000+ chemicals in Canada still lack full toxicity data. Millions of animals used annually in Canada. Modern Human-Based Science: Uses human cells, tissues, or data to study biology and disease. More predictive, faster, scalable, and reduces costly failures. Canada’s opportunity: Lead in a $30 billion global industry by 2030. 2. Hill Times Ad: \u0026ldquo;A National Focus on New Approaches to Life Sciences Is Urgently Needed\u0026rdquo; # National focus to NAM needed\nView original pdf Key Points: # 90% of drugs tested on animals fail in humans, wasting resources and delaying cures. Three actionable steps for Canada: End the federal requirement for animal drug testing. Fund a national centre for NAM (using part of the $552M research funding). Direct CIHR/NSERC to transition funding toward non-animal approaches. 3. Hill Times Ad: \u0026ldquo;A monkey used in research can cost over $30K\u0026rdquo; # Cost of one monkey vs human brain-on-a-chip\nView original pdf Key Points: # Cost comparison of experiment done on monkey vs brain-on-a-chip in $1K ($1000)\nItem Non-human primate Brain-on-a-chip The Brain $17-33K $0.8K Maintenance $7-30K/year $0 Biological Inputs NA $2-6K Additional costs permit, transport, etc none Total $24–63K+ first year $1.5K Brain-on-a-chip process is over $60 thousand dollars less than non-human primate research in the first year along. The results from NAM technology are\nhuman-relevant (unlike non-human primate) faster, scalable, and more accurate (than non-human primate) safer and sustainable (compared to non-human primate results) Finally, the Canadian government has funded a new primate research centre at Laval University for $42 million, while the allocation for a National Centre for Alternatives is exactly $0!\nPNARS Editorial Note:\nWhy is Canada not funding New Approach Methodologies? This technology is cheaper, faster, more ethical. Furthermore it is more scalable meaning the technology can easily expand and adapt to meet research demands without proportional increases in cost, time, or complexity. NAM allow researchers to run more experiments, get results faster, lower costs, while improving accuracy compared to animal experimentation.\nSee article Reducing drug failures with AI, human liver organoids as one reference on failure rates and alternatives.\n","date":"2026-04-13","externalUrl":null,"permalink":"/projects/campaigns/hillad2604/","section":"Projects","summary":"","title":"Ottawa Hill Times Ad 2026-04","type":"projects"},{"content":"","date":"2026-01-13","externalUrl":null,"permalink":"/categories/business/","section":"Categories","summary":"","title":"Business","type":"categories"},{"content":"","date":"2026-01-13","externalUrl":null,"permalink":"/tags/human-relevant-science/","section":"Tags","summary":"","title":"Human-Relevant-Science","type":"tags"},{"content":"","date":"2026-01-13","externalUrl":null,"permalink":"/tags/inotiv/","section":"Tags","summary":"","title":"Inotiv","type":"tags"},{"content":" Inotiv Advances NAM # Inotiv, Inc. has announced a strategic initiative to leverage LifeNet Health’s proprietary TruVivo® platform within its Discovery and Translational Sciences business. This collaboration aims to advance New Approach Methodologies (NAM) by improving human-relevant science and translational predictivity in drug discovery. The TruVivo® platform uses primary human hepatocytes cultured with human-derived feeder cells to create physiologically relevant in vitro models.\nKey Highlights # The TruVivo® platform uses primary human hepatocytes cultured with human-derived feeder cells to create physiologically relevant in vitro models. The initiative focuses on aligning preclinical models with human biology to accelerate therapy development. The platform’s versatility allows for the expansion of human-relevant tissue models beyond the liver, supporting innovation for a wide range of diseases. Statements # Translational science is about connecting basic research to patient outcomes. Integrating the TruVivo® platform into our disease pharmacology offering allows us to better align preclinical models with human biology.\n— Scott Daniels, PhD, Senior Vice President of Discovery \u0026amp; Translational Sciences at Inotiv\nOur mission is to save lives, restore health, and give hope by accelerating scientific innovation that translates into meaningful human impact. This collaboration underscores our shared vision of transforming preclinical research through human-relevant technologies.\n— Susan Campbell, General Manager LifeSciences at LifeNet Health\nAbout the Organizations # Inotiv, Inc. is a leading Contract Research Organization (CRO) specializing in nonclinical and analytical drug discovery and development services. LifeNet Health LifeSciences delivers human-based research solutions that accelerate discovery and improve patient safety.\nLearn More # Read the full press release at LifeNet Health LifeSciences Inotiv’s Official Announcement\n","date":"2026-01-13","externalUrl":null,"permalink":"/news/inotiv-advances-nam/","section":"News","summary":"Inotiv partners with LifeNet Health to integrate TruVivo® platform for advancing NAM in drug discovery.","title":"Inotiv Advances NAM","type":"news"},{"content":"","date":"2026-01-13","externalUrl":null,"permalink":"/tags/lifenet-health/","section":"Tags","summary":"","title":"Lifenet-Health","type":"tags"},{"content":"","date":"2026-01-13","externalUrl":null,"permalink":"/categories/regulatory/","section":"Categories","summary":"","title":"Regulatory","type":"categories"},{"content":"","date":"2026-01-13","externalUrl":null,"permalink":"/tags/translational-drug-discovery/","section":"Tags","summary":"","title":"Translational-Drug-Discovery","type":"tags"},{"content":"","date":"2026-01-13","externalUrl":null,"permalink":"/tags/truvivo/","section":"Tags","summary":"","title":"Truvivo","type":"tags"},{"content":" Animal Research vs NAM Costs # (All dollar values are in USD as of 2026-06 and from the references cited. Be aware that financial numbers may vary dependent on source, methodology, and point-of-time for the analysis.)\nThe Economic Case for NAM # Category Animal Research NAM Preclinical Success 95% of new drugs fail in slow, animal-based laboratory tests before being tried on humans 1. Bypasses early bottlenecks using fast, automated human cell models and computer programs 2. Clinical Success Up to 92% of drugs passing animal testing safely fail in human clinical trials 3 4. Uses human-relevant data from the start to predict safety accurately and avoid late-stage failures 4. Cost per Approved Drug Establishes a massive baseline range of $1.9 billion to $2.6 billion per successful drug 1 3. Significantly lower—saves money by catching toxic or ineffective drugs early before spending billions 5. True Corporate Burn Scales to staggering $4-11 billion per drug when counting a company\u0026rsquo;s total losses 6. Drops structural overhead by moving away from expensive, large-scale animal facility maintenance 7. Core Strategic Callouts # For Scientists # Stop wasting time and resources on dead ends. Animal models frequently fail to predict human responses, leading to a 95% preclinical failure rate 1. Switching to an integrated technology stack, like human organ-chips and advanced computer modeling, lets you test on human biology from day one 8. Studies show these modern methods give much more accurate, reproducible data on drug safety and efficacy 4 9.\nFor Policymakers # Protect public and private R\u0026amp;D budgets from an unsustainable multi-billion dollar system 1 3. Modern non-animal methods (NAMs) offer a cost-effective, highly scalable alternative that gets safer treatments to patients faster. New regulatory updates, like the FDA Modernization Act 2.0, explicitly allow these human-relevant methods to be used instead of animal tests for drug approvals 2 10.\nFor Economists # Shift capital to methodologies that offer sublinear data scaling. Traditional animal testing costs rise linearly because you constantly have to buy, breed, and house more physical animals 11. In contrast, automated chips and cloud computing platforms can screen millions of chemical compounds at a fraction of the cost, reducing overall lifecycle expenses and accelerating market entry 5 7.\nFrequently Asked Questions # Why do 95% of drugs fail in preclinical animal tests?\nAnimals are not human beings. Because their biology and metabolic pathways are entirely different, animal tests give false reassurance or miss critical toxicities 4. Human-based NAMs solve this by testing directly on human cells, tissues, and advanced digital models 8 9.\nWhat drives the $4.0 billion to $11.0 billion corporate burn rate?\nThis large number comes from dividing a pharmaceutical firm\u0026rsquo;s total aggregate R\u0026amp;D budget by the few drugs that actually make it to market 6. It reflects the massive financial penalty of maintaining massive corporate operations that are completely dragged down by constant animal testing failures 1.\nHow does NAM reduce costs?\nNAM eliminates the need to run expensive, multi-year animal labs 7. By using automated human cell arrays and cloud computing, scientists can compress years of observational testing into weeks of precise data, securing massive cumulative operational savings 5 12.\nWhat are real-world examples of NAM technologies?\nKey technologies include organ-on-a-chip (microfluidic devices lined with living human cells), 3D bioprinting of human tissues, computer-simulated human trials, and AI-driven screening platforms 8 9.\nWhat is the regulatory status of NAM?\nRegulators like the FDA and EMA are actively expanding their frameworks to accept non-animal data 2. Laws have changed to explicitly state that drug companies no longer face a mandatory requirement to test on animals if human-predictive methods are used instead 10.\nHow can institutions transition to NAM?\nOrganizations can start small by integrating automated non-animal testing into early-stage discovery, shifting capital away from legacy animal facility expansion, and working with specialized networks like PNARS for curriculum audits and training support 7 12 13.\nCan I print this document?\nThis Talking Point is available for download right here.\nFootnotes # Pharmaceutical Drug Lifecycle: A Comprehensive Scientific Review of Research and Development Phases, Attrition Rates, and Global Disparities\nComprehensive analysis outlining the 95% preclinical attrition rate and baseline operational development costs.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nRoadmap to Reducing Animal Testing in Preclinical Safety Studies | FDA\nOfficial agency framework details structural initiatives to replace, reduce, and refine animal testing in favor of human-predictive models.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nWhy Drug Development Takes Decades: Process \u0026amp; Challenges | IntuitionLabs\nDetailed timeline study mapping the multi-decade pipeline challenges and the standard $2.6 billion capitalized baseline cost.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nPoor Translatability of Biomedical Research Using Animals - A Narrative Review\nHigh-impact scientific review evaluating why animal biology fundamentally fails to translate or predict safe outcomes in human clinical trials.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nImpact of organ-on-a-chip technology on pharmaceutical R\u0026amp;D costs\nEconomic model demonstrating significant financial savings and trial failure reductions by integrating microfluidic chips.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nThe Truly Staggering Cost Of Inventing New Drugs\nInfluential Forbes macroeconomic audit tracking multi-firm aggregate cash burn rates up to $11 billion per approved drug.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nCosts of animal and non-animal testing | Humane World\nOperational cost comparison showing the massive overhead penalty of physical animal labs versus automated alternative methods.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nWhat are Organ-Chips? | Emulate, Inc.\nTechnical brief detailing how living human cells inside microfluidic environments accurately simulate high-fidelity tissue biology.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nState-of-the-art in high throughput organ-on-chip for biotechnology and pharmaceuticals | PubMed Central\nPeer-reviewed study on scaling up organ-on-chip systems into automated arrays for massive, high-velocity compound library screening.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nFDA\u0026rsquo;s emerging framework to reduce animal testing: Implications for drug development timelines, cost, and clinical strategy | pharmaphorum\nStrategic assessment of the regulatory pivot following the FDA Modernization Act 2.0 and its impact on clinical trial acceleration.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nHow much money is spent on animal testing every year? | HowMuchBlog\nIndustry spending data tracking global capital allocation toward legacy physical live-animal testing methods.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nNew Approach Methodologies: What Clinical Pharmacologists Should Prepare For | Clinical Pharmacology \u0026amp; Therapeutics\nClinical review outlining the technical, computing, and screening architectures required for professional pharmacology integration.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\u0026#160;\u0026#x21a9;\u0026#xfe0e;\nCreating training opportunities in new approach methodologies for early-career researchers | ScienceDirect / COLAAB\nAcademic paper detailing current global curriculum audits, educational partnerships, and specialized training programs for NAM implementation.\u0026#160;\u0026#x21a9;\u0026#xfe0e;\n","externalUrl":null,"permalink":"/resources/assets/animal-research-vs-nam-costs/","section":"Resources","summary":"Legacy animal research costs up to $2.6B per pipeline asset vs NAM’s streamlined, human-predictive framework.","title":"Animal Research vs NAM Costs TP","type":"resources"},{"content":"","externalUrl":null,"permalink":"/authors/","section":"Authors","summary":"","title":"Authors","type":"authors"},{"content":"","externalUrl":null,"permalink":"/series/","section":"Series","summary":"","title":"Series","type":"series"}]